WorldWideScience

Sample records for vacuna anti influenza

  1. Immunogenicity and tolerability of inactivated flu vaccine In high risk and healthy children Inmunogenicidad y tolerancia de la vacuna inactivada anti-influenza en niños en alto riesgo y en controles sanos

    Directory of Open Access Journals (Sweden)

    Maria Luisa Avila Aguero

    2007-08-01

    Full Text Available We conducted this open study to evaluate the immunogenicity and safety of the inactivated influenza vaccine, Imovax Gripe® in 154 children between 6 and 36 months of age at high risk of influenza- related complications, and in a reference group of 64 healthy children. The study was conducted over two flu seasons, in which the vaccine contained the same A strains but different B strains. The results for the A/H3N2 and A/H1N1 strains from the two flu seasons were pooled, but those for the B strains were not. Anti-hemagglutinin (HA antibody titers were determined before, and one month after each vaccination, and safety was evaluated based on diary card reporting any adverse event observed, either included or not in the list of "solicited events". Within each group of vaccines, the seroconversion rates, seroprotection rates, and ratio of post- to prevaccination geometric mean titers (GMTR for the A/H3N2 and the A/H1N1 strains fulfilled all requirements of the criteria of the European Union Committee for Proprietary Medicinal Products (CPMP. The immune responses in high-risk and in healthy children were similar, and consistent with those observed in previous studies conducted in healthy children. The vaccine was equally well tolerated by all study groups. Reactogenicity was low and similar in both high-risk and healthy children. Overall from 9.5% to 15.4% of at-risk children and 12% of healthy children reported a solicited local reaction; 23.0 to 28.8% of high-risk and 25.3% of healthy children reported a solicited systemic reaction. The study results provide support for vaccination of children at high-risk of influenza related complications.Se realizó un estudio clínico abierto para evaluar la inmunogenícidad y la seguridad de la vacuna inactivada anti-influenza, Imovax Gripe®, en 154 niños entre 6 y 36 meses de edad con alto riesgo de complicaciones ligadas a la influenza, y en un grupo de referencia de 64 niños sanos. El estudio fue

  2. Efectividad de la vacuna contra influenza: metanálisis de literatura

    Directory of Open Access Journals (Sweden)

    José Moreno

    2009-03-01

    Conclusiones. Los análisis sugieren la vacunación como medida masiva de control para influenza en adultos mayores de 65 años. Existe un importante vacío de conocimiento en la efectividad de la vacuna en niños menores de dos años y madres gestantes.

  3. Influenza. Vacunas clásicas y novedosas a las puertas de otra pandemia

    Directory of Open Access Journals (Sweden)

    Raiza Martínez

    2006-08-01

    Full Text Available Los virus de la influenza A, además del hombre, infectan otros mamíferos y una gran variedad de especies de aves. Desde 1997 se sabe que cepas aviares son capaces de infectar al hombre provocando una enfermedad generalmente leve. El brote actual de gripe aviar H5N1 en humanos ha puesto en alerta a la comunidad científica internacional, no solo por su elevada mortalidad sino por su potencialidad en la generación de una nueva pandemia. Las autoridades sanitarias han puesto en marcha un amplio programa para la preparación ante esta contingencia, que abarca diferentes campos, desde el diagnóstico y la detección precoz de los brotes tanto en animales como en humanos, la caracterización sistemática de las cepas circulantes, el sacrificio de aves infectadas, la producción masiva de antivirales y por supuesto el desarrollo y producción a gran escala de vacunas eficaces. En este último tema se trabaja intensamente tanto en el mejoramiento de las vacunas ya existentes como en la búsqueda de alternativas basadas en tecnologías de nueva generación.

  4. Polyarteritis nodosa related with influenza vaccine = Poliarteritis nodosa relacionada con vacuna contra la influenza

    Directory of Open Access Journals (Sweden)

    Restrepo Escobar, Mauricio

    2013-01-01

    Full Text Available Vasculitis can be secondary to various processes, among them infections, malignancies, connective tissue diseases or medications, or primary, generally idiopathic. The reported adverse events after vaccination can be mild and transient or more serious such as autoimmune diseases. Possibly the most frequently described autoimmune phenomena after influenza vaccination are different forms of vasculitis. We report the case of a patient who presented a clinical picture of vasculitis classified as polyarteritis nodosa that began two weeks after receiving the influenza vaccine. After critically reviewing the literature, this would be the first clearly documented case of polyarteritis nodosa associated with vaccination against influenza.

  5. Anti-influenza M2e antibody

    Science.gov (United States)

    Bradbury, Andrew M [Santa Fe, NM

    2011-12-20

    Humanized recombinant and monoclonal antibodies specific for the ectodomain of the influenza virus M2 ion channel protein are disclosed. The antibodies of the invention have anti-viral activity and may be useful as anti-viral therapeutics and/or prophylactic/vaccine agents for inhibiting influenza virus replication and for treating individuals infected with influenza.

  6. Anti-influenza M2e antibody

    Energy Technology Data Exchange (ETDEWEB)

    Bradbury, Andrew M.

    2013-04-16

    Humanized recombinant and monoclonal antibodies specific for the ectodomain of the influenza virus M2 ion channel protein are disclosed. The antibodies of the invention have anti-viral activity and may be useful as anti-viral therapeutics and/or prophylactic/vaccine agents for inhibiting influenza virus replication and for treating individuals infected with influenza.

  7. Fallos vacunales a vacunas conjugadas de Streptococcus pneumoniae y Haemophilus influenzae tipo b

    Directory of Open Access Journals (Sweden)

    Gonzalo Angulo

    2016-11-01

    Full Text Available Haemophilus influenzae type b and Streptococcus pneumoniae are the main cause agents of otitis, pneumonia, sepsis and meningitis, affecting mainly children under 5 years. Conjugate vaccines for encapsulated germs have dramatically decreased, the various diseases caused by these germs. Despite the decrease in morbidity and mortality, vaccine failures were observed. Children who experienced vaccine failures to Haemophilus influenzae type b had associated comorbidities more frequently than the general population (prematurity, HIV, Down syndrome, tumors, etc.. Nevertheless, most of these children have no medical history or immunological disorders. There is no consensus on whether all patients with vaccine failures should be assessed immunologically and how. There are recommendations to indicate a booster dose to patients with certain comorbidities and patients experiencing vaccine failure even in the absence of theses. Of the vaccine preparations available for Haemophilus influenzae type b association with acellular Bordetella pertussis proved to be less immunogenic and is currently being discouraged. Streptococcus pneumoniae serotypes 6B and 19F are less immunogenics and explain most of the vaccine failures in some series.

  8. Reacciones adversas a la vacuna contra influenza A (H1N1 en trabajadores de salud de una institución pública peruana

    Directory of Open Access Journals (Sweden)

    Pedro P. Álvarez-Falconí

    2011-07-01

    Full Text Available Introducción: En abril de 2009 se produjo un brote de influenza en la frontera de México y EE UU por el nuevo virus A(H1N1 2009. La pandemia no fue severa y la vacuna aplicada en diversos países produjo diversas reacciones adversas a medicamentos (RAM. Objetivos: Evaluar la posible relación entre las RAM notificadas espontáneamente y la vacunación en trabajadores de salud de un instituto. Así mismo, identificar tópicos afines a las RAM por dicha vacuna. Diseño: Estudio prospectivo y descriptivo basado en la notificación espontánea. Institución: Local central del Instituto Nacional de Salud en Lima. Participantes: Trabajadores de salud. Metodología: Las RAM notificadas espontáneamente fueron registradas en Hojas RAM. Se aplicó un algoritmo para buscar una relación causa-efecto. Principales medidas de resultados: Reacciones adversas a la vacuna influenza A(H1N1. Resultados: Hubo tres notificaciones espontáneas entre 148 trabajadores de salud vacunados (2% contra la influenza A(H1N1 2009. La relación causa-efecto fue ‘cierta’ para fiebre y fatiga y ‘posible’ para afecciones respiratorias en tres mujeres (faringitis aguda, catarro nasal agudo, bronquitis catarral. Conclusiones: Entre los pocos trabajadores de salud que presentaron RAM, las afecciones respiratorias con una relación considerada ‘posible’ podría interpretarse que las mujeres serían más sensibles para esa RAM comparadas con los varones. Las RAM fiebre y fatiga alcanzaron una relación considerada ‘cierta’. La menor cantidad de infectados en personas de tercera edad en el país y en otros podría explicarse por la presencia de ‘anticuerpos protectores’ en ellos.

  9. Impact of Haemophilus influenzae type b conjugate vaccine on bacterial meningitis in the Dominican Republic Impacto de la vacuna conjugada contra Haemophilus influenzae tipo b sobre la meningitis bacteriana en la República Dominicana

    Directory of Open Access Journals (Sweden)

    Ellen H. Lee

    2008-09-01

    Full Text Available OBJECTIVES: Widespread use of Haemophilus influenzae type b (Hib vaccines has dramatically reduced the burden of Hib disease throughout the Americas. Few studies have evaluated the impact of Hib vaccination on non-culture-confirmed disease. This study analyzed trends in probable bacterial meningitis before and after the introduction of Hib vaccine in the Dominican Republic and estimated vaccine effectiveness against Hib meningitis. METHODS: Meningitis cases among children OBJETIVOS: El uso generalizado de la vacuna contra Haemophilus influenzae tipo b (Hib ha permitido reducir radicalmente la carga de enfermedad por Hib en las Américas. Pocos estudios han evaluado el impacto de la vacunación contra Hib sobre los casos no confirmados mediante cultivo. En este estudio se analizaron las tendencias en el número de casos probables de meningitis bacteriana antes y después de la introducción de la vacuna contra Hib en la República Dominicana y se estimó la eficacia de la vacuna contra la meningitis. MÉTODOS: Se identificaron los casos de meningitis en niños menores de 5 años a partir de los registros de ingreso del principal hospital pediátrico de Santo Domingo entre 1998 y 2004. Los casos de meningitis con probable etiología bacteriana se clasificaron según criterios de laboratorio; los casos confirmados contaban con cultivo bacteriano positivo o detección de antígenos específicos en el líquido cefalorraquídeo. Se calcularon las tasas de incidencia acumulada de casos confirmados y probables de meningitis en los niños que vivían en el Distrito Nacional. Los casos confirmados de meningitis por Hib se incorporaron a un estudio de casos y controles -pareados según la edad y el barrio de residencia- para calcular la eficacia de la vacuna. RESULTADOS: Antes de la introducción de la vacuna, la tasa anual de meningitis de posible etiología bacteriana era de 49 casos por 100 000 niños menores de 5 años; de los casos confirmados de

  10. Efectividad de una vacuna antigripal en una población laboral colombiana Effectiveness of an influenza vaccine in a working population in Colombia

    Directory of Open Access Journals (Sweden)

    Stella Sofía Mesa Duque

    2001-10-01

    Full Text Available Objetivos. Determinar si una vacuna contra la influenza disminuye significativamente los episodios de infección respiratoria superior aguda (IRSA y la incapacidad laboral por esta causa, en trabajadores adultos sanos de una entidad bancaria en la ciudad de Medellín. Métodos. Se realizó un estudio aleatorizado con doble enmascaramiento y placebo en 493 voluntarios. Mediante asignación aleatoria se conformaron dos grupos, uno de estudio y otro de control, con 247 y 246 empleados, respectivamente. Se utilizaron por participante dosis de 0,5 mL de una vacuna contra la influenza que contiene antígenos de superficie de las cepas recomendadas por la OMS para el período 1996-1997 con los subtipos A/Wahan/359/95 (H3N2, A/Texas/36/91 (H1N1 y B/Beijing/184/93. Se consideró episodio de IRSA cuando algún participante refería dolor de garganta, fiebre y tos con más de 24 horas de duración. La evaluación se realizó quincenalmente durante seis meses; la gravedad de los episodios se estudió por el ausentismo laboral debido a IRSA, según la novena Clasificación Internacional de Enfermedades (CIE-9, mediante la evaluación mensual de las ausencias laborales por incapacidad certificada por la Seguridad Social en Salud, a lo largo de un año. Resultados. La descripción de los efectos colaterales asociados con la vacuna fueron el eritema (riesgo relativo (RR = 8,0; P = 0,02 y el edema local (RR = 4,5; P = 0,03. La incidencia acumulada anual de los episodios de IRSA fue 78,5% para los vacunados y 91,5% para el grupo placebo, con una reducción de 14%, observándose valores entre 7 y 20% (RR = 0,86; IC95%: 0,80-0,93. La incidencia acumulada anual de IRSA con discapacidad fue de 15,8% en el grupo de vacunados, con una reducción de 31% respecto al grupo placebo (22,8%, con valores entre 0 y 52% (RR = 0,69; IC95%: 0,48-1,0. Estos niveles de protección, tanto contra las formas menos sintomáticas de IRSA como contra las causantes de incapacidad laboral

  11. Impacto del neumococo y de los virus influenza en niños y adultos : su prevención con vacunas

    Directory of Open Access Journals (Sweden)

    María Hortal

    2015-07-01

    Full Text Available Durante siglos las enfermedades infecciosas han diezmado a poblaciones enteras, por lo que se ha procurado descubrir su causa y así lograr su prevención. Actualmente, la vacunación es una de las intervenciones en salud más costo-efectivas para reducir la morbilidad y mortalidad por enfermedades infecciosas. La historia así lo confirma con la erradicación de la viruela, y el control de la poliomielitis y del sarampión a nivel mundial. En Uruguay, el inicio de la vacunación obligatoria contra la viruela se remonta a 1911, en tanto que la vacunación contra la poliomielitis y el sarampión, se implementaron en 1957 y 1966 respectivamente. Dentro de las enfermedades inmunoprevenibles, las infecciones respiratorias agudas son notoriamente las más frecuentes. Su impacto urgió la necesidad de contar con medidas de control. La neumonía, aunque se observa en todas las edades, predomina en los extremos de la vida. En la infancia, en menores de cinco años, es una de las causas más frecuentes de hospitalización y en las poblaciones más desfavorecidas provoca elevada mortalidad. En los adultos con comorbilidades ocurre en todas las edades, pero es más frecuente en los mayores de 65 años, en los que patologías asociadas aumentan el riesgo vital, que es mayor cuanto mayor es la persona. Una vez controladas las neumonías por la vacuna conjugada de Haemophilus influenzae tipo b, el agente bacteriano de mayor frecuencia es Streptococcus pneumoniae y, entre los virus respiratorios, los brotes anuales y las pandemias por virus influenza contribuyen al aumento de hospitalizaciones y decesos por neumonía. Cuando ambos agentes se asocian en un paciente, sus efectos se potencian mutuamente y sus resultados pueden ser fatales. En consecuencia, la prevención de esas infecciones con las vacunas disponibles, neumocóccica y de influenza, es una prioridad de Salud Pública para asegurar la supervivencia infantil y disminuir costos sociales y económicos.

  12. Interacción del componente pertussis de células completas con los antígenos tetánico, Haemophilus influenzae tipo B y hepatitis B en ensayos de potencia para vacunas combinadas

    Directory of Open Access Journals (Sweden)

    Mario Landys

    2008-04-01

    Full Text Available Las vacunas combinadas permiten un grado de aceptación mayor entre la población, dado que se requiere de menos inmunizaciones para proteger contra las enfermedades infecciosas. Sin embargo, esto ha generado nuevos retos, ya que se han reportado numerosas interacciones entre los diferentes antígenos que conforman estas vacunas. El propósito del presente trabajo fue evaluar la interferencia potencial del componente pertussis de células completas sobre los ensayos para determinar la actividad biológica de otros antígenos como toxoide tetánico, Haemophilus influenzae tipo b (Hib y hepatitis B. Para ello se estudiaron mediante ensayos de potencia vacunas combinadas que contenían estos antígenos y se compararon con vacunas monovalentes. A su vez se prepararon adyuvaciones experimentales cuya composición permitió estimar adecuadamente la extensión y naturaleza de la interacción entre componentes. Se obtuvo que el componente pertussis incrementó significativamente la actividad biológica de Hib y tétanos, aunque esto puede depender mucho del modelo animal y el diseño experimental utilizado. En cuanto al antígeno de hepatitis B se demostró que pertussis inhibía la potencia de este antígeno, tanto in vitro como in vivo, aunque por mecanismos diferentes y de forma no significativa.

  13. Mielitis transversa relacionada con vacunación anti-influenza A(H1N1

    Directory of Open Access Journals (Sweden)

    María Florencia Arcondo

    2011-04-01

    Full Text Available La mielitis transversa es una enfermedad inflamatoria que se caracteriza por disfunción de la médula espinal. Las causas reconocidas de mielitis transversa son autoinmunes, enfermedades desmielinizantes, post infecciosas y post vacunales, aunque hasta el 50% de los casos son idiopáticas. Las vacunas contra la rubéola, paperas, rabia y gripe estacional han sido asociadas a diversos trastornos neurológicos, como el Síndrome de Guillain Barré, la encefalomielitis diseminada aguda (ADEM y la mielitis transversa. Como mecanismo preventivo luego de la pandemia de 2009, en febrero del año 2010 se inició en nuestro país la campaña de vacunación contra la Influenza A (H1N1. Se presenta el caso de una paciente con hipoestesias que aparecieron cuatro días después de haber recibido la vacuna monovalente anti-influenza A (H1N1 y progresaron con evidente nivel sensitivo. La paciente cumplía criterios diagnósticos de mielitis transversa, según el Transverse Myelitis Consortium Working Group. Tuvo remisión de las imágenes de la resonancia magnética y estabilidad clínica sin tratamiento con corticoides. Se discuten aspectos diagnósticos, pronósticos y terapéuticos de esta entidad clínica.

  14. Resultados al primer año de aplicada la vacuna recombinante cubana antiHVB en esquemas 012 y 016 meses

    Directory of Open Access Journals (Sweden)

    O. Juliao

    1993-09-01

    Full Text Available Los resultados obtenidos por el método inmunoenzimático cuantitativo de Abbott al primer año de completados los esquemas 012 y 016 meses, con la vacuna recombinante cubana contra la hepatitis viral B, muestran la inmunogenicidad en los vacunados con los dos esquemas, viéndose que el 100% tienen seroprotección y el 97% de estos tienen valores 100 Ul/l para ambos esquemas. En cuanto a los valores de las medias geométricas, observamos que no se evidencian disminuciones significativas con el esquema 012, pero sí con el esquema 016, por lo cual sugerimos el uso del esquema 012, debido a su corta latencia, simetría y estabilidad de los valores de anticuerpos anti-HBs.

  15. Mielitis transversa relacionada con vacunación anti-influenza A(H1N1 Transverse myelitis associated with anti-influenza A (H1N1 vaccination

    Directory of Open Access Journals (Sweden)

    María Florencia Arcondo

    2011-04-01

    Full Text Available La mielitis transversa es una enfermedad inflamatoria que se caracteriza por disfunción de la médula espinal. Las causas reconocidas de mielitis transversa son autoinmunes, enfermedades desmielinizantes, post infecciosas y post vacunales, aunque hasta el 50% de los casos son idiopáticas. Las vacunas contra la rubéola, paperas, rabia y gripe estacional han sido asociadas a diversos trastornos neurológicos, como el Síndrome de Guillain Barré, la encefalomielitis diseminada aguda (ADEM y la mielitis transversa. Como mecanismo preventivo luego de la pandemia de 2009, en febrero del año 2010 se inició en nuestro país la campaña de vacunación contra la Influenza A (H1N1. Se presenta el caso de una paciente con hipoestesias que aparecieron cuatro días después de haber recibido la vacuna monovalente anti-influenza A (H1N1 y progresaron con evidente nivel sensitivo. La paciente cumplía criterios diagnósticos de mielitis transversa, según el Transverse Myelitis Consortium Working Group. Tuvo remisión de las imágenes de la resonancia magnética y estabilidad clínica sin tratamiento con corticoides. Se discuten aspectos diagnósticos, pronósticos y terapéuticos de esta entidad clínica.Transverse myelitis is an inflammatory disorder characterized by spinal cord dysfunction. Infectious, autoimmune, postinfectious and postvaccination diseases are the most common recognized causes of transverse myelitis, but near 50% of the cases are finally assumed as idiopathic. Rubeolla, mumps, rabies and influenza vaccines were associated with many neurologic complications, such as Guillain Barré Syndrome, acute disseminated encephalomyelitis (ADEM and transverse myelitis. As a prevention measure after the 2009 pandemia, in February 2010 a National Campaigne of Vaccination against the Influenza A (H1N1 was started in our country. We report a case of a woman who received a monovalent Influenza A (H1N1 vaccine and four days after, began with sensory

  16. Anti-influenza activity of c60 fullerene derivatives.

    Science.gov (United States)

    Shoji, Masaki; Takahashi, Etsuhisa; Hatakeyama, Dai; Iwai, Yuma; Morita, Yuka; Shirayama, Riku; Echigo, Noriko; Kido, Hiroshi; Nakamura, Shigeo; Mashino, Tadahiko; Okutani, Takeshi; Kuzuhara, Takashi

    2013-01-01

    The H1N1 influenza A virus, which originated in swine, caused a global pandemic in 2009, and the highly pathogenic H5N1 avian influenza virus has also caused epidemics in Southeast Asia in recent years. Thus, the threat from influenza A remains a serious global health issue, and novel drugs that target these viruses are highly desirable. Influenza A RNA polymerase consists of the PA, PB1, and PB2 subunits, and the N-terminal domain of the PA subunit demonstrates endonuclease activity. Fullerene (C60) is a unique carbon molecule that forms a sphere. To identify potential new anti-influenza compounds, we screened 12 fullerene derivatives using an in vitro PA endonuclease inhibition assay. We identified 8 fullerene derivatives that inhibited the endonuclease activity of the PA N-terminal domain or full-length PA protein in vitro. We also performed in silico docking simulation analysis of the C60 fullerene and PA endonuclease, which suggested that fullerenes can bind to the active pocket of PA endonuclease. In a cell culture system, we found that several fullerene derivatives inhibit influenza A viral infection and the expression of influenza A nucleoprotein and nonstructural protein 1. These results indicate that fullerene derivatives are possible candidates for the development of novel anti-influenza drugs.

  17. Hepatitis B: Inmunogenicidad de la vacuna recombinante cubana anti-hbv en trabajadores de la salud vacunados sin seroprotección

    Directory of Open Access Journals (Sweden)

    Angela B. Hoyos

    1991-12-01

    Full Text Available Medimos anti-HBVs a 153 trabajadores de la salud del Hospital Infantil Universitario, "Lorencita Villegas de Santos" en Santafé de Bogotá, a quien se les había vacunado contra la Hepatitis B en los últimos 4 años. 124 habían recibido tres dosis (6 con refuerzo, 18 dos dosis y 11 una sola dosis; no tenían títulos el 25%. 33% Y 73% respectivamente. Estos trabajadores tenían promedios de edad de 40 años. Se vacunaron 32 de estos trabajadores sin títulos con 1 dosis de 20 mgms de la vacuna cubana recombinante y se cuantificaron títulos anti-HBVs antes y 15 días después de la vacunación con método inmuno-enzimático cuantitativo a ciegas; obteniéndose seroconversión en el 81% (> UI/L, seroprotección en el 75% (> 10 UI/L, y 56% de los individuos tuvieron valores superiores a 100 UI/L. Estos resultados son altamente significativos y dan una alternativa para un grupo de trabajadores de la salud que no ha logrado títulos protectores y plantea un posibilidad para las poblaciones con factores que los cataloguen como "malos respondedores".

  18. Vacina contra influenza: conhecimentos, atitudes e práticas de idosos em Teresina Vacuna contra gripe: conocimiento, actitudes y práctica de ancianos en Teresina Vaccine influenza: knowledge, attitudes and practices of elderly in Teresina

    Directory of Open Access Journals (Sweden)

    Telma Maria Evangelista de Araújo

    2007-08-01

    Full Text Available Este estudo objetiva levantar os conhecimentos, atitudes e práticas dos idosos de uma área do Programa de Saúde da Família (PSF sobre a vacina contra influenza e identificar os motivos que levaram alguns a não se vacinarem. Consiste em um inquérito domiciliar, em uma área do PSF de Teresina, com 74 idosos a partir de 60 anos. Os resultados evidenciaram que não obstante 85,3% tenham conhecimento inadequado sobre a vacina, 89,1% são favoráveis. Os motivos mais freqüentes para a não vacinação foram doença e temor dos eventos adversos. Conclui-se que a atitude favorável a respeito da vacinação pode modificar a prática frente a ela, instaurando comportamento de autoproteção e maior adesão.Este estudio objetivo para levantar el conocimiento, práctico y actitudes envejecidos de un área del programa de la salud de Familia (PSF en la vacuna cuenta gripe e identificar las razones que habían tomado alguno para no ser vaccined. Consiste en una investigación domiciliaria, un área del PSF de Teresina, con 74 envejeció unos a partir de 60 años. El resultado había evidenciado que sin embargo 85.3% tienen conocimiento inadecuado en la vacuna, 89.1% es favorable. Las razones más frecuentes para la vacunación no habían sido enfermedad y miedo de los acontecimientos adversos. Se concluye que la actitud favorable con respecto a la vacunación puede modificar el frente práctico él, restaurando el comportamiento de la uno mismo-protección y de la mayor adherencia.This objective study to raise the knowledge, practical and attitudes of the aged ones of an area of the Program of Health of Família (PSF on the vaccine it counts influenza and to identify the reasons that had taken some not to be vaccined. It consists of a domiciliary inquiry, an area of the PSF of Teresina, with 74 aged ones from 60 years. The result had evidenced that even so 85.3% have inadequate knowledge on the vaccine, 89.1% is favorable. The reasons most frequent

  19. Inmunogenicidad y tolerancia de una vacuna contra influenza, en una población mexicana mayor de 55 años de edad Immunogenicity and safety of the influenza vaccine, in a population older than 55-years in Mexico

    Directory of Open Access Journals (Sweden)

    Octavio Ayala-Montiel

    2005-04-01

    Full Text Available OBJETIVO: Verificar la inmunogenicidad y tolerancia de una vacuna purificada, inactivada y fraccionada contra influenza, en adultos mexicanos derechohabientes de Petróleos Mexicanos (Pemex. MATERIAL Y MÉTODOS: Se incluyeron 90 adultos mayores de 55 años de edad, derechohabientes de los servicios médicos del Hospital Central Sur Pemex, durante los meses de noviembre y diciembre de 2000. Los criterios evaluados en relación con la inmunogenicidad incluyeron el porcentaje de sujetos protegidos, cuantificados por medio de anticuerpos antihemaglutininas superior o igual a 1:40, así como por el porcentaje de seroconversión determinado por el título inicial de anticuerpos multiplicado por un factor 4X. Los criterios secundarios fueron la frecuencia de reacciones adversas tanto locales como sistémicas. Se realizaron estudios de afinidad antígeno-anticuerpo para determinar la respuesta policlonal de anticuerpos y de anticuerpos de alta afinidad prevacunación y posvacunación. Se calcularon frecuencias y porcentajes. RESULTADOS: Se identificó una seroprotección en 95.6% de los sujetos a la cepa H1N1, de 98.9% a la cepa H3N2 y de 100% a la cepa B/ Yamanashi. En cuanto a los porcentajes de seroconversión, se identificó un incremento 4X de 74.4 para la cepa H1N1, de 88.9 para la cepa H3N2, y de 82.2 para la cepa B / Yamanashi. Un total de 18 individuos (20% presentaron reacciones locales, mientras que 17 (18.8% presentaron reacciones sistémicas a los cinco días posvacunación y nueve sujetos (10% a los 28 días. Las reacciones locales a los cinco días consistieron en dolor, en 10 individuos (11.1%; enrojecimiento, en ocho (8.8%, e induración, en seis (6.6%. Malestar general, cefalea y fiebre se presentaron a los cinco días en 10, 8.8, y 0% de individuos, respectivamente, y en 4.4, 6.6, y 0%, respectivamente, a los 28 días. CONCLUSIONES: Esta vacuna contra influenza demostró ser altamente inmunogénica en adultos mexicanos mayores de 55 a

  20. Influenza pandemic (H1N1 2009 activity during summer 2009: Effectiveness of the 2008-9 trivalent vaccine against pandemic influenza in Spain Actividad de la gripe pandémica (H1N1 2009 durante el verano de 2009: Efectividad de la vacuna trivalente 2008-9 frente a la gripe pandémica en España

    Directory of Open Access Journals (Sweden)

    Amparo Larrauri

    2011-02-01

    Full Text Available Introduction: The Spanish influenza surveillance system (SISS maintained its activity during the summer of 2009 to monitor the influenza pandemic. Objectives: To describe pandemic influenza activity from May to September 2009 and to estimate the effectiveness of the 2008-9 seasonal influenza vaccine against laboratory-confirmed pandemic (H1N1 2009 influenza. Methods: Data from the SISS were used to identify the trend of pandemic (H1N1 2009 influenza outside the influenza season. For the effectiveness study, we compared the vaccination status of notified cases [influenza-like illnesses (ILI laboratory confirmed as pandemic influenza] with that of the test-negative controls. Results: The first laboratory-confirmed case of the pandemic virus was notified in the system in week 20/2009. The ILI rate increased gradually in the study period, exceeding basic activity in week 38. The proportion of pandemic (H1N1 2009 influenza viruses detected by the system represented 14% in week 20/2009 and rapidly increased to 90% in week 34. The adjusted vaccine effectiveness of the 2008-9 seasonal vaccine against laboratory-confirmed pandemic influenza was 12% (-30; 41. Conclusions: The SISS became an essential tool for pandemic monitoring in Spain. The improved SISS will provide more accurate information on influenza activity in future seasonal or pandemic waves. Using surveillance data, we could not demonstrate the effectiveness of the seasonal 2008-9 vaccine against laboratory-confirmed pandemic influenza.Introducción: El Sistema de Vigilancia de Gripe en España (SVGE continuó y reforzó su actividad durante el verano de 2009 con el objetivo de vigilar la evolución de la pandemia en España. Objetivos: Describir la actividad de la gripe pandémica en España de mayo a septiembre de 2009 y estimar la efectividad de la vacuna antigripal estacional 2008-2009 frente a casos confirmados de gripe pandémica (H1N1 2009. Métodos: Se utilizaron datos del SVGE para

  1. Vigilancia de serotipos en infecciones invasivas por Haemophilus influenzae en la Argentina en la era de la vacuna conjugada contra el serotipo b durante el período 2005-2010

    Directory of Open Access Journals (Sweden)

    Adriana M. Efron

    Full Text Available La introducción de la vacuna contra Haemophilus influenzae tipo b en los programas de inmunización de muchos países produjo una reducción marcada en la incidencia de enfermedad invasiva causada por este serotipo y en su portación y un incremento de otros tipos capsulares y de aislamientos no capsulados. Se estudiaron 313 aislamientos de H. influenzae recuperados de sitio estéril, provenientes de pacientes pediátricos y adultos con enfermedad invasiva atendidos en 90 hospitales de la Red Nacional de Laboratorios para Meningitis e Infecciones Respiratorias Agudas Bacterianas durante el período 2005-2010. Las patologías más frecuentes fueron neumonía, 40,3 % (n = 126, meningitis, 30,0 % (n = 94 y bacteriemia, 26,5 % (n = 83. En los pacientes pediátricos (n = 279, la mayor frecuencia de aislamientos correspondió a menores de 2 años, 74,5 % (n = 208. Con respecto a la distribución de tipos, el 61,3 %, correspondió a H. influenzae no capsulados (n = 192; el 20,1 % al b (n = 63; 11,2 % al a (n = 35; 4,8 % al f y 2,6 % a otros. En meningitis predominaron H. influenzae capsulados mientras que en neumonía y bacteriemia resultaron dominantes los tipos no capsulados. Se determinó el biotipo en 306 aislamientos. Todos los aislamientos de tipo a correspondieron al biotipo II; el 66,7 % de los tipo b pertenecieron al biotipo I. Mediante las técnicas de aglutinación en lámina y PCR se estudiaron 220 aislamientos; la concordancia entre ambas fue de 0,982 (IC: 0,92-1,00. En el último año se encontró un aumento significativo del tipo b, lo cual indica la importancia de mantener la vigilancia clínica y laboratorial de la enfermedad invasiva por H. influenzae.

  2. Anti-influenza virus effect of aqueous extracts from dandelion

    Directory of Open Access Journals (Sweden)

    He Wen

    2011-12-01

    Full Text Available Abstract Background Human influenza is a seasonal disease associated with significant morbidity and mortality. Anti-flu Traditional Chinese Medicine (TCM has played a significant role in fighting the virus pandemic. In TCM, dandelion is a commonly used ingredient in many therapeutic remedies, either alone or in conjunction with other natural substances. Evidence suggests that dandelion is associated with a variety of pharmacological activities. In this study, we evaluated anti-influenza virus activity of an aqueous extract from dandelion, which was tested for in vitro antiviral activity against influenza virus type A, human A/PR/8/34 and WSN (H1N1. Results Results obstained using antiviral assays, minigenome assay and real-time reverse transcription-PCR analysis showed that 0.625-5 mg/ml of dandelion extracts inhibited infections in Madin-Darby canine kidney (MDCK cells or Human lung adenocarcinoma cell line (A549 of PR8 or WSN viruses, as well as inhibited polymerase activity and reduced virus nucleoprotein (NP RNA level. The plant extract did not exhibit any apparent negative effects on cell viability, metabolism or proliferation at the effective dose. This result is consistent with the added advantage of lacking any reported complications of the plant's utility in traditional medicine over several centuries. Conclusion The antiviral activity of dandelion extracts indicates that a component or components of these extracts possess anti-influenza virus properties. Mechanisms of reduction of viral growth in MDCK or A549 cells by dandelion involve inhibition on virus replication.

  3. Inhibition of MLC phosphorylation restricts replication of influenza virus--a mechanism of action for anti-influenza agents.

    Directory of Open Access Journals (Sweden)

    Mehran Haidari

    Full Text Available Influenza A viruses are a severe threat worldwide, causing large epidemics that kill thousands every year. Prevention of influenza infection is complicated by continuous viral antigenic changes. Newer anti-influenza agents include MEK/ERK and protein kinase C inhibitors; however, the downstream effectors of these pathways have not been determined. In this study, we identified a common mechanism for the inhibitory effects of a significant group of anti-influenza agents. Our studies showed that influenza infection activates a series of signaling pathways that converge to induce myosin light chain (MLC phosphorylation and remodeling of the actin cytoskeleton. Inhibiting MLC phosphorylation by blocking RhoA/Rho kinase, phospholipase C/protein kinase C, and HRas/Raf/MEK/ERK pathways with the use of genetic or chemical manipulation leads to the inhibition of influenza proliferation. In contrast, the induction of MLC phosphorylation enhances influenza proliferation, as does activation of the HRas/Raf/MEK/ERK signaling pathway. This effect is attenuated by inhibiting MLC phosphorylation. Additionally, in intracellular trafficking studies, we found that the nuclear export of influenza ribonucleoprotein depends on MLC phosphorylation. Our studies provide evidence that modulation of MLC phosphorylation is an underlying mechanism for the inhibitory effects of many anti-influenza compounds.

  4. VACUNAS E INFECCIONES RESPIRATORIAS

    OpenAIRE

    Villena, Rodolfo

    2017-01-01

    Las vacunas han demostrado ser una excelente estrategia para reducir la morbimortalidad en infecciones respiratorias, con un perfil de seguridad adecuado. Nuestro PNI incorpora varias de ellas con este objetivo, logrando resultados de alto impacto a nivel de salud pública. Para que esto prosiga se requiere de nuestro compromiso y conocimiento para estimular, difundir y obtener altas tasas de cobertura, de manera de lograr efectos de protección indirecta, conocidos como inmunidad comunitaria. ...

  5. Vacuna contra la malaria

    OpenAIRE

    Patarroyo, Manuel Elkin

    2017-01-01

    La malaria es una enfermedad parasitaria producida por la picadura de un mosquito; una afección que en el año 2015 registró 212 millones de casos y 429.000 muertes. Cada dos minutos, la malaria provocó la muerte de un niño menor de cinco años en todo el mundo. Diferentes científicos a lo largo de todo el mundo han hecho múltiples intentos para combatir esta enfermedad con una vacuna efectiva que pueda erradicarla de raíz.

  6. Anti-influenza activity of marchantins, macrocyclic bisbibenzyls contained in liverworts.

    Directory of Open Access Journals (Sweden)

    Yuma Iwai

    Full Text Available The H1N1 influenza A virus of swine-origin caused pandemics throughout the world in 2009 and the highly pathogenic H5N1 avian influenza virus has also caused epidemics in Southeast Asia in recent years. The threat of influenza A thus remains a serious global health issue and novel drugs that target these viruses are highly desirable. Influenza A possesses an endonuclease within its RNA polymerase which comprises PA, PB1 and PB2 subunits. To identify potential new anti-influenza compounds in our current study, we screened 33 different types of phytochemicals using a PA endonuclease inhibition assay in vitro and an anti-influenza A virus assay. The marchantins are macrocyclic bisbibenzyls found in liverworts, and plagiochin A and perrottetin F are marchantin-related phytochemicals. We found from our screen that marchantin A, B, E, plagiochin A and perrottetin F inhibit influenza PA endonuclease activity in vitro. These compounds have a 3,4-dihydroxyphenethyl group in common, indicating the importance of this moiety for the inhibition of PA endonuclease. Docking simulations of marchantin E with PA endonuclease suggest a putative "fitting and chelating model" as the mechanism underlying PA endonuclease inhibition. The docking amino acids are well conserved between influenza A and B. In a cultured cell system, marchantin E was further found to inhibit the growth of both H3N2 and H1N1 influenza A viruses, and marchantin A, E and perrotein F showed inhibitory properties towards the growth of influenza B. These marchantins also decreased the viral infectivity titer, with marchantin E showing the strongest activity in this assay. We additionally identified a chemical group that is conserved among different anti-influenza chemicals including marchantins, green tea catechins and dihydroxy phenethylphenylphthalimides. Our present results indicate that marchantins are candidate anti-influenza drugs and demonstrate the utility of the PA endonuclease assay in

  7. VACUNAS E INFECCIONES RESPIRATORIAS

    Directory of Open Access Journals (Sweden)

    Dr. Rodolfo Villena

    2017-01-01

    Full Text Available Las vacunas han demostrado ser una excelente estrategia para reducir la morbimortalidad en infecciones respiratorias, con un perfil de seguridad adecuado. Nuestro PNI incorpora varias de ellas con este objetivo, logrando resultados de alto impacto a nivel de salud pública. Para que esto prosiga se requiere de nuestro compromiso y conocimiento para estimular, difundir y obtener altas tasas de cobertura, de manera de lograr efectos de protección indirecta, conocidos como inmunidad comunitaria. Por otro lado, se debe mantener la vigilancia epidemiológica de los agentes inmunoprevenibles para conocer su oscilación temporal, serogrupos, sero y/o genotipos, de manera de establecer directrices adecuadas de edad y esquemas de vacunación para la población. Debemos avanzar en estos temas y realizar estudios de efectividad de las vacunas que hemos introducido, para conocer su aporte en la prevención de infecciones respiratorias, de manera de objetivar sus beneficios, conocer el impacto en poblaciones de riesgo y avanzar en la vacunación de embarazadas, para otorgar mejores estrategias de prevención a nuestra población.

  8. Estudio de inmunogenicidad para dos vacunas recombinantes contra hepatitis B

    OpenAIRE

    O. Juliao; González, A.; V. Ramírez; Rojas, M. C.; Boschell, J; L. S. Hernández; T. E. Camacho; Martínez, M.; Saad, C.; de la Hoz, F; González, M.; Avendaño,J; Silva, A. (Álvaro); J. Pabón; Giraldo, A.

    1991-01-01

    Este estudio compara la inmunogenicidad (seroconversión, seroprotección e Hiperrespuesta), producida por dos vacunas recombinantes contra la hepatitis B (Engerix-B de Bélgica y Cubana), en dos esquemas (012 y 016 meses), empleando los métodos de cuantificación para Anti-HBsAg (Abbott y Organón), los cuales fueron también comparados. En el estudio participaron 257 voluntarios,  divididos al azar en 4 grupos (dos vacunas, dos esquemas). Resultados: los dos métodos de Abbon y Organon, no present...

  9. Estudio de inmunogenicidad para dos vacunas recombinantes contra hepatitis B

    Directory of Open Access Journals (Sweden)

    O. Juliao

    1991-12-01

    Full Text Available Este estudio compara la inmunogenicidad (seroconversión, seroprotección e Hiperrespuesta, producida por dos vacunas recombinantes contra la hepatitis B (Engerix-B de Bélgica y Cubana, en dos esquemas (012 y 016 meses, empleando los métodos de cuantificación para Anti-HBsAg (Abbott y Organón, los cuales fueron también comparados. En el estudio participaron 257 voluntarios,  divididos al azar en 4 grupos (dos vacunas, dos esquemas. Resultados: los dos métodos de Abbon y Organon, no presentan diferencias estadísticas significativas. La vacuna cubana muestra una mayor respuesta inmunogénica para dos dosis de vacuna y para el esquema 012. No hay diferencia entre los esquemas 012 y 016 y en el esquema 016 no se ven diferencias estadísticamente significativas con la vacuna Engerix-B. En esta Última el esquema 016 muestra mejores resultados que el 012.

  10. Influenza A virus infection in zebrafish recapitulates mammalian infection and sensitivity to anti-influenza drug treatment

    Directory of Open Access Journals (Sweden)

    Kristin A. Gabor

    2014-11-01

    Full Text Available Seasonal influenza virus infections cause annual epidemics and sporadic pandemics. These present a global health concern, resulting in substantial morbidity, mortality and economic burdens. Prevention and treatment of influenza illness is difficult due to the high mutation rate of the virus, the emergence of new virus strains and increasing antiviral resistance. Animal models of influenza infection are crucial to our gaining a better understanding of the pathogenesis of and host response to influenza infection, and for screening antiviral compounds. However, the current animal models used for influenza research are not amenable to visualization of host-pathogen interactions or high-throughput drug screening. The zebrafish is widely recognized as a valuable model system for infectious disease research and therapeutic drug testing. Here, we describe a zebrafish model for human influenza A virus (IAV infection and show that zebrafish embryos are susceptible to challenge with both influenza A strains APR8 and X-31 (Aichi. Influenza-infected zebrafish show an increase in viral burden and mortality over time. The expression of innate antiviral genes, the gross pathology and the histopathology in infected zebrafish recapitulate clinical symptoms of influenza infections in humans. This is the first time that zebrafish embryos have been infected with a fluorescent IAV in order to visualize infection in a live vertebrate host, revealing a pattern of vascular endothelial infection. Treatment of infected zebrafish with a known anti-influenza compound, Zanamivir, reduced mortality and the expression of a fluorescent viral gene product, demonstrating the validity of this model to screen for potential antiviral drugs. The zebrafish model system has provided invaluable insights into host-pathogen interactions for a range of infectious diseases. Here, we demonstrate a novel use of this species for IAV research. This model has great potential to advance our

  11. [Prophylactic use of anti-influenza and anti-pneumococcal vaccines in industrial workers].

    Science.gov (United States)

    Spiridonov, V L; Akopian, K A

    2014-01-01

    Efficiency of vaccination against respiratory tract infections was proved by long worldwide experience. The article covers analysis of vaccination results in 26,852 workers of major industrial enterprises of RUSAL company in 12 cities of Russia, using anti-influenza vaccine Vaxigrip, and combined vaccination in 466 workers with anti-influenza vaccine Vaxigrip and anti-pneumococcal vaccine Pneumo 23. Reference group of non-vaccinated workers randomly included 7,520 workers of the same enterprises and comparable in age and length of service. Efficiency of vaccination was assessed in a year through analysis of transitory disablement morbidity due to respiratory tract infections and clinical data. Vaccinated with Vaxigrip and Pneumo 23, the workers with chronic bronchitis demonstrated inconstant cough in statistically significantly more rare occasions in comparison with non-vaccinated workers (24,75% vs. 75,25% in vaccinated and non-vaccinated groups respectively, p < 0,05). In the group vaccinated with Vaxigrip, the transitory disablement morbidity equalled 42,06 per 1000 workers. In the group vaccinated with Vaxigrip and Pneumo 23, the transitory disablement morbidity equalled 46,07 per 1000 workers. In the group of non-vaccinated workers, the morbidity equalled 158,6 per 1,000 workers.

  12. Vacunas de bacterias recombinantes vivas

    OpenAIRE

    Blanco León, Marina

    2016-01-01

    La vacunación es uno de los logros más importantes en la historia de la medicina, que ha ido evolucionando a lo largo de los años permitiendo una reducción significativa de la mortalidad infantil, una disminución de la incidencia de enfermedades e incluso la erradicación de algunas de ellas en países enteros. Las vacunas de nueva generación surgen para reducir o eliminar las carencias de las vacunas “tradicionales”. Técnicas biotecnológicas basadas en el ADN recombinante han dado lugar, entre...

  13. Targeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy.

    Science.gov (United States)

    Perwitasari, Olivia; Yan, Xiuzhen; Johnson, Scott; White, Caleb; Brooks, Paula; Tompkins, S Mark; Tripp, Ralph A

    2013-01-01

    Influenza A virus infection is a major global health concern causing significant mortality, morbidity, and economic loss. Antiviral chemotherapeutics that target influenza A virus are available; however, rapid emergence of drug-resistant strains has been reported. Consequently, there is a burgeoning need to identify novel anti-influenza A drugs, particularly those that target host gene products required for virus replication, to reduce the likelihood of drug resistance. In this study, a small interfering RNA (siRNA) screen was performed to identify host druggable gene targets for anti-influenza A virus therapy. The host organic anion transporter-3 gene (OAT3), a member of the SLC22 family of transporters, was validated as being required to support influenza A virus replication. Probenecid, a prototypical uricosuric agent and chemical inhibitor of organic anion transporters known to target OAT3, was shown to be effective in limiting influenza A virus infection in vitro (50% inhibitory concentration [IC(50)] of 5.0 × 10(-5) to 5.0 × 10(-4) μM; P Probenecid is widely used for treatment of gout and related hyperuricemic disorders, has been extensively studied for pharmacokinetics and safety, and represents an excellent candidate for drug repositioning as a novel anti-influenza A chemotherapeutic.

  14. Screen Anti-influenza Lead Compounds That Target the PAC Subunit of H5N1 Viral RNA Polymerase

    Science.gov (United States)

    Xiang, Junfeng; Li, Qian; Liang, Huanhuan; Tang, Yalin; Liu, Yingfang

    2012-01-01

    The avian influenza (H5N1) viral RNA polymerase protein PAC was used as a target to screen nine chlorogenic acid derivatives for their polymerase inhibitor activity. Among them, seven compounds were PAC ligands, and four inhibited influenza RNA polymerase activity. These results aid in the design of anti-influenza agents based on caffeoylquinic acid. PMID:22936968

  15. Caffeoylquinic Acids Are Major Constituents with Potent Anti-Influenza Effects in Brazilian Green Propolis Water Extract

    Directory of Open Access Journals (Sweden)

    Tomohiko Urushisaki

    2011-01-01

    Full Text Available Influenza A viral infections reached pandemic levels in 1918, 1957, 1968, and, most recently, in 2009 with the emergence of the swine-origin H1N1 influenza virus. The development of novel therapeutics or prophylactics for influenza virus infection is urgently needed. We examined the evaluation of the anti-influenza virus (A/WSN/33 (H1N1 activity of Brazilian green propolis water extract (PWE and its constituents by cell viability and real-time PCR assays. Our findings showed strong evidence that PWE has an anti-influenza effect and demonstrate that caffeoylquinic acids are the active anti-influenza components of PWE. Furthermore, we have found that the amount of viral RNA per cell remained unchanged even in the presence of PWE, suggesting that PWE has no direct impact on the influenza virus but may have a cytoprotective activity by affecting internal cellular process. These findings indicate that caffeoylquinic acids are the active anti-influenza components of PWE. Above findings might facilitate the prophylactic application of natural products and the realization of novel anti-influenza drugs based on caffeoylquinic acids, as well as further the understanding of cytoprotective intracellular mechanisms in influenza virus-infected cells.

  16. Anti-influenza Virus Effects of Catechins: A Molecular and Clinical Review.

    Science.gov (United States)

    Ide, Kazuke; Kawasaki, Yohei; Kawakami, Koji; Yamada, Hiroshi

    2016-01-01

    Influenza infection and associated epidemics represent a serious public health problem. Several preventive and curative measures exist against its spread including vaccination and therapeutic agents such as neuraminidase inhibitors (e.g., oseltamivir, zanamivir, as well as peramivir and laninamivir, which are licensed in several countries) and adamantanes (e.g., amantadine and rimantadine). However, neuraminidase inhibitor- and adamantane- resistant viruses have been detected, whereas vaccines exhibit strain-specific effects and are limited in supply. Thus, new approaches are needed to prevent and treat influenza infections. Catechins, a class of polyphenolic flavonoids present in tea leaves, have been reported as potential anti-influenza virus agents based on experimental and clinical studies. (-)-epigallocatechin gallate (EGCG), a major and highly bioactive catechin, is known to inhibit influenza A and B virus infections in Madin-Darby canine kidney cells. Additionally, EGCG and other catechin compounds such as epicatechin gallate and catechin-5-gallate also show neuraminidase inhibitory activities as demonstrated via molecular docking. These catechins can bind differently to neuraminidase and might overcome known drug resistancerelated virus mutations. Furthermore, the antiviral effects of chemically modified catechin derivatives have also been investigated, and future structure-based drug design studies of catechin derivatives might contribute to improvements in influenza prevention and treatment. This review briefly summarizes probable mechanisms underlying the inhibitory effects of tea catechins against influenza infection and their clinical benefits on influenza prevention and treatment. Additionally, the great potential of tea catechins and their chemical derivatives as effective antiviral agents is described.

  17. Pyrazole compound BPR1P0034 with potent and selective anti-influenza virus activity

    Directory of Open Access Journals (Sweden)

    Yeh Jiann-Yih

    2010-02-01

    Full Text Available Abstract Background Influenza viruses are a major cause of morbidity and mortality around the world. More recently, a swine-origin influenza A (H1N1 virus that is spreading via human-to-human transmission has become a serious public concern. Although vaccination is the primary strategy for preventing infections, influenza antiviral drugs play an important role in a comprehensive approach to controlling illness and transmission. In addition, a search for influenza-inhibiting drugs is particularly important in the face of high rate of emergence of influenza strains resistant to several existing influenza antivirals. Methods We searched for novel anti-influenza inhibitors using a cell-based neutralization (inhibition of virus-induced cytopathic effect assay. After screening 20,800 randomly selected compounds from a library from ChemDiv, Inc., we found that BPR1P0034 has sub-micromolar antiviral activity. The compound was resynthesized in five steps by conventional chemical techniques. Lead optimization and a structure-activity analysis were used to improve potency. Time-of-addition assay was performed to target an event in the virus life cycle. Results The 50% effective inhibitory concentration (IC50 of BPR1P0034 was 0.42 ± 0.11 μM, when measured with a plaque reduction assay. Viral protein and RNA synthesis of A/WSN/33 (H1N1 was inhibited by BPR1P0034 and the virus-induced cytopathic effects were thus significantly reduced. BPR1P0034 exhibited broad inhibition spectrum for influenza viruses but showed no antiviral effect for enteroviruses and echovirus 9. In a time-of-addition assay, in which the compound was added at different stages along the viral replication cycle (such as at adsorption or after adsorption, its antiviral activity was more efficient in cells treated with the test compound between 0 and 2 h, right after viral infection, implying that an early step of viral replication might be the target of the compound. These results suggest

  18. Hablemos de la Influenza

    Centers for Disease Control (CDC) Podcasts

    2010-12-08

    En la charla, un médico responde a las preguntas frecuentes sobre la vacuna contra la influenza (gripe).  Created: 12/8/2010 by Centro Nacional para la Inmunización y Enfermedades Respiratorias (NCIRD).   Date Released: 12/8/2010.

  19. Assessment of Anti-Influenza Activity and Hemagglutination Inhibition of Plumbago indica and Allium sativum Extracts.

    Science.gov (United States)

    Chavan, Rahul Dilip; Shinde, Pramod; Girkar, Kaustubh; Madage, Rajendra; Chowdhary, Abhay

    2016-01-01

    Human influenza is a seasonal disease associated with significant morbidity and mortality. Anti-flu ayurvedic/herbal medicines have played a significant role in fighting the virus pandemic. Plumbagin and allicin are commonly used ingredients in many therapeutic remedies, either alone or in conjunction with other natural substances. Evidence suggests that these extracts are associated with a variety of pharmacological activities. To evaluate anti-influenza activity from Plumbago indica and Allium sativum extract against Influenza A (H1N1)pdm09. Different extraction procedures were used to isolate the active ingredient in the solvent system, and quantitative HPLTC confirms the presence of plumbagin and allicin. The cytotoxicity was carried out on Madin-Darby Canine kidney cells, and the 50% cytotoxic concentration (CC50) values were below 20 mg/mL for both plant extracts. To assess the anti-influenza activity, two assays were employed, simultaneous and posttreatment assay. A. sativum methanolic and ethanolic extracts showed only 14% reduction in hemagglutination in contrast to P. indica which exhibited 100% reduction in both simultaneous and posttreatment assay at concentrations of 10 mg/mL, 5 mg/mL, and 1 mg/mL. Our results suggest that P. indica extracts are good candidates for anti-influenza therapy and should be used in medical treatment after further research. The search for natural antiviral compounds from plants is a promising approach in the development of new therapeutic agents. In the past century, several scientific efforts have been directed toward identifying phytochemicals capable of inhibiting virus. Knowledge of ethnopharmacology can lead to new bioactive plant compounds suitable for drug discovery and development. Macromolecular docking studies provides most detailed possible view of drug-receptor interaction where the structure of drug is designed based on its fit to three dimensional structures of receptor site rather than by analogy to other

  20. Fibroblast activation protein is dispensable in the anti-influenza immune response in mice.

    Directory of Open Access Journals (Sweden)

    Sioh-Yang Tan

    Full Text Available Fibroblast activation protein alpha (FAP is a unique dual peptidase of the S9B serine protease family, being capable of both dipeptidyl peptidase and endopeptidase activities. FAP is expressed at low level in healthy adult organs including the pancreas, cervix, uterus, submaxillary gland and the skin, and highly upregulated in embryogenesis, chronic inflammation and tissue remodelling. It is also expressed by cancer-associated stromal fibroblasts in more than 90% of epithelial tumours. FAP has enzymatic and non-enzymatic functions in the growth, immunosuppression, invasion and cell signalling of tumour cells. FAP deficient mice are fertile and viable with no gross abnormality, but little data exist on the role of FAP in the immune system. FAP is upregulated in association with microbial stimulation and chronic inflammation, but its function in infection remains unknown. We showed that major populations of immune cells including CD4+ and CD8+ T cells, B cells, dendritic cells and neutrophils are generated and maintained normally in FAP knockout mice. Upon intranasal challenge with influenza virus, FAP mRNA was increased in the lungs and lung-draining lymph nodes. Nonetheless, FAP deficient mice showed similar pathologic kinetics to wildtype controls, and were capable of supporting normal anti-influenza T and B cell responses. There was no evidence of compensatory upregulation of other DPP4 family members in influenza-infected FAP-deficient mice. FAP appears to be dispensable in anti-influenza adaptive immunity.

  1. Relación costo-efectividad de la vacuna contra Haemophilus influenzae tipo b en niños menores de dos años de edad en Colombia The cost-effectiveness of Haemophilus influenzae type b vaccine for children under 2 years of age in Colombia

    Directory of Open Access Journals (Sweden)

    Nelson Alvis Guzmán

    2006-10-01

    Full Text Available OBJETIVOS: Las vacunas conjugadas contra Haemophilus influenzae tipo b (Hib son la herramienta más importante para prevenir la mayoría de las enfermedades invasoras producidas por dicho patógeno, pero debido a su costo, aún no se han introducido mundialmente de manera masiva. En el presente estudio se determinó la relación costo-efectividad de una vacuna contra Hib para prevenir la neumonía y la meningitis bacterianas en niños menores de 2 años en Colombia. MÉTODOS: Se estimaron los costos directos e indirectos de la neumonía y la meningitis hospitalaria y siguiendo las recomendaciones de la Organización Mundial de la Salud (OMS, la relación costo-efectividad de los programas de vacunación contra Hib. Se estimaron también las razones de costos por caso evitado de enfermedad invasora por Hib y el costo por año de vida salvado en dos situaciones hipotéticas: con vacunación contra Hib (cobertura vacunal: 90% y sin vacunación. RESULTADOS: El costo medio del tratamiento hospitalario de un caso de neumonía fue de 611,5 dólares estadounidenses (US$ (intervalo de confianza del 95% [IC95%]: 532,2 - 690,8, el costo medio del tratamiento hospitalario de un caso de meningitis fue de US$ 848,9 (IC95%: 716,8 - 981,0 y el costo por caso evitado de enfermedad invasora por Hib, de US$ 316,7 (IC95%: 294,2 - 339,2. La relación costo-efectividad en la hipótesis con vacunación fue de 2,38, frente a 3,81 en la hipótesis sin vacunación. CONCLUSIÓN: La aplicación de un programa adecuado de vacunación contra Hib en Colombia puede prevenir cerca de 25 000 casos de enfermedad invasora por año, lo que representa un ahorro de por lo menos US$ 15 millones anuales. Además, puede evitar cerca de 700 defunciones y salvar anualmente 44 054 años de vida.OBJECTIVE: Conjugate vaccines are the best public health tools available for preventing most invasive diseases caused by Haemophilus influenzae type b (Hib, but the high cost of the vaccines has so

  2. Direct Optical Detection of Viral Nucleoprotein Binding to an Anti-Influenza Aptamer

    OpenAIRE

    Negri, Pierre; Chen, Guojun; Kage, Andreas; Nitsche, Andreas; Naumann, Dieter; Xu, Bingqian; Dluhy, Richard A.

    2012-01-01

    We have demonstrated label-free optical detection of viral nucleoprotein binding to a polyvalent anti-influenza aptamer by monitoring the surface-enhanced Raman (SERS) spectra of the aptamer-nucleoprotein complex. The SERS spectra demonstrated that selective binding of the aptamer-nucleoprotein complex could be differentiated from that of the aptamer alone based solely on the direct spectral signature for the aptamer-nucleoprotein complex. Multivariate statistical methods, including principal...

  3. H3N2 influenza infection elicits more cross-reactive and less clonally expanded anti-hemagglutinin antibodies than influenza vaccination.

    Directory of Open Access Journals (Sweden)

    M Anthony Moody

    Full Text Available BACKGROUND: During the recent H1N1 influenza pandemic, excess morbidity and mortality was seen in young but not older adults suggesting that prior infection with influenza strains may have protected older subjects. In contrast, a history of recent seasonal trivalent vaccine in younger adults was not associated with protection. METHODS AND FINDINGS: To study hemagglutinin (HA antibody responses in influenza immunization and infection, we have studied the day 7 plasma cell repertoires of subjects immunized with seasonal trivalent inactivated influenza vaccine (TIV and compared them to the plasma cell repertoires of subjects experimentally infected (EI with influenza H3N2 A/Wisconsin/67/2005. The majority of circulating plasma cells after TIV produced influenza-specific antibodies, while most plasma cells after EI produced antibodies that did not react with influenza HA. While anti-HA antibodies from TIV subjects were primarily reactive with single or few HA strains, anti-HA antibodies from EI subjects were isolated that reacted with multiple HA strains. Plasma cell-derived anti-HA antibodies from TIV subjects showed more evidence of clonal expansion compared with antibodies from EI subjects. From an H3N2-infected subject, we isolated a 4-member clonal lineage of broadly cross-reactive antibodies that bound to multiple HA subtypes and neutralized both H1N1 and H3N2 viruses. This broad reactivity was not detected in post-infection plasma suggesting this broadly reactive clonal lineage was not immunodominant in this subject. CONCLUSION: The presence of broadly reactive subdominant antibody responses in some EI subjects suggests that improved vaccine designs that make broadly reactive antibody responses immunodominant could protect against novel influenza strains.

  4. H3N2 Influenza Infection Elicits More Cross-Reactive and Less Clonally Expanded Anti-Hemagglutinin Antibodies Than Influenza Vaccination

    Science.gov (United States)

    Walter, Emmanuel B.; Woods, Christopher W.; Ginsburg, Geoffrey S.; McClain, Micah T.; Denny, Thomas N.; Chen, Xi; Munshaw, Supriya; Marshall, Dawn J.; Whitesides, John F.; Drinker, Mark S.; Amos, Joshua D.; Gurley, Thaddeus C.; Eudailey, Joshua A.; Foulger, Andrew; DeRosa, Katherine R.; Parks, Robert; Meyerhoff, R. Ryan; Yu, Jae-Sung; Kozink, Daniel M.; Barefoot, Brice E.; Ramsburg, Elizabeth A.; Khurana, Surender; Golding, Hana; Vandergrift, Nathan A.; Alam, S. Munir; Tomaras, Georgia D.; Kepler, Thomas B.; Kelsoe, Garnett; Liao, Hua-Xin; Haynes, Barton F.

    2011-01-01

    Background During the recent H1N1 influenza pandemic, excess morbidity and mortality was seen in young but not older adults suggesting that prior infection with influenza strains may have protected older subjects. In contrast, a history of recent seasonal trivalent vaccine in younger adults was not associated with protection. Methods and Findings To study hemagglutinin (HA) antibody responses in influenza immunization and infection, we have studied the day 7 plasma cell repertoires of subjects immunized with seasonal trivalent inactivated influenza vaccine (TIV) and compared them to the plasma cell repertoires of subjects experimentally infected (EI) with influenza H3N2 A/Wisconsin/67/2005. The majority of circulating plasma cells after TIV produced influenza-specific antibodies, while most plasma cells after EI produced antibodies that did not react with influenza HA. While anti-HA antibodies from TIV subjects were primarily reactive with single or few HA strains, anti-HA antibodies from EI subjects were isolated that reacted with multiple HA strains. Plasma cell-derived anti-HA antibodies from TIV subjects showed more evidence of clonal expansion compared with antibodies from EI subjects. From an H3N2-infected subject, we isolated a 4-member clonal lineage of broadly cross-reactive antibodies that bound to multiple HA subtypes and neutralized both H1N1 and H3N2 viruses. This broad reactivity was not detected in post-infection plasma suggesting this broadly reactive clonal lineage was not immunodominant in this subject. Conclusion The presence of broadly reactive subdominant antibody responses in some EI subjects suggests that improved vaccine designs that make broadly reactive antibody responses immunodominant could protect against novel influenza strains. PMID:22039424

  5. Vacuna contra el VPH (HPV Vaccine)

    Centers for Disease Control (CDC) Podcasts

    2013-07-25

    Desde el 2006, hay una vacuna que protege contra los tipos de VPH que causan cáncer con mayor frecuencia. Este podcast habla sobre la importancia de que los padres hablen con los proveedores de atención médica de sus hijos sobre ponerles la vacuna contra el VPH.  Created: 7/25/2013 by MMWR.   Date Released: 11/4/2013.

  6. Administración de vacunas y casos de muerte súbita del lactante en el Perú, 2001: ¿asociación o coincidencia temporal?

    Directory of Open Access Journals (Sweden)

    Javier Vargas H

    Full Text Available Objetivos: Describir las características clínicas, socioeconómicas, y patológicas de nueve casos de lactantes que fallecieron horas después de administrárseles vacunas antipolio y DPT junto con anti Haemophilus influenzae b o asociada con antihepatitis B o BCG. Materiales y métodos: Revisión de la historia clínica, entrevista con el equipo de salud a cargo de la vacunación y con los padres del lactante fallecido. Revisión de los informes del protocolo de autopsia e informes de anatomía patológica y entrevista con los médicos legistas y patólogos. Evaluación de control de calidad de las vacunas administradas. Realización de exámenes de inmunohistoquímica de tejidos pulmonares para el diagnóstico de virus. Resultados: Entre agosto y diciembre de 2001 se notificaron en el Perú, nueve casos de fallecimiento de lactantes entre ocho horas y tres días después de la aplicación de vacunas DPT y antipolio. Después de la vacunación, los síntomas iniciaron entre 30 minutos a tres horas y la muerte se produjo entre ocho a 78 horas. Los síntomas más frecuentes fueron irritabilidad 8/9, llanto persistente 6/9, somnolencia 5/9, sangrado por nariz y boca 5/9. Todos los casos procedieron de familias pobres o muy pobres. El control de calidad se corroboró que las vacunas cumplieron con los estándares establecidos por la OMS. Las causas de la muerte reportadas en las necropsias fueron neumonía en dos casos y edema pulmonar en cinco casos, los informes de anatomía patológica mostraron una neumonitis intersticial y meningitis linfocitaria. No se observaron efectos citopáticos virales en los tejidos pulmonares y los estudios toxicológicos fueron negativos. Conclusiones: No existe evidencia de una asociación causal entre los eventos fatales y la administración de las vacunas.

  7. Characterization of the Anti-Influenza Activity of the Chinese Herbal Plant Paeonia lactiflora

    Directory of Open Access Journals (Sweden)

    Jin-Yuan Ho

    2014-04-01

    Full Text Available Bai Shao (BS, the root of Paeonia lactiflora Pall., a common Chinese herb in many recipes used to treat viral infection and liver diseases, is recognized for its ability to nourish menstruation, its Yin convergence, and as an antiperspirant. However, the mechanism and components for its antiviral function remain to be elucidated. In this study, an ethanolic extract of BS was further partitioned into aqueous and organic parts (EAex for in vitro functional study and in vivo efficacy testing. EAex exhibited an IC50 of 0.016 ± 0.005 mg/mL against influenza virus A/WSN/33 (H1N1, with broad-spectrum inhibitory activity against different strains of human influenza A viruses, including clinical oseltamivir-resistant isolates and an H1N1pdm strain. The synthesis of both viral RNA and protein was profoundly inhibited when the cells were treated with EAex. A time-of-addition assay demonstrated that EAex exerted its antiviral activity at various stages of the virus replication cycle. We addressed its antiviral activity at virus entry and demonstrated that EAex inhibits viral hemagglutination and viral binding to and penetration into host cells. In vivo animal testing showed that 200 mg/kg/d of EAex offered significant protection against viral infection. We conclude that BS possesses antiviral activity and has the potential for development as an anti-influenza agent.

  8. A dual vaccine against influenza & Alzheimer's disease failed to enhance anti-β-amyloid antibody responses in mice with pre-existing virus specific memory.

    Science.gov (United States)

    Davtyan, Hayk; Ghochikyan, Anahit; Hovakimyan, Armine; Davtyan, Arpine; Cadagan, Richard; Marleau, Annette M; Albrecht, Randy A; García-Sastre, Adolfo; Agadjanyan, Michael G

    2014-12-15

    Novel dual vaccine, WSN-Aβ(1-10), based on the recombinant influenza virus, expressing immunodominant B-cell epitope of β-amyloid, simultaneously induced therapeutically potent anti-Aβ and anti-influenza antibodies. In this study we showed that boosting of WSN-WT primed mice with WSN-Aβ(1-10) enhances anti-viral, but fails to induce anti-Aβ antibody responses. This inhibition is associated with expression of Aβ(1-10) within the context of an inactivated influenza virus vaccine. These results demonstrate that the use of an inactivated influenza virus as a carrier for AD vaccine may not be applicable due to the possible inhibition of anti-Aβ antibody response in individuals previously vaccinated or infected with influenza. Copyright © 2014 Elsevier B.V. All rights reserved.

  9. Ethanolic Extract of Melia Fructus Has Anti-influenza A Virus Activity by Affecting Viral Entry and Viral RNA Polymerase.

    Science.gov (United States)

    Jin, Young-Hee; Choi, Jang-Gi; Cho, Won-Kyung; Ma, Jin Yeul

    2017-01-01

    Meliae Fructus (MF) is the dried ripe fruit of Melia toosendan Siebold et Zuccarini, Meliaceae family. MF is widely used in traditional medicine to treat inflammation and helminthic infection and has anti-bacterial, anti-oxidant, anti-cancer, anti-inflammatory, and analgesic activities. However, potential anti-influenza properties of MF have yet to be investigated. We determined whether an ethanolic extract of MF (EMF) has anti-viral activity via an EMF pre-, co-, and post-treatment assay, using the Influenza A/PR/8/34 and H3N2 virus on Madin-Darby canine kidney (MDCK) cells. The EMF had anti-influenza virus activity in pre- and co-treated cells in a dose-dependent manner, but not in post-treated cell. EMF inhibited the activity of hemagglutinin (HA) and neuraminidase (NA) of influenza virus. EMF inhibited viral HA, nucleoprotein (NP), matrix protein 2 (M2), non-structural protein 1 (NS1), polymerase acidic protein (PA), polymerase basic protein 1 (PB1), and polymerase basic protein 2 (PB2) mRNA synthesis at 5 h post infection (hpi), however, the levels of PA, PB1, and PB2 mRNA were increased in pre- and co-EMF treated cells compared with control virus-infected and EMF post-treated cells at 18 hpi. The level of M2 protein expression was also decreased upon pre- and co-treatment with EMF. The PA protein was accumulated and localized in not only the nucleus but also the cytoplasm of virus-infected MDCK cells at 18 hpi. Pre-EMF treatment inhibited the expression of pAKT, which is induced by influenza virus infection, at the stage of virus entry. We also found that treatment of EMF up-regulated the antiviral protein Mx1, which may play a partial role in inhibiting influenza virus infection in pre- and co-EMF treated MDCK cells. In summary, these results strongly suggested that an ethanolic extract of Meliae Fructus inhibited influenza A virus infection by affecting viral entry, PA proteins of the RNA polymerase complex, and Mx1 induction and may be a potential and

  10. Ethanolic Extract of Melia Fructus Has Anti-influenza A Virus Activity by Affecting Viral Entry and Viral RNA Polymerase

    Science.gov (United States)

    Jin, Young-Hee; Choi, Jang-Gi; Cho, Won-Kyung; Ma, Jin Yeul

    2017-01-01

    Meliae Fructus (MF) is the dried ripe fruit of Melia toosendan Siebold et Zuccarini, Meliaceae family. MF is widely used in traditional medicine to treat inflammation and helminthic infection and has anti-bacterial, anti-oxidant, anti-cancer, anti-inflammatory, and analgesic activities. However, potential anti-influenza properties of MF have yet to be investigated. We determined whether an ethanolic extract of MF (EMF) has anti-viral activity via an EMF pre-, co-, and post-treatment assay, using the Influenza A/PR/8/34 and H3N2 virus on Madin-Darby canine kidney (MDCK) cells. The EMF had anti-influenza virus activity in pre- and co-treated cells in a dose-dependent manner, but not in post-treated cell. EMF inhibited the activity of hemagglutinin (HA) and neuraminidase (NA) of influenza virus. EMF inhibited viral HA, nucleoprotein (NP), matrix protein 2 (M2), non-structural protein 1 (NS1), polymerase acidic protein (PA), polymerase basic protein 1 (PB1), and polymerase basic protein 2 (PB2) mRNA synthesis at 5 h post infection (hpi), however, the levels of PA, PB1, and PB2 mRNA were increased in pre- and co-EMF treated cells compared with control virus-infected and EMF post-treated cells at 18 hpi. The level of M2 protein expression was also decreased upon pre- and co-treatment with EMF. The PA protein was accumulated and localized in not only the nucleus but also the cytoplasm of virus-infected MDCK cells at 18 hpi. Pre-EMF treatment inhibited the expression of pAKT, which is induced by influenza virus infection, at the stage of virus entry. We also found that treatment of EMF up-regulated the antiviral protein Mx1, which may play a partial role in inhibiting influenza virus infection in pre- and co-EMF treated MDCK cells. In summary, these results strongly suggested that an ethanolic extract of Meliae Fructus inhibited influenza A virus infection by affecting viral entry, PA proteins of the RNA polymerase complex, and Mx1 induction and may be a potential and

  11. Asparagine endopeptidase controls anti-influenza virus immune responses through TLR7 activation.

    Directory of Open Access Journals (Sweden)

    Sophia Maschalidi

    Full Text Available Intracellular Toll-like receptors (TLRs expressed by dendritic cells recognize nucleic acids derived from pathogens and play an important role in the immune responses against the influenza virus (IAV, a single-stranded RNA sensed by different receptors including TLR7. However, the importance of TLR7 processing in the development of anti-viral immune responses is not known. Here we report that asparagine endopeptidase (AEP deficient mice are unable to generate a strong anti-IAV response, as demonstrated by reduced inflammation, cross presentation of cell-associated antigens and priming of CD8(+ T cells following TLR7-dependent pulmonary infection induced by IAV. Moreover, AEP deficient lung epithelial- or myeloid-cells exhibit impaired TLR7 signaling due to defective processing of this receptor. Indeed, TLR7 requires a proteolytic cleavage by AEP to generate a C-terminal fragment competent for signaling. Thus, AEP activity is critical for TLR7 processing, opening new possibilities for the treatment of influenza and TLR7-dependent inflammatory diseases.

  12. A new DTPw-HB/Hib combination vaccine for primary and booster vaccination of infants in Latin America Nueva vacuna combinada DTPw-HB/Hib para la vacunación primaria y de refuerzo de menores de un año en América Latina

    Directory of Open Access Journals (Sweden)

    Miguel Tregnaghi

    2006-03-01

    , la Organización Mundial de la Salud (OMS recomendó que se incluyeran vacunas conjugadas contra Haemophilus influenzae tipo B (Hib en los programas de vacunación de niños menores de un año, siempre que ello estuviera en consonancia con las prioridades nacionales. La compañía GlaxoSmithKline Biologicals ha creado una nueva vacuna pentavalente que es una combinación de la vacuna contra la difteria (D, el tétanos (T y la tos ferina (P (con antígeno tosferínico a base de células completas y las vacunas contra la hepatitis B (HB y contra Haemophilus influenzae tipo B (Hib (DTPw-HB/Hib, con un total de 5 µg de fosfato de polirribosilrribitol (FPR. Hemos evaluado la inmunogenia y reactogenia observadas al aplicarse las dosis primaria y de refuerzo de esta nueva vacuna a niños sanos y las hemos comparado con las observadas al aplicar un régimen de referencia a base de las vacunas autorizadas DTPw-HB (Tritanrix y antiHib (Hiberix en forma de inyecciones simultáneas. MÉTODOS: Llevamos a cabo un estudio aleatorizado y con doble enmascaramiento de septiembre de 1998 a agosto de 1999 para establecer la inmunogenia y reactogenia observadas al administrarles a niños sanos la nueva vacuna combinada pentavalente (DTPw-HB/Hib en una sola inyección, y compararlas con las observadas con el régimen de referencia. RESULTADOS: Se obtuvieron excelentes respuestas inmunitarias con ambos regímenes. Todos los niños vacunados en ambos grupos alcanzaron concentraciones séricas protectoras de anticuerpos antiFPR > 0,15 µg un mes después de recibir la dosis primaria. La vacuna combinada DTPw-HB/Hib no dio resultados inferiores a los obtenidos con las vacunas autorizadas en términos de los porcentajes de seroprotección, seropositividad y respuesta frente a todos los componentes antigénicos de la vacuna. La persistencia de anticuerpos contra todos los antígenos contenidos en ella hasta el momento en que se administró la dosis de refuerzo fue parecida en ambos grupos, y

  13. A novel anti-influenza copper oxide containing respiratory face mask.

    Directory of Open Access Journals (Sweden)

    Gadi Borkow

    Full Text Available BACKGROUND: Protective respiratory face masks protect the nose and mouth of the wearer from vapor drops carrying viruses or other infectious pathogens. However, incorrect use and disposal may actually increase the risk of pathogen transmission, rather than reduce it, especially when masks are used by non-professionals such as the lay public. Copper oxide displays potent antiviral properties. A platform technology has been developed that permanently introduces copper oxide into polymeric materials, conferring them with potent biocidal properties. METHODOLOGY/PRINCIPAL FINDINGS: We demonstrate that impregnation of copper oxide into respiratory protective face masks endows them with potent biocidal properties in addition to their inherent filtration properties. Both control and copper oxide impregnated masks filtered above 99.85% of aerosolized viruses when challenged with 5.66+/-0.51 and 6.17+/-0.37 log(10TCID(50 of human influenza A virus (H1N1 and avian influenza virus (H9N2, respectively, under simulated breathing conditions (28.3 L/min. Importantly, no infectious human influenza A viral titers were recovered from the copper oxide containing masks within 30 minutes (< or = 0.88 log(10TCID(50, while 4.67+/-1.35 log(10TCID(50 were recovered from the control masks. Similarly, the infectious avian influenza titers recovered from the copper oxide containing masks were < or = 0.97+/-0.01 log(10TCID(50 and from the control masks 5.03+/-0.54 log(10TCID(50. The copper oxide containing masks successfully passed Bacterial Filtration Efficacy, Differential Pressure, Latex Particle Challenge, and Resistance to Penetration by Synthetic Blood tests designed to test the filtration properties of face masks in accordance with the European EN 14683:2005 and NIOSH N95 standards. CONCLUSIONS/SIGNIFICANCE: Impregnation of copper oxide into respiratory protective face masks endows them with potent anti-influenza biocidal properties without altering their physical

  14. Influenza

    Directory of Open Access Journals (Sweden)

    Eduardo Forleo-Neto

    2003-04-01

    Full Text Available A influenza (gripe é doença infecciosa aguda de origem viral que acomete o trato respiratório e a cada inverno atinge mais de 100 milhões de pessoas na Europa, Japão e Estados Unidos, causando anualmente a morte de cerca de 20 a 40 mil pessoas somente neste último país. O agente etiológico é o Myxovirus influenzae, ou vírus da gripe. Este subdivide-se nos tipos A, B e C, sendo que apenas os do tipo A e B apresentam relevância clínica em humanos. O vírus influenza apresenta altas taxas de mutação, o que resulta freqüentemente na inserção de novas variantes virais na comunidade, para as quais a população não apresenta imunidade. São poucas as opções disponíveis para o controle da influenza. Dentre essas, a vacinação constitui a forma mais eficaz para o controle da doença e de suas complicações. Em função das mutações que ocorrem naturalmente no vírus influenza, recomenda-se que a vacinação seja realizada anualmente. No Brasil, segundo dados obtidos pelo Projeto VigiGripe - ligado à Universidade Federal de São Paulo -, verifica-se que a influenza apresenta pico de atividade entre os meses de maio e setembro. Assim, a época mais indicada para a vacinação corresponde aos meses de março e abril. Para o tratamento específico da influenza estão disponíveis quatro medicamentos antivirais: os fármacos clássicos amantadina e rimantidina e os antivirais de segunda geração oseltamivir e zanamivir. Os últimos, acrescentam alternativas para o tratamento da influenza e ampliam as opções disponíveis para o seu controle.

  15. Influenza

    Directory of Open Access Journals (Sweden)

    Forleo-Neto Eduardo

    2003-01-01

    Full Text Available A influenza (gripe é doença infecciosa aguda de origem viral que acomete o trato respiratório e a cada inverno atinge mais de 100 milhões de pessoas na Europa, Japão e Estados Unidos, causando anualmente a morte de cerca de 20 a 40 mil pessoas somente neste último país. O agente etiológico é o Myxovirus influenzae, ou vírus da gripe. Este subdivide-se nos tipos A, B e C, sendo que apenas os do tipo A e B apresentam relevância clínica em humanos. O vírus influenza apresenta altas taxas de mutação, o que resulta freqüentemente na inserção de novas variantes virais na comunidade, para as quais a população não apresenta imunidade. São poucas as opções disponíveis para o controle da influenza. Dentre essas, a vacinação constitui a forma mais eficaz para o controle da doença e de suas complicações. Em função das mutações que ocorrem naturalmente no vírus influenza, recomenda-se que a vacinação seja realizada anualmente. No Brasil, segundo dados obtidos pelo Projeto VigiGripe - ligado à Universidade Federal de São Paulo -, verifica-se que a influenza apresenta pico de atividade entre os meses de maio e setembro. Assim, a época mais indicada para a vacinação corresponde aos meses de março e abril. Para o tratamento específico da influenza estão disponíveis quatro medicamentos antivirais: os fármacos clássicos amantadina e rimantidina e os antivirais de segunda geração oseltamivir e zanamivir. Os últimos, acrescentam alternativas para o tratamento da influenza e ampliam as opções disponíveis para o seu controle.

  16. Identification of traditional medicinal plant extracts with novel anti-influenza activity.

    Directory of Open Access Journals (Sweden)

    Dhivya Rajasekaran

    Full Text Available The emergence of drug resistant variants of the influenza virus has led to a need to identify novel and effective antiviral agents. As an alternative to synthetic drugs, the consolidation of empirical knowledge with ethnopharmacological evidence of medicinal plants offers a novel platform for the development of antiviral drugs. The aim of this study was to identify plant extracts with proven activity against the influenza virus. Extracts of fifty medicinal plants, originating from the tropical rainforests of Borneo used as herbal medicines by traditional healers to treat flu-like symptoms, were tested against the H1N1 and H3N1 subtypes of the virus. In the initial phase, in vitro micro-inhibition assays along with cytotoxicity screening were performed on MDCK cells. Most plant extracts were found to be minimally cytotoxic, indicating that the compounds linked to an ethnomedical framework were relatively innocuous, and eleven crude extracts exhibited viral inhibition against both the strains. All extracts inhibited the enzymatic activity of viral neuraminidase and four extracts were also shown to act through the hemagglutination inhibition (HI pathway. Moreover, the samples that acted through both HI and neuraminidase inhibition (NI evidenced more than 90% reduction in virus adsorption and penetration, thereby indicating potent action in the early stages of viral replication. Concurrent studies involving Receptor Destroying Enzyme treatments of HI extracts indicated the presence of sialic acid-like component(s that could be responsible for hemagglutination inhibition. The manifestation of both modes of viral inhibition in a single extract suggests that there may be a synergistic effect implicating more than one active component. Overall, our results provide substantive support for the use of Borneo traditional plants as promising sources of novel anti-influenza drug candidates. Furthermore, the pathways involving inhibition of hemagglutination

  17. Virus susceptibility and clinical effectiveness of anti-influenza drugs during the 2010–2011 influenza season in Russia

    Directory of Open Access Journals (Sweden)

    I.A. Leneva

    2016-02-01

    Conclusions: This study provided experimental and clinical evidence of the efficacy of oseltamivir and umifenovir against influenza viruses, representatives of which have continued to circulate in post-pandemic seasons.

  18. A natural component from Euphorbia humifusa Willd displays novel, broad-spectrum anti-influenza activity by blocking nuclear export of viral ribonucleoprotein

    Energy Technology Data Exchange (ETDEWEB)

    Chang, So Young; Park, Ji Hoon [Respiratory Viruses Research Laboratory, Discovery Biology Department, Institut Pasteur Korea, 16, Daewangpangyo-ro 712 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-400 (Korea, Republic of); Kim, Young Ho; Kang, Jong Seong [College of Pharmacy, Chungnam National University, Daejeon, 305-764 (Korea, Republic of); Min, Ji-Young, E-mail: jiyoung.min@ip-korea.org [Respiratory Viruses Research Laboratory, Discovery Biology Department, Institut Pasteur Korea, 16, Daewangpangyo-ro 712 Beon-gil, Bundang-gu, Seongnam-si, Gyeonggi-do, 463-400 (Korea, Republic of)

    2016-03-04

    The need to develop anti-influenza drugs with novel antiviral mechanisms is urgent because of the rapid rate of antigenic mutation and the emergence of drug-resistant viruses. We identified a novel anti-influenza molecule by screening 861 plant-derived natural components using a high-throughput image-based assay that measures inhibition of the influenza virus infection. 1,3,4,6-tetra-O-galloyl-β-D-glucopyranoside (TGBG) from Euphorbia humifusa Willd showed broad-spectrum anti-influenza activity against two seasonal influenza A strains, A/California/07/2009 (H1N1) and A/Perth/16/2009 (H3N2), and seasonal influenza B strain B/Florida/04/2006. We investigated the mode of action of TGBG using neuraminidase activity inhibition and time-of-addition assays, which evaluate the viral release and entry steps, respectively. We found that TGBG exhibits a novel antiviral mechanism that differs from the FDA-approved anti-influenza drugs oseltamivir which inhibits viral release, and amantadine which inhibits viral entry. Immunofluorescence assay demonstrated that TGBG significantly inhibits nuclear export of influenza nucleoproteins (NP) during the early stages of infection causing NP to accumulate in the nucleus. In addition, influenza-induced activation of the Akt signaling pathway was suppressed by TGBG in a dose-dependent manner. These data suggest that a putative mode of action of TGBG involves inhibition of viral ribonucleoprotein (vRNP) export from the nucleus to the cytoplasm consequently disrupting the assembly of progeny virions. In summary, TGBG has potential as novel anti-influenza therapeutic with a novel mechanism of action. - Highlights: • The plant-derived natural product TGBG has broad-spectrum antiviral activity against seasonal influenza A and B viruses. • TGBG has a novel anti-viral mechanism of action that from differs from the currently available anti-influenza drugs. • TGBG hinders nuclear export of the influenza virus ribonucleoprotein (v

  19. Autismo y vacunas pediátricas

    Directory of Open Access Journals (Sweden)

    Alejandro Roque Valdés

    2004-04-01

    Full Text Available El presente trabajo es un artículo de revisión que pretende abordar un tema tan controvertido como actual: la posible asociación causal que se ha querido establecer entre el autismo y las vacunas infantiles. A partir de la última década del siglo XX se producen una serie de cambios en la clasificación, nomenclatura y criterios diagnósticos del autismo. Los hallazgos de estudios epidemiológicos llevados a cabo bajo estos nuevos ponderados han revelado que las tasas de prevalencia del autismo son en la actualidad muy superiores a las de hace 15 años. Entre los factores que se esgrimen para explicar este fenómeno están las vacunas, y entre los mecanismos que se invocan para tratar de inculpar a las vacunas en la etiología del autismo están el exceso de mercurio derivado del tiomersal que se emplea como conservante de las mismas y procesos autoinmunes que de forma directa o indirectamente actúan sobre el SNC, induciendo lesiones a nivel de la mucosa intestinal, lo cual favorecerá la absorción de macromoléculas, antígenos y toxinas que una vez en el torrente sanguíneo llegarían al SNC produciendo allí las lesiones responsables de la génesis del autismo.

  20. Computational screen and experimental validation of anti-influenza effects of quercetin and chlorogenic acid from traditional Chinese medicine.

    Science.gov (United States)

    Liu, Zekun; Zhao, Junpeng; Li, Weichen; Shen, Li; Huang, Shengbo; Tang, Jingjing; Duan, Jie; Fang, Fang; Huang, Yuelong; Chang, Haiyan; Chen, Ze; Zhang, Ran

    2016-01-12

    The Influenza A virus is a great threat for human health, while various subtypes of the virus made it difficult to develop drugs. With the development of state-of-art computational chemistry, computational molecular docking could serve as a virtual screen of potential leading compound. In this study, we performed molecular docking for influenza A H1N1 (A/PR/8/34) with small molecules such as quercetin and chlorogenic acid, which were derived from traditional Chinese medicine. The results showed that these small molecules have strong binding abilities with neuraminidase from H1N1 (A/PR/8/34). Further details showed that the structural features of the molecules might be helpful for further drug design and development. The experiments in vitro, in vivo have validated the anti-influenza effect of quercetin and chlorogenic acid, which indicating comparable protection effects as zanamivir. Taken together, it was proposed that chlorogenic acid and quercetin could be employed as the effective lead compounds for anti-influenza A H1N1.

  1. Computational screen and experimental validation of anti-influenza effects of quercetin and chlorogenic acid from traditional Chinese medicine

    Science.gov (United States)

    Liu, Zekun; Zhao, Junpeng; Li, Weichen; Shen, Li; Huang, Shengbo; Tang, Jingjing; Duan, Jie; Fang, Fang; Huang, Yuelong; Chang, Haiyan; Chen, Ze; Zhang, Ran

    2016-01-01

    The Influenza A virus is a great threat for human health, while various subtypes of the virus made it difficult to develop drugs. With the development of state-of-art computational chemistry, computational molecular docking could serve as a virtual screen of potential leading compound. In this study, we performed molecular docking for influenza A H1N1 (A/PR/8/34) with small molecules such as quercetin and chlorogenic acid, which were derived from traditional Chinese medicine. The results showed that these small molecules have strong binding abilities with neuraminidase from H1N1 (A/PR/8/34). Further details showed that the structural features of the molecules might be helpful for further drug design and development. The experiments in vitro, in vivo have validated the anti-influenza effect of quercetin and chlorogenic acid, which indicating comparable protection effects as zanamivir. Taken together, it was proposed that chlorogenic acid and quercetin could be employed as the effective lead compounds for anti-influenza A H1N1.

  2. Elevated serum anti-phosphatidylcholine IgG antibodies in patients with influenza vaccination-associated optic neuritis.

    Science.gov (United States)

    Korematsu, Seigo; Miyahara, Hiroaki; Kakita, Akiyoshi; Izumi, Tatsuro

    2014-11-12

    Because the optic nerve is mainly comprised from phospholipids such as phosphatidylcholine, the association between optic neuritis, anti-phospholipids antibodies and vaccination was examined. Two female pediatric patients suddenly presented bilateral optic neuritis after administration of trivalent inactivated influenza vaccine. These two patients and another 11 patients with central nervous system demyelinating diseases were examined these anti-phospholipids antibodies. And immune histopathology was examined using serum derived from a patient with optic neuritis. High serum titer of anti-phosphatidylcholine antibody levels were detected during acute phase in patients with optic neuritis. The patient's serum IgG antibodies were found to have stained the capillary endotheliums in the preserved autopsied optic nerve. Patients with optic neuritis had significantly elevated serum levels of anti-phosphatidylcholine antibody in comparison to the other patients without optic neuritis. Anti-phosphatidylcholine antibodies may be one of the causes of optic neuritis. Copyright © 2014 Elsevier Ltd. All rights reserved.

  3. Vacina contra o vírus da influenza e mortalidade por doenças cardiovasculares na cidade de São Paulo Vacuna contra el virus de la Influenza y mortalidad por enfermedades cardiovasculares en la Ciudad de São Paulo Vaccination against the influenza virus and mortality due to cardiovascular diseases in the city of Sao Paulo

    Directory of Open Access Journals (Sweden)

    Antonio de Padua Mansur

    2009-10-01

    programa de vacunación contra la gripe. Las estimativas de la población y los datos de mortalidad fueron, respectivamente, obtenidos del Instituto Brasileño de Geografía y Estadística (IBGE; www.ibge.gov.br y del Ministerio de la Salud (www.datasus.gov.br para el período entre el 1980 y 2006. Se estimó el riesgo de muerte por el método directo de ajuste, en el que se utilizó la población estándar (mundial referente al 1960. RESULTADOS: Las comparaciones entre las inclinaciones de las líneas de regresión resultaron semejantes para las ECbV (p = 0,931 y CE (p = 0,941, sin embargo, para las EIC (p = 0,022, se observó significativa reducción de la línea del período postvacuna cuando comparada con la línea del período prevacuna. El cambio en la tendencia de la mortalidad tras el 1996 fue significativo sólo para las EIC (p = 0,022, permaneciendo inalterada para las ECbV (p = 0,931 y EE (p = 0,941. CONCLUSIÓN: La vacunación contra la gripe se asoció a la significativa reducción de la mortalidad por EIC.BACKGROUND: The effect of vaccination against the influenza virus on the mortality due to cardiovascular diseases (CVD remains controversial. OBJECTIVE: To analyze the mortality by CVD before and after the start of the vaccination against the Influenza virus in the city of Sao Paulo, Brazil. METHODS: We analyzed the mortality due to ischemic heart diseases (IHD, cerebrovascular diseases (CbVD and external causes (EC in the population of the metropolitan region of the city of Sao Paulo, Brazil, aged > 60 years, before and after the start of the vaccination program against Influenza. The population estimates and mortality data were obtained, respectively, from the Brazilian Institute of Geography and Statistics (IBGE; www.ibge.gov.br and from the Brazilian Ministry of Health (www.datasus.gov.br for the period between 1980 and 2006. The risk of death was adjusted by the direct method, using the 1960 world standard population. RESULTS: The comparisons between

  4. Futuro de las vacunas contra hepatitis B

    Directory of Open Access Journals (Sweden)

    Fernando de la Hoz Restrepo

    2004-03-01

    Full Text Available

    Las hepatitis virales representan una de las amenazas más importantes para la salud del hombre. Más de 350 millones de personas son portadoras del virus de la hepatitis B (VHB y más de 900 millones han sido infectados alrededor del mundo. En este momento se cuenta con una vacuna recombinante segura y efectiva contra este virus, la cual es producida en células de levadura y contiene el antígeno de superficie del VHB como inmunogeno. En Colombia han recibido la vacuna mas de 5 millones de personas, especialmente menores de 15 años, mientras que en el mundo llega a más de 500 millones de personas. Muchos han sido los países donde la introducción de la vacuna ha llevado a una dramática reducción de los niveles de endemicidad de VHB y entre ellos pueden contarse algunas zonas endémicas de nuestro país. En esos sitios se ha constatado que la prevalencia de la infección y de portadores, se ha reducido en más de un 70% después de la introducción de la vacuna e incluso en Taiwán se ha demostrado ya, una reducción en la incidencia de carcinoma hepatocelular.

    Pese a estos éxitos, algunas características epidemiológicas de la hepatitis B como el alto número de portadores y la posibilidad de transmisión intrauterina, hacen pensar que la eliminación de la infección por VHB está lejos todavía. Adicionalmente hay una proporción de personas, que no desarrolla anticuerpos protectores contra el virus a pesar de recibir un esquema de vacunación adecuado. Debido a ello se ha avanzado en el diseño de vacunas contra VHB mejoradas en su capacidad inmunogénica, tales como vacunas que contienen combinaciones de antígeno de superficie (HBsAg y de otras dos proteínas de la envoltura, las pre S. Otra variación de la vacuna que está en desarrollo, es la incorporación de antígenos mutantes

  5. Designing anti-influenza aptamers: novel quantitative structure activity relationship approach gives insights into aptamer-virus interaction.

    Directory of Open Access Journals (Sweden)

    Boaz Musafia

    Full Text Available This study describes the development of aptamers as a therapy against influenza virus infection. Aptamers are oligonucleotides (like ssDNA or RNA that are capable of binding to a variety of molecular targets with high affinity and specificity. We have studied the ssDNA aptamer BV02, which was designed to inhibit influenza infection by targeting the hemagglutinin viral protein, a protein that facilitates the first stage of the virus' infection. While testing other aptamers and during lead optimization, we realized that the dominant characteristics that determine the aptamer's binding to the influenza virus may not necessarily be sequence-specific, as with other known aptamers, but rather depend on general 2D structural motifs. We adopted QSAR (quantitative structure activity relationship tool and developed computational algorithm that correlate six calculated structural and physicochemical properties to the aptamers' binding affinity to the virus. The QSAR study provided us with a predictive tool of the binding potential of an aptamer to the influenza virus. The correlation between the calculated and actual binding was R2 = 0.702 for the training set, and R2 = 0.66 for the independent test set. Moreover, in the test set the model's sensitivity was 89%, and the specificity was 87%, in selecting aptamers with enhanced viral binding. The most important properties that positively correlated with the aptamer's binding were the aptamer length, 2D-loops and repeating sequences of C nucleotides. Based on the structure-activity study, we have managed to produce aptamers having viral affinity that was more than 20 times higher than that of the original BV02 aptamer. Further testing of influenza infection in cell culture and animal models yielded aptamers with 10 to 15 times greater anti-viral activity than the BV02 aptamer. Our insights concerning the mechanism of action and the structural and physicochemical properties that govern the interaction

  6. Designing anti-influenza aptamers: novel quantitative structure activity relationship approach gives insights into aptamer-virus interaction.

    Science.gov (United States)

    Musafia, Boaz; Oren-Banaroya, Rony; Noiman, Silvia

    2014-01-01

    This study describes the development of aptamers as a therapy against influenza virus infection. Aptamers are oligonucleotides (like ssDNA or RNA) that are capable of binding to a variety of molecular targets with high affinity and specificity. We have studied the ssDNA aptamer BV02, which was designed to inhibit influenza infection by targeting the hemagglutinin viral protein, a protein that facilitates the first stage of the virus' infection. While testing other aptamers and during lead optimization, we realized that the dominant characteristics that determine the aptamer's binding to the influenza virus may not necessarily be sequence-specific, as with other known aptamers, but rather depend on general 2D structural motifs. We adopted QSAR (quantitative structure activity relationship) tool and developed computational algorithm that correlate six calculated structural and physicochemical properties to the aptamers' binding affinity to the virus. The QSAR study provided us with a predictive tool of the binding potential of an aptamer to the influenza virus. The correlation between the calculated and actual binding was R2 = 0.702 for the training set, and R2 = 0.66 for the independent test set. Moreover, in the test set the model's sensitivity was 89%, and the specificity was 87%, in selecting aptamers with enhanced viral binding. The most important properties that positively correlated with the aptamer's binding were the aptamer length, 2D-loops and repeating sequences of C nucleotides. Based on the structure-activity study, we have managed to produce aptamers having viral affinity that was more than 20 times higher than that of the original BV02 aptamer. Further testing of influenza infection in cell culture and animal models yielded aptamers with 10 to 15 times greater anti-viral activity than the BV02 aptamer. Our insights concerning the mechanism of action and the structural and physicochemical properties that govern the interaction with the influenza

  7. Futuro de las vacunas contra hepatitis B

    OpenAIRE

    Fernando de la Hoz Restrepo

    2004-01-01

    Las hepatitis virales representan una de las amenazas más importantes para la salud del hombre. Más de 350 millones de personas son portadoras del virus de la hepatitis B (VHB) y más de 900 millones han sido infectados alrededor del mundo. En este momento se cuenta con una vacuna recombinante segura y efectiva contra este virus, la cual es producida en células de levadura y contiene el antígeno de superficie de...

  8. Autismo y vacunas pediátricas

    OpenAIRE

    Alejandro Roque Valdés

    2004-01-01

    El presente trabajo es un artículo de revisión que pretende abordar un tema tan controvertido como actual: la posible asociación causal que se ha querido establecer entre el autismo y las vacunas infantiles. A partir de la última década del siglo XX se producen una serie de cambios en la clasificación, nomenclatura y criterios diagnósticos del autismo. Los hallazgos de estudios epidemiológicos llevados a cabo bajo estos nuevos ponderados han revelado que las tasas de prevalencia del autismo s...

  9. Large-scale sequence analysis of hemagglutinin of influenza A virus identifies conserved regions suitable for targeting an anti-viral response.

    Science.gov (United States)

    Sahini, Leepakshi; Tempczyk-Russell, Anna; Agarwal, Ritu

    2010-02-17

    Influenza A viral surface protein, hemagglutinin, is the major target of neutralizing antibody response and hence a main constituent of all vaccine formulations. But due to its marked evolutionary variability, vaccines have to be reformulated so as to include the hemagglutinin protein from the emerging new viral strain. With the constant fear of a pandemic, there is critical need for the development of anti-viral strategies that can provide wider protection against any Influenza A pathogen. An anti-viral approach that is directed against the conserved regions of the hemaggutinin protein has a potential to protect against any current and new Influenza A virus and provide a solution to this ever-present threat to public health. Influenza A human hemagglutinin protein sequences available in the NCBI database, corresponding to H1, H2, H3 and H5 subtypes, were used to identify highly invariable regions of the protein. Nine such regions were identified and analyzed for structural properties like surface exposure, hydrophilicity and residue type to evaluate their suitability for targeting an anti-peptide antibody/anti-viral response. This study has identified nine conserved regions in the hemagglutinin protein, five of which have the structural characteristics suitable for an anti-viral/anti-peptide response. This is a critical step in the design of efficient anti-peptide antibodies as novel anti-viral agents against any Influenza A pathogen. In addition, these anti-peptide antibodies will provide broadly cross-reactive immunological reagents and aid the rapid development of vaccines against new and emerging Influenza A strains.

  10. Enfermedad invasora por Haemophilus Influenzae antes y después de la campaña de vacunación en la población infantil de la Comunidad Valenciana (1996-2000

    Directory of Open Access Journals (Sweden)

    Goicoechea Sáez Mercedes

    2002-01-01

    Full Text Available Fundamento: La introducción de la vacuna conjugada anti Haemophilus influenzae tipo b (Hib en niños ha provocado un llamativo descenso de la incidencia de la enfermedad por H. influenzae. El objetivo de este estudio es analizar las características más relevantes de la enfermedad invasora por H. influenzae en cuanto a la epidemiología, clínica, evolución y estado de vacunación de la población infantil de la Comunidad Valenciana en el periodo 1996-2000. Método: Los datos se recogen de las historias clínicas de los niños menores de 15 años que hayan presentado síntomas y signos clínicos sugestivos de enfermedad invasora con aislamiento de Haemophilus influenzae y/o que cumple con los criterios de definición de caso establecidos, atendidos en todos los hospitales públicos de la Comunidad Valenciana entre 1996 y 2000. La evolución de la incidencia se valoró mediante tasas de incidencia. La clínica y su evolución (secuelas y letalidad mediante la frecuencia y distribución por edad. Resultados: Se registraron un total de 36 casos de enfermedad invasora por Haemophilus influenzae. La tasa de incidencia en niños menores de 15 años pasó de 3,56/10(5 en 1996 a 1,07/10(5 en 1997 (coincidiendo con la campaña de vacunación y la posterior inclusión de la vacuna conjugada anti Hib en el Calendario de Vacunaciones Sistemáticas de la Comunidad Valenciana y 0,30/10(5 en 1998, situación que se sigue manteniendo en los años posteriores. El 53% de los casos se dan en menores de 18 meses. Tanto las secuelas como los fallecimientos se producen en la época anterior a la aplicación rutinaria de la vacuna conjugada. Ningún niño vacunado correctamente falleció. Se registraron 2 casos de H. influenzae tipo no b en niños vacunados. Conclusiones: La incidencia de la infección por Haemophilus influenzae tipo b disminuyó drásticamente desde el inicio de la vacunación sistemática de la población infantil.

  11. ENFERMEDAD INVASORA POR HAEMOPHILUS INFLUENZAE ANTES Y DESPUÉS DE LA CAMPAÑA DE VACUNACIÓN EN LA POBLACIÓN INFANTIL DE LA COMUNIDAD VALENCIANA (1996-2000

    Directory of Open Access Journals (Sweden)

    Mercedes Goicoechea Sáez

    2002-01-01

    Full Text Available Fundamento: La introducción de la vacuna conjugada anti Haemophilus influenzae tipo b (Hib en niños ha provocado un llamativo descenso de la incidencia de la enfermedad por H. influenzae. El objetivo de este estudio es analizar las características más relevantes de la enfermedad invasora por H. influenzae en cuanto a la epidemiología, clínica, evolución y estado de vacunación de la población infantil de la Comunidad Valenciana en el periodo 1996-2000. Método: Los datos se recogen de las historias clínicas de los niños menores de 15 años que hayan presentado síntomas y signos clínicos sugestivos de enfermedad invasora con aislamiento de Haemophilus influenzae y/o que cumple con los criterios de definición de caso establecidos, atendidos en todos los hospitales públicos de la Comunidad Valenciana entre 1996 y 2000. La evolución de la incidencia se valoró mediante tasas de incidencia. La clínica y su evolución (secuelas y letalidad mediante la frecuencia y distribución por edad. Resultados: Se registraron un total de 36 casos de enfermedad invasora por Haemophilus influenzae. La tasa de incidencia en niños menores de 15 años pasó de 3,56/105 en 1996 a 1,07/105 en 1997 (coincidiendo con la campaña de vacunación y la posterior inclusión de la vacuna conjugada anti Hib en el Calendario de Vacunaciones Sistemáticas de la Comunidad Valenciana y 0,30/105 en 1998, situación que se sigue manteniendo en los años posteriores. El 53% de los casos se dan en menores de 18 meses. Tanto las secuelas como los fallecimientos se producen en la época anterior a la aplicación rutinaria de la vacuna conjugada. Ningún niño vacunado correctamente falleció. Se registraron 2 casos de H. influenzae tipo no b en niños vacunados. Conclusiones: La incidencia de la infección por Haemophilus influenzae tipo b disminuyó drásticamente desde el inicio de la vacunación sistemática de la población infantil.

  12. Properties of polysaccharides in several seaweeds from Atlantic Canada and their potential anti-influenza viral activities

    Science.gov (United States)

    Jiao, Guangling; Yu, Guangli; Wang, Wei; Zhao, Xiaoliang; Zhang, Junzeng; Ewart, Stephen H.

    2012-06-01

    To explore the polysaccharides from selected seaweeds of Atlantic Canada and to evaluate their potential anti-influenza virus activities, polysaccharides were isolated from several Atlantic Canadian seaweeds, including three red algae ( Polysiphonia lanosa, Furcellaria lumbricalis, and Palmaria palmata), two brown algae ( Ascophyllum nodosum and Fucus vesiculosus), and one green alga ( Ulva lactuca) by sequential extraction with cold water, hot water, and alkali solutions. These polysaccharides were analyzed for monosaccharide composition and other general chemical properties, and they were evaluated for anti-influenza virus activities. Total sugar contents in these polysaccharides ranged from 15.4% (in U. lactuca) to 91.4% (in F. lumbricalis); sulfation level was as high as 17.6% in a polysaccharide from U. lactuca, whereas it could not be detected in an alikali-extract from P. palmaria. For polysaccharides from red seaweeds, the main sugar units were sulfated galactans (agar or carrageenan) for P. lanosa, F. lumbricalis, and xylans for P. palmata. In brown seaweeds, the polysaccharides largely contained sulfated fucans, whereas the polysaccharides in green seaweed were mainly composed of heteroglycuronans. Screening for antiviral activity against influenza A/PR/8/34 (H1N1) virus revealed that brown algal polysaccharides were particularly effective. Seaweeds from Atlantic Canada are a good source of marine polysaccharides with potential antiviral properties.

  13. La vacuna contra el virus del papiloma humano

    OpenAIRE

    Tobar Ruiz, María

    2015-01-01

    La carciogénesis está condicionada por factores dependientes del virus como de los hábitos del huésped. En cuanto a la vacunación se han descubierto vacunas seguras y eficaces, siendo las dos vacunas destacadas la tetravalente o Gardasil y la bivalente o Cervarix. E nfermería es la profesional que administra la vacuna y conoce los efectos adversos posibl es a causa de su administración, y es por esa razón por la que mi interés se centró en la vacunación.

  14. Type II transmembrane serine proteases as potential target for anti-influenza drug discovery.

    Science.gov (United States)

    Shin, Woo-Jin; Seong, Baik Lin

    2017-11-01

    The outbreak of an influenza pandemic as well as the continued circulation of seasonal influenza highlights the need for effective antiviral therapies. The emergence of drug-resistant strains further necessitates the development of novel antivirals that target the host factors crucial for viral replication. Area covered: This review summarizes the current understanding of the structural and functional properties of type II transmembrane serine proteases (TTSPs) as a proteolytic activator of influenza virus infection and discusses their potential as antiviral targets. It also explores the experimental evidence accumulated for inhibitors of TTSPs as novel, broad-spectrum antivirals against various influenza virus subtypes. The review also provides an overview of the properties of small molecules, proteins, and peptides that efficiently inhibit the proteolytic activation of the influenza virus. Expert opinion: TTSPs activate a wide range of influenza virus subtypes including avian influenza viruses, both in vitro and in vivo, via proteolytic cleavage of influenza hemagglutinin (HA) into infection-competent fusogenic conformation. Other viruses such as SARS-, MERS-coronaviruses and human metapneumoviruses may use the same host cell proteases for activation, implying that TTSP inhibition might be a novel strategy for developing broad-spectrum antiviral agents for respiratory viral infections.

  15. Novel Ranking System for Identifying Efficacious Anti-Influenza Virus PB2 Inhibitors.

    Science.gov (United States)

    Tsai, Alice W; McNeil, Colleen F; Leeman, Joshua R; Bennett, Hamilton B; Nti-Addae, Kwame; Huang, Cassey; Germann, Ursula A; Byrn, Randal A; Berlioz-Seux, Francoise; Rijnbrand, Rene; Clark, Michael P; Charifson, Paul S; Jones, Steven M

    2015-10-01

    Through antigenic drift and shifts, influenza virus infections continue to be an annual cause of morbidity in healthy populations and of death among elderly and at-risk patients. The emergence of highly pathogenic avian influenza viruses such as H5N1 and H7N9 and the rapid spread of the swine-origin H1N1 influenza virus in 2009 demonstrate the continued need for effective therapeutic agents for influenza. While several neuraminidase inhibitors have been developed for the treatment of influenza virus infections, these have shown a limited window for treatment initiation, and resistant variants have been noted in the population. In addition, an older class of antiviral drugs for influenza, the adamantanes, are no longer recommended for treatment due to widespread resistance. There remains a need for new influenza therapeutic agents with improved efficacy as well as an expanded window for the initiation of treatment. Azaindole compounds targeting the influenza A virus PB2 protein and demonstrating excellent in vitro and in vivo properties have been identified. To evaluate the in vivo efficacy of these PB2 inhibitors, we utilized a mouse influenza A virus infection model. In addition to traditional endpoints, i.e., death, morbidity, and body weight loss, we measured lung function using whole-body plethysmography, and we used these data to develop a composite efficacy score that takes compound exposure into account. This model allowed the rapid identification and ranking of molecules relative to each other and to oseltamivir. The ability to identify compounds with enhanced preclinical properties provides an opportunity to develop more-effective treatments for influenza in patients. Copyright © 2015, American Society for Microbiology. All Rights Reserved.

  16. A contributing role for anti-neuraminidase antibodies on immunity to pandemic H1N1 2009 influenza A virus.

    Directory of Open Access Journals (Sweden)

    Glendie Marcelin

    Full Text Available Exposure to contemporary seasonal influenza A viruses affords partial immunity to pandemic H1N1 2009 influenza A virus (pH1N1 infection. The impact of antibodies to the neuraminidase (NA of seasonal influenza A viruses to cross-immunity against pH1N1 infection is unknown.Antibodies to the NA of different seasonal H1N1 influenza strains were tested for cross-reactivity against A/California/04/09 (pH1N1. A panel of reverse genetic (rg recombinant viruses was generated containing 7 genes of the H1N1 influenza strain A/Puerto Rico/08/34 (PR8 and the NA gene of either the pandemic H1N1 2009 strain (pH1N1 or one of the following contemporary seasonal H1N1 strains: A/Solomon/03/06 (rg Solomon or A/Brisbane/59/07 (rg Brisbane. Convalescent sera collected from mice infected with recombinant viruses were measured for cross-reactive antibodies to pH1N1 via Hemagglutinin Inhibition (HI or Enzyme-Linked Immunosorbent Assay (ELISA. The ectodomain of a recombinant NA protein from the pH1N1 strain (pNA-ecto was expressed, purified and used in ELISA to measure cross-reactive antibodies. Analysis of sera from elderly humans immunized with trivalent split-inactivated influenza (TIV seasonal vaccines prior to 2009 revealed considerable cross-reactivity to pNA-ecto. High titers of cross-reactive antibodies were detected in mice inoculated with either rg Solomon or rg Brisbane. Convalescent sera from mice inoculated with recombinant viruses were used to immunize naïve recipient Balb/c mice by passive transfer prior to challenge with pH1N1. Mice receiving rg California sera were better protected than animals receiving rg Solomon or rg Brisbane sera.The NA of contemporary seasonal H1N1 influenza strains induces a cross-reactive antibody response to pH1N1 that correlates with reduced lethality from pH1N1 challenge, albeit less efficiently than anti-pH1N1 NA antibodies. These findings demonstrate that seasonal NA antibodies contribute to but are not sufficient for cross

  17. Estudio transversal basado en la población sobre la aceptabilidad de la vacuna y la percepción de la gravedad de la gripe A/H1N1: opinión de la población general y de los profesionales sanitarios Population-based cross sectional study about vaccine acceptability and perception of the severity of A/H1N1 influenza: Opinion of the general population and health professionals

    Directory of Open Access Journals (Sweden)

    Antxon Apiñaniz

    2010-08-01

    Full Text Available Objetivos: Determinar la intención de la población general y de los profesionales sanitarios de vacunarse contra la gripe A/H1N1, así como la percepción que tienen de la gravedad de la gripe A/H1N1 en comparación con la gripe estacional. Métodos: Estudio transversal mediante encuesta telefónica a una muestra de población general, a partir de la guía telefónica, y electrónica a profesionales sanitarios de los centros asistenciales públicos de Vitoria-Gasteiz, entre los días 6 y 16 de noviembre de 2009. En ambos colectivos se calcularon las frecuencias absolutas y relativas de los que se querían vacunar y de los que perciben la gripe como un riesgo alto para la vida. Resultados: Contestaron al cuestionario el 33% (n=219 de las 637 personas contactadas y se obtuvieron 109 respuestas de profesionales. El 63,0% (n=138 de la población general y el 73,4% (n=80 de la población sanitaria no se vacunaría si la vacuna fuese gratis (p=0,595. En caso de pertenecer a alguno de los grupos de riesgo no se vacunaría el 14,6% (n=32 de la población ni el 40,4% (n=44 de los sanitarios (pObjectives: To determine the intention of general population and health professionals to vaccinate against the H1N1 influenza A virus. To determine the perception of severity of the H1N1 influenza A in both groups compared to that of seasonal influenza. Methods: Cross-sectional telephone survey performed to a sample of population (obtained randomly from the Vitoria-Gasteiz telephone directory and cross-sectional electronically-administered survey to a sample of health professionals from public health centres in Vitoria-Gasteiz, conducted between 6th and 16th November 2009. The relative and absolute frecuency of persons willing to be vaccinated and the proportion of those considering the H1N1 influenza A as a life-threatening risk were calculated in both groups. Results: 219 (33% persons out of 637 contacted telephone numbers answered the questionnaire, as well as

  18. A humanized anti-M2 scFv shows protective in vitro activity against influenza

    Energy Technology Data Exchange (ETDEWEB)

    Bradbury, Andrew M [Los Alamos National Laboratory; Velappan, Nileena [Los Alamos National Laboratory; Schmidt, Jurgen G [Los Alamos National Laboratory

    2008-01-01

    M2 is one of the most conserved influenza proteins, and has been widely prospected as a potential universal vaccine target, with protection predominantly mediated by antibodies. In this paper we describe the creation of a humanized single chain Fv from 14C2, a potent monoclonal antibody against M2. We show that the humanized scFv demonstrates similar activity to the parental mAb: it is able to recognize M2 in its native context on cell surfaces and is able to show protective in vitro activity against influenza, and so represents a potential lead antibody candidate for universal prophylactic or therapeutic intervention in influenza.

  19. A readability comparison of anti- versus pro-influenza vaccination online messages in Japan

    Directory of Open Access Journals (Sweden)

    Tsuyoshi Okuhara

    2017-06-01

    When health professionals prepare pro-influenza vaccination materials for publication online, we recommend they check for readability using readability assessment tools and improve the text for easy reading if necessary.

  20. Pharmacodynamics, Pharmacokinetics, and Antiviral Activity of BAY 81-8781, a Novel NF-κB Inhibiting Anti-influenza Drug

    Directory of Open Access Journals (Sweden)

    Karoline Droebner

    2017-11-01

    Full Text Available Influenza is a respiratory disease that causes annual epidemics. Antiviral treatment options targeting the virus exist, but their efficiency is limited and influenza virus strains easily develop resistance. Thus, new treatment strategies are urgently needed. In the present study, we investigated the anti-influenza virus properties of D,L-lysine acetylsalicylate ⋅ glycine (BAY 81-8781; LASAG that is approved as Aspirin i.v. for intravenous application. Instead of targeting the virus directly BAY 81-8781 inhibits the activation of the NF-κB pathway, which is required for efficient influenza virus propagation. Using highly pathogenic avian influenza virus strains we could demonstrate that BAY 81-8781 was able to control influenza virus infection in vitro. In the mouse infection model, inhalation of BAY 81-8781 resulted in reduced lung virus titers and protection of mice from lethal infection. Pharmacological studies demonstrated that the oral route of administration was not suitable to reach the sufficient concentrations of BAY 81-8781 for a successful antiviral effect in the lung. BAY 81-8781 treatment of mice infected with influenza virus started as late as 48 h after infection was still effective in protecting 50% of the animals from death. In summary, the data represent a successful proof of the novel innovative antiviral concept of targeting a host cell signaling pathway that is required for viral propagation instead of viral structures.

  1. Vacunas contra el VIH, Papilomavirus, Rotavirus, Virus Respiratorio Sincitial. Futuro de las vacunas

    OpenAIRE

    Farjas Abadía, Mª Pilar

    2005-01-01

    El desarrollo de la vacunología desde el descubrimiento de Jenner de la capacidad de prevenir la viruela mediante la inoculación del virus de la vacuna, ha permitido erradicar la viruela y controlar enfermedades como la difteria, el tétanos, el sarampión, la tos ferina y la parotiditis entre otras, siendo una de las causas del espectacular aumento en la esperanza de vida de las últimas décadas. El desarrollo de la biotecnología e ingeniería genética está permitiendo el estudio de nuevas vacun...

  2. OPTIMIZATION OF ANTI-VIRAL THERAPY OF INFLUENZA IN CHILDREN AND ADULTS

    Directory of Open Access Journals (Sweden)

    V. A. Isakov

    2013-01-01

    Full Text Available High efficacy of inosine pranobex in treatment and prophylaxis of influenza and other acute respiratory infections in children and adults accordingly to various concurrent diseases has been proved by numerous authors. Inosine pranobex is an example of significant clinical efficacy and high safety level unity. This drug is appropriate to children and adults both with immunocompromised and normal immune status.

  3. Anti-Hemagglutinin Antibody Derived Lead Peptides for Inhibitors of Influenza Virus Binding.

    Directory of Open Access Journals (Sweden)

    Henry Memczak

    Full Text Available Antibodies against spike proteins of influenza are used as a tool for characterization of viruses and therapeutic approaches. However, development, production and quality control of antibodies is expensive and time consuming. To circumvent these difficulties, three peptides were derived from complementarity determining regions of an antibody heavy chain against influenza A spike glycoprotein. Their binding properties were studied experimentally, and by molecular dynamics simulations. Two peptide candidates showed binding to influenza A/Aichi/2/68 H3N2. One of them, termed PeB, with the highest affinity prevented binding to and infection of target cells in the micromolar region without any cytotoxic effect. PeB matches best the conserved receptor binding site of hemagglutinin. PeB bound also to other medical relevant influenza strains, such as human-pathogenic A/California/7/2009 H1N1, and avian-pathogenic A/Mute Swan/Rostock/R901/2006 H7N1. Strategies to improve the affinity and to adapt specificity are discussed and exemplified by a double amino acid substituted peptide, obtained by substitutional analysis. The peptides and their derivatives are of great potential for drug development as well as biosensing.

  4. A novel antibody discovery platform identifies anti-influenza A broadly neutralizing antibodies from human memory B cells.

    Science.gov (United States)

    Xiao, Xiaodong; Chen, Yan; Varkey, Reena; Kallewaard, Nicole; Koksal, Adem C; Zhu, Qing; Wu, Herren; Chowdhury, Partha S; Dall'Acqua, William F

    2016-07-01

    Monoclonal antibody isolation directly from circulating human B cells is a powerful tool to delineate humoral responses to pathological conditions and discover antibody therapeutics. We have developed a platform aimed at improving the efficiencies of B cell selection and V gene recovery. Here, memory B cells are activated and amplified using Epstein-Barr virus infection, co-cultured with CHO-muCD40L cells, and then assessed by functional screenings. An in vitro transcription and translation (IVTT) approach was used to analyze variable (V) genes recovered from each B cell sample and identify the relevant heavy/light chain pair(s). We achieved efficient amplification and activation of memory B cells, and eliminated the need to: 1) seed B cells at clonal level (≤1 cell/well) or perform limited dilution cloning; 2) immortalize B cells; or 3) assemble V genes into an IgG expression vector to confirm the relevant heavy/light chain pairing. Cross-reactive antibodies targeting a conserved epitope on influenza A hemagglutinin were successfully isolated from a healthy donor. In-depth analysis of the isolated antibodies suggested their potential uses as anti-influenza A antibody therapeutics and uncovered a distinct affinity maturation pathway. Importantly, our results showed that cognate heavy/light chain pairings contributed to both the expression level and binding abilities of our newly isolated VH1-69 family, influenza A neutralizing antibodies, contrasting with previous observations that light chains do not significantly contribute to the function of this group of antibodies. Our results further suggest the potential use of the IVTT as a powerful antibody developability assessment tool.

  5. Modulating the innate immune response to influenza A virus: potential therapeutic use of anti-inflammatory drugs

    Directory of Open Access Journals (Sweden)

    Irene eRamos

    2015-07-01

    Full Text Available Infection by influenza A viruses (IAV is frequently characterized by robust inflammation that is usually more pronounced in the case of avian influenza. It is becoming clearer that the morbidity and pathogenesis caused by IAV is a consequence of this inflammatory response, with several components of the innate immune system acting as the main players. It has been postulated that using a therapeutic approach to limit the innate immune response in combination with antiviral drugs has the potential to diminish symptoms and tissue damage caused by IAV infection. Indeed, some anti-inflammatory agents have been shown to be effective in animal models at reducing IAV pathology as a proof of principle. The main challenge in developing such therapies is to selectively modulate signaling pathways that contribute to lung injury while maintaining the ability of the host cells to mount an antiviral response to control virus replication. However, the dissection of those pathways is very complex given the numerous components regulated by the same factors (i.e. NF kappa B transcription factors and the large number of players involved in this regulation, some of which may be undescribed or unknown. This article provides a comprehensive review of the current knowledge regarding the innate immune responses associated with tissue damage by IAV infection, the understanding of which is essential for the development of effective immunomodulatory drugs. Furthermore, we summarize the recent advances on the development and evaluation of such drugs as well as the lessons learned from those studies.

  6. Una vacuna contra la tuberculosi, provada en cabres

    OpenAIRE

    Pérez del Val, Bernat

    2012-01-01

    Investigadors del CReSA han dut a terme el primer estudi de vacunació contra la tuberculosi utilitzant com a model experimental la cabra domèstica, que reprodueix amb molta similitud la resposta a la tuberculosi en humans. La vacuna, anomenada AdAg85A, ha estat dissenyada per investigadors de McMaster University (Canadà) per prevenir la tuberculosi en humans, i actualment es troba en fase I d’assajos clínics. De moment, aquest estudi mostra que la inoculació d’aquesta nova vacuna, com a refor...

  7. N-acetylcysteine: an old drug with variable Anti-influenza properties

    Directory of Open Access Journals (Sweden)

    Tomas Casanova

    2016-03-01

    Full Text Available N-acetylcysteine (NAC is a mucolytic drug commonly used as an adjuvant therapy in patients with respiratory conditions associated with excessive mucus production. NAC also has antioxidant activities which proved useful in the management of oxidative stress. These antioxidant capacities of NAC are mostly indirect, via a pro-glutathione effect where NAC provides L-cysteine residues required for glutathione synthesis. This activity is thought to be the basis of the protective effect of NAC administration in influenza patients and in mouse models of the disease. NAC was shown to limit lung inflammation, damage associated with the virus, and limit viral growth, at least in vitro. However, the antiviral activity was highly variable depending on the influenza A strain. The reasons for these inter-strain variations are still unknown but might be related to the level of NF-κB activation required for the virus to achieve its infectious cycle.

  8. Universal vaccine against influenza virus: linking TLR signaling to anti-viral protection.

    Science.gov (United States)

    Schmitz, Nicole; Beerli, Roger R; Bauer, Monika; Jegerlehner, Andrea; Dietmeier, Klaus; Maudrich, Melanie; Pumpens, Paul; Saudan, Philippe; Bachmann, Martin F

    2012-04-01

    A vaccine protecting against all influenza strains is a long-sought goal, particularly for emerging pandemics. As previously shown, vaccines based on the highly conserved extracellular domain of M2 (M2e) may protect against all influenza A strains. Here, we demonstrate that M2e-specific monoclonal antibodies (mAbs) protect mice from a lethal influenza infection. To be protective, antibodies had to be able to bind to Fc receptors and fix complement. Furthermore, mAbs of IgG2c isotype were protective in mice, while antibodies of identical specificity, but of the IgG1 isotype, failed to prevent disease. These findings readily translated into vaccine design. A vaccine targeting M2 in the absence of a toll-like receptor (TLR) 7 ligand primarily induced IgG1, whilst the same vaccine linked to a TLR7 ligand yielded high levels of IgG2c antibodies. Although both vaccines protected mice from a lethal challenge, mice treated with the vaccine containing a TLR7 ligand showed significantly lower morbidity. In accordance with these findings, vaccination of TLR7(-/-) mice with a vaccine containing a TLR7 ligand did not result in protection from a lethal challenge. Hence, the innate immune system is required to direct isotype switching toward the more protective IgG2a/c antibodies. © 2012 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

  9. LA VACUNACIÓN ANTI-NEUMOCÓCICA CON LA VACUNA CONJUGADA 13-VALENTE EN POBLACIÓN INMUNOCOMPETENTE DE 65 AÑOS: ANALISIS DEL IMPACTO PRESUPUESTARIO EN ESPAÑA APLICANDO UN MODELO DE TRANSMISIÓN DINÁMICA

    Directory of Open Access Journals (Sweden)

    Reyes Lorente Antoñanzas

    2016-01-01

    Full Text Available Fundamentos: Las infecciones causadas por el Streptococcus pneumoniae en el adulto tienen repercusiones importantes en la salud. El objetivo fue analizar el impacto económico y sanitario en 5 años de la vacunación de la cohorte española de 65 años inmunocompetente con la vacuna antineumocócica conjugada 13-valente.Métodos: Mediante un modelo de transmisión dinámica basado en ecuaciones diferenciales se analizó la carga de la enfermedad neumocócica (EN en sujetos de 65 años en 5 años, siendo vacunada anualmente el 36,5% de la cohorte. Se aplicó la eficacia de la vacuna del 52,5% observada en el estudio CAPITA en pacientes de 65 años inmunocompetentes, cobertura de serotipos vacunales del 63,4% (estudio CAPA, incidencia de infección neumocócica de 162,2/100.000 casos año (CMBD 2010-2013 y proporción de vacunados previamente al arranque del modelo del 0,99%. La perspectiva fue la del Sistema Nacional de Salud (SNS. Costes de casos de EN según CMBD y precio de venta de laboratorio de la vacuna conjugada.Resultados: En 5 años la vacunación con vacuna conjugada 13-valente espera evitar 10.360 casos de EN (7.411 hospitalizaciones por neumonías y 699 muertes (14.736 años de vida ganados -AVG-, en una cohorte de 65 a 69 años de edad. El coste de vacunación esperado de 36,5 millones de euros se compensaría completamente por la reducción de 41,5 millones de costes médicos evitados, con un ahorro neto acumulado de 3,8 millones de euros a precios constantes (4,9 a precios corrientes.Conclusión: La vacunación con vacuna conjugada 13-valente en adultos de 65 años inmunocompetentes resulta eficiente para el Sistema Nacional de Salud, reduciendo la carga de enfermedad y evitando un número importante de muertes.

  10. Prevención de las neumonías mediante vacunas

    Directory of Open Access Journals (Sweden)

    Roberto Razón Behar

    Full Text Available La neumonía es una infección respiratoria aguda que afecta a los pulmones. La neumonía adquirida en la comunidad, es la principal causa individual de mortalidad infantil en todo el mundo. Se calcula que cada año mueren por su causa más de 1,5 millones de niños menores de 5 años, lo que supone el 18 % de todas las defunciones de este grupo etario en todo el mundo. Diversos agentes infecciosos, particularmente los virus y bacterias, causan neumonía, y son los más comunes el Streptococcus pneumoniae -la causa más común de neumonía bacteriana en niños-; el Haemophilus influenzae de tipo b -la segunda causa más común de neumonía bacteriana-; así como el virus sincitial respiratorio. La prevención de la neumonía infantil es un componente fundamental de toda estrategia para reducir la mortalidad infantil. La inmunización, particularmente contra el Haemophilus influenzae de tipo b, los neumococos, el sarampión y la tos ferina, es la forma más eficaz de prevenirla. Por tal motivo se considera importante una revisión y actualización de las principales vacunas existentes hoy en día.

  11. An up date on influenza Influenza: actualización de conceptos

    Directory of Open Access Journals (Sweden)

    Helí Salgado Vélez

    2002-04-01

    Full Text Available A review is presented on present-day concepts on influenza with emphasis on vaccination; included are considerations about the etiologic agent, pathogenesis, clinical picture, laboratory diagnosis, epidemiology and vaccines; concerning the latter, the following aspects are included: administration, secondary reactions, indications and contraindications. Se presenta una actualización de conceptos sobre la influenza con énfasis en la vacuna; se incluyen consideraciones sobre el virus, la patogénesis, la clínica, el diagnóstico de laboratorio, la epidemiología y las vacunas; acerca de éstas se detallan sus características, esquemas de aplicación, reacciones secundarias, indicaciones y contraindicaciones.

  12. Las vacunas nos protegen (Vaccines Help Protect Us)

    Centers for Disease Control (CDC) Podcasts

    2013-04-23

    En este podcast, los niños de Kidtastics hablan sobre la importancia de las vacunas y cómo funcionan.  Created: 4/23/2013 by Centers for Disease Control and Prevention (CDC).   Date Released: 12/11/2013.

  13. The semi-synthesis of novel andrographolide analogues and anti-influenza virus activity evaluation of their derivatives.

    Science.gov (United States)

    Yuan, Lei; Zhang, Chunfeng; Sun, Hongxin; Liu, Qingyin; Huang, Jian; Sheng, Lei; Lin, Bin; Wang, Jinhui; Chen, Lixia

    2016-02-01

    Two novel andrographolide analogues with the structural motif of Δ(8,17)-alkene exo-to-endo isomerization, AI78 and AI89, were semi-synthesized firstly. Two series of derivatives were designed and synthesized based on the synthetic pathway (including series I: olefin isomerizing to endocyclic Δ(8,9) and series II: olefin isomerizing to endocyclic Δ(7,8)). The anti-influenza virus activity in vitro for all derivatives was evaluated. Among the compounds synthesized, compound 38 with benzyl amino group showed the greatest potency against H3N2 and was approximately 1.5-fold more potent than that of Lianbizhi, andrographolide analogue used clinically in China. Adamantyl derivative, 43, presented the lowest toxicity, with a higher TC50 and TI values than Lianbizhi. The structure-activity relationships studies of the synthetic analogues indicated that the endocyclic Δ(7,8)-double bond is preferable for anti-viral effect. Furthermore, the introduction of the fatty amino attached to the rigid skeleton at C-17 is beneficial for activity. Copyright © 2016 Elsevier Ltd. All rights reserved.

  14. T-705 (Favipiravir) suppresses tumor necrosis factor α production in response to influenza virus infection: A beneficial feature of T-705 as an anti-influenza drug.

    Science.gov (United States)

    Tanaka, T; Kamiyama, T; Daikoku, T; Takahashi, K; Nomura, N; Kurokawa, M; Shiraki, K

    Influenza virus infection induces the production of various cytokines, which play important roles in the pathogenesis of infection. Among the cytokines induced by influenza, tumor necrosis factor α (TNF-α) production has been correlated with the severity of lung lesions. We investigated the effects of T-705 (Favipiravir, 6-fluoro-3-hydroxy-2-pyrazinecarboxamide) on cytokine production due to influenza virus infection in vitro and in vivo, compared with oseltamivir or GS 4071, an active form of oseltamivir. TNF-α production in mouse macrophage-derived P388D1 cells infected with the influenza virus was lower following treatment with T-705 at concentrations of 0.3 to 100 µg/ml than treatment with GS 4071 at the same concentrations. The effect of treatment with T-705 on the cytokine production induced by the influenza virus infection was investigated in mouse influenza virus infection model. At 48 h post-infection (p.i.) T-705 significantly suppressed the viral load in the lungs and TNF-α production in the airways of infected mice even when viral loads were high. Furthermore, T-705 suppressed only TNF-α production from the early phase of infection. In this study, T-705 showed the antiviral activity of reducing pulmonary viral load compared with oseltamivir, thereby suppressing the TNF-α production. This feature of T-705 is benefit against severe influenza infection.

  15. Asparagine endopeptidase controls anti-influenza virus immune responses through TLR7 activation

    National Research Council Canada - National Science Library

    Maschalidi, Sophia; Hässler, Signe; Blanc, Fany; Sepulveda, Fernando E; Tohme, Mira; Chignard, Michel; van Endert, Peter; Si-Tahar, Mustapha; Descamps, Delphyne; Manoury, Bénédicte

    2012-01-01

    .... Here we report that asparagine endopeptidase (AEP) deficient mice are unable to generate a strong anti-IAV response, as demonstrated by reduced inflammation, cross presentation of cell-associated antigens and priming of CD8...

  16. Antioxidant activities, sensory and anti-influenza activity of grape skin tea infusion.

    Science.gov (United States)

    Bekhit, Alaa El-Din A; Cheng, Vern Jou; McConnell, Michelle; Zhao, Jenny H; Sedcole, Richard; Harrison, Roland

    2011-12-01

    Grape skin extracts from pinot noir and pinot gris exhibited significant in vitro antiviral (influenza virus) activity. Five tea infusions from grape skins (Vitis vinifera var. pinot noir and pinot gris) without any additives (control pinot noir and control pinot gris) or by adding variable amounts of green tea and hibiscus were investigated as a means to utilise wine wastes. The antioxidant activities (DPPH scavenging capacity and superoxide anion radical scavenging capacity), total phenolics, the polyphenolics profile and objective colour measurements (CIELab) were determined on freeze-dried water extracts of all five tea infusions, hibiscus and green tea. The colour parameters, L(∗) and a(∗) values, varied widely (P<0.05) for all the infusions as a result of having different levels and variety of pigments. The tea infusions exhibited weak antioxidant activity and the antiviral activity in grape skin appears not related to phenolics contents. Copyright © 2011 Elsevier Ltd. All rights reserved.

  17. Realidad y nuevos horizontes de la vacuna del virus del papiloma humano

    OpenAIRE

    García Gómez, Nuria

    2014-01-01

    La vacuna frente al VPH es la primera vacuna destinada a la prevención del cáncer inducido por un virus, el CCU (problema de salud pública mundial), y de lesiones precursoras. Disponemos de 2 vacunas profilácticas: Gardasil® (frente a VPH 6, 11, 16 y 18) y Cervarix® (frente a VPH 16 y 18). El trabajo consiste en una revisión bibliográfica que tiene como objetivo conocer la situación que vive actualmente la vacuna del VPH en España, utilizando como palabras clave virus, vacun...

  18. Vacunas, biotecnología y su relación con el aborto provocado

    OpenAIRE

    José Luis Redondo Calderón

    2008-01-01

    Las vacunas de células diploides humanas (WI-38, MRC-5) tienen un origen éticamente objetable, dado que dichas células proceden de abortos provocados. Entre ellas destacan vacunas empleadas contra rubéola, sarampión, parotiditis, rabia, poliomielitis, viruela, hepatitis A, varicela y herpes zóster. Actualmente se encuentran en desarrollo otras vacunas cultivadas en células (293, PER.C6) transformadas mediante virus, procedentes de abortos. Entre ellas hay vacunas contra la gripe, virus respi...

  19. Anticorpo protetor anti influenza humana detectado em cavalos, como virose zoonótica

    Directory of Open Access Journals (Sweden)

    Dalva Assunção Portari Mancini

    2004-11-01

    Full Text Available O objetivo deste estudo foi investigar em cavalos, a incidência do vírus influenza e seu ciclo de transmissão interespécies. Portanto, levantamento sorológico foi realizado em soro de cavalos, confrontados com ambas cepas, as específicas (eqüino e não específicas (humana deste vírus. Sangrias de cavalos realizadas nos anos de 1999 e de 2000, forneceram soros que, após tratamento com Caolim (20% e hemácias de galo(50% para remoção dos anticorpos inespecíficos, foram titulados contra ambas referidas cepas, através do teste de Inibição da Hemaglutinação (recomendado pela OMS. Os resultados, demonstraram que as respostas sorológicas dos cavalos apresentaram reação cruzada entre as cepas específicas e as não específicas. As porcentagens de títulos IH obtidos foram de 62,75% e de 60,65% para as cepas específicas A/Eq1 (H7N7 e A/Eq2 (H3N8, respectivamente. E às cepas não específicas essas porcentagens foram de: 79,05% para A (H1N1, de 94,45% para A (H3N2 e de 77,75% ao tipo B. O mais relevante nestes dados comparativos com vírus influenza, foi a alta porcentagem de resposta protetora à cepa não específica comparada àquela específica, detectada nos soros eqüinos. Considerando o fato de que o tipo B, deste vírus, ser restrito à espécie humana, portanto a resposta de proteção nos cavalos sugere uma direta transmissão interspécies, como em viroses zoonóticas. Os autores relatam pela primeira vez este tipo de evento no Brasil.

  20. Palmitoylethanolamide: A Natural Body-Own Anti-Inflammatory Agent, Effective and Safe against Influenza and Common Cold

    Directory of Open Access Journals (Sweden)

    J. M. Keppel Hesselink

    2013-01-01

    Full Text Available Palmitoylethanolamide (PEA is a food component known since 1957. PEA is synthesized and metabolized in animal cells via a number of enzymes and exerts a multitude of physiological functions related to metabolic homeostasis. Research on PEA has been conducted for more than 50 years, and over 350 papers are referenced in PubMed describing the physiological properties of this endogenous modulator and its pharmacological and therapeutical profile. The major focus of PEA research, since the work of the Nobel laureate Levi-Montalcini in 1993, has been neuropathic pain states and mast cell related disorders. However, it is less known that 6 clinical trials in a total of nearly 4000 people were performed and published last century, specifically studying PEA as a therapy for influenza and the common cold. This was done before Levi-Montalcini’s clarification of PEA’s mechanism of action, analyzing the role of PEA as an anti-inflammatory agent. We will review in depth these studies, as the results support the effectiveness and safety of PEA in flu and respiratory infections.

  1. La vacuna en Cuba durante el gobierno de Someruelos

    OpenAIRE

    Vázquez Cienfuegos, Sigfrido

    2004-01-01

    La Real Expedición Filantrópica de la Vacuna (1803-1806), dirigida por Francisco Javier de Balmis, se dirigió al Nuevo Mundo para paliar las epidemias de viruelas que habían venido asolando América desde casi el mismo momento del Descubrimiento. Para entonces en la isla de Cuba ya se había iniciado una labor con el mismo objetivo por el médico cubano Tomás Romay, apoyado en el fomento de la introducción y aplicación de la vacuna por el marqués de Someruelos gobernador y capitán general de la ...

  2. EPs® 7630 (Umckaloabo®), an extract from Pelargonium sidoides roots, exerts anti-influenza virus activity in vitro and in vivo.

    Science.gov (United States)

    Theisen, Linda L; Muller, Claude P

    2012-05-01

    A prodelphinidin-rich extract from Pelargonium sidoides DC, EPs® 7630 (Umckaloabo®), which is licensed to treat respiratory tract infections such as acute bronchitis, was investigated for its antiviral effects. EPs® 7630 showed dose-dependent anti-influenza activity at non-toxic concentrations against pandemic H1N1, oseltamivir-sensitive and -resistant seasonal H1N1, seasonal H3N2 and the laboratory H1N1 strain A/Puerto Rico/8/34, while it had no antiviral activity against adenovirus or measles virus. The extract inhibited an early step of influenza infection and impaired viral hemagglutination as well as neuraminidase activity. However, EPs® 7630 did not exhibit a direct virucidal effect, as virus preincubation (unlike cell preincubation) with the extract did not influence infectivity. Importantly, EPs® 7630 showed no propensity to resistance development in vitro. Analysis of EPs® 7630 constituents revealed that prodelphinidins represent the active principle. Chain length influenced antiviral activity, as monomers and dimers were less effective than oligo- and polymers. Importantly, gallocatechin and its stereoisomer epigallocatechin exert antiviral activity also in their monomeric form. In addition, EPs® 7630 administered by inhalation significantly improved survival, body weight and body temperature of influenza-infected mice, without obvious toxicity, demonstrating the benefit of EPs® 7630 in treatment of influenza. Copyright © 2012 Elsevier B.V. All rights reserved.

  3. Estimating influenza vaccine effectiveness in an outbreak when anti-viral medications were used as a control measure.

    Science.gov (United States)

    Guy, Rebecca; Lambert, Stephen; Kelly, Heath

    2005-12-01

    To estimate influenza vaccine effectiveness (VE) from an outbreak of influenza A in an aged care facility in which neuraminidase inhibitors were used as part of outbreak control measures. The outbreak occurred between 25 December 2001 and 21 January 2002. Neuraminidase inhibitors were used to control the outbreak. Residents and staff with respiratory symptoms were tested for influenza using RT-PCR and/or serology. Vaccine effectiveness (VE) was estimated for the prevention of laboratory-confirmed influenza. Nineteen of 42 (45%) residents and four of 29 (14%) staff were laboratory-confirmed as cases. The outbreak was caused by an influenza A (H3N2) strain, antigenically matched to that season's vaccine. The VE for preventing laboratory-confirmed influenza infection was 61% (95% CI 41-73) among residents and 100% (95% CI 63-100) among staff. The VE estimates calculated from this outbreak were consistent with other published results. Outbreaks of influenza in institutions provide a good opportunity to review influenza VE, but use of antiviral medications as control measures may affect interpretation of findings.

  4. Generation and testing anti-influenza human monoclonal antibodies in a new humanized mouse model (DRAGA: HLA-A2. HLA-DR4. Rag1 KO. IL-2Rγc KO. NOD).

    Science.gov (United States)

    Mendoza, Mirian; Ballesteros, Angela; Qi, Qiu; Sang, Luis Pow; Shashikumar, Soumya; Casares, Sofia; Brumeanu, Teodor-D

    2017-11-14

    Pandemic outbreaks of influenza type A viruses have resulted in numerous fatalities around the globe. Since the conventional influenza vaccines (CIV) provide less than 20% protection for individuals with weak immune system, it has been considered that broadly cross-neutralizing antibodies may provide a better protection. Herein, we showed that a recently generated humanized mouse (DRAGA mouse; HLA-A2. HLA-DR4. Rag1KO. IL-2Rγc KO. NOD) that lacks the murine immune system and expresses a functional human immune system can be used to generate cross-reactive, human anti-influenza monoclonal antibodies (hu-mAb). DRAGA mouse was also found to be suitable for influenza virus infection, as it can clear a sub-lethal infection and sustain a lethal infection with PR8/A/34 influenza virus. The hu-mAbs were designed for targeting a human B-cell epitope (180WGIHHPPNSKEQ QNLY195) of hemagglutinin (HA) envelope protein of PR8/A/34 (H1N1) virus with high homology among seven influenza type A viruses. A single administration of HA180-195 specific hu-mAb in PR8-infected DRAGA mice significantly delayed the lethality by reducing the lung damage. The results demonstrated that DRAGA mouse is a suitable tool to (i) generate heterotype cross-reactive, anti-influenza human monoclonal antibodies, (ii) serve as a humanized mouse model for influenza infection, and (iii) assess the efficacy of anti-influenza antibody-based therapeutics for human use.

  5. Analysis of Anti-Influenza Virus Neuraminidase Antibodies in Children, Adults, and the Elderly by ELISA and Enzyme Inhibition: Evidence for Original Antigenic Sin.

    Science.gov (United States)

    Rajendran, Madhusudan; Nachbagauer, Raffael; Ermler, Megan E; Bunduc, Paul; Amanat, Fatima; Izikson, Ruvim; Cox, Manon; Palese, Peter; Eichelberger, Maryna; Krammer, Florian

    2017-03-21

    Antibody responses to influenza virus hemagglutinin provide protection against infection and are well studied. Less is known about the human antibody responses to the second surface glycoprotein, neuraminidase. Here, we assessed human antibody reactivity to a panel of N1, N2, and influenza B virus neuraminidases in different age groups, including children, adults, and the elderly. Using enzyme-linked immunosorbent assays (ELISA), we determined the breadth, magnitude, and isotype distribution of neuraminidase antibody responses to historic, current, and avian strains, as well as to recent isolates to which these individuals have not been exposed. It appears that antibody levels against N1 neuraminidases were lower than those against N2 or B neuraminidases. The anti-neuraminidase antibody levels increased with age and were, in general, highest against strains that circulated during the childhood of the tested individuals, providing evidence for "original antigenic sin." Titers measured by ELISA correlated well with titers measured by the neuraminidase inhibition assays. However, in the case of the 2009 pandemic H1N1 virus, we found evidence of interference from antibodies binding to the conserved stalk domain of the hemagglutinin. In conclusion, we found that antibodies against the neuraminidase differ in magnitude and breadth between subtypes and age groups in the human population. (This study has been registered at ClinicalTrials.gov under registration no. NCT00336453, NCT00539981, and NCT00395174.)IMPORTANCE Anti-neuraminidase antibodies can afford broad protection from influenza virus infection in animal models and humans. However, little is known about the breadth and magnitude of the anti-neuraminidase response in the human population. Here we assessed antibody levels of children, adults, and the elderly against a panel of N1, N2, and type B influenza virus neuraminidases. We demonstrated that antibody levels measured by ELISA correlate well with functional

  6. Vacuna Sintética contra la Malaria

    Directory of Open Access Journals (Sweden)

    Manuel Elkin Patarroyo

    1993-12-01

    Full Text Available

    El doctor Manuel Elkin Patarroyo hace un recuento de lo que fueron sus primeros años de estudio y los primeros pasos que se dieron para fundar el Instituto de Inmunología, ayudado por muchos de los Académicos. Siempre ha querido representar al pueblo colombiano en sus valores de trabajo, disciplina, estudio, pensamiento y generosidad, en aras de un pueblo que sufre, que en definitiva es el objetivo del Médico, el paciente.

    Posteriormente comenta qué es lo que se ha hecho con toda la profundidad que se merece pero con simpleza de palabras y en términos sencillos, cómo se desarrolló la Vacuna Sintética contra la malaria: ¿Por qué malaria?, porque esta es una enfermedad de gran trascendencia; aclara que él no le teme ni le molesta el cuestionamiento científico sobre el desarrollo de esta investigación, por el contrario lo acepta y lo goza porque es el ejercicio intelectual; lo que sí le molesta es el morbo alrededor de ello, por esto pidió al doctor Muñoz que al final se adelante un debate al respecto.

    Dice a continuación que las vacunas tradicionales son biológicas como todo el mundo lo sabe, es el microorganismo causal mismo que se muta ose mata, pero que descomponiendo la estructura química de sus moléculas, con el concepto de la síntesis química se podrían rehacer químicamente y ser utilizadas como vacuna.

    Decidieron entonces atacar el problema de la vacuna a través de esta metodología creando la vacuna contra la malaria de la cual se conoce su estructura química, y aclara que las vacunas químicas tienen otra ventaja, que son puras, con menos reacciones adversas que las tradicionales.

    Dice el doctor Patarroyo que decidieron aislar, e identificar más de la mitad de las proteínas del parásito y dividiendo la muestra en dos fracciones, una de ellas se seleccionó para averiguar su composición química y la otra para saber cuál podría ser útil como vacuna. Así, fueron al Amazonas y all

  7. Combination Chemotherapy for Influenza

    Directory of Open Access Journals (Sweden)

    Robert G. Webster

    2010-07-01

    Full Text Available The emergence of pandemic H1N1 influenza viruses in April 2009 and the continuous evolution of highly pathogenic H5N1 influenza viruses underscore the urgency of novel approaches to chemotherapy for human influenza infection. Anti-influenza drugs are currently limited to the neuraminidase inhibitors (oseltamivir and zanamivir and to M2 ion channel blockers (amantadine and rimantadine, although resistance to the latter class develops rapidly. Potential targets for the development of new anti-influenza agents include the viral polymerase (and endonuclease, the hemagglutinin, and the non-structural protein NS1. The limitations of monotherapy and the emergence of drug-resistant variants make combination chemotherapy the logical therapeutic option. Here we review the experimental data on combination chemotherapy with currently available agents and the development of new agents and therapy targets.

  8. Anti-inflammatory effects of rosmarinic acid-4-O-β-D-glucoside in reducing acute lung injury in mice infected with influenza virus.

    Science.gov (United States)

    Liu, Jian-Xing; Zhang, Ying; Hu, Qiu-Ping; Li, Ji-Qiang; Liu, Yun-Tao; Wu, Qing-Guang; Wu, Jian-Guo; Lai, Xiao-Ping; Zhang, Zhong-de; Li, Xiong; Li, Geng

    2017-08-01

    Rosmarinic acid-4-O-β-D-glucoside (RAG) is a dicaffeoyl phenolic compound isolated from Sarcandra glabra (Thunb.) Nakai. Preliminary studies show that RAG has significant anti-inflammatory properties and can alleviate ear swelling in mice and the paw swelling in rats. Here, the anti-influenza effects of RAG were investigated in mice infected with A/FM/1/47 H1N1 virus. The survival rate and body weight were observed, the lung edema, virus copies, inflammatory cytokines (including IL-4, IL-5, TNF-α and IFN-γ) and oxidative damage indexes (including SOD, MDA, NO, and CAT) were measured. Moreover, immune cell recruitment in alveoli was measured with white blood cells and differential counts. Therapeutic RAG concentrations substantially improve the symptoms, mitigate body weight loss and alleviate lung edema induced by virus, thus improve survival protection effects. Furthermore, RAG was shown to regulate influenza virus-induced inflammatory cytokine expression, specifically by downregulating the Th1 cell cytokines IFN-γ, TNF-α and upregulating the Th2 cell cytokines IL-4, IL-5. Cell migration and infiltration were also diminished after RAG administration. Copyright © 2017. Published by Elsevier B.V.

  9. Aceptabilidad de la vacuna contra el virus papiloma humano en padres de adolescentes, en colombia

    OpenAIRE

    Wiesner, Carolina; Piñeros, Marion; Cortés, Claudia; Jaime Ardila, Jaime Ardila

    2012-01-01

    Objetivo La vacuna contra el VPH es una nueva tecnología disponible para el control del cáncer de cuello uterino. Se espera, que en el menor tiempo posible esta vacuna pueda tener cobertura universal. Este artículo presenta la aceptabilidad que tiene los padres de adolescentes en Colombia hacia la vacuna contra el VPH y hace una aproximación a sus determinantes. Métodos Estudio cualitativo en cuatro regiones en Colombia. Se realizaron 17 grupos focales con padres de niñas y niños entre 11 a 1...

  10. Conocimientos, actitudes y prácticas sobre la influenza A(H1N1 2009 y la vacunación contra influenza pandémica: resultados de una encuesta poblacional Knowledge, attitudes and practices about influenza A(H1N1 2009, and influenza vaccine in Mexico: results of a population survey

    Directory of Open Access Journals (Sweden)

    María Eugenia Jiménez-Corona

    2012-12-01

    Full Text Available OBJETIVO: Evaluar conocimientos, actitudes y prácticas respecto a la pandemia de influenza, con especial énfasis en la vacuna contra influenza estacional y pandémica. MATERIAL Y MÉTODOS: Estudio transversal con muestreo polietápico probabilístico, realizado durante diciembre de 2009 en residentes mayores de 18 años de la Ciudad de México (y área metropolitana, Monterrey, Guadalajara y Mérida. RESULTADOS: Se incluyeron 1 600 sujetos (48.9% masculino; 34% había recibido vacuna contra influenza estacional en años pasados, 90.6% estaba dispuesto a recibir la vacuna contra A(H1N1. La principal causa de rechazo a la vacunación fue no confiar en la vacuna (46.5%. Principales medidas preventivas identificadas por los encuestados: lavado de manos (47.5%, vacuna contra A(H1N1 (28% y etiqueta respiratoria (19.4%. El nivel escolar (1.7, p=0.006 y edad (1.02, pOBJECTIVE: To assess knowledge, attitudes and practices regarding influenza pandemic, with special emphasis on issues related to influenza vaccine, seasonal and pandemic. MATERIALS AND METHODS: Cross-sectional study, probabilistic multistage sampling in patients over 18 years, residents of Mexico City (and metropolitan area, Monterrey, Guadalajara and Merida in December 2009. RESULTS: A total of 1.600 subjects (48.9% male were interviewed, 34% had previously received seasonal flu vaccine, 90.6% were willing to be vaccinated against A(H1N1, 46.5% of those who would not receive the vaccine was because they did not trust A (H1N1, 68% considered influenza A (H1N1 as a risk for their family. Hand washing was the preventive measure most commonly reported (47.5%, secondly influenza vaccine (28%. Schooling (1.7, p=0.006 and age (1.02, p<0.001 influence rejection to get vaccine. 82.9% of respondents rate the federal government's management as good or very good. CONCLUSIONS: There was a high acceptance rate for the pandemic influenza vaccine in Mexico when compared to similar studies in other

  11. Vacunas: progresos y nuevos retos para el control de enfermedades prevenibles

    National Research Council Canada - National Science Library

    Fonseca Pinto, Eduardo; Matta, Nubia Estela; Da-Cruz, Alda Maria

    2011-01-01

    .... Sin embargo, el desarrollo de vacunas sigue siendo un objetivo importante en inmunologia y en la ultima decada ha habido un cambio hacia un enfoque mas racional, basada en los hallazgos moleculares...

  12. Inmunogenicidad de la vacuna cubana recombinante heberbiovac HB en modelos experimentales y aplicados al humano

    National Research Council Canada - National Science Library

    González Ramírez, Victoria Esther; González Griego, Antonio; Ramírez Albajés, Victoria; Alerm González, Alina

    2000-01-01

    ... la utilización de la vacuna de producción cubana contra la hepatitis B. Se desarrollaron modelos experimentales y aplicados al humano que permitieron el estudio de inmunogenicidad mediante distintas...

  13. A plant extract of Ribes nigrum folium possesses anti-influenza virus activity in vitro and in vivo by preventing virus entry to host cells.

    Science.gov (United States)

    Ehrhardt, Christina; Dudek, Sabine Eva; Holzberg, Magdalena; Urban, Sabine; Hrincius, Eike Roman; Haasbach, Emanuel; Seyer, Roman; Lapuse, Julia; Planz, Oliver; Ludwig, Stephan

    2013-01-01

    Infections with influenza A viruses (IAV) are still amongst the major causes of highly contagious severe respiratory diseases not only bearing a devastating effect to human health, but also significantly impact the economy. Besides vaccination that represents the best option to protect from IAV infections, only two classes of anti-influenza drugs, inhibitors of the M2 ion channel and the neuraminidase, often causing resistant IAV variants have been approved. That is why the need for effective and amply available antivirals against IAV is of high priority. Here we introduce LADANIA067 from the leaves of the wild black currant (Ribes nigrum folium) as a potent compound against IAV infections in vitro and in vivo. LADANIA067 treatment resulted in a reduction of progeny virus titers in cell cultures infected with prototype avian and human influenza virus strains of different subtypes. At the effective dose of 100 µg/ml the extract did not exhibit apparent harming effects on cell viability, metabolism or proliferation. Further, viruses showed no tendency to develop resistance to LADANIA067 when compared to amantadine that resulted in the generation of resistant variants after only a few passages. On a molecular basis the protective effect of LADANIA067 appears to be mainly due to interference with virus internalisation. In the mouse infection model LADANIA067 treatment reduces progeny virus titers in the lung upon intranasal application. In conclusion, an extract from the leaves of the wild black currant might be a promising source for the development of new antiviral compounds to fight IAV infections.

  14. Estructura molecular y antigénica de la vacuna

    OpenAIRE

    SÁNCHEZ GLORIA INÉS; BEDOYA ASTRID MILENA; RUBIO ARLETH IVONNE; VANEGAS VÍCTOR ANDRÉS

    2009-01-01

    La proteína L1 del Virus del Papiloma Humano (VPH) constituye el 80% de la cápside viral. Las vacunas profilácticas contra el VPH son sintetizadas a partir de la proteína L1 ensamblada en Partículas similares al Virus (del inglés VLP), las cuales son altamente inmunogénicas generando anticuerpos específicos de tipo y en algunos casos pueden presentar reacción cruzada entre tipos de VPH filogenéticamente próximos. La estructura de la proteína L1 del VPH es importante porque confiere estabilida...

  15. Reacciones Secundarias Producidas por La Vacuna Oral Contra la Poliomielitis

    OpenAIRE

    Arias Segovia, Mesías; Departamento de Medicina, Area Hospitalaria N° 7 de Chorrillos, Lima, Perú; Pando Ramos, Enrique; Departamento de Medicina, Area Hospitalaria N° 7 de Chorrillos, Lima, Perú; De Baer, Eva J.; Departamento de Medicina, Area Hospitalaria N° 7 de Chorrillos, Lima, Perú

    2014-01-01

    El presente trabajo fué realizado durante las campañas de inmunización contra las poliomelitis mediante la vacuna oral tipo Sabin, vacunándose niños de 2 meses a 10 años de edad. La cantidad de niños utilizados en el presente estudio fué de 1,138, de los cuales 159 hicieron reacciones secundarias o sea en el 13.97%. Las manifestaciones reaccionales fueron las diarreas en 50.32 %, fiebre alta en 21.38%, malestar general en 7.55%, vómitos en 6.28%, naúseas y dolores abdominales en 3.77%, las ot...

  16. Controversias sobre vacunas en España, una oportunidad para la vacunología social

    OpenAIRE

    Tuells, José

    2016-01-01

    Durante los últimos meses, las noticias sobre vacunas en los medios de comunicación han tenido una significativa visibilidad en España. Distintas vacunas han acaparado titulares con trasfondo polémico. Se ha debatido sobre la baja adherencia a la vacuna antigripal o sobre la conveniencia de incluir las vacunas contra el neumococo y la varicela en el calendario infantil. Asimismo, el caso de difteria en Olot ha señalado a las minorías que rechazan la vacunación y reabierto la discusión sobre l...

  17. Efficacy and safety of treatment with an anti-m2e monoclonal antibody in experimental human influenza.

    Science.gov (United States)

    Ramos, Eleanor L; Mitcham, Jennifer L; Koller, Teri D; Bonavia, Aurelio; Usner, Dale W; Balaratnam, Ganesh; Fredlund, Paul; Swiderek, Kristine M

    2015-04-01

    The efficacy of TCN-032, a human monoclonal antibody targeting a conserved epitope on M2e, was explored in experimental human influenza. Healthy volunteers were inoculated with influenza A/Wisconsin/67/2005 (H3N2) and received a single dose of the study drug, TCN-032, or placebo 24 hours later. Subjects were monitored for symptoms, viral shedding, and safety, including cytokine measurements. Oseltamivir was administered 7 days after inoculation. Although the primary objective of reducing the proportion of subjects developing any grade ≥2 influenza symptom or pyrexia, was not achieved, TCN-032-treated subjects showed 35% reduction (P = .047) in median total symptom area under the curve (days 1-7) and 2.2 log reduction in median viral load area under the curve (days 2-7) by quantitative polymerase chain reaction (P = .09) compared with placebo-treated subjects. TCN-032 was safe and well tolerated with no additional safety signals after administration of oseltamivir. Serum cytokine levels (interferon γ, tumor necrosis factor α, and interleukin 8 and 10) were similar in both groups. Genotypic and phenotypic analyses showed no difference between virus derived from subjects after TCN-032 treatment and parental strain. These data indicate that TCN-032 may provide immediate immunity and therapeutic benefit in influenza A infection, with no apparent emergence of resistant virus. TCN-032 was safe with no evidence of immune exacerbation based on serum cytokine expression. Clinicaltrials.gov registry number. NCT01719874. © The Author 2014. Published by Oxford University Press on behalf of the Infectious Diseases Society of America. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.

  18. Bacterial ribonuclease binase exerts an intra-cellular anti-viral mode of action targeting viral RNAs in influenza a virus-infected MDCK-II cells.

    Science.gov (United States)

    Shah Mahmud, Raihan; Mostafa, Ahmed; Müller, Christin; Kanrai, Pumaree; Ulyanova, Vera; Sokurenko, Yulia; Dzieciolowski, Julia; Kuznetsova, Irina; Ilinskaya, Olga; Pleschka, Stephan

    2018-01-05

    Influenza is a severe contagious disease especially in children, elderly and immunocompromised patients. Beside vaccination, the discovery of new anti-viral agents represents an important strategy to encounter seasonal and pandemic influenza A virus (IAV) strains. The bacterial extra-cellular ribonuclease binase is a well-studied RNase from Bacillus pumilus. Treatment with binase was shown to improve survival of laboratory animals infected with different RNA viruses. Although binase reduced IAV titer in vitro and in vivo, the mode of action (MOA) of binase against IAV at the molecular level has yet not been studied in depth and remains elusive. To analyze whether binase impairs virus replication by direct interaction with the viral particle we applied a hemagglutination inhibition assay and monitored the integrity of the viral RNA within the virus particle by RT-PCR. Furthermore, we used Western blot and confocal microscopy analysis to study whether binase can internalize into MDCK-II cells. By primer extension we examined the effect of binase on the integrity of viral RNAs within the cells and using a mini-genome system we explored the effect of binase on the viral expression. We show that (i) binase does not to attack IAV particle-protected viral RNA, (ii) internalized binase could be detected within the cytosol of MDCK-II cells and that (iii) binase impairs IAV replication by specifically degrading viral RNA species within the infected MDCK-II cells without obvious effect on cellular mRNAs. Our data provide novel evidence suggesting that binase is a potential anti-viral agent with specific intra-cellular MOA.

  19. New treatments for influenza

    Directory of Open Access Journals (Sweden)

    Barik Sailen

    2012-09-01

    Full Text Available Abstract Influenza has a long history of causing morbidity and mortality in the human population through routine seasonal spread and global pandemics. The high mutation rate of the RNA genome of the influenza virus, combined with assortment of its multiple genomic segments, promote antigenic diversity and new subtypes, allowing the virus to evade vaccines and become resistant to antiviral drugs. There is thus a continuing need for new anti-influenza therapy using novel targets and creative strategies. In this review, we summarize prospective future therapeutic regimens based on recent molecular and genomic discoveries.

  20. Influenza Photos

    Science.gov (United States)

    ... Polio Whooping cough Influenza (flu) Rabies Yellow fever Influenza Photos Photographs accompanied by text that reads "Courtesy ... of these photos are quite graphic. Shows how influenza germs spread through the air when someone coughs ...

  1. ESTRUCTURA MOLECULAR Y ANTIGÉNICA DE LA VACUNA

    Directory of Open Access Journals (Sweden)

    SÁNCHEZ GLORIA INÉS

    2008-12-01

    Full Text Available La proteína L1 del Virus del Papiloma Humano (VPH constituye el 80% de la cápside viral. Las vacunas profilácticas contra el VPH son sintetizadas a partir de la proteína L1 ensamblada en Partículas similares al Virus (del inglés VLP, las cuales son altamente inmunogénicas generando anticuerpos específicos de tipo y en algunos casos pueden presentar reacción cruzada entre tipos de VPH filogenéticamente próximos. La estructura de la proteína L1 del VPH es importante porque confiere estabilidad a la cápside mediante el establecimiento de interacciones intra e intercapsoméricas lo que asegura la integridad viral y antigénicamente porque contiene los epítopes que inducen la respuesta inmune protectora. En estudios en los que se evaluó la antigenicidad de la proteína L1 se determinó que los epítopes inmunodominantes de la cápside viral se encuentran en los bucles B-C, D-E, F-G, H-I y en el extremo C-terminal. Estos bucles son poco conservados entre los diferentes genotipos y se encuentran en segmentos de la proteína expuestos en la superficie de la cápside. Los aminoácidos situados en los bucles B-C, F-G y H-I son primordiales para el reconocimiento por los anticuerpos neutralizantes. Los diferentes subtipos y variantes presentan cambios en estos aminoácidos o en residuos que conforman otros epítopes. En esta revisión se presentará un estado del arte de la proteína L1 del VPH genotipo 16, la estructura y su importancia en el desarrollo de vacunas contra la infección producida por este virus.

  2. [Accessing the features of surface neuraminidase (N1) of influenza A virus presenting on the platforms for anti-NA Abs screening].

    Science.gov (United States)

    Huang, Lan; Qin, Kun; Zhou, Jian-fang; Shu, Yue-long; Wei, Hong

    2013-02-01

    To understand if the Neuraminidase (N1) of Influenza A virus at the surface of yeast-displaying system, eukaryotic expression system and the infected cells could be used for anti-NA Abs screening, their activities and bindings to five candidate Abs were assayed. The surface NA expression was obtained by transfecting by recombinant NA constructors with specific tag-labels or live virus infection. The functional activity was measured by the fluorescent assay. Their bindings to the Abs were detected by flow cytometry. The surface NAs presenting on the yeast-displaying system and eukaryotic expression system exhibited functional NA activities as the NA at the surface of virus-infected cells which showed affinities to Ab1, 4, and 5. The same bindings to Abl and 5 were found in the surface NA expressed by eukaryotic expression system while minor binding was observed in the yeast displayed-NA. The epitopes of yeast-displayed NA may be different from the NAs present at eukaryotic expression system and the infected cells which more likely suitable for the screening of anti-NA Abs.

  3. Anti-influenza virus activity of two extracts of the blackcurrant (Ribes nigrum L.) from New Zealand and Poland.

    Science.gov (United States)

    Ikuta, Kazufumi; Mizuta, Katsumi; Suzutani, Tatsuo

    2013-01-01

    We investigated the inhibitory effect of extracts of blackcurrant (Ribes nigrum L.) from New Zealand and Poland on 4 strains of influenza virus (IFV) by the inhibition of virus adsorption; pandemic flu from 2009-2010 (IFV-AH1pdm), Hong Kong flu (IFV-AH3), oseltamivir phosphate-resistant Russian flu (IFV-AH1tamr) and influenza virus type B (IFV-B). The inhibitory effect of the extracts of blackcurrant or blueberry on the infectivity of the virion were evaluated by the inhibition of virus adsorption on the cell surface (adsorption-inhibitory assay). Three percent solutions of the blackcurrant extracts from New Zealand and Poland were enough to disinfect more than half of IFV-AH1pdm and IFV-B, and 10% solutions from both regions disinfected all IFV strains completely. Our previous study showed that the antiviral effect of the blackcurrant differed according to viral species. Here we showed that although the antiviral effect of Blackcurrant was slightly different within viral strains from one species, the extract of Blackcurrant could disinfect all of 4 IFV strains we examined. The extracts of blackcurrant showed definite potential for use as a disinfectant and antiseptic agent to prevent IFV infection.

  4. Los laboratorios públicos productores de vacunas: el nuevo paradigma

    Directory of Open Access Journals (Sweden)

    Akira Homma

    1998-10-01

    Full Text Available Los laboratorios públicos productores de vacunas de América Latina y el Caribe han contribuido en diferente grado al control y a la erradicación de las enfermedades prevenibles por vacunación y varios están produciendo las vacunas que se aplican rutinariamente en los programas nacionales de inmunización, como la vacuna antituberculosa (a base del bacilo de Calmette-Guérin, BCG, la vacuna contra difteria-tétanos-pertussis (DTP, el toxoide tetánico (TT, la vacuna antisarampionosa y la vacuna antipoliomielítica oral. Gracias a los adelantos científicos recientes, se prevé un aumento importante del número de vacunas seguras y eficaces que estarán disponibles en un futuro cercano para uso en los programas normales de vacunación. Sin embargo, los gastos asociados con el desarrollo de estas vacunas y con los derechos de propiedad intelectual que las protegen son cuantiosos. Además, pocos laboratorios en América Latina poseen la capacidad técnica para investigar y elaborar estas vacunas. Tales factores tendrán un impacto en la celeridad con que se incorporarán en los esquemas de vacunación de los países de la Región. En la actualidad, los laboratorios públicos productores de vacunas de la Región no están capacitados para competir en este nuevo contexto y corren el riesgo de ser desplazados del mercado por completo. De ahí la necesidad de que cambien radicalmente su manejo gerencial y su capacidad cientificotécnica, lo cual exige que los gobiernos se comprometan a mejorar y fortalecer aquellos aspectos políticos y financieros que garanticen la participación de los laboratorios nacionales en el suministro sostenible de vacunas a los programas de vacunación, así como en la investigación, desarrollo y producción de vacunas nuevasIn Latin America and the Caribbean, public laboratories that produce vaccines have contributed in varying degrees to the control and eradication of vaccine-preventable diseases, and several of them

  5. EFECTIVIDAD DE LA VACUNA CONTRA LA ENFERMEDAD DE NEWCASTLE EN EL CONTROL DE LA PAPILOMATOSIS BOVINA

    OpenAIRE

    Puri C., Oswaldo; Clínica de Animales Mayores, Facultad de Medicina Veterinaria, Universidad Nacional Mayor de San Marcos, Lima-Perú.; Delgado C., Alfredo; Clínica de Animales Mayores, Facultad de Medicina Veterinaria, Universidad Nacional Mayor de San Marcos, Lima-Perú.; Falcón P., Néstor; Facultad de Veterinaria y Zootecnia, Universidad Peruana Cayetano Heredia, Lima; Manchego S., Alberto; Laboratorio de Microbiología y Parasitología Veterinaria, Facultad de Medicina Veterinaria, Universidad Nacional Mayor de San Marcos, Lima

    2012-01-01

    Se evaluó la eficacia de la vacuna atenuada del virus de la enfermedad de Newcastle cepa La Sota (NDV-LS) en el tratamiento de la papilomatosis bovina. Se trabajó con 64 bovinos hembras mestizas con papilomatosis cutánea diagnosticada clínicamente, criados en fundos de la zona del Alto Mayo, San Martín. Un grupo (n=34) fue inoculado subcutáneamente (2 ml) con la vacuna atenuada del NDV-LS (109 dosis 50 infectiva en huevo) en dos oportunidades con intervalo de una semana, y evaluados clínicame...

  6. Perspectivas para el desarrollo de vacunas e inmunoterapia contra cáncer cervicouterino

    OpenAIRE

    GUZMÁN-ROJAS LILIANA; ALCOCER-GONZÁLEZ JUAN MANUEL; MADRID-MARINA VICENTE

    1998-01-01

    El cáncer cervicouterino representa un grave problema de salud pública, debido a la asociación de la neoplasia con el virus del papiloma humano; actualmente se realizan estudios usando estrategias dirigidas a combatir este patógeno, mediante vacunas, que podrían ser de gran utilidad para el control de la progresión de la enfermedad. El estudio tanto de la inmunología humoral como celular ha servido para el desarrollo de vacunas. Así, la utilización de partículas virales sintéticas para el est...

  7. Desarrollo de vacunas antipertúsicas via genómica-proteómica

    OpenAIRE

    Celso Pérez-Bolaños; Lourdes Lisbet Proenza-Alfonzo; Rafael Fando-Calzada

    2013-01-01

    Las vacunas convencionales se basan en la aplicación de diversos métodos bioquímicos, microbiológicos e inmunológicos sobre los agentes causales de las enfermedades. A pesar del éxito alcanzado en el control y prevención vacunal de muchas patologías infecciosas, en otros casos los resultados no han sido fructíferos, de modo que se impone explorar nuevos enfoques y posibilidades. El desarrollo y auge de la biología molecular representa una revolución en el diseño de nuevas vacunas contra una g...

  8. Vacuna contra virus del Papiloma Humano: Análisis de esquemas de dos dosificaciones

    OpenAIRE

    Acuña Rojas, Karen; Vega Quesada, Marco; Salazar Arias, Nazaret; Escalante Gómez, Carlos

    2016-01-01

    La infección por el virus del Papiloma Humano (VPH) es la enfermedad de transmisión sexual más frecuente alrededor del mundo, documenta-da tanto en mujeres como en hombres. Debido a su papel etiológico en el desarrollo de lesiones premalignas y malignas en diversos sitios anató-micos, se han desarrollado vacunas como herra-mientas en prevención primaria de estas neopla-sias y principalmente en el cáncer de cérvix. Las vacunas aprobadas han demostrado ser altamente efectivas en evitar la trans...

  9. La vacuna contra el virus del papiloma humano en la actualidad

    OpenAIRE

    Villacorta Martín, Diana

    2013-01-01

    La identificación del virus de papiloma humano como causa principal del desarrollo de cáncer de cuello uterino entre otras lesiones (también cáncer oral, vaginal, de vulva…) ha permitido el desarrollo de diferentes medidas de prevención entre las cuales se encuentran las vacunas. Las dos vacunas destacadas son la tetravalente (frente a los genotipos 6, 11,16, 18) o Gardasil, y la bivalente o Cervarix (sólo frente a los genotipos 16 y 18), éstos últimos son los más asociados a lesiones cancero...

  10. Influenza vaccination

    DEFF Research Database (Denmark)

    Østerhus, Sven Frederick

    2015-01-01

    The Cochrane Library was systematically searched for meta-analyses regarding influenza vaccination of various populations, both healthy and sick. An effect in reducing the number of cases of influenza, influenza-like illness or complications to influenza was found in some studies, but, generally......, the quality of the studies was low, and several studies lacked hard clinical endpoints. Data on adverse effects were scarce. More randomised controlled trials investigating the effects of influenza vaccination are warranted....

  11. Pitfalls in anti-influenza T cell detection by Elispot using thimerosal containing pandemic H1N1 vaccine as antigen.

    Science.gov (United States)

    Chauvat, A; Benhamouda, N; Loison, E; Gougeon, M L; Gey, A; Levionnois, E; Ravel, P; Abitbol, V; Roncelin, S; Marcheteau, E; Quintin-Colonna, F; Fridman, W H; Launay, O; Tartour, E

    2012-04-30

    Monitoring T cells in combination with humoral response may be of value to predict clinical protection and cross-protective immunity after influenza vaccination. Elispot technique which measures cytokine produced after antigen-specific T cell stimulation is used routinely to detect and characterize anti-viral T cells. We found that the preservative thimerosal present in most H1N1 pandemic vaccines, induced in vitro abortive activation of T cells followed by cell death leading to false-positive results with the Elispot technique. The size of the spots, usually not measured in routine analysis, appears to be a discriminative criterion to detect this bias. Multi-dose vials of vaccine containing thimerosal remain important for vaccine delivery and our results alert about false-positive results of Elispot to monitor the clinical efficacy of these vaccines. We showed that this finding extends for other T cell monitoring techniques based on cytokine production such as ELISA. Although measuring in vitro immune response using the whole vaccine used for human immunization directly reflects in vivo global host response to the vaccine, the present study strongly supports the use of individual vaccine components for immune monitoring due to the presence of contaminants, such as thimerosal, leading to a bias in interpretation of the results. Copyright © 2012 Elsevier B.V. All rights reserved.

  12. El legado de la Real Expedición Filantrópica de la Vacuna (1803-1810: las juntas de vacuna

    Directory of Open Access Journals (Sweden)

    Ramírez Martín, Susana María

    2004-06-01

    Full Text Available The Royal Vaccination Expedition, directed by the physicians Francisco Xavier Balmis and José Salvany, was the most important scientific and medical achievement of the Spanish colonial era. It took place at a time of political restlessness, and its achievements were thus conditioned by each of the cultures into which the vaccine was introduced. As its legacy, the philantropic expedition left the Vaccination Boards, established in the Americas as centers of medical expertise to sustain the expedition´s principal objetive: the battle against the smallpox epidemics in pursuit of public health.

    La Expedición de la Vacuna, dirigida por los médicos Francisco Xavier Balmis y José Salvany, es la gesta científica y sanitaria más importante de época colonial. Su desarrollo tuvo lugar en un momento político convulso y los resultados estuvieron condicionados por las sociedades donde la vacuna se estableció. El legado de esta expedición filantrópica fue la creación de las Juntas de Vacuna. Estas instituciones se erigieron como centros creadores de saber médico en América y consolidaron el objetivo primario de la expedición: la búsqueda de la salud pública luchando contra las epidemias de viruela.

  13. INFLUENCIA DE UNA VACUNA VECTORIZADA (MAREKGUMBORO) EN POLLOS DE LA LÍNEA GENÉTICA COBB 500

    OpenAIRE

    Fátima Graciela Arteaga Chávez; Gabriela Natalí Narváez Borja; Zoyla Estefany Sánchez Santana

    2013-01-01

    El presente trabajo tuvo como objetivo evaluar el efecto de una vacuna vectorizada (Marek - Gumboro) en pollos COBB 500. Se utilizaron 1300 pollitos con pesos promedio al nacer de 43 g los cuales se dividieron en dos grupos, el primero con 625 pollitos BB se aplicó la vacuna vectorizada y el segundo, con 675 pollitos BB, se aplicó la vacuna tradicional. Como indicado- res productivos se midió peso vivo semanal, peso a la canal y conversión alimenticia; para los indicadores de salud e inocuida...

  14. Vacuna per escurçar el tractament contra la tuberculosi

    OpenAIRE

    Cardona, Pere-Joan

    2006-01-01

    Un grup d'investigadors de la Unitat de Tuberculosi Experimental de la Fundació Institut Germans Trias i Pujol ha creat una vacuna que permet reduir la durada del tractament de la infecció latent que provoca la tuberculosi de nou mesos a només un.

  15. Protection against Influenza Virus Infection of Mice Fed Bifidobacterium breve YIT4064

    OpenAIRE

    Yasui, Hisako; Kiyoshima, Junko; Hori, Tetuji; SHIDA, Kan

    1999-01-01

    Mice fed Bifidobacterium breve YIT4064 and immunized orally with influenza virus were more strongly protected against influenza virus infection of the lower respiratory tract than ones immunized with influenza virus only. The number of mice with enhanced anti-influenza virus immunoglobulin G (IgG) in serum upon oral administration of B. breve YIT4064 and oral immunization with influenza virus was significantly greater than that upon oral immunization with influenza...

  16. Influenza virus neutralizing antibodies and IgG isotype profiles after immunization of mice with influenza A subunit vaccine using various adjuvants

    NARCIS (Netherlands)

    Benne, CA; Harmsen, M; vanderGraaff, W; Verheul, AFM; Snippe, H; Kraaijeveld, CA

    The influence of various adjuvants on the development of influenza virus neutralizing antibodies and distribution of anti-influenza virus IgG isotypes after immunization of mice with influenza A (H3N2) subunit vaccine was investigated. Serum titres of influenza virus neutralizing antibodies and

  17. Efecto protector de una vacuna recombinante contra la hepatitis B siguiendo tres esquemas de inmunización: Lima - Perú 2004

    Directory of Open Access Journals (Sweden)

    Luis Marocho

    2006-03-01

    Full Text Available Objetivo: Demostrar que el efecto protector contra la hepatitis B en estudiantes del área de ciencias de la salud susceptibles se logra igualmente luego de completar tres esquemas de vacunación, uno convencional y dos acortados en tiempo y dosis. Diseño: Estudio experimental, controlado, abierto y con asignación aleatoria de grupo. Materiales y Métodos: Participaron 89 alumnos del último año de estudios (internado de la Escuela Académico Profesional de Tecnología Médica, Facultad de Medicina, UNMSM, de ambos sexos y menores de 30 años, a quienes se asignó aleatoriamente a tres grupos de receptores de la vacuna, siguiendo uno de tres esquemas de vacunación: el convencional de tres dosis (0, 1 y 6 meses , el acortado de tres dosis (0, 1 y 2 meses y acortado de dos dosis (0 y 1 mes. Se excluyó los vacunados contra hepatitis B y aquellos que fueron positivos a marcadores de antígeno de superficie (HBsAg o anti core total (anti-HBc IgG. Según el cronograma establecido, se administró las dosis de vacuna recombinante contra virus de hepatitis B (REVAC-B en concentraciones de 20 mcg/mL y se tomó muestras de sangre para la titulación de anticuerpos. Resultados: La edad promedio de los 89 alumnos fue 23,5 años, siendo 51,7% (46 del sexo masculino y 48,3% (43 del femenino. A los 30 días de la primera dosis, el 12,4% alcanzó protección, a los 30 días posterior a la segunda dosis, 98,8%, y a los 180 días, hubo 100% de protección. Conclusiones: En el presente estudio se obtuvo igual efecto protector contra la hepatitis B mediante la administración de la vacuna con tres esquemas diferentes: esquema convencional (tres dosis, esquema acortado (dos dosis y esquema acortado (tres dosis. Se plantea la posibilidad de un esquema con dos dosis, el cual tendría un menor costo e igual beneficio.

  18. Avian influenza

    Science.gov (United States)

    Bird flu; H5N1; H5N2; H5N8; H7N9; Avian influenza A (HPAI) H5 ... The first avian influenza in humans was reported in Hong Kong in 1997. It was called avian influenza (H5N1). The outbreak was linked ...

  19. Emerging influenza

    NARCIS (Netherlands)

    E. de Wit (Emmie); R.A.M. Fouchier (Ron)

    2008-01-01

    textabstractIn 1918 the Spanish influenza pandemic, caused by an avian H1N1 virus, resulted in over 50 million deaths worldwide. Several outbreaks of H7 influenza A viruses have resulted in human cases, including one fatal case. Since 1997, the outbreaks of highly pathogenic avian influenza (HPAI)

  20. INFLUENCIA DE UNA VACUNA VECTORIZADA (MAREKGUMBORO EN POLLOS DE LA LÍNEA GENÉTICA COBB 500

    Directory of Open Access Journals (Sweden)

    Fátima Graciela Arteaga Chávez

    2013-12-01

    Full Text Available El presente trabajo tuvo como objetivo evaluar el efecto de una vacuna vectorizada (Marek - Gumboro en pollos COBB 500. Se utilizaron 1300 pollitos con pesos promedio al nacer de 43 g los cuales se dividieron en dos grupos, el primero con 625 pollitos BB se aplicó la vacuna vectorizada y el segundo, con 675 pollitos BB, se aplicó la vacuna tradicional. Como indicado- res productivos se midió peso vivo semanal, peso a la canal y conversión alimenticia; para los indicadores de salud e inocuidad de la vacuna se consideró morbilidad y mortalidad; los indi- cadores inmunológicos fueron el peso y tamaño de bolsa de Fabricio, bazo y timo. Además, se registró los ingresos y egresos de la producción. Se observó que los parámetros productivos tan- to peso vivo, conversión alimenticia, mortalidad, peso a la canal, estuvieron influenciados por la aplicación de la vacuna vectorizada (p<0.001 entre las semanas cuarta y sexta de edad. En la vacuna tradicional se tuvo un mayor grado de mortalidad con 1.62%. Los órganos linfoides tuvieron diferencias significativa (p<0.05 siendo de mayor tamaño en el grupo que recibió la vacuna vectorizada. Para el parámetro costo beneficio se observó una utilidad de 0.05 centavos por cada dólar invertido. El uso de la vacuna vectorizada en la producción de pollos de ceba COBB 500 favorece, tanto los parámetros productivos, como económicos.

  1. Perfil de seguridad de la vacuna antileptospirósica trivalente vax-SPIRAL®

    Directory of Open Access Journals (Sweden)

    Giset Jiménez

    2010-12-01

    Full Text Available Con el objetivo de mostrar el perfil de seguridad de la vacuna antileptospirósica cubana, vax-SPIRAL®, se realizó un estudio observacional descriptivo y transversal, a partir de la base de datos de la red nacional de farmacovigilancia a medicamentos. Se estimó la frecuencia de reportes por dosis de vacunas administradas, la valoración de causalidad, severidad, localización y los eventos adversos con mayor asociación estadística, a partir del cálculo de disproporcionalidad de las combinaciones de eventos adversos a vacunas de todos los diagnósticos en los reportes de eventos del grupo farmacológico de vacunas y el cálculo de la Razón de Riesgo Proporcional (PRR y la Razón Diferencial de Riesgo (ROR. Hubo 1,62 reportes por 100 000 dosis administradas y 1,9 diagnósticos por reporte en personas entre 18 y 77 años de edad y una media ±DE de 40 ± 13 años, con predominio del sexo femenino (65,54%. No se reportaron casos graves; el 74,17% fueron con severidad leve y el 66,96% fueron manifestaciones adversas sistémicas. El 94,17% de los reportes estuvieron relacionados con la vacuna. Los eventos adversos más frecuentes fueron: fiebre/hipertermia (18,75%, cefalea (14,73%, dolor local (13,84%, enrojecimiento/eritema/rubor en el sitio de inyección (12,05%, malestar general (8,48% y manifestaciones de hipersensibilidad mínimas, sólo a nivel cutáneo. Entre los que mostraron mayor asociación: cefalea, malestar general y rubor. Los resultados obtenidos son similares y con mejor perfil de seguridad que los de la vacuna francesa SPIROLEPT, por lo cual se recomienda para la protección en grupos de riesgo de leptospirosis.

  2. Meningitis - H. influenzae

    Science.gov (United States)

    H. influenzae meningitis; H. flu meningitis; Haemophilus influenzae type b meningitis ... H. influenzae meningitis is caused by Haemophilus influenzae type b bacteria. This illness is not the same as the flu ( influenza ), ...

  3. Análisis económico de las vacunas 10-valente y 13-valente contra neumococo: revisión sistemática

    OpenAIRE

    Torres Garrido, Alba Luz; Vargas-Zambrano, Juan-Camilo

    2014-01-01

    Introducción: Las vacunas clásicamente han representado un método económico y eficaz para el control y prevención de múltiples enfermedades infecciosas. En los últimos años se han introducido nuevas vacunas contra neumococo a precios elevados, y los diferentes análisis económicos a nivel mundial de estas vacunas no muestran tendencias. El objetivo de este trabajo era resumir la evidencia existente a través de los diferentes estudios económicos evaluando las dos vacunas de segunda generación c...

  4. Provada amb èxit en cabres una nova vacuna contra la tuberculosi

    OpenAIRE

    Pérez del Val, Bernat

    2014-01-01

    Investigadors del CReSA proven per primer cop i amb èxit una nova vacuna contra la tuberculosi que millora la protecció de l’única vacuna existent en l’actualitat, l’eficàcia de la qual és força limitada. Els estudis s’han realitzat emprant cabres domèstiques, que reprodueixen amb elevada similitud les característiques patològiques i la resposta immunològica a la infecció tuberculosa activa en humans i que, pel fet de ser hostes naturals de la tuberculosi, també permeten estudiar l’ús potenci...

  5. Conocimientos de los pediatras de Salvador, Brasil, sobre la vacuna antisarampionosa

    Directory of Open Access Journals (Sweden)

    Luiza A. Cabus Moreira

    1997-12-01

    Full Text Available El éxito de las iniciativas internacionales para la erradicación del sarampión depende en gran medida del grado de conocimiento sobre la vacunación. En 1992 se evaluaron mediante un estudio transversal los conocimientos sobre la vacuna antisarampionosa de los pediatras de la ciudad brasileña de Salvador, Bahia. Del total de 506 pediatras residentes en la ciudad, 299 (59% pudieron ser localizados y respondieron a un cuestionario de 15 preguntas en las que se planteaban situaciones hipotéticas sobre indicaciones y contraindicaciones de esta vacuna. El promedio de aciertos fue de 9,3 preguntas de las 15, lo que muestra el poco conocimiento de los pediatras sobre la vacunación antisarampiososa. Situaciones comunes en la práctica pediátrica brasileña -desnutrición, infección de vías respiratorias altas, diarrea y estado prematuro- fueron a menudo erróneamente consideradas como contraindicaciones para la inmunización. Más de la mitad (62% de los pediatras no conocían la vía correcta de administración de la vacuna. Los conocimientos sobre la vacuna no variaron en función del tiempo transcurrido desde la formación universitaria del pediatra o de su trabajo en centros sanitarios de la Secretaría Estatal de Salud. Los profesores universitarios, los pediatras con maestría y los que cursaban estudios de posgrado tuvieron una media de aciertos ligeramente superior a la del resto. Estos resultados indican la necesidad de reforzar la enseñanza sobre la vacunación antisarampionosa en las facultades de medicina y en los programas de formación continuada para pediatras.

  6. Vacunas para la prevención de la gripe en personas de edad avanzada

    Directory of Open Access Journals (Sweden)

    Tom Jefferson

    2010-09-01

    Conclusiones de los autores: Las pruebas disponibles son de calidad deficiente y no proporcionan orientación con respecto a la seguridad, la eficacia o la efectividad de las vacunas contra la gripe en las personas de 65 años de edad o más. Para resolver la incertidumbre se debe realizar un ensayo aleatorio controlado con placebo, con financiamiento público y con poder estadístico adecuado, durante varias estaciones.

  7. Evaluación de la inmunogenicidad de una vacuna recombinante antivirus hepatitis B en mujeres adultas sanas, Santafé de Bogotá, D.C., julio 1997 - noviembre 1998

    National Research Council Canada - National Science Library

    María T. Herrera Mendoza; Jaime Escobar López; Clara l. Saavedra Abril; Claudia P. Robles Roa; Fritz Gempele; Eduardo Egea Bermejo; Antonio Iglesias Gamarra

    1999-01-01

    Este estudio se realizó con el propósito de evaluar la inmunogenicidad de la vacuna recombinante antivirus de la hepatitis B HEPRECOMB BERNABy el desarrollo de efectos secundarios atribuibles a la vacuna y a la...

  8. PRACTICAS MEDICAS, PRACTICAS POLITICAS. ROSAS Y LA «VACUNA INDIGENA»

    Directory of Open Access Journals (Sweden)

    MARÍA SILVIA DI LISCIA

    2011-10-01

    Full Text Available BUENOS AIRES, 1830. Se declara una epidemia de viruela entre los indios «pampas» que están en la ciudad para honrar al Restaurador de las Leyes. Los caciques no disimulan su admiración ante la valentía de Rosas, quien los visita sin alarma ante el contagio y los estimula a vacunarse para eliminar el temible mal. Un número estimado en más de cien indios acepta, entonces, inmunizarse, colocándose, según el testimonio de Parish, la «vacuna a indígenas ». Buenos Aires, 1833. Francisco X. Muñiz, médico de la campaña bonaerense, inicia las investigaciones con las que diez años después se logra el redescubrimiento del cow pox, es decir, la viruela vacuna, llamada por Sarmiento «la vacuna indígena».

  9. La Real Expedición Filantrópica de la vacuna (1803 - 1810

    Directory of Open Access Journals (Sweden)

    Jorge Veiga de Cabo

    2007-12-01

    Full Text Available La Expedición Filantrópica de la vacuna supuso una de las empresas sanitarias realizadas en el Siglo XVIII de mayor envergadura, por su complejidad, dificultad y sobre todo, por constituir una de las misiones de Salud Pública más importantes realizadas en la Historia. Supone el resultado de un proceso en el que una serie de acontecimientos históricos, sanitarios y sociales confluyen para generar uno de los primeros programas de intervención en salud pública a escala internacional y de expansión de la vacuna de la viruela. Se crean Centros de producción, almacenamiento y distribución de la vacuna, y programas de capacitación técnica enfocados a mantener campañas de vacunación poblacional.One of the most important medical achievements made in the eighteenth century was the Philanthropic Expedition of the Vaccine. Due to its complexity and difficulty it was one of the most important Public Health undertakings in history. It was the outcome of a series of historical, social and health advances that converged in creating one of the earliest international programs for the expansion of the smallpox vaccine, creating centres for the production, storage and distribution of the vaccine together with technical training programs aimed at maintaining population vaccination campaigns.

  10. Perspectivas para nuevas vacunas antituberculosas en la era posgenómica.

    Directory of Open Access Journals (Sweden)

    Luis F. García

    2004-06-01

    Full Text Available A pesar de que la vacunación con Mycobacterium bovis BCG es el procedimiento más utilizado a nivel mundial para prevenir la tuberculosis, su eficicacia es muy cuestionable, lo cual ha motivado la búsqueda de nuevas opciones inmunoprofilácticas. El conocimiento generado con el secuenciamiento completo de una cepa de Mycobacterium tuberculosis H37Rv y la aplicación de nuevas tecnologías inmunológicas, bioquímicas y genéticas han permitido realizar una disección fina del transcriptoma y el proteoma de M. tuberculosis, lo cual ha generado una gran cantidad de conocimiento sobre la biología de este microorganismo. Dado que alrededor de una tercera parte de la población mundial puede estar infectada con M. tuberculosis y que éste sólo se detecta cuando se inicia la enfermedad, la mayor parte de los esfuerzos se han dedicado al diseño de vacunas posinfección que induzcan un aumento selectivo de la inmunidad celular específica del hospedero a largo plazo, no generen reacciones adversas y sean de bajo costo. Dentro de las nuevas estrategias que están siendo utilizadas para el desarrollo de vacunas, se destaca la utilización de mezclas de proteínas con una alta inmunogenicidad, cepas de M. bovis BCG recombinantes y de M. tuberculosis genéticamente atenuadas o modificadas para inducir una mayor respuesta inmune, y las vacunas de ADN desnudo. Los candidatos con más potencial incluyen las vacunas de subunidades micobacterianas, las cuales expresan moléculas ampliamente reconocidas por el sistema inmune y cuyo reconocimiento resulta en el incremento de la respuesta Th1 y aquéllas que utilizan vectores virales diseñados para expresar moléculas micobacterianas antigénicas. Aunque los modelos animales son de valor limitado, puesto que la patología observada en ellos sólo reproduce parcialmente la observada en humanos, los resultados obtenidos con estas vacunas son muy prometedores y algunas están siendo actualmente evaluadas en

  11. Evaluación de la inmunogenicidad de una vacuna recombinante antivirus hepatitis B en mujeres adultas sanas, Santafé de Bogotá, D.C., julio 1997 - noviembre 1998

    Directory of Open Access Journals (Sweden)

    María T. Herrera Mendoza

    1999-06-01

    Full Text Available Este estudio se realizó con el propósito de evaluar la inmunogenicidad de la vacuna recombinante antivirus de la hepatitis B HEPRECOMB BERNABy el desarrollo de efectos secundarios atribuibles a la vacuna y a la vía de aplicación, empleando y comparando dos dosis distintas en individuos sanos sin evidencia clínica de enfermedad hepática y sin evidencia serológica de contacto previo con VHB (virus hepatitis 6. Igualmente se monitorizó la respuesta humoral in vivo inducida por la aplicación de esta vacuna. Se incluyeron 50 voluntarios del sexo femenino en Santafé de Bogotá, los cuales fueron divididos al azar en dos grupos: El grupo 1, vacunado con tres dosis de 20pg, y el grupo 2, vacunado con tres dosis de 10pg; en ambos grupos se utilizó el esquema O, 1, 6 meses y fueron observados durante 7 meses. Los criterios de inclusión en el estudio fueron la participación voluntaria, edad mayor de 18 años y ausencia de antiHBsAg. El título de anticuerpos fue significativamente mayor para el grupo 2 ( P= 0.03 a los dos y seis meses, aunque al séptimo mes los títulos se igualaron. El trabajo concluyó que lavacuna recombinante antivirus de la hepatitis B HEPRECOMB BERNA 8 con la dosis de 10pg tiene una mayor respuesta a los dos y seis meses de observación, que con la dosis de 20pg, llegando a resultados similares al séptimo mes. Se recomienda realizar estudios con una muestra mayor.

  12. La influenza, un problema vigente de salud pública Influenza, an existing public health problem

    Directory of Open Access Journals (Sweden)

    Juan García-García

    2006-06-01

    Full Text Available La influenza estacional es una enfermedad respiratoria aguda, recurrente y común que se conoce desde la antigüedad y se presenta sobre todo durante los meses de invierno con un elevado impacto para la salud pública mundial. La enfermedad se manifiesta con altas tasas de morbilidad en individuos de todas las edades y elevadas tasas de mortalidad en niños, individuos mayores de 60 años, pacientes con enfermedades crónicas y mujeres en gestación. Las estrategias de prevención incluyen el uso de vacunas: inactivadas, subunitarias o vacuna con virus genéticamente modificados. Dos subtipos de virus de influenza tipo A y un virus de influenza tipo B causan la enfermedad en humanos. Los virus de influenza A que afectan a los humanos mutan con facilidad, por lo que con frecuencia aparecen nuevas variantes antigénicas de cada subtipo, lo que obliga a incluir dichas variantes en las vacunas anuales para brindar una adecuada protección a la población. La influenza pandémica se refiere a la introducción y posterior diseminación mundial de un nuevo virus de influenza en la población humana, lo que ocurre de manera esporádica, y que debido a que los humanos carecen de inmunidad para el nuevo virus pueden suscitarse epidemias graves con elevadas tasas de morbilidad y mortalidad. Históricamente el origen de las pandemias de influenza se debe a la transmisión de virus de aves al hombre o la transferencia de genes de éstos a los virus de la influenza estacional. En las aves acuáticas silvestres, tanto migratorias como costeras, se mantiene una gran diversidad de subtipos de virus de influenza, los cuales se introducen eventualmente en aves domésticas, donde algunos virus adquieren la capacidad de infectar a mamíferos, incluido el hombre. El proceso de adaptación de los virus aviarios a hospederos mamíferos requiere tiempo, por lo que la presentación de estos casos puede tardar varios años. Desde diciembre de 2003, en varios países del

  13. Mejorar el acceso mundial a las nuevas vacunas: propiedad intelectual, transferencia de tecnología y vías de reglamentación

    Directory of Open Access Journals (Sweden)

    Sara Eve Crager

    2015-01-01

    Full Text Available En el Plan de acción mundial sobre vacunas, aprobado por la Asamblea Mundial de la Salud en el 2012, se hizo un llamamiento en pro del acceso mundial a las nuevas vacunas en un plazo de 5 años desde que se otorga la licencia. Sin embargo, los métodos actuales han resultado insuficientes para lograr fijar precios sostenibles para las vacunas en dicho plazo. En paralelo con la estrategia exitosa de la competencia de los genéricos para reducir el precio de los medicamentos, está surgiendo un consenso claro sobre el hecho de que la entrada en el mercado de múltiples proveedores es un factor fundamental para reducir rápidamente el precio de las nuevas vacunas. En este contexto, los principales objetivos para mejorar el acceso a las nuevas vacunas incluyen superar los obstáculos de la propiedad intelectual, simplificar las vías de reglamentación de las vacunas biosimilares y reducir los plazos de entrada en el mercado de los fabricantes de vacunas de los países en desarrollo mediante la transferencia de tecnología y conocimientos prácticos. En este artículo propongo crear un banco de propiedad intelectual, tecnología y conocimientos prácticos como un nuevo enfoque a fin de facilitar el acceso generalizado a las nuevas vacunas en los países de ingresos medianos y bajos mediante la transferencia eficaz de las técnicas de producción de vacunas patentadas a múltiples fabricantes de vacunas en los países en desarrollo.

  14. Enfermedad meningocócica: epidemiología y vacunas, un enfoque práctico

    Directory of Open Access Journals (Sweden)

    C. Giannina Izquierdo, Dra.

    2014-05-01

    Las principales estrategias para la prevención de la enfermedad son el uso de vacunas (prevención primaria y el uso de quimioprofilaxis a los contactos de un caso índice (prevención secundaria. A la fecha existen numerosas vacunas contra Nmen, todas ellas con adecuados perfiles de seguridad e inmunogenicidad, por lo que la elección de la vacuna a utilizar dependerá del serogrupo prevalente en cada país; de las características de la población más afectada y de la factibilidad de disponer de ella e insertarla dentro de los programas nacionales o campañas respectivas de vacunación.

  15. Vacuna contra la fiebre hemorrágica argentina Candid#1 producida en la Argentina: Inmunogenicidad y seguridad

    Directory of Open Access Journals (Sweden)

    Delia A. Enria

    2010-06-01

    Full Text Available Se realizó un estudio clínico en 946 voluntarios humanos sanos, donde se comparó la vacuna Candid#1 producida en Argentina con la elaborada en EE.UU., que había sido utilizada en estudios previos. Como objetivo primario se evaluó la equivalencia en la eficacia utilizando como marcador subrogante a la inmunogenicidad medida por detección de anticuerpos neutralizantes. Como objetivo secundario se evaluó la equivalencia en inocuidad comparando las tasas de reacciones adversas. Ambas vacunas mostraron una tasa equivalente de inmunogenicidad ligeramente superior al 95.5%, que es la eficacia estimada para Candid #1 en estudios previos. No se observaron eventos adversos graves relacionados con la vacuna. Los eventos adversos generales considerados relacionados fueron de escasa significación clínica y de resolución espontánea o con tratamiento sintomático; se presentaron en los receptores de ambas vacunas en tasas equivalentes (29.9% para la vacuna fabricada en la Argentina y 35.0% para la fabricada en EE.UU., e incluyeron: cefalea, decaimiento, mialgias, plaquetopenia leve (< 150 000 plaquetas/mm³, náuseas y/o vómitos, leucopenia leve (< 4 000 blancos/mm³, fiebre, dolor retroocular, mareos, microhematuria, lumbalgia y exantema. Estos resultados indican que la vacuna Candid #1 elaborada en la Argentina es equivalente a la elaborada en los EE.UU. Este estudio permitió el registro del biológico producido en la Argentina ante la autoridad regulatoria del país (ANMAT.

  16. Refrigeración de vacunas mediante una máquina frigorífica por efecto Peltier

    OpenAIRE

    Lucas Guerra, Ana

    2011-01-01

    El proyecto “Refrigeración de vacunas mediante una máquina frigorífica por efecto Peltier” estudia el control de la temperatura dentro de un volumen fijo de aire a fin de conservar vacunas. En este proyecto se describen las nuevas tecnologías refrigeración más demandadas y estudiadas en la actualidad en concreto de la tecnología de la termoelectricidad. La tecnología termoeléctrica en el campo de la refrigeración está basada en el principio del efecto Peltier que permite el bombeo de calor de...

  17. Vacunas de ADN: inducción de la respuesta inmunitaria DNA Vaccines: Induction of the immune response

    OpenAIRE

    Javier Mota-Sánchez

    2009-01-01

    La efectividad de las vacunas y la inmunización en la prevención de las enfermedades infecciosas es uno de los grandes avances de la medicina. En la actualidad, el acceso a la tecnología de punta en el área de la genómica y la proteómica ha hecho posible acelerar el desarrollo de nuevos modelos de vacunas con características mejoradas en aspectos fundamentales, como la inmunogenicidad y la seguridad. A casi dos décadas del primer informe, en el cual se demostró que un gen puede expresarse med...

  18. Inmunoterapia en melanoma: vacunas de células dendríticas

    Directory of Open Access Journals (Sweden)

    Ivan Lozada-Requena

    Full Text Available La presente es una revisión narrativa que muestra la información accesible a la comunidad científica sobre melanoma e inmunoterapia. Las células dendríticas tienen la capacidad de participar en la inmunidad innata y adaptativa, pero no son ajenas a la evasión inmune de los tumores. Conocer su biología y rol ha llevado a generar in vitro varios prospectos de vacunas celulares autólogas contra diversos tipos de cáncer en humanos y modelos animales; sin embargo, en vista de la poca eficiencia que han mostrado, se deben implementar estrategias para potenciar su capacidad natural ya sea a través de la coexpresión de moléculas clave para activar o reactivar al sistema inmune, en combinación con biosimilares o drogas quimioterapeúticas y no se debe descartar la acción de productos naturales como alternativa inmunoestimulante o adyuvante. Todos los tipos de inmunoterapía deberían medir el impacto de las células supresoras de origen mieloide, las que pueden atacar al sistema inmune y ayudar a la progresión tumoral, respectivamente. Esto puede reducir la actividad de las vacunas celulares y/o sus combinaciones pudiendo ser la diferencia entre el éxito o no de la inmunoterapia. Aunque en melanoma existen biosimilares aprobados por la Food and Drug Administration (FDA no todos tienen el éxito esperado por lo que es necesario evaluar otras estrategias que incluyan vacunas celulares cargadas con péptidos antigénicos tumorales expresados exclusivamente o antígenos provenientes de extractos tumorales y sus respectivos adyuvantes.

  19. Swine Influenza/Variant Influenza Viruses

    Science.gov (United States)

    ... Address What's this? Submit What's this? Submit Button Influenza Types Seasonal Avian Swine Variant Other Information on Swine Influenza/Variant Influenza Virus Language: English (US) Español Recommend ...

  20. Vacuna en front al virus del ebola: un repte de desenvolupament i comunicació

    OpenAIRE

    Velasco, César; Casajuana, Cristina; Bosque-Prous, Marina

    2015-01-01

    L'Ebola és una malaltia transmissible, greu i sovint mortal. Els epidemiòlegs controlen les epidèmies d'ebola mitjançant mesures d'aïllament i seguiment de contactes. Quan el nombre de contagis és elevat una vacuna pot ser crucial en la disminució de la transmissió. La necessitat de disposar de vacunes enfront del virus de la ebola ha accelerat el desenvolupament experimental i els assajos clínics. En aquest article s'introdueix el virus de la ebola, s'exposen les fases de desenvolupament de ...

  1. Una vacuna pel virus de l’Ebola : un repte de desenvolupament i comunicació

    OpenAIRE

    Velasco Muñoz, César

    2015-01-01

    L'Ebola es una malaltia transmissible, greu i sovint mortal. Els epidemiòlegs controlen les epidèmies d'ebola mitjançant mesures d'aïllament i seguiment de contactes. Quan el nombre de contagis és elevat una vacuna pot ser crucial en la disminució de la transmissió. La necessitat de disposar de vacunes enfront del virus de la ebola ha accelerat el desenvolupament experimental i els assajos clínics. En aquest article s'introdueix el virus de la ebola, s'exposen les fases de desenvolupament de ...

  2. Validación de inmunoensayos cualitativos usados para evaluar la inmunogenicidad de vacunas

    Directory of Open Access Journals (Sweden)

    Rolando Ochoa

    2000-03-01

    Full Text Available Se realizó una revisión y actualización sobre la importancia de la validación de los inmunoensayos cualitativos usados para evaluar la inmunogenicidad de vacunas, sus principios y procedimientos. Se discutieron los principales parámetros empleados para evaluar estas técnicas. Se analizaron detalladamente los procedimientos para estudiar la sensibilidad, especificidad, valores predictivos positivos y negativos, valor de discriminación y zona gris. Se exponen nuestras experiencias.

  3. Vectores recombinantes basados en el virus Vaccinia modificado de Ankara (MVA) como vacunas contra la leishmaniasis

    OpenAIRE

    Pérez Jiménez, Eva; Larraga, Vicente; Esteban, Mariano

    2005-01-01

    Vectores recombinantes basados en el virus vaccinia modificado de Ankara (MVA) como vacunas contra la leishmaniasis. Los vectores de la invención contienen secuencias codificantes de la proteína LACK, preferentemente insertadas en el locus de hemaglutinina del virus y bajo el control de un promotor que permite su expresión a lo largo del ciclo de infección del virus. Son vectores seguros, estables, que dan lugar a una potente respuesta inmune que confiere protección frente a la leishmaniasis,...

  4. Estudio de tolerancia local de la vacuna vax-TyVi® en ratas Sprague Dawley

    Directory of Open Access Journals (Sweden)

    Eligio Sosa Roble

    2005-05-01

    Full Text Available La vacuna antitifoídica vax-TyVi® consiste en una preparación de polisacárido capsular Vi de Salmonella typhi, el cual es diluido en una solución buffer isotónica solución amortiguador, a la que se le añade fenol como preservo. Cada dosis de 0,5 mL contiene 25 μg de polisacárido como sustancia activa. En nuestro país el esquema de vacunación contra la fiebre tifoidea con vax- TyVi® se aplica a los alumnos de 9-10 años (5to grado, una 2da dosis a la edad de 12-13 años (8vo grado y una 3ra dosis a la edad de 16-17 años (11no grado. Además, es vacunado el personal de riesgo de Salud Pública y el personal que manipula alimentos. En el presente trabajo se describe el ensayo de tolerancia local llevado a cabo con la vacuna vax-TyVi® durante su fase de estudios preclínicos, actualmente utilizada en la vacunación contra la fiebre tifoidea en Cuba. Se empleó un total de 170 ratas que fueron tratadas con la vacuna, su placebo (todos los componentes, excepto la materia prima activa, o que no recibieron tratamiento alguno (controles. Se realizaron observaciones clínicas diarias durante todo el ensayo, se determinó el consumo de agua y alimentos y se realizaron investigaciones anatomopatológicas a animales sacrificados 3, 7, 14, 21, 28, 35 y 42 días después de la inoculación. No se observaron muertes ni síntomas de toxicidad; no se encontraron diferencias estadísticamente significativas entre los pesos vivos, el consumo de agua ni el de alimentos entre los grupos del ensayo. Tampoco se observaron lesiones anatomopatológicas que indicaran toxicidad por parte del producto inoculado. Los resultados permitieron concluir que la potencialidad de la vacuna vax-TyVi® para producir efectos adversos locales es baja.

  5. Uso de agonistas de TLRs para mejorar la respuesta inmune en vacunas

    OpenAIRE

    Barettino Luengo, Elena

    2016-01-01

    Los receptores TLR (Toll-Like Receptor) son proteínas transmembrana presentes en células del sistema inmune innato. Su activación desencadena una respuesta inflamatoria e inmune dirigida a destruir el patógeno y es una pieza decisiva en la maduración de las células presentadoras de antígeno, sirviendo de puente entre la inmunidad innata y la adaptativa. Esta estimulación del sistema inmune supone que los ligandos de los TLRs puedan tener aplicación como adyuvantes en vacunas. En esta revis...

  6. Vacuna frente a infestaciones provocadas por artrópodos hematófagos

    OpenAIRE

    Fuente, José de la; Villar, Margarita; Prudencio, Carlos Roberto; Pérez de Lastra, José Manuel

    2012-01-01

    La presente invención describe una vacuna frente a infestaciones provocadas por artrópodos hematófagos preferentemente garrapatas, mosquitos, flebótomos, ácaros rojos de las gallinas, pulgas, piojos, piojos de mar, etc. Así mismo, se protege un péptido capaz de inducir una respuesta inmune protectora y de reacción cruzada frente a una infestación provocada por artrópodos hematófagos, un polinucleótido, un vector de expresión, una célula hospedadora, un animal no hum...

  7. MEJORAMIENTO DE LA PRODUCCIÓN DE UNA VACUNA OLEOSA CONTRA ESTOMATITIS VESICULAR BIVALENTE

    OpenAIRE

    Arbeláez, Gustavo; Departamento de Microbiología, Facultad de Ciencias, Pontificia Universidad Javeriana, Cra. 7 Nº 43 - 82, Bogotá; Mondragón, Nestor; Empresa Colombiana de Productos Veterinarios Vecol S.A., Bogotá; Turriago, Clara; Empresa Colombiana de Productos Veterinarios Vecol S.A., Bogotá; Mora, Nelson; Empresa Colombiana de Productos Veterinarios Vecol S.A., Bogotá; Méndez, María; Empresa Colombiana de Productos Veterinarios Vecol S.A., Bogotá

    2008-01-01

    El presente estudio calculó diferentes MI (Multiplicidad de Infección) para la producción de cultivos industriales de virus de Estomatitis Vesicular (EV) y evaluó el efecto de la cantidad de glicoproteína G en la inducción de respuesta de anticuerpos neutralizantes contra el virus de EV en cobayos inmunizados con una vacuna oleosa bivalente (Indiana (I) y New Jersey (NJ)). Al establecer el MI más eficiente se logró mejorar la cinética de infección de los cultivos industriales disminuyendo los...

  8. Epidemiological and Virological Characterization of Influenza B Virus Infections.

    Directory of Open Access Journals (Sweden)

    Sivan Sharabi

    Full Text Available While influenza A viruses comprise a heterogeneous group of clinically relevant influenza viruses, influenza B viruses form a more homogeneous cluster, divided mainly into two lineages: Victoria and Yamagata. This divergence has complicated seasonal influenza vaccine design, which traditionally contained two seasonal influenza A virus strains and one influenza B virus strain. We examined the distribution of the two influenza B virus lineages in Israel, between 2011-2014, in hospitalized and in non-hospitalized (community influenza B virus-infected patients. We showed that influenza B virus infections can lead to hospitalization and demonstrated that during some winter seasons, both influenza B virus lineages circulated simultaneously in Israel. We further show that the influenza B virus Yamagata lineage was dominant, circulating in the county in the last few years of the study period, consistent with the anti-Yamagata influenza B virus antibodies detected in the serum samples of affected individuals residing in Israel in the year 2014. Interestingly, we found that elderly people were particularly vulnerable to Yamagata lineage influenza B virus infections.

  9. Antigenic Fingerprinting of Antibody Response in Humans following Exposure to Highly Pathogenic H7N7 Avian Influenza Virus: Evidence for Anti-PA-X Antibodies

    Science.gov (United States)

    Chung, Ka Yan; Coyle, Elizabeth M.; Meijer, Adam; Golding, Hana

    2016-01-01

    ABSTRACT Infections with H7 highly pathogenic avian influenza (HPAI) viruses remain a major public health concern. Adaptation of low-pathogenic H7N7 to highly pathogenic H7N7 in Europe in 2015 raised further alarm for a potential pandemic. An in-depth understanding of antibody responses to HPAI H7 virus following infection in humans could provide important insight into virus gene expression as well as define key protective and serodiagnostic targets. Here we used whole-genome gene fragment phage display libraries (GFPDLs) expressing peptides of 15 to 350 amino acids across the complete genome of the HPAI H7N7 A/Netherlands/33/03 virus. The hemagglutinin (HA) antibody epitope repertoires of 15 H7N7-exposed humans identified clear differences between individuals with no hemagglutination inhibition (HI) titers (1:40. Several potentially protective H7N7 epitopes close to the HA receptor binding domain (RBD) and neuraminidase (NA) catalytic site were identified. Surface plasmon resonance (SPR) analysis identified a strong correlation between HA1 (but not HA2) binding antibodies and H7N7 HI titers. A proportion of HA1 binding in plasma was contributed by IgA antibodies. Antibodies against the N7 neuraminidase were less frequent but targeted sites close to the sialic acid binding site. Importantly, we identified strong antibody reactivity against PA-X, a putative virulence factor, in most H7N7-exposed individuals, providing the first evidence for in vivo expression of PA-X and its recognition by the immune system during human influenza A virus infection. This knowledge can help inform the development and selection of the most effective countermeasures for prophylactic as well as therapeutic treatments of HPAI H7N7 avian influenza virus. IMPORTANCE An outbreak of pathogenic H7N7 virus occurred in poultry farms in The Netherlands in 2003. Severe outcome included conjunctivitis, influenza-like illness, and one lethal infection. In this study, we investigated convalescent

  10. Avian Influenza

    Data.gov (United States)

    US Fish and Wildlife Service, Department of the Interior — This is a letter from a professor at Clemson University about waterfowl that had been tested for avian influenza at Santee National Wildlife Refuge

  11. Risk factors for reported influenza and influenza-like symptoms in patients with rheumatoid arthritis.

    Science.gov (United States)

    Dirven, L; Huizinga, T W J; Allaart, C F

    2012-10-01

    To determine the prevalence and predictors of influenza and influenza-like symptoms in patients with rheumatoid arthritis (RA). Questionnaires were sent to patients registered as having RA and they were asked to fill in per month any period and details of influenza-like symptoms and vaccination. An experienced rheumatologist assessed the level of disease activity and use of anti-rheumatic medication. The prevalence of reported influenza (fever > 38°C, headache, muscle soreness, and coughing and/or dyspnoea) and influenza-like symptoms was determined and risk factors were identified by logistic regression analysis. Of the 1692 patients approached, 783 (46%) patients were eligible for follow-up. Fifty per cent of the patients reported influenza-like symptoms, 5.9% had symptoms suggesting influenza, and 74% reported vaccination. The prevalence of influenza and influenza-like symptoms per month ranged from 0.0% to 2.3% and from 10.4% to 19.7%, respectively. Anti-tumour necrosis factors (anti-TNFs) [odds ratio (OR) 2.4, 95% confidence interval (CI) 1.2-4.8] and body mass index (BMI) (OR 1.06, 95% CI 1.0-1.1) were independently associated with symptoms of influenza. A trend was found for patients not in remission, patients using leflunomide, and patients with previous lung conditions. Independent risk factors of influenza-like symptoms were age (OR 0.98, 95% CI 0.97-0.99), female gender (OR 1.8, 95% CI 1.3-2.5), influenza vaccination (OR 1.6, 95% CI 1.1-2.4), and previous lung condition (OR 1.7, 95% CI 1.2-2.4). In 2009-2010, the prevalence of reported influenza in patients with RA was 5.9%. Patients using anti-TNFs and with higher BMI seemed to be more at risk for influenza symptoms. Milder upper respiratory tract infections were reported more often by females, younger patients, and those vaccinated against influenza or with previous lung conditions.

  12. Perspectivas para el desarrollo de vacunas e inmunoterapia contra cáncer cervicouterino

    Directory of Open Access Journals (Sweden)

    GUZMÁN-ROJAS LILIANA

    1998-01-01

    Full Text Available El cáncer cervicouterino representa un grave problema de salud pública, debido a la asociación de la neoplasia con el virus del papiloma humano; actualmente se realizan estudios usando estrategias dirigidas a combatir este patógeno, mediante vacunas, que podrían ser de gran utilidad para el control de la progresión de la enfermedad. El estudio tanto de la inmunología humoral como celular ha servido para el desarrollo de vacunas. Así, la utilización de partículas virales sintéticas para el estudio de anticuerpos neutralizantes y el uso de proteínas tempranas virales, entre otras, para la inducción de inmunidad mediada por células, han sido la pauta para realizar estudios que dirijan la respuesta inmune para prevenir la infección celular tanto hacia células infectadas no transformadas como hacia células transformadas viralmente con resultados favorables.

  13. Vacunas y evolución: ¿Por qué es importante entender la diversidad genética de los patógenos?

    OpenAIRE

    Comas Espadas, Iñaki

    2013-01-01

    Desde el punto de vista de las intervenciones en salud pública no hay mejor arma que aquella que permite prevenir la transmisión o aparición de la enfermedad. Dentro del campo de las enfermedades infecciosas las vacunas se han convertido en esa arma y han permitido controlar muchas de ellas. Hoy en día hay un gran número de enfermedades infecciosas emergentes para las que no existen vacunas o enfermedades olvidadas que están reemergiendo. Nuevas vacunas se están desarrollando para atacar a lo...

  14. Eficacia de la vacuna meningocócica de polisacárido capsular del grupo C

    Directory of Open Access Journals (Sweden)

    González Enríquez Jesús

    1997-01-01

    Full Text Available FUNDAMENTO: Este trabajo consiste esencialmente en una revisión sistemática de la literatura científica sobre los efectos, intensidad y duración de la respuesta serológica, así como sobre la eficacia, efectividad y seguridad de la vacuna meningocócica de polisacárido capsular del grupo C. MÉTODOS: Búsqueda en repertorio MEDLINE en el periodo 1970-1996. Búsqueda específica de ensayos clínicos aleatorizados y estudios de intervención prospectivos en humanos con vacunas de polisacáridos capsulares de meningococo en el mismo repertorio y periodo. Análisis crítico de literatura científica y síntesis de evidencia. RESULTADOS: La vacuna de polisacárido capsular del serogrupo C es considerada segura y ha mostrado una eficacia superior al 85% en adultos y niños mayores, 70% (IC95%: 5-91% en niños menores de 5 años y 55% (IC90%: 14-76% en niños de 2-3 años. La vacuna no se ha mostrado eficaz en niños menores de 2 años. La duración de niveles de anticuerpos protectores disminuye con la edad. La proporción de niños menores de 6 años efectivamente protegidos al año de la vacunación es baja. La vacunación no limita la respuesta serológica de vacunaciones ulteriores. CONCLUSIONES: La vacuna meningocócica de polisacárido capsular del serogrupo C está indicada en adultos y niños mayores de 2 años como protección contra la enfermedad meningocócica causada por este serogrupo en situaciones de alto riesgo de enfermedad. La escasa protección que ofrece la vacuna en los menores de 2 años, la limitada eficacia en menores de 5 años y la corta duración de la inmunidad que confiere a estas edades, hace que la vacunación rutinaria no esté recomendada y que la vacuna se use fundamentalmente en el control de brotes epidémicos causados por serogrupo C.

  15. Dot Blot para determinar la identidad antigénica en vacunas conjugadas contra Streptococcus pneumoniae serotipo 19F

    Directory of Open Access Journals (Sweden)

    Osmir Cabrera-Blanco

    2017-04-01

    Full Text Available Las autoridades regulatorias recomiendan el uso de técnicas de Resonancia Magnética Nuclear o técnicas serológicas para la determinación de la identidad de los antígenos presentes en las vacunas conjugadas. Con la aparición de las vacunas conjugadas multivalentes, se ha hecho necesario recurrir a técnicas inmunoquímicas con la utilización de anticuerpos monoclonales para aumentar la sensibilidad en la determinación de la identidad de los antígenos en dichas vacunas conjugadas. El objetivo del presente trabajo fue establecer las condiciones óptimas de trabajo que permitieran utilizar la técnica del Dot Blot para determinar la identidad de los antígenos en vacunas conjugadas de Streptococcus pneumoniae serotipo 19F. Para ello se estudiaron los tiempos de incubación, la influencia del reactivo en la solución de bloqueo; también las concentraciones óptimas del anticuerpo monoclonal y de los ingredientes farmacéuticos activos, así como los volúmenes de aplicación óptimos para estos y vacunas. Se utilizó un anticuerpo monoclonal contra el polisacárido capsular del serotipo 19F de neumococo. Las muestras empleadas en este trabajo fueron lotes de ingredientes farmacéuticos activos de conjugados de polisacárido capsular 19F y lotes de un candidato vacunal cubano conjugado heptavalente contra neumococos. Los resultados mostraron que para la determinación de la identidad antigénica fueron suficientes 10 µL de muestras de los principios activos a una concentración de 125 µg/mL e igual volumen para las vacunas heptavalentes. Quedó demostrado que una concentración de 1 µg/mL para el anticuerpo monoclonal y tiempos de incubación de 30 min a 37 °C fueron suficientes para la determinación. Estos resultados permiten concluir que quedaron establecidas las condiciones óptimas de trabajo para determinar la identidad antigénica por Dot Blot del polisacárido capsular de S. pneumoniae serotipo 19F presente en las vacunas

  16. Comparative Safety and Efficacy Profile of a Novel Oil in Water Vaccine Adjuvant Comprising Vitamins A and E and a Catechin in Protective Anti-Influenza Immunity

    Directory of Open Access Journals (Sweden)

    Sapna Patel

    2017-05-01

    Full Text Available Non-replicating vaccines, such as those based on recombinant proteins, require adjuvants and delivery systems, which have thus far depended on mimicking pathogen danger signals and strong pro-inflammatory responses. In search of a safer and more efficacious alternative, we tested whether vaccinations with influenza recombinant hemagglutinin (HA mixed with a novel vegetable oil in water emulsion adjuvant (Natural Immune-enhancing Delivery System, NIDS, based on the immune-enhancing synergy of vitamins A and E and a catechin, could protect against intra-nasal challenge with live influenza virus. Vaccinations of inbred Brag Albino strain c (BALB/c mice, with HA mixed with NIDS compared to other adjuvants, i.e., a squalene oil in water emulsion (Sq. oil, and the Toll Like Receptor 3 (TLR3 agonist Poly (I:C, induced significantly lower select innate pro-inflammatory responses in serum, but induced significantly higher adaptive antibody and splenic T Helper 1 (TH1 or TH2, but not TH17, responses. Vaccinations with NIDS protected against infection, as measured by clinical scores, lung viral loads, and serum hemagglutination inhibition titers. The NIDS exhibited a strong dose sparing effect and the adjuvant action of NIDS was intact in the outbred CD1 mice. Importantly, vaccinations with the Sq. oil, but not NIDS, induced a significantly higher Serum Amyloid P component, an acute phase reactant secreted by hepatocytes, and total serum IgE. Thus, the NIDS may be used as a clinically safer and more efficacious vaccine adjuvant against influenza, and potentially other infectious diseases.

  17. Mechanisms of Action and Efficacy of Statins against Influenza

    Directory of Open Access Journals (Sweden)

    Parvaneh Mehrbod

    2014-01-01

    Full Text Available The influenza virus (IV is known to be a resistant virus with frequent mutations, causing severe respiratory diseases in the upper respiratory system. Public health concerns about clinical efficacy of all conventional drugs are ambiguous; therefore, finding additional therapeutic agents is critical to prevent and control influenza outbreaks. Influenza is associated with the induction of proinflammatory cytokines. Scientists have reported that anti-inflammatory drugs, with pleiotropic effects, reduce the burden of severe influenza diseases. Therefore, statins, which are cardioprotective drugs with anti-inflammatory and immunomodulatory effects, may help patients suffering from influenza virus (IV. This review delineates the potential use of statins as an alternative therapy in treating influenza related illness.

  18. Anti-influenza A virus characteristics of a fucoidan from sporophyll of Undaria pinnatifida in mice with normal and compromised immunity.

    Science.gov (United States)

    Hayashi, Kyoko; Lee, Jung-Bum; Nakano, Takahisa; Hayashi, Toshimitsu

    2013-04-01

    Undaria pinnatifida, an edible brown alga, contains fucoidan (FuC), a sulfated polysaccharide, that inhibited the in vitro replication of influenza A virus, and stimulated both innate and adaptive immune defense functions in virus-infected mice. In the present study, the effects of oral administration of FuC were evaluated on influenza virus infection in immunocompetent and immunocompromised mice, where the efficacy of FuC was demonstrated in reducing viral replication, decreasing weight loss and mortality, and prolonging survival. Oral FuC resulted in increased neutralizing antibody production in the mucosa and blood. In contrast, while suppressing virus yields in mice more markedly than FuC, oseltamivir significantly reduced the neutralizing antibody titers in both the mucosa and blood. In immunocompromised mice, drug-resistant viruses frequently recovered after oseltamivir treatment; no resistant viruses were isolated from FuC-treated mice. FuC could be a candidate for the development of new therapeutic options including its combination with neuraminidase inhibitors such as oseltamivir. Copyright © 2013 Institut Pasteur. Published by Elsevier Masson SAS. All rights reserved.

  19. Influenza A (H1N1) neuraminidase inhibitors from Vitis amurensis

    DEFF Research Database (Denmark)

    Nguyen, Ngoc Anh; Dao, Trong Tuan; Tung, Bui Thanh

    2011-01-01

    Recently, a novel H1N1 influenza A virus (H1N1/09 virus) was identified and considered a strong candidate for a novel influenza pandemic. As part of an ongoing anti-influenza screening programme on natural products, eight oligostilbenes were isolated as active principles from the methanol extract...

  20. Avian influenza.

    Science.gov (United States)

    Zeitlin, Gary A; Maslow, Melanie J

    2006-03-01

    The current epidemic of H5N1 highly pathogenic avian influenza in Southeast Asia raises serious concerns that genetic reassortment will result in the next influenza pandemic. There have been 164 confirmed cases of human infection with avian influenza since 1996. In 2004 alone, there were 45 cases of human H5N1 in Vietnam and Thailand, with a mortality rate over 70%. In addition to the potential public health hazard, the current zoonotic epidemic has caused severe economic losses. Efforts must be concentrated on early detection of bird outbreaks with aggressive culling, quarantines, and disinfection. To prepare for and prevent increased human cases, it is essential to improve detection methods and stockpile effective antivirals. Novel therapeutic modalities, including short, interfering RNAs and new vaccine strategies that use plasmid-based genetic systems offer promise, should a pandemic occur.

  1. VIGILANCIA DE LA GRIPE PANDÉMICA EN LA COMUNIDAD VALENCIANA Y VACUNA ANTIGRIPAL ESTACIONAL

    Directory of Open Access Journals (Sweden)

    Rosa María Carbó Malonda

    2010-01-01

    Full Text Available Fundamento: En la Comunidad Valenciana se ha llevado a cabo la vigilancia de la Gripe pandémica. Algunos estudios sobre efectividad de la vacuna estacional para Gripe AnH1N1 han presentado resultados no consistentes. El objetivo del trabajo es describir los resultados de la vigilancia epidemiológica y la efectividad de la vacuna estacional para Gripe pandémica en las semanas 28 a 51 de 2009. Métodos: Se estudiaron los casos en atención primaria, hospitalizados confirmados, aislamientos virales y proteína C reactiva (PCR y coberturas vacunales. Se calculó la efectividad vacunal por el método de screening de Farrington, en tres grupos de edad y dos periodos: vacunados de las temporadas 2008-9 y 2009-10. Resultados: En el primer periodo (semanas 28 a 40 los casos se concentraron en el grupo de 15 a 64 años (7.207 casos, seguido de los menores de 15 años (1.596 casos. En el segundo periodo (semanas 45 a 47 afectó más a menores de 15 años (28.218 casos. En ambos periodos las tasas de incidencia en mayores de 65 años fue de 56,3 y 125,1 respectivamente. En el periodo estudiado (semanas 28 a 51 se confirmaron 5.481 casos de los que 1.746 (31,8% fueron hospitalizados. La curva de personas hospitalizadas presentaba un perfil similar al de atención primaria, y también el seguimiento microbiológico del virus. La efectividad vacunal en el segundo periodo fue del 25% en adultos entre 15 y 64 años y del 51% en mayores de 64 años. Conclusiones: Se observó una protección edad dependiente con efectividad vacunal positiva en los mayores de 64 años, aunque puede estar confundida por exposición natural al virus, vacunas previas y o respuesta inmunitaria.

  2. Drug screening for autophagy inhibitors based on the dissociation of Beclin1-Bcl2 complex using BiFC technique and mechanism of eugenol on anti-influenza A virus activity.

    Directory of Open Access Journals (Sweden)

    Jian-Ping Dai

    Full Text Available Autophagy is involved in many human diseases, such as cancer, cardiovascular disease and virus infection, including human immunodeficiency virus (HIV, hepatitis C virus (HCV, influenza A virus (IAV and coxsackievirus B3/B4 (CVB3/B4, so a drug screening model targeting autophagy may be very useful for the therapy of these diseases. In our study, we established a drug screening model based on the inhibition of the dissociation of Beclin1-Bcl2 heterodimer, an important negative regulator of autophagy, using bimolecular fluorescence complementation (BiFC technique for developing novel autophagy inhibitors and anti-IAV agents. From 86 examples of traditional Chinese medicines, we found Syzygium aromaticum L. had the best activity. We then determined the anti-autophagy and anti-IAV activity of eugenol, the major active compound of Syzygium aromaticum L., and explored its mechanism of action. Eugenol could inhibit autophagy and IAV replication, inhibited the activation of ERK, p38MAPK and IKK/NF-κB signal pathways and antagonized the effects of the activators of these pathways. Eugenol also ameliorated the oxidative stress and inhibited the expressions of autophagic genes. We speculated that the mechanism underlying might be that eugenol inhibited the oxidative stress and the activation of ERK1/2, p38MAPK and IKK/NF-κB pathways, subsequently inhibited the dissociation of Beclin1-Bcl2 heterodimer and autophagy, and finally impaired IAV replication. These results might conversely display the reasonableness of the design of our screening model. In conclusion, we have established a drug screening model for developing novel autophagy inhibitor, and find eugenol as a promising inhibitor for autophagy and IAV infection.

  3. Drug Screening for Autophagy Inhibitors Based on the Dissociation of Beclin1-Bcl2 Complex Using BiFC Technique and Mechanism of Eugenol on Anti-Influenza A Virus Activity

    Science.gov (United States)

    Dai, Jian-Ping; Zhao, Xiang-Feng; Zeng, Jun; Wan, Qian-Ying; Yang, Jia-Cai; Li, Wei-Zhong; Chen, Xiao-Xuan; Wang, Ge-Fei; Li, Kang-Sheng

    2013-01-01

    Autophagy is involved in many human diseases, such as cancer, cardiovascular disease and virus infection, including human immunodeficiency virus (HIV), hepatitis C virus (HCV), influenza A virus (IAV) and coxsackievirus B3/B4 (CVB3/B4), so a drug screening model targeting autophagy may be very useful for the therapy of these diseases. In our study, we established a drug screening model based on the inhibition of the dissociation of Beclin1-Bcl2 heterodimer, an important negative regulator of autophagy, using bimolecular fluorescence complementation (BiFC) technique for developing novel autophagy inhibitors and anti-IAV agents. From 86 examples of traditional Chinese medicines, we found Syzygium aromaticum L. had the best activity. We then determined the anti-autophagy and anti-IAV activity of eugenol, the major active compound of Syzygium aromaticum L., and explored its mechanism of action. Eugenol could inhibit autophagy and IAV replication, inhibited the activation of ERK, p38MAPK and IKK/NF-κB signal pathways and antagonized the effects of the activators of these pathways. Eugenol also ameliorated the oxidative stress and inhibited the expressions of autophagic genes. We speculated that the mechanism underlying might be that eugenol inhibited the oxidative stress and the activation of ERK1/2, p38MAPK and IKK/NF-κB pathways, subsequently inhibited the dissociation of Beclin1-Bcl2 heterodimer and autophagy, and finally impaired IAV replication. These results might conversely display the reasonableness of the design of our screening model. In conclusion, we have established a drug screening model for developing novel autophagy inhibitor, and find eugenol as a promising inhibitor for autophagy and IAV infection. PMID:23613775

  4. Influenza Vaccine, Live Intranasal

    Science.gov (United States)

    ... influenza vaccine (RIV). The nasal spray flu vaccine (live attenuated influenza vaccine or LAIV) should NOT be ... What is live, attenuated influenza vaccine-LAIV (nasal spray)?A dose of flu vaccine is recommended every flu season. Children younger ...

  5. Xanthones from Polygala karensium inhibit neuraminidases from influenza A viruses

    DEFF Research Database (Denmark)

    Dao, Trong Tuan; Dang, Thai Trung; Nguyen, Phi Hung

    2012-01-01

    The emergence of the H1N1 swine flu pandemic has the possibility to develop the occurrence of disaster- or drug-resistant viruses by additional reassortments in novel influenza A virus. In the course of an anti-influenza screening program for natural products, 10 xanthone derivatives (1-10) were...

  6. Estudio de tolerancia local de la vacuna vax-TyVi® en ratas Sprague Dawley

    OpenAIRE

    Eligio Sosa Roble; Sergio Sifontes Rodríguez; Juan Francisco Infante Bourzac; Daiyana Díaz Rivero; Yulieé López Feria; Viviana Pérez Amat; Tamara Hernández Salazar; Luis Riverón Martínez; Yolanda Valdés Abreu; Isabel García Riva; Mildrey Fariñas Medina; Elina Parajón Góngora; Niurka Rodríguez González

    2005-01-01

    La vacuna antitifoídica vax-TyVi® consiste en una preparación de polisacárido capsular Vi de Salmonella typhi, el cual es diluido en una solución buffer isotónica solución amortiguador, a la que se le añade fenol como preservo. Cada dosis de 0,5 mL contiene 25 μg de polisacárido como sustancia activa. En nuestro país el esquema de vacunación contra la fiebre tifoidea con vax- TyVi® se aplica a los alumnos de 9-10 años (5to grado), una 2da dosis a la edad de 12-13 años (8vo grado) y una 3ra do...

  7. Información sobre las vacunas y el tiomersal en la internet

    OpenAIRE

    Vargas, Javier

    2005-01-01

    La información inexacta sobre la asociación entre las vacunas y el autismo propagada en las últimas semanas por los medios de comunicación, impacta de manera desfavorable en la salud pública del país, restando mérito a los logros alcanzados por la inmunización en la erradicación de la viruela en el mundo y la erradicación de la viruela en el mundo y la erradicación en marcha de la poliomelitis y la eliminación del sarampión en el Perú; confundiendo con la población sobre los beneficios holgad...

  8. Vacuna atenuada de Salmonella como vector de antígenos heterólogos

    Directory of Open Access Journals (Sweden)

    Oscar G. Gómez

    2000-06-01

    Full Text Available Salmonella enterica, serotipo Typhi, es el agente etiológico de la fiebre tifoidea de los habitantes de las regiones más pobres del mundo y es, además. el centro de atención de muchos investigadores dados sus fascinantes mecanismos de invasión, multiplicación intracelular y diseminación intercelular que expresa in vivo e in vitro. Aunque estos mecanismos se asocian directamente con la patogenicidad y la severidad de la enfermedad, las mutaciones definidas en el cromosoma de Salmonella han permitido que estos mecanismos de virulencia se puedan utilizar en beneficio del hospedero. Las mutantes atenuadas de Salmonella son capaces de invadir las células M de la mucosa intestinal y de migrar a las células linfoides del sistema reticuloendotelial donde, en lugar de causar enfermedad, activan eficazmente las respuestas inmunes humoral y celular no sólo contra el microorganismo mismo sino también contra aquellos antigenos heterólogos recombinantes que la bacteria pueda expresar y transportar. En la presente revisión, se discutirán los avances más recientes en el campo de las vacunas vivas atenuadas de Salmonella, su evaluación preclinica y clinica y, también, su aplicación como vector de antigenos. Se darán a conocer las técnicas biomoleculares de clonación y expresión procariótica de las toxinas diftérica, tetánica y de pertusis. así como de los antígenos de Helicobacterpylori y de Plasmodium falciparum. Finalmente, se propone el uso de Salmonella atenuada como vector de vacunas de ADN para expresión eucariótica de los antígenos recombinantes. Los continuos esfuerzos cientificos y tecnológicos en el campo de la vacunación con vectores vivos atenuados sugieren que Salmonella es una herramienta potencialmente útil para enfrentar el constante reto de la fiebre tifoidea. Igualmente, los estudios preclínicos y clínicos de fase I demuestran la eficacia de la vacuna de Salmonella viva atenuada como vector de antígenos heter

  9. Why European and United States drug regulators are not speaking with one voice on anti-influenza drugs: regulatory review methodologies and the importance of 'deep' product reviews.

    Science.gov (United States)

    Mulinari, Shai; Davis, Courtney

    2017-11-09

    Relenza represents the first neuraminidase inhibitor (NI), a class of drugs that also includes the drug Tamiflu. Although heralded as breakthrough treatments in influenza, NI efficacy has remained highly controversial. A key unsettled question is why the United States Food and Drug Administration (FDA) has approved more cautious efficacy statements in labelling than European regulators for both drugs. We conducted a qualitative analysis of United States and European Union regulatory appraisals for Relenza to investigate the reasons for divergent regulatory interpretations, pertaining to Relenza's capacity to alleviate symptoms and reduce frequency of complications of influenza. In Europe, Relenza was evaluated via the so-called national procedure with Sweden as the reference country. We show that FDA reviewers, unlike their European (i.e. Swedish) counterpart, (1) rejected the manufacturer's insistence on pooling efficacy data, (2) remained wary of subgroup analyses, and (3) insisted on stringent statistical analyses. These differences meant that the FDA was less likely to depart from prevailing regulatory and scientific standards in interpreting trial results. We argue that the differences are explained largely by divergent institutionalised review methodologies, i.e. the European regulator's reliance on manufacturer-compiled summaries compared to the FDA's examination of original data and documentation from trials. The FDA's more probing and meticulous evaluative methodology allowed its reviewers to develop 'deep' knowledge concerning the clinical and statistical facets of trials, and more informed opinions regarding suitable methods for analysing trial results. These findings challenge the current emphasis on evaluating regulatory performance mainly in terms of speed of review. We propose that persistent uncertainty and knowledge deficits regarding NIs could have been ameliorated had regulators engaged in the public debates over the drugs' efficacy and

  10. Preventive vaccines for cervical cancer Vacunas para prevenir el cáncer cervical

    Directory of Open Access Journals (Sweden)

    COSETTE M WHEELER

    1997-07-01

    Full Text Available The potential use of vaccines for the human papillomavirus (HPV in the prevention and treatment of cervical cancer is a possibility in the near future. Close to 20 genotypes of HPV, of the 75 that have been identified, infect the femine genital tract, but four subtypes (16, 18, 31 and 45 have been associated in close to 80% of cervical cancers. this article proposes that in order to design an effective prophylactic vaccine against HPV infection, an adequate immune response should be guaranteed through four goals; a activation of antigens present in the cell; b overcoming the host response and viral genetic variability in the T cell response; c generation of high levels of T and B memory cells; and d persistence of antigens.El potencial uso de vacunas de virus del papiloma humano (VPH en la prevención y tratamiento del cáncer cervical posiblemente será implementado durante los próximos años. Cerca de los 20 genotipos de VPH de los 75 que se encuentran identificados infectan el tracto genital femenino, pero son cuatro subtipos: 16, 18, 31 y 45 los que se han asociado en cerca de 80% a cáncer cervical. En este ensayo se plantea que para poder diseñar una vacuna profiláctica contra la infección de VPH, efectiva, se debe garantizar una adecuada respuesta inmune a través de cuatro metas: a activación de antígenos presentes en la célula; b superar la respuesta del huésped y la variabilidad genética viral en la respuesta de células T; c generación de altos niveles de células T y B de memoria, y d persistencia de antígenos.

  11. Anti-viral properties and mode of action of standardized Echinacea purpurea extract against highly pathogenic avian influenza virus (H5N1, H7N7) and swine-origin H1N1 (S-OIV).

    Science.gov (United States)

    Pleschka, Stephan; Stein, Michael; Schoop, Roland; Hudson, James B

    2009-11-13

    Influenza virus (IV) infections are a major threat to human welfare and animal health worldwide. Anti-viral therapy includes vaccines and a few anti-viral drugs. However vaccines are not always available in time, as demonstrated by the emergence of the new 2009 H1N1-type pandemic strain of swine origin (S-OIV) in April 2009, and the acquisition of resistance to neuraminidase inhibitors such as Tamiflu (oseltamivir) is a potential problem. Therefore the prospects for the control of IV by existing anti-viral drugs are limited. As an alternative approach to the common anti-virals we studied in more detail a commercial standardized extract of the widely used herb Echinacea purpurea (Echinaforce, EF) in order to elucidate the nature of its anti-IV activity. Human H1N1-type IV, highly pathogenic avian IV (HPAIV) of the H5- and H7-types, as well as swine origin IV (S-OIV, H1N1), were all inactivated in cell culture assays by the EF preparation at concentrations ranging from the recommended dose for oral consumption to several orders of magnitude lower. Detailed studies with the H5N1 HPAIV strain indicated that direct contact between EF and virus was required, prior to infection, in order to obtain maximum inhibition in virus replication. Hemagglutination assays showed that the extract inhibited the receptor binding activity of the virus, suggesting that the extract interferes with the viral entry into cells. In sequential passage studies under treatment in cell culture with the H5N1 virus no EF-resistant variants emerged, in contrast to Tamiflu, which produced resistant viruses upon passaging. Furthermore, the Tamiflu-resistant virus was just as susceptible to EF as the wild type virus. As a result of these investigations, we believe that this standard Echinacea preparation, used at the recommended dose for oral consumption, could be a useful, readily available and affordable addition to existing control options for IV replication and dissemination.

  12. Anti-viral properties and mode of action of standardized Echinacea purpurea extract against highly pathogenic avian Influenza virus (H5N1, H7N7 and swine-origin H1N1 (S-OIV

    Directory of Open Access Journals (Sweden)

    Schoop Roland

    2009-11-01

    Full Text Available Abstract Background Influenza virus (IV infections are a major threat to human welfare and animal health worldwide. Anti-viral therapy includes vaccines and a few anti-viral drugs. However vaccines are not always available in time, as demonstrated by the emergence of the new 2009 H1N1-type pandemic strain of swine origin (S-OIV in April 2009, and the acquisition of resistance to neuraminidase inhibitors such as Tamiflu® (oseltamivir is a potential problem. Therefore the prospects for the control of IV by existing anti-viral drugs are limited. As an alternative approach to the common anti-virals we studied in more detail a commercial standardized extract of the widely used herb Echinacea purpurea (Echinaforce®, EF in order to elucidate the nature of its anti-IV activity. Results Human H1N1-type IV, highly pathogenic avian IV (HPAIV of the H5- and H7-types, as well as swine origin IV (S-OIV, H1N1, were all inactivated in cell culture assays by the EF preparation at concentrations ranging from the recommended dose for oral consumption to several orders of magnitude lower. Detailed studies with the H5N1 HPAIV strain indicated that direct contact between EF and virus was required, prior to infection, in order to obtain maximum inhibition in virus replication. Hemagglutination assays showed that the extract inhibited the receptor binding activity of the virus, suggesting that the extract interferes with the viral entry into cells. In sequential passage studies under treatment in cell culture with the H5N1 virus no EF-resistant variants emerged, in contrast to Tamiflu®, which produced resistant viruses upon passaging. Furthermore, the Tamiflu®-resistant virus was just as susceptible to EF as the wild type virus. Conclusion As a result of these investigations, we believe that this standard Echinacea preparation, used at the recommended dose for oral consumption, could be a useful, readily available and affordable addition to existing control options

  13. DETERMINACIÓN DE LA POTENCIA DEL COMPONENTE “SARAMPIÓN” DE LA VACUNA DE VIRUS VIVO DE SARAMPIÓN Y RUBÉOLA USP UTILIZADA EN LA JORNADA DE VACUNACIÓN 2005

    OpenAIRE

    A. Bermúdez-Forero; M. Mercado-Reyes; Tavera, P.; Rey-Benito, G.

    2007-01-01

    Un factor clave para el éxito y la eficacia de los programas de vacunación, es la utilización de vacunas de calidad. Este estudio se realizó con el fin de verificar si la vacuna bivalente (vacuna de virus vivo de sarampión y rubéola USP) empleada durante la Jornada Nacional de Vacunación 2005, mantenía las especificaciones de 1000 DICT50. Se emplearon 6 frascos por lote de vacuna bivalente, muestreados aleatoriamente en diferentes regiones del país. Se utilizó la metodología descrita en el Ma...

  14. Ensayo preclínico de la vacuna candid #1 producida en Argentina contra la Fiebre Hemorrágica Argentina Preclinical assay of Candid #1 vaccine against Argentine Hemorrhagic Fever made in Argentina

    Directory of Open Access Journals (Sweden)

    Ana M. Ambrosio

    2005-08-01

    Full Text Available Se comparó en cobayos la seguridad, inmunogenicidad y eficacia protectora de un lote de vacuna Candid #1(C#1 fabricada en Estados Unidos de América (EE.UU. y distintos lotes de la misma vacuna fabricados en Argentina (Arg. El lote TSI 5-1-92 (EE.UU. y los lotes Exp Nº 3, 7A y 8A (Arg fueron inoculados (0.5 ml, IM en cobayos de 250-400 g. Para cada ensayo diez animales recibieron solución fisiológica y sirvieron como control. Todos fueron desafiados con la cepa patógena P23790 de virus Junin. Se registró: a temperatura rectal, b peso corporal, c presencia de anticuerpos neutralizantes (AcNT pre y post-vacunación, d respuesta al desafío. Todos los animales vacunados desarrollaron AcNT anti virus Junin (rango = 40- 81920 y sobrevivieron al desafío. En cada grupo control 8/10 animales murieron (día 23.3 ± 5.4 post-desafío. Los cobayos resultaron idénticamente protegidos de una descarga letal de virus Junin por la vacuna importada y los diferentes lotes de C#1 producidos en Argentina.Candid #1 vaccine against Argentine Hemorrhagic Fever produced in USA versus lots of the same vaccine made in Argentina were compared in guinea pigs regarding safety, immunogenicity and protective efficacy against a challenge with pathogenic Junin virus. Lots Nº Exp 3, 7A and 8A of Argentine origin as well as lot TSI 5-1-92 from USA were inoculated in guinea pigs of 250-400 g in two consecutive assays. Ten animals inoculated with saline performed as normal controls in each experiment. Parameters studied were: a temperature; b body weight; c neutralizing antibodies to Junin virus; d response to viral challenge. Animals gained weight and remained normothermic up to the challenge. Guinea pigs that received Candid #1 from any manufacturer elicited neutralizing antibodies to Junin virus (titles from 40 to 81920 and survived to challenge whilst 8/10 animals died in each control group. Data presented demonstrated that Candid #1 vaccines from USA or Argentine

  15. Desarrollo de una vacuna profiláctica de segunda generación contra el papilomavirus humano

    Directory of Open Access Journals (Sweden)

    Alonso Leonardo

    2011-06-01

    Full Text Available Los papilomavirus humanos (HPV son el agente etiológico del cáncer cervical (CC, la segunda causa de muerte por cáncer en mujeres. Se estima que medio millón de nuevos cánceres se diagnostica cada año, ocurriendo la mayoría de ellos en países en vías de desarrollo debido a la ausencia o ineficiencia de los programas masivos de detección temprana. Recientemente se han introducido en el mercado dos vacunas profilácticas contra las principales cepas oncogénicas de HPV, la cepa 16 y 18, responsables por el 80% de todos los CC. Estas vacunas se obtienen en forma recombinante y han demostrado ser extremadamente seguras y eficaces. Sin embargo, su impacto inmediato en la incidencia de la infección por HPV en países en vías de desarrollo será mínimo, debido principalmente al alto costo de las mismas. Existe la necesidad de contar con vacunas de segunda generación, de bajo costo y de aplicación masiva que permitan disminuir sensiblemente el número de CC en la población. Con este objetivo hemos desarrollado una plataforma de expresión recombinante que permite obtener partículas tipo virus (VLPs con las cuales es posible formular vacunas efectivas y accesibles contra la infección por HPV.

  16. VACUNAS CONTRA EL HERPESVIRUS BOVINO-1: UNA MIRADA DESDE EL PASADO HACIA EL FUTURO DE LA INMUNIZACIÓN

    Directory of Open Access Journals (Sweden)

    JULIÁN RUIZ-SAENZ

    2009-01-01

    Full Text Available El herpesvirus Bovino-1 (BHV-1 es uno de los principales patógenos que afecta el ganado; la infección primaria se acompaña de varias manifestaciones clínicas tales como la rinotraqueitis, aborto, vulvovaginitis/balanopostitis pustular y en algunos casos, enfermedad neurológica. Luego de la recuperación, la infección persiste durante toda la vida del individuo en un estado de latencia en ganglios nervioso trigémino o sacro. La Organización Mundial de Sanidad Animal (OIE reporta que la vacunación contra el BHV-1 puede ser efectiva en reducir las manifestaciones clínicas y en consecuencia las pérdidas económicas, pero no logra proteger completamente de la infección. Es por esto que durante los últimos años se han desarrollado gran cantidad de agentes vacunales que van desde las vacunas clásicas inactivadas hasta aquellas que usan tecnología de DNA recombinante. El presente artículo se enfoca en presentar una actualización acerca de las vacunas más usadas desde hace ya varios años y resumir los avances más importantes en la generación de nuevas vacunas contra el BHV-1; tratando así de abrir un nuevo panorama para la generación de vacunas en Colombia.

  17. VACUNAS CONTRA EL HERPESVIRUS BOVINO-1: UNA MIRADA DESDE EL PASADO HACIA EL FUTURO DE LA INMUNIZACIÓN

    Directory of Open Access Journals (Sweden)

    Ruiz Saenz Julian

    2009-08-01

    Full Text Available El herpesvirus Bovino-1 (BHV-1 es uno de los principales patógenos que afecta el
    ganado; la infección primaria se acompaña de varias manifestaciones clínicas tales
    como la rinotraqueitis, aborto, vulvovaginitis/balanopostitis pustular y en algunos
    casos, enfermedad neurológica. Luego de la recuperación, la infección persiste durante
    toda la vida del individuo en un estado de latencia en ganglios nervioso trigémino o
    sacro. La Organización Mundial de Sanidad Animal (OIE reporta que la vacunación
    contra el BHV-1 puede ser efectiva en reducir las manifestaciones clínicas y en consecuencia
    las pérdidas económicas, pero no logra proteger completamente de la infección.
    Es por esto que durante los últimos años se han desarrollado gran cantidad
    de agentes vacunales que van desde las vacunas clásicas inactivadas hasta aquellas que
    usan tecnología de DNA recombinante. El presente artículo se enfoca en presentar una
    actualización acerca de las vacunas más usadas desde hace ya varios años y resumir los
    avances más importantes en la generación de nuevas vacunas contra el BHV-1;
    tratando así de abrir un nuevo panorama para la generación de vacunas en Colombia.

  18. Vacunas de ADN: inducción de la respuesta inmunitaria DNA Vaccines: Induction of the immune response

    Directory of Open Access Journals (Sweden)

    Javier Mota-Sánchez

    2009-01-01

    Full Text Available La efectividad de las vacunas y la inmunización en la prevención de las enfermedades infecciosas es uno de los grandes avances de la medicina. En la actualidad, el acceso a la tecnología de punta en el área de la genómica y la proteómica ha hecho posible acelerar el desarrollo de nuevos modelos de vacunas con características mejoradas en aspectos fundamentales, como la inmunogenicidad y la seguridad. A casi dos décadas del primer informe, en el cual se demostró que un gen puede expresarse mediante la inyección directa de ADN desnudo, las vacunas de ADN han probado ser eficientes para inducir una respuesta inmunitaria protectora contra parásitos, virus y bacterias en diversos modelos animales. Esta revisión tiene por objetivo presentar un panorama general de las vacunas de ADN y los mecanismos mediante los cuales la inmunización con antígenos insertados en vectores de ADN (plásmidos inducen una respuesta inmunitaria.The effectiveness of vaccines and immunization in the prevention of infectious diseases is one of the greatest successes in medicine. In recent years, with access to cutting edge genomic and proteomic technology, it is possible to accelerate the development of new and improved vaccines with better immunogenicity and safety characteristics. Since the first report almost two decades ago, where it was demonstrated that gene expression is possible by directed injection of naked DNA, DNA vaccines have been proven to induce protective immune responses against parasites, virus and bacterium in diverse animal disease models. This review aims to present an overview about DNA vaccines and the mechanisms by which immune responses are induced after immunization with plasmid DNA-encoded antigens.

  19. Desarrollo de vacunas contra el virus de la inmunodeficiencia humana tipo 1: Relevancia de la inmunidad celular contra subtipos

    Directory of Open Access Journals (Sweden)

    Ana María Rodríguez

    2010-12-01

    Full Text Available Han pasado casi 30 años de la detección de los primeros casos de infección con HIV-1 y aún no se ha conseguido desarrollar una vacuna efectiva y segura. A pesar del impacto positivo sobre la pandemia que se ha conseguido gracias a los avances en la terapia antirretroviral (TARV, el HIV/sida sigue constituyendo un grave problema para la salud pública, especialmente en los países en desarrollo, donde es difícil el acceso al tratamiento. En el mundo, 33 millones de personas viven con el virus del sida, mientras que en la Argentina se calcula que habría unos 120 000 infectados. Uno de los desafíos para lograr una vacuna contra el HIV es la variabilidad viral. El grupo M, responsable de la pandemia, se encuentra dividido en 10 subtipos y varios sub-subtipos, además de las 48 formas recombinantes circulantes y más de cien formas recombinantes únicas. La epidemia de HIV en nuestro país es tan compleja como en el resto del mundo, con la co-circulación principalmente de virus pertenecientes al subtipo B y recombinantes BF (CRF12_BF y derivadas. A pesar de la cantidad de trabajos dedicados a la caracterización de la respuesta inmune y al desarrollo de vacunas, no queda claro cuál es el impacto de la variabilidad en la elección del antígeno. Trabajos realizados en nuestro laboratorio demuestran el papel que juega la inmunidad celular con respecto a las variantes recombinantes BF, tanto en humanos como en modelos animales. Estos resultados son de importancia en el desarrollo de futuras vacunas para nuestra región.

  20. [Real-time monitoring of anti-influenza vaccination in the 65 and over population in France based on vaccine sales].

    Science.gov (United States)

    Pivette, M; Auvigne, V; Guérin, P; Mueller, J E

    2017-04-01

    The aim of this study was to describe a tool based on vaccine sales to estimate vaccination coverage against seasonal influenza in near real-time in the French population aged 65 and over. Vaccine sales data available on sale-day +1 came from a stratified sample of 3004 pharmacies in metropolitan France. Vaccination coverage rates were estimated between 2009 and 2014 and compared with those obtained based on vaccination refund data from the general health insurance scheme. The seasonal vaccination coverage estimates were highly correlated with those obtained from refund data. They were also slightly higher, which can be explained by the inclusion of non-reimbursed vaccines and the consideration of all individuals aged 65 and over. We have developed an online tool that provides estimates of daily vaccination coverage during each vaccination campaign. The developed tool provides a reliable and near real-time estimation of vaccination coverage among people aged 65 and over. It can be used to evaluate and adjust public health messages. Copyright © 2017 Elsevier Masson SAS. All rights reserved.

  1. Fatores associados à adesão à vacinação anti-influenza em idosos não institucionalizados, São Paulo, Brasil

    Directory of Open Access Journals (Sweden)

    Roudom Ferreira Moura

    2015-10-01

    Full Text Available Resumo O objetivo do estudo foi estimar a cobertura vacinal contra a influenza em idosos e identificar os fatores associados à adesão à vacinação. Foi realizado estudo transversal de base populacional, com dados coletados, em 2006, pelo estudo Saúde, Bem-estar e Envelhecimento. A amostra foi composta por 1.399 idosos do Município de São Paulo, Brasil. A associação entre a adesão à vacina e as variáveis independentes foi avaliada por meio da razão de prevalências, estimada pela regressão de Poisson. A vacinação autorreferida foi de 73,8%. No modelo explicativo final, a vacinação contra a gripe foi associada à idade mais elevada, à presença de doenças crônicas e ao atendimento à saúde no ano anterior. Foi observada associação negativa com a internação no ano anterior. Concluiu-se ser necessário incentivar a vacinação de idosos com menos de 70 anos e sem doenças crônicas, assim como orientar os profissionais de saúde para ampliar a cobertura nos grupos com menor participação nas campanhas.

  2. Drug Discovery of Host CLK1 Inhibitors for Influenza Treatment

    Directory of Open Access Journals (Sweden)

    Mian Zu

    2015-11-01

    Full Text Available The rapid evolution of influenza virus makes antiviral drugs less effective, which is considered to be a major bottleneck in antiviral therapy. The key proteins in the host cells, which are related with the replication cycle of influenza virus, are regarded as potential drug targets due to their distinct advantage of lack of evolution and drug resistance. Cdc2-like kinase 1 (CLK1 in the host cells is responsible for alternative splicing of the M2 gene of influenza virus during influenza infection and replication. In this study, we carried out baculovirus-mediated expression and purification of CLK1 and established a reliable screening assay for CLK1 inhibitors. After a virtual screening of CLK1 inhibitors was performed, the activities of the selected compounds were evaluated. Finally, several compounds with strong inhibitory activity against CLK1 were discovered and their in vitro anti-influenza virus activities were validated using a cytopathic effect (CPE reduction assay. The assay results showed that clypearin, corilagin, and pinosylvine were the most potential anti-influenza virus compounds as CLK1 inhibitors among the compounds tested. These findings will provide important information for new drug design and development in influenza treatment, and CLK1 may be a potent drug target for anti-influenza drug screening and discovery.

  3. Pandemisk influenza

    DEFF Research Database (Denmark)

    Andersen, Nina Blom; Almlund, Pernille

    danske myndigheder kommunikerede åbent og løbende om influenza-krisen og dens trusler. Indsatsen blev anerkendt fra alle sider og førte på intet tidspunkt til alvorlig og længerevarende kritik af myndighederne. Der var tale om en tilfredsstillende krisehåndtering, hvad angår den del, der fokuserede på...... kommunikation om denne tog en drejning i forhold til selve influenza-krisen. Myndighedernes kommunikation blev mere uklar, forvirringen voksede i befolkningen, og der blev rejst kritik i offentligheden. Forløbet rejser spørgsmålene om, den samlede håndtering af kommunikationsindsatsen kunne have været mere...

  4. A randomized controlled trial comparing split and subunit influenza vaccines in adults in Colombia

    Directory of Open Access Journals (Sweden)

    A. Morales

    2003-06-01

    Full Text Available In a two-center, comparative trial, 344 adults were randomly assigned to receive a single dose of inactivated split-virion (Imovax Gripeâ or sub-unit (Agrippal S1â influenza vaccine (1999-2000 formulations. For analysis, study groups were subdivided into adult (18-60 years old and elderly (over 60 years subjects. Blood was drawn immediately before and one month after vaccination, safety was evaluated using a blind-observer design based on reporting of solicited and unsolicited adverse events. Both vaccines were very well tolerated, had similar reactogenicity profiles, and elicited fewer reports of reactions in elderly individuals. Post-vaccination Imovax Gripeâ induced seroprotective antibody titers against the three vaccine strains in 94-99% of adults and 88-97% of elderly subjects, compared with 88-100% and 88-98%, respectively, of those given Agrippal S1â. In conclusion, the split-virion and sub-unit influenza vaccines had similar safety and reactogenicity profiles, and elicited satisfactory immunity in adult and elderly subjects. However, higher post-vaccination geometric mean titer (GMT values in response to the B strain were seen with the split vaccine Imovax Gripeâ, giving it a better overall immunogenicity.En un ensayo comparativo realizado en dos centros, se asignaron de manera aleatoria 344 adultos para recibir una dosis de vacuna contra la gripe de virus fraccionado inactivado (Imovax Gripeâ o de vacuna de subunidades (Agrippal S1â (formulaciones 1999-2000. Para el análisis, los grupos estudiados fueron subdivididos en adultos (18-60 años y ancianos (más de 60 años. La sangre fue extraída justo antes y un mes después de la vacunación. La inocuidad fue evaluada utilizando un informe sobre reacciones adversas, usando un diseño de observador a ciegas. Ambas vacunas fueron muy bien toleradas, con perfiles de reactogenicidad similares y desarrollaron escasas reacciones adversas en los individuos ancianos. La vacunación con

  5. Desarrollo de un método de CLAR-IR para la determinación de etanol residual en vacuna Development of a HPLC-IR method for determination of residual ethanol in vaccine

    Directory of Open Access Journals (Sweden)

    Matilde Cuevas Valdespino

    2009-08-01

    Full Text Available Los ingredientes farmacéuticos activos de la vacuna antimeningocócica cubana VA-MENGOC-BC TM (vesículas de membrana externa purificadas de Neisseria meningitidis, serogrupo B y polisacárido capsular purificado de Neisseria meningitidis, serogrupo C son conservados en etanol, de ahí que dicha vacuna posea un contenido de etanol residual, cuya concentración real no se conocía hasta el momento. Las regulaciones internacionales plantean que los productos biofarmacéuticos y sus ingredientes farmacéuticos activos deben tener bien caracterizadas todas sus impurezas, por lo que el objetivo de este trabajo fue el desarrollo de un método de determinación de etanol mediante cromatografía líquida de alta resolución-índice de refracción para estos fines y su comparación con un método utilizado frecuentemente para cuantificar este solvente, como es la cromatografía gaseosa. El método evaluado resultó ser útil y con una buena robustez para la determinación de este solvente orgánico en esta vacuna antimenigocócica. No se detectaron diferencias estadísticamente significativas entre los resultados obtenidos al evaluar las mismas muestras de vacuna mediante ambos métodos cromatográficos (cromatografía líquida de alta resolución y cromatografía gaseosa, lo que indica la posibilidad del uso de la cromatografía líquida de alta resolución en sustitución de la cromatografía gaseosa para esta determinación.Active pharmaceutical ingredients of Cuban anti-meningococcal vaccine VA-MENGOC-BC TM (vesicles of purified external membranes of Neisseria meningitidis, B serum-group, and purified capsular polysaccharide of Neisseria meningitidis, serum-group C are stored in ethanol, thus that such vaccine has residual ethanol content, of which real concentration is not known just now. International regulations propose that the biopharmaceutical products and its active pharmaceutical ingredients must to have well defined all impurities, thus

  6. Avian influenza

    Directory of Open Access Journals (Sweden)

    Tjandra Y. Aditama

    2006-06-01

    Full Text Available Avian influenza, or “bird flu”, is a contagious disease of animals which crossed the species barrier to infect humans and gave a quite impact on public health in the world since 2004, especially due to the threat of pandemic situation. Until 1st March 2006, laboratory-confirmed human cases have been reported in seven countries: Cambodia, Indonesia, Thailand, Viet Nam, China, Iraq and Turkey with a total of 174 cases and 94 dead (54.02%. Indonesia has 27 cases, 20 were dead (74.07%. AI cases in Indonesia are more in male (62.5% and all have a symptom of fever. An influenza pandemic is a rare but recurrent event. An influenza pandemic happens when a new subtype emerges that has not previously circulated in humans. For this reason, avian H5N1 is a strain with pandemic potential, since it might ultimately adapt into a strain that is contagious among humans. Impact of the pandemic could include high rates of illness and worker absenteeism are expected, and these will contribute to social and economic disruption. Historically, the number of deaths during a pandemic has varied greatly. Death rates are largely determined by four factors: the number of people who become infected, the virulence of the virus, the underlying characteristics and vulnerability of affected populations, and the effectiveness of preventive measures. Accurate predictions of mortality cannot be made before the pandemic virus emerges and begins to spread. (Med J Indones 2006; 15:125-8Keywords: Avian Influenza, Pandemic

  7. Eventos adversos de la vacuna cubana antimeningocóccica Adverse events of antimeningococcal Cuban vaccine

    Directory of Open Access Journals (Sweden)

    Georgina Cruz Martínez

    2011-06-01

    Full Text Available Introducción: en nuestro país hay un sistema de vigilancia exhaustivo que brinda información estadística sobre los eventos adversos a vacunas graves, menos graves y leves. Esta vigilancia es llevada a cabo por el Equipo Básico de Salud; no obstante, en muchas ocasiones al presentar estos eventos una sintomatología poco definida y de poca gravedad, pueden quedar sin diagnóstico y sin investigación. Objetivo: caracterizar los eventos adversos a la vacuna antimeningocóccica VAMENGOC-BC® en los lactantes del municipio Caimito durante el año 2006. Métodos: con un diseño de estudio descriptivo retrospectivo, se analizaron los 381 lactantes de 3 y 5 meses de edad que recibieron de forma programada la vacuna VAMENGOC-BC® según esquema nacional en el año 2006. El instrumento que se empleó para la recogida de la información de las historias clínicas fue la Encuesta Epidemiológica de Eventos Adversos a la Vacunación, establecida por el Programa Nacional de Inmunización. Resultados: de los 381 lactantes que recibieron la vacuna en ese año, hubo 17 con eventos adversos. El mayor porcentaje fue después de administrar la primera dosis (3,01 %. Las manifestaciones locales más frecuentes fueron dolor en el sitio de la inyección con un 50,00 % después de la primera dosis y la induración (66,67 % después de la segunda. Los eventos adversos sistémicos más frecuentes en la primera dosis fueron la fiebre (54,55 % e irritabilidad (27,27 %. La incidencia de lactantes con eventos adversos fue mayor en las primeras 72 horas (3,41 % y en la primera dosis (2,46 %. Sin embargo, la mayoría de las manifestaciones desaparecieron en las primeras 72 horas (3,41 x cada 100 lactantes vacunados, es decir que la recuperación fue rápida. Conclusiones: los eventos adversos locales y sistémicos fueron discretos, con predominio de los segundos, para ambas dosis de la vacuna, y fue la fiebre el evento más frecuente después de aplicadas las dos dosis

  8. PC61 (anti-CD25) treatment inhibits influenza A virus-expanded regulatory T cells and severe lung pathology during a subsequent heterologous lymphocytic choriomeningitis virus infection.

    Science.gov (United States)

    Kraft, Anke R M; Wlodarczyk, Myriam F; Kenney, Laurie L; Selin, Liisa K

    2013-12-01

    Prior immunity to influenza A virus (IAV) in mice changes the outcome to a subsequent lymphocytic choriomeningitis virus (LCMV) infection and can result in severe lung pathology, similar to that observed in patients that died of the 1918 H1N1 pandemic. This pathology is induced by IAV-specific memory CD8(+) T cells cross-reactive with LCMV. Here, we discovered that IAV-immune mice have enhanced CD4(+) Foxp3(+) T-regulatory (Treg) cells in their lungs, leading us to question whether a modulation in the normal balance of Treg and effector T-cell responses also contributes to enhancing lung pathology upon LCMV infection of IAV-immune mice. Treg cell and interleukin-10 (IL-10) levels remained elevated in the lungs and mediastinal lymph nodes (mLNs) throughout the acute LCMV response of IAV-immune mice. PC61 treatment, used to decrease Treg cell levels, did not change LCMV titers but resulted in a surprising decrease in lung pathology upon LCMV infection in IAV-immune but not in naive mice. Associated with this decrease in pathology was a retention of Treg in the mLN and an unexpected partial clonal exhaustion of LCMV-specific CD8(+) T-cell responses only in IAV-immune mice. PC61 treatment did not affect cross-reactive memory CD8(+) T-cell proliferation. These results suggest that in the absence of IAV-expanded Treg cells and in the presence of cross-reactive memory, the LCMV-specific response was overstimulated and became partially exhausted, resulting in a decreased effector response. These studies suggest that Treg cells generated during past infections can influence the characteristics of effector T-cell responses and immunopathology during subsequent heterologous infections. Thus, in humans with complex infection histories, PC61 treatment may lead to unexpected results.

  9. Seguimiento de la reactogenicidad de la vacuna DTP cubana, utilizando dos métodos paralelos

    Directory of Open Access Journals (Sweden)

    María de los Ángeles Peña Machado

    2005-05-01

    Full Text Available Con el objetivo de caracterizar la reactogenicidad de la vacuna Antidiftérica-Antitetánica- Antipertusis (DTP cubana, desarrollada por el Instituto Finlay, se realizó un estudio utilizando dos métodos o fuentes de información diferentes y paralelos. La primera se obtuvo de un ensayo clínico (EC Fase IV, abierto, no controlado, en el que se incluyeron 57 lactantes. La segunda fuente de información se obtuvo de los reportes de los eventos temporalmente asociados a la vacunación (ETAV, recepcionados por la Unidad Coordinadora Nacional de Farmacovigilancia (UCNFv que incluyen a 86 lactantes que fueron atendidos por sospechas de ETAV. En el EC se aplicaron 167 dosis, los eventos adversos esperados e inesperados se observaron en un escaso número de lactantes, fueron mayoritariamente ligeros y autolimitados en el tiempo y su frecuencia de aparición se redujo en la 2da y 3ra dosis. El dolor fue el evento local más frecuente y la fiebre fue el evento general que más se presentó. No se reportaron vómitos y la anorexia, la somnolencia, y el llanto persistente aparecieron en un número limitado de sujetos vacunados.Se presentaron 12 eventos no esperados, solo en 2 de ellos se consideró que existía relación causal con la vacunación. Se reportó un evento adverso grave (niña hospitalizada por síndrome febril prolongado postvacunación, que se estudió y demostró que fue causado por una sepsis urinaria persistente provocada por una malformación vesico-ureteral. Los 86 reportes recepcionados por la UCNFv incluían un total de 141 ETAV, dentro de los síntomas locales, el eritema alcanzó un 9,30% y la induración un 5,81%, la fiebre fue un síntoma frecuente aunque no se especifica la temperatura corporal alcanzada. Aunque existen varias diferencias con relación a las condiciones en que se realiza la vigilancia de eventos adversos en un EC o en la práctica clínica habitual, los resultados aquí analizados nos confirman que la

  10. Prescripción de vacunas no incluidas en el calendario vacunal en la Comunitat Valenciana durante el período 2004-2009

    Directory of Open Access Journals (Sweden)

    Ana Ruiz Palacio

    2011-01-01

    Full Text Available Fundamentos, En el marco de las políticas de uso racional del medicamento, y al objeto de conseguir una gestión eficiente de los programas de vacunaciones, el objetivo de este trabajo es conocer el número de envases de las vacunas prescritas no incluidas en los programas de vacunación en la Comunitat Valenciana y en sus departamentos de salud, así como el gasto que produjeron en 2009, y analizar la evolución desde 2004, centrando el análisis en la vacuna heptavalente conjugada frente al Streptococcus pneumoniae en menores de dos años. Método, Estudio descriptivo retrospectivo de las vacunas prescritas mediante receta en la Comunitat Valenciana durante el año 2009 y su evolución desde 2004. Variables, número de envases, tipo de beneficiario (activo/pensionista, departamento y gasto generado. Fuentes, Gestor de Prestación Farmacéutica (GAIA y Sistema Información Poblacional (SIP. Resultados: En 2009 la prescripción mediante receta de vacunas no incluidas en los programas de vacunación generó un gasto de 683.445,71 ] correspondiente a 17.353 envases, lo que supuso el 87! del total del gasto en vacunas recetadas. La vacuna frente al S. pneumoniae generó el 72! del gasto total de las vacunas no incluidas en el calendario. La evolución 2004-2009 muestra un aumento del gasto de 735.334 ] (24,66! en 2005 a partir del cual se produjo un descenso acusado y paulatino que alcanzó los 1.562.650,67 ] (-228.64!. El gasto por departamentos para la vacuna del neumococo conjugada heptavalente por mil niños/as menores de dos años osciló entre 17.377 y 324 ]. Conclusiones: La tendencia descendente del gasto en recetas prescritas se mantuvo durante 2009, fundamentalmente de vacunas conjugadas frente a neumococo. No obstante, se observó gran variabilidad interdepartamental en las tasas de prescripción que debe ser corregida.

  11. Avances en el desarrollo de vacunas contra la neosporosis bovina Advances in the development of vaccines for bovine neosporosis

    Directory of Open Access Journals (Sweden)

    Yanina P. Hecker

    2012-09-01

    Full Text Available La neosporosis es una enfermedad que ocasiona abortos en bovinos y está causada por un protozoo intracelular obligado denominado Neospora caninum. Las graves pérdidas económicas que provoca en los sistemas de producción de bovinos justifica la necesidad de avanzar en el desarrollo de vacunas. La resistencia a parásitos Apicomplexa está asociada a una respuesta inmune T helper 1 mediada por linfocitos T CD4 citotóxicos y a la producción de interferón-gamma, interleuquina-12, factor de necrosis tumoral e inmunoglobulina G2. La disminución de la transmisión vertical en las sucesivas preñeces y el bajo nivel de repetición de abortos en animales infectados sugieren la existencia de mecanismos inmunitarios de protección. Hasta el momento se conoce que la inoculación pre-servicio con taquizoítos vivos protege contra la infección y el aborto. Los antecedentes de desarrollo de vacunas vivas contra otros protozoos estimulan a los investigadores a continuar en la búsqueda de una vacuna de este tipo contra N. caninum de buena eficacia. Por otra parte, una vacuna inactivada, aun con una baja eficacia, es útil en la prevención del aborto en aquellos establecimientos donde la enfermedad es epizoótica. Una vacuna contra la neosporosis debería evitar el aborto, la transmisión transplacental y la persistencia de la infección. Este trabajo menciona los diversos tipos de vacunas que han sido evaluados hasta el momento, incluyendo inmunógenos inactivos, taquizoítos vivos, antígenos recombinantes y vacunas en vectores.Neosporosis, a disease caused by the obligate intracellular protozoan Neospora caninum, produces abortions in cattle. The severe economic losses in cattle industry justify the need to develop control measures for preventing bovine abortion. Apicomplexan parasitic resistance is associated with T helper 1 immune response mediated by CD4 cytotoxic T lymphocytes, the production of interferon-gamma, interleukin-12, tumor necrosis

  12. Estudio de toxicidad por dosis única y tolerancia local de una vacuna antimeningocócica tipo B en ratas Sprague Dawley

    Directory of Open Access Journals (Sweden)

    Juan F. Núñez

    2006-08-01

    Full Text Available La vacuna antimeningocócica tipo B, objetivo de este estudio, contiene vesículas purificadas de la membrana externa del meningococo del serogrupo B de la cepa (Cu- 385 - 83 B:4:P1.19,15. El esquema de vacunación propuesto en humanos consiste en tres dosis de 0,5 mL, separadas por un intervalo óptimo de ocho semanas. El objetivo de este estudio de toxicidad en ratas Sprague Dawley (SD fue determinar la toxicidad potencial, letalidad, órganos, sistemas susceptibles y otros eventos adversos, así como la toxicidad en el sitio de inoculación después de la administración de una dosis de la vacuna en estudio. Los resultados indicaron que, bajo las condiciones del estudio y según los criterios establecidos para evaluar los resultados, la vacuna antimeningocócica tipo B, no produce efectos tóxicos en el modelo animal usado. Todo lo que se observó fueron formaciones granulomatosas a nivel del punto de inoculación. Estas formaciones han sido reportadas como pertenecientes a los adyuvantes de depósito, como el hidróxido de aluminio, usado en otras vacunas parenterales. Se concluye que la vacuna antimeningocócica tipo B resultó satisfactoria en las pruebas de toxicidad por dosisúnica y tolerancia local realizadas en la especie rata.

  13. Evaluación de la toxicidad por dosis única de la vacuna antidiftérica-antitetánica en ratas Sprague-Dawley

    Directory of Open Access Journals (Sweden)

    Yulieé López

    2005-12-01

    Full Text Available En el presente ensayo se evaluó la toxicidad por dosis única de la vacuna antitetánicaantidiftérica (VA-DIFTET® en ratas Sprague-Dawley. Para ello se utilizó la vía intramuscular por ser la propuesta a usar en humanos. Se administraron 0,3 mL de la vacuna o sus componentes a un total de 20 animales por grupo (10 de cada sexo. Los mismos se observaron diariamente: se midió el consumo de agua y alimento en días alternos y se determinó el peso corporal con intervalos semanales. Se incluyó el análisis anatomopatológico de los animales al final del estudio. Ninguno murió durante el ensayo ni se observaron síntomas clínicos. No hubo diferencias estadísticamente significativas (p>0,1 en cuanto al consumo de agua, alimentos y el peso corporal. En el estudio anatomopatológico se observaron lesiones granulomatosas macrofágicas en las ratas tratadas con la vacuna o con el placebo, hallazgo este característico de las vacunas adyuvadas con hidróxido de aluminio. Los resultados sugirieron que la vacuna VADIFTET® es potencialmente inocua al administrar la dosis única por vía intramuscular

  14. Validación de un ELISA tipo inhibición para cuantificar polisacárido Vi en la vacuna antitifoídica cubana vax-TyVi

    Directory of Open Access Journals (Sweden)

    Esther María Fajardo

    2006-08-01

    Full Text Available Se describe la validación de un ELISA tipo inhibición, reportado por primera vez en la literatura científica para cuantificar un antígeno vacunal: el polisacárido Vi de Salmonella Typhi, para ser empleado en el control de la calidad de la vacuna antitifoídica cubana vax- TyViâ. El ensayo consta de seis pasos: 1 Recubrimiento de placa de reacción con poli-L-lisina y posteriormente polisacárido Vi; 2 Bloqueo con leche descremada; 3 Inhibición o neutralización en tubos de suero anti-Vi de conejo, respectivamente, con polisacárido Vi de Curva de Calibración (concentraciones desde 1–32 μg/mL, control positivo y muestras de vacuna (3 diluciones; 4 Neutralización de anticuerpos anti-Vi libres, presentes en las mezclas anteriores, por el Polisacárido de Recubrimiento; 5 Reconocimiento de anticuerpos anti-Vi unidos a la placa (conjugado anti-IgG de conejo-fosfatasa alcalina y 6 Revelado por reacción enzima-sustrato. Los parámetros de validación estudiados y sus resultados fueron: 1 Precisión, expresada como coeficiente de variación a tres niveles de concentración de polisacárido, comprendidos en el rango de su especificación (35, 50 y 70 μg/mL y evaluada en términos de repetibilidad; precisión intraensayos (cuatro analistas y reproducibilidad (seis analistas: £ 20%; 2 Linealidad (100*R2: 99,68 %; 3 Límite de detección: 0,5 μg/mL; 4 Exactitud (recuperación para las tres diluciones de la muestra: entre 100 y 118%, y 5 Robustez: no influye 1,5 h de bloqueo (p = 0,52 ni ± 5 min para leer placa (p = 0,56; influye grandemente la calidad del agua (p = 0,026, a favor del agua para inyección. El ensayo es adecuado para los fines propuestos y es una medida de la inmunogenicidad in vitro del polisacárido Vi.

  15. Vigilancia de eventos adversos a vacunas: Un problema de salud en la comunidad

    Directory of Open Access Journals (Sweden)

    Denis Berdasquera Corcho

    2000-08-01

    Full Text Available Nuestro país cuenta con un programa de inmunizaciones de un gran impacto a escala mundial, sin embargo carece de un sistema de vigilancia exhaustivo que permita detectar aquellos eventos adversos que son susceptibles de quedar sin diagnóstico. Este trabajo va dirigido especialmente a los Médicos de Familia quienes constituyen el eslabón fundamental en la notificación de estos eventos, y le brinda los elementos esenciales sobre las principales reacciones adversas de cada vacuna y los procedimientos a seguir para su notificaciónOur program of immunization has a great impact in the world; however, it does not have an exhaustive system of surveillance that allows to detect those adverse events that are susceptible to remain undiagnosed. This paper is specially directed to family physicians that are the fundamental link in the notification of these events and gives them the essential elements on the main adverse reactions of each vaccine, as well as the steps to be followed to notify them

  16. Pseudomonas aeruginosa. Vacunas: un reto a la investigación

    Directory of Open Access Journals (Sweden)

    Sara C. Esnard

    2004-04-01

    Full Text Available Pseudomonas aeruginosa, patógeno gramnegativo versátil y oportunista debido a su gran adaptabilidad fisiológica, potencial metabólico y mecanismos de virulencia, es causa frecuente a escala mundial de severas o letales infecciones en pacientes hospitalizados. El empeño por lograr terapias alternativas para prevenir o combatir las infecciones producidas por P. aeruginosa ha ocupado a investigadores de todo el mundo desde la segunda mitad del pasado siglo y actualmente se continúan reportando trabajos que respaldan los ensayos de candidatos vacunales, fundamentalmente a partir de antígenos proteicos, mayoritariamente basados en la construcción de vacunas recombinantes. En este artículo se presenta una revisión de trabajos publicados sobre las investigaciones desarrolladas en diferentes países, con el objetivo de obtener candidatos vacunales para la prevención o tratamiento de las infecciones causadas por Pseudomonas aeruginosa, a partir de la década de los años 50 del siglo XX hasta el 2003.

  17. ESTUDIO cycEVA: CASOS Y CONTROLES PARA LA ESTIMACIÓN DE LA EFECTIVIDAD DE LA VACUNA ANTIGRIPAL EN ESPAÑA, 2008-2013

    Directory of Open Access Journals (Sweden)

    Silvia Jiménez-Jorge

    2014-01-01

    Full Text Available Fundamentos: Desde 2008-09 la efectividad de la vacuna (EV antigripal en España se estima con el estudio de casos y controles para la evaluación de la EV antigripal (cycEVA, componente español de la red europea (Influenza-Monitoring Vaccine Effectiveness (I-MOVE. El objetivo es describir la evolución del estudio cycEVA durante las cinco temporadas del período 2008/09– 2012/13. Métodos: Se analizaron los siguientes indicadores: 1 participación de los médicos/pediatras centinela (MP; 2 población y periodo de estudio, 3 calidad de los datos y 4 difusión de los resultados mediantes publicaciones. Se calculó el porcentaje anual de cambio constante de los indicadores analizándose su tendencia mediante el test de Cochran-Armitage. Resultados: El número de MP participantes aumentó de 164 en 2008-09 hasta 246 en ediciones posteriores. El porcentaje de médicos que reclutaron al menos un paciente experimentó un cambio anual significativo (PCA del 15,33%. El porcentaje de pacientes reclutados incluidos en el análisis aumen- tó del 77% en 2008-09 a más del 95% en las siguientes ediciones (PCA=5,91%. El porcentaje de casos y controles participantes en cycEVA sobre el total de pacientes que contribuyeron al estudio europeo I-MOVE osciló entre el 23% en la edición piloto y 30% en la temporada 2011-12. Los resultados finales se difundieron en revistas científicas con un factor de impacto situado en el cuartil 2 y en 2010-11 y 2011-12 se publicaron resultados preliminares en revistas con un factor de impacto situado en el cuartil 1 (97 citas. Conclusiones: La experiencia del estudio cycEVA se reflejó en una mejora en la oportunidad e impacto de sus resultados, cruciales para orientar las recomendaciones anuales de vacunación antigripal.

  18. Influence of Media on Seasonal Influenza Epidemic Curves.

    Science.gov (United States)

    Saito, Satoshi; Saito, Norihiro; Itoga, Masamichi; Ozaki, Hiromi; Kimura, Toshiyuki; Okamura, Yuji; Murakami, Hiroshi; Kayaba, Hiroyuki

    2016-09-01

    Theoretical investigations predicting the epidemic curves of seasonal influenza have been demonstrated so far; however, there is little empirical research using ever accumulated epidemic curves. The effects of vaccine coverage and information distribution on influenza epidemics were evaluated. Four indices for epidemics (i.e., onset-peak duration, onset-end duration, ratio of the onset-peak duration to onset-end duration and steepness of epidemic curves) were defined, and the correlations between these indices and anti-flu drug prescription dose, vaccine coverage, the volume of media and search trend on influenza through internet were analyzed. Epidemiological data on seasonal influenza epidemics from 2002/2003 to 2013/2014 excluding 2009/2010 season were collected from National Institute of Infectious Diseases of Japan. The onset-peak duration and its ratio to onset-end duration correlated inversely with the volume of anti-flu drug prescription. Onset-peak duration correlated positively with media information volume on influenza. The steepness of the epidemic curve, and anti-flu drug prescription dose inversely correlated with the volume of media information. Pre-epidemic search trend and media volume on influenza correlated with the vaccine coverage in the season. Vaccine coverage had no strong effect on epidemic curve. Education through media has an effect on the epidemic curve of seasonal influenza. Copyright © 2016 The Author(s). Published by Elsevier Ltd.. All rights reserved.

  19. Nasal commensal Staphylococcus epidermidis counteracts influenza virus

    Science.gov (United States)

    Chen, Hui-Wen; Liu, Pei-Feng; Liu, Yu-Tsueng; Kuo, Sherwin; Zhang, Xing-Quan; Schooley, Robert T.; Rohde, Holger; Gallo, Richard L.; Huang, Chun-Ming

    2016-01-01

    Several microbes, including Staphylococcus epidermidis (S. epidermidis), a Gram-positive bacterium, live inside the human nasal cavity as commensals. The role of these nasal commensals in host innate immunity is largely unknown, although bacterial interference in the nasal microbiome may promote ecological competition between commensal bacteria and pathogenic species. We demonstrate here that S. epidermidis culture supernatants significantly suppressed the infectivity of various influenza viruses. Using high-performance liquid chromatography together with mass spectrometry, we identified a giant extracellular matrix-binding protein (Embp) as the major component involved in the anti-influenza effect of S. epidermidis. This anti-influenza activity was abrogated when Embp was mutated, confirming that Embp is essential for S. epidermidis activity against viral infection. We also showed that both S. epidermidis bacterial particles and Embp can directly bind to influenza virus. Furthermore, the injection of a recombinant Embp fragment containing a fibronectin-binding domain into embryonated eggs increased the survival rate of virus-infected chicken embryos. For an in vivo challenge study, prior Embp intranasal inoculation in chickens suppressed the viral titres and induced the expression of antiviral cytokines in the nasal tissues. These results suggest that S. epidermidis in the nasal cavity may serve as a defence mechanism against influenza virus infection. PMID:27306590

  20. siRNA for Influenza Therapy

    Directory of Open Access Journals (Sweden)

    Sailen Barik

    2010-07-01

    Full Text Available Influenza virus is one of the most prevalent and ancient infections in humans. About a fifth of world's population is infected by influenza virus annually, leading to high morbidity and mortality, particularly in infants, the elderly and the immunocompromised. In the US alone, influenza outbreaks lead to roughly 30,000 deaths each year. Current vaccines and anti-influenza drugs are of limited use due to high mutation rate of the virus and side effects. In recent years, RNA interference, triggered by synthetic short interfering RNA (siRNA, has rapidly evolved as a potent antiviral regimen. Properly designed siRNAs have been shown to function as potent inhibitors of influenza virus replication. The siRNAs outperform traditional small molecule antivirals in a number of areas, such as ease of design, modest cost, and fast turnaround. Although specificity and tissue delivery remain major bottlenecks in the clinical applications of RNAi in general, intranasal application of siRNA against respiratory viruses including, but not limited to influenza virus, has experienced significant success and optimism, which is reviewed here.

  1. siRNA for Influenza Therapy.

    Science.gov (United States)

    Barik, Sailen

    2010-07-01

    Influenza virus is one of the most prevalent and ancient infections in humans. About a fifth of world's population is infected by influenza virus annually, leading to high morbidity and mortality, particularly in infants, the elderly and the immunocompromised. In the US alone, influenza outbreaks lead to roughly 30,000 deaths each year. Current vaccines and anti-influenza drugs are of limited use due to high mutation rate of the virus and side effects. In recent years, RNA interference, triggered by synthetic short interfering RNA (siRNA), has rapidly evolved as a potent antiviral regimen. Properly designed siRNAs have been shown to function as potent inhibitors of influenza virus replication. The siRNAs outperform traditional small molecule antivirals in a number of areas, such as ease of design, modest cost, and fast turnaround. Although specificity and tissue delivery remain major bottlenecks in the clinical applications of RNAi in general, intranasal application of siRNA against respiratory viruses including, but not limited to influenza virus, has experienced significant success and optimism, which is reviewed here.

  2. Seguridad, reactogenicidad e inmunogenicidad de una nueva vacuna de polisacáridos meningocócicos en adultos jóvenes cubanos

    Directory of Open Access Journals (Sweden)

    Rossana Estruch–de la Guardia

    2017-04-01

    Full Text Available Se realizó un estudio aleatorizado, controlado y a doble ciegas, en 352 adultos jóvenes cubanos entre 18 y 35 años de edad, con el objetivo de evaluar la seguridad, reactogenicidad y la inmunogenicidad de una nueva vacuna de polisacáridos de Neisseria meningitidis serogrupos A, C y W135, producida por el Instituto Finlay de Vacunas (La Habana, Cuba, con respecto a su similar comercial Mencevax® ACW de Glaxo Smith Kline. Se tomaron muestras de suero antes y 28 días después de la vacunación. La reactogenicidad de ambas vacunas fue similar. Los síntomas y signos, tanto locales como generales fueron leves y aparecieron principalmente durante las primeras 48 h después de la vacunación. Ningún sujeto presentó eventos adversos graves durante los 28 días del período de vigilancia. La vacuna en estudio mostró ser segura y poco reactogénica; sus porcentajes de seroconversión a los 28 días posteriores a la vacunación fueron de: 92,19 % para el serogrupo A, 88,89 % para C y 90,06 % para W135. No se detectaron diferencias con respecto a la seroconversión. La seroprotección alcanzada con la vacuna en estudio fue de 98,44 %, 91,81 % y 95,32 % para los serogrupos A, C y W135 respectivamente y no fue inferior con respecto a la vacuna control para los tres serogrupos estudiados.

  3. Evaluación de la toxicidad por dosis única y tolerancia local de la vacuna vax-SPIRAL® en ratas Sprague Dawley

    Directory of Open Access Journals (Sweden)

    Juan F. Infante

    2004-04-01

    Full Text Available Las pruebas preclínicas de toxicidad en dosis única y en dosis repetidas brindan una valiosa información sobre la seguridad del producto, al incluir el estudio macroscópico e histopatológico de órganos importantes, así como evaluaciones de las vías de administración y el régimen de dosificación. Cuba desarrolló una vacuna polivalente de células inactivadas químicamente adyuvadas con hidróxido de aluminio, vax-SPIRAL®. Esta vacuna presenta ventajas en relación con otras vacunas como la procedente de la antigua URSS. El esquema de vacunación para humanos consiste en dos dosis de 0,5 mL, separadas por un intervalo óptimo de seis semanas. El objetivo de este estudio de toxicidad en ratas Sprague Dawley fue determinar la toxicidad potencial, letalidad, órganos y sistemas susceptibles y otros eventos adversos, así como la toxicidad en el sitio de inoculación después de la administración de una dosis de la vacuna en estudio. Los resultados indicaron que, bajo las condiciones en estudio y según los criterios establecidos para evaluar los datos obtenidos, la vacuna antileptospirósica trivalente no produce efectos tóxicos en el modelo animal usado. Las únicas alteraciones encontradas fueron formaciones granulomatosas a nivel del sitio de inoculación. Estas formaciones han sido reportadas como pertenecientes al adyuvante de depósito (hidróxido de aluminio, también usado en otras vacunas de aplicación parenteral.

  4. Perspectivas para el desarrollo de vacunas e inmunoterapia contra cáncer cervicouterino Perspectives for vaccines and immunotherapy against cervical cancer

    OpenAIRE

    LILIANA GUZMÁN-ROJAS; JUAN MANUEL ALCOCER-GONZÁLEZ; VICENTE MADRID-MARINA

    1998-01-01

    El cáncer cervicouterino representa un grave problema de salud pública, debido a la asociación de la neoplasia con el virus del papiloma humano; actualmente se realizan estudios usando estrategias dirigidas a combatir este patógeno, mediante vacunas, que podrían ser de gran utilidad para el control de la progresión de la enfermedad. El estudio tanto de la inmunología humoral como celular ha servido para el desarrollo de vacunas. Así, la utilización de partículas virales sintéticas para el est...

  5. INTRODUCCIÓN DE NUEVAS VACUNAS: PROCESOS POLÍTICOS, ADMINISTRATIVOS Y FINANCIEROS EN LA TOMA DE DECISIONES DEL PAI-BRASIL

    OpenAIRE

    Carla Magda A.S. Domingues

    2012-01-01

    Se presentan los antecedentes del PAI en el Brasil remontándose al año de 1804 en que se inicia el programa de vacunación en Brasil aplicando la vacuna contra la viruela hasta llegar a 1973 cuando se crea el Programa Nacional de Inmunizaciones en Brasil, y a partir de ahí se mantiene un esquema básico de vacunación hasta llegar al 2012 cuando se introducen las vacunas VIP y pentavalentes. Muestra las alteraciones sufridas en el Calendario de Vacunación del 2012, para llegar a la reformulación...

  6. Methamphetamine reduces human influenza A virus replication.

    Directory of Open Access Journals (Sweden)

    Yun-Hsiang Chen

    Full Text Available Methamphetamine (meth is a highly addictive psychostimulant that is among the most widely abused illicit drugs, with an estimated over 35 million users in the world. Several lines of evidence suggest that chronic meth abuse is a major factor for increased risk of infections with human immunodeficiency virus and possibly other pathogens, due to its immunosuppressive property. Influenza A virus infections frequently cause epidemics and pandemics of respiratory diseases among human populations. However, little is known about whether meth has the ability to enhance influenza A virus replication, thus increasing severity of influenza illness in meth abusers. Herein, we investigated the effects of meth on influenza A virus replication in human lung epithelial A549 cells. The cells were exposed to meth and infected with human influenza A/WSN/33 (H1N1 virus. The viral progenies were titrated by plaque assays, and the expression of viral proteins and cellular proteins involved in interferon responses was examined by Western blotting and immunofluorescence staining. We report the first evidence that meth significantly reduces, rather than increases, virus propagation and the susceptibility to influenza infection in the human lung epithelial cell line, consistent with a decrease in viral protein synthesis. These effects were apparently not caused by meth's effects on enhancing virus-induced interferon responses in the host cells, reducing viral biological activities, or reducing cell viability. Our results suggest that meth might not be a great risk factor for influenza A virus infection among meth abusers. Although the underlying mechanism responsible for the action of meth on attenuating virus replication requires further investigation, these findings prompt the study to examine whether other structurally similar compounds could be used as anti-influenza agents.

  7. Vacunas y autoinmunidad: una rara asociación bajo debate Vaccines and autoimmunity: a strange association under debate

    Directory of Open Access Journals (Sweden)

    Alexander Batista-Duharte

    2012-06-01

    Full Text Available La posible asociación entre vacunas y enfermedades autoinmunes es un tema controversial. Existen elementos a favor de esta relación basados en modelos teóricos, ensayos de laboratorio y varios casos clínicos publicados. En cambio, los estudios epidemiológicos no han confirmado esta asociación y, de ellos, puede inferirse que las vacunas no constituyen una causa demostrada de enfermedades autoinmunes. En este trabajo se analizan las evidencias a favor y en contra de esta controversial asociación, además, se aborda un nuevo síndrome asociado con la administración continuada de adyuvantes vacunales. Se concluye que debido al gran impacto en beneficio de la salud logrado con las vacunas, es necesario continuar desarrollando esta tecnología, pero también se debe seguir perfeccionando los diseños de las nuevas formulaciones y profundizando estudios básicos, preclínicos, ensayos clínicos y farmacovigilancia de los nuevos candidatos vacunales para establecer el riesgo real de desarrollo de un evento autoinmune posvacunación.The occurrence and significance of autoimmune manifestations after administration of vaccines remain controversial. Evidence for immunization triggered autoimmunity come from several sources including theoretical models, animal studies, single and multiple case reports. In contrast, several epidemiological studies don’t report this association, which is reassuring and at least indicates that vaccines are not a major cause of autoimmune diseases. We analyzed current scientific data concluded that vaccines bring a positive impact on public health, so it is necessary to continue developing this technology. Evaluation methods should be improved to avoid or anticipate the possible autoimmune side effects that can be presented.

  8. Seguridad e inmunogenicidad de la vacuna oral contra el cólera: estudio en 20 voluntarios

    Directory of Open Access Journals (Sweden)

    Elizabeth Castañeda

    1995-06-01

    Full Text Available Se realizó un estudio de seguridad e inmunogenicidad de la vacuna de células enteras de Vibrio cholerae 01 más la subunidad B recombinante de la toxina (CE/sBr en 20 voluntarios sanos, en el Laboratorio de Microbiología del Instituto Nacional de Salud. Se suministraron tres dosis de la vacuna con intervalos de dos semanas entre cada una y se recolectaron muestras de sangre el día de la primera dosis y semanalmente durante ocho semanas. Se anotaron los efectos secundarios durante los cinco días siguientes a la ingestión de cada una de las dosis. En los sueros, se determinaron los niveles de anticuerpos antibacterianos empleando la técnicavibriocida y los de anticuerpos antitoxina de las clases IgG e IgA empleando la técnica de ELISA. Se presentaron efectos secundarios leves como náuseas, cefalea y malestar abdominal después de cada una de las dosis en 4,5 y 2 de los voluntarios. El porcentaje de seroconversión más alto para títulos vibriocida fue del 50% y la mayor media geométrica fue de 21,38 (15,3-2935 ambos eventos en la tercera semana. El porcentaje máximo de seroconversión para los anticuerpos antitoxina fue del 84% en la octava semana para IgG y del 89% en la sexta semana para IgA y la media geométrica fue de 245,5 (198-305 en la sexta semana para IgG y de 74,13 (60-98 en la tercera semana para IgA. Con estos datos podemos concluir que la vacuna CEIsBrfue segura e inmunogénica en los voluntarios estudiados.

  9. VARIABILIDAD EN LA NOTIFICACIÓN DE REACCIONES ADVERSAS A LAS VACUNAS DE LA GRIPE PANDÉMICA Y ESTACIONAL. TEMPORADAS 2009-2010 Y 2010-2011, COMUNITAT VALENCIANA

    Directory of Open Access Journals (Sweden)

    Ana María Alguacil Ramos

    2012-01-01

    Full Text Available Fundamentos: La pérdida de confianza en la seguridad de las vacunas derivada de situaciones de alarma, como en el caso de la gripe pandémica, puede afectar tanto a las coberturas vacunales como a la sensibilidad frente a la notificación de las sospechas de reacciones adversas asociadas a vacunas (SRAAV. El objetivo del trabajo es describir los efectos adversos a la vacuna frente a la gripe pandémica notificados en la temporada 2009-2010 y comparar si existen diferencias con los descritos con la vacuna de la gripe estacional en las temporadas 2009-2010 y 2010-2011 en la Comunitat Valenciana (CV. Métodos: Se realizó un estudio descriptivo de los individuos vacunados frente a la gripe que presentaron alguna SRAAV a la vacuna antigripal y que fue notificada a través del Sistema de Información Vacunal, durante las temporadas 2009-2010 (incluyendo la vacunación pandémica y 2010-2011 en CV. se calcularon las tasas de notificación de sospechas de reacciones adversas asociadas a vacunas por cada mil dosis de vacunas administradas y sus intervalos de confianza al 95%. Resultados: Durante el periodo 2009-2010 la tasa de notificación de SRAAV para la vacuna de la gripe estacional fue de 0,02 por mil dosis administradas, para la vacuna pandémica de 0,95. En el periodo 2010-2011 la tasa para la vacuna de la gripe estacional fue de 0,04 por mil. Conclusiones: Durante las temporadas analizadas se incrementó el número de notificaciones de SRAAV para las vacunas pandémicas en comparación con el resto de vacunas antigripales. La mayor tasa de notificación de SRAAV correspondió al grupo de profesionales sociosanitarios, tanto para las vacunas frente a la gripe estacional como pandé- mica.

  10. Un momento de reflexión acerca de las vacunas Just a moment for thinking about vaccines

    OpenAIRE

    G.G. Cáceres Bermejo

    2012-01-01

    Durante muchos siglos, los primeros atisbos de vacunación estuvieron ligados a la práctica de la variolización. En 1796 Edward Jenner desarrolló la primera vacuna contra la viruela: gracias a la vacunación se ha conseguido la erradicación de esta mortal enfermedad sobre el planeta. En otras enfermedades como el tétanos neonatal, la poliomielitis o el sarampión las campañas de vacunación han conseguido una drástica disminución de la morbi-mortalidad. Actualmente, estos logros conseguidos por l...

  11. Desarrollo de vacunas contra el virus de la inmunodeficiencia humana tipo 1: Relevancia de la inmunidad celular contra subtipos

    OpenAIRE

    Ana María Rodríguez; Gabriela Turk; María Fernanda Pascutti; Juliana Falivene; María Magdalena Gherardi

    2010-01-01

    Han pasado casi 30 años de la detección de los primeros casos de infección con HIV-1 y aún no se ha conseguido desarrollar una vacuna efectiva y segura. A pesar del impacto positivo sobre la pandemia que se ha conseguido gracias a los avances en la terapia antirretroviral (TARV), el HIV/sida sigue constituyendo un grave problema para la salud pública, especialmente en los países en desarrollo, donde es difícil el acceso al tratamiento. En el mundo, 33 millones de personas viven con el virus d...

  12. - Las vacunas de ADN: una promisoria medicina para el paciente veterinario (DNA vaccines: a promising medicine for the veterinary patient)

    OpenAIRE

    Juan Carlos Díaz David; Maritza Barrera Valle

    2006-01-01

    Resumen. Las vacunas de ADN constituyen una promisoria herramienta en vacunología moderna. Al tratarse de una tecnología fácil de aplicar y de gran versatilidad, capaz de estimular una respuesta inmune humoral y celular, esenciales en la lucha contra infecciones virales, constituye una línea primordial de investigación y desarrollo. Esta revisión aborda las características de un vector de ADN y los mecanismos propuestos para la generación de la respuesta inmune mediante este tipo de vacunació...

  13. Desarrollo y efecto antitumoral de vacunas génicas celulares y silenciamiento génico

    OpenAIRE

    Miguel Matas, Antonio

    2015-01-01

    La presente tesis utiliza las vacunas antitumorales basadas en células modificadas genéticamente como principal estrategia para intentar lograr una respuesta inmune antitumoral eficaz. La vacunación preventiva con células tumorales modificadas genéticamente ha logrado muy buenos resultados en ratones consiguiendo la inhibición del crecimiento tumoral y la supervivencia final de los mismos. Sin embargo, en la clínica la disponibilidad de ciertas células tumorales es muy baja y su transfección ...

  14. Avian Influenza (Bird Flu)

    Science.gov (United States)

    ... Submit What's this? Submit Button Archived Flu Emails Influenza Types Seasonal Avian Swine/Variant Pandemic Other Information on Avian Influenza Language: English (US) Español Recommend on Facebook Tweet ...

  15. Influenza-Associated Encephalitis

    Directory of Open Access Journals (Sweden)

    J. Gordon Millichap

    2002-02-01

    Full Text Available Twenty patients with influenza-associated encephalitis/encephalopathy treated during the 1997-2001 influenza A epidemics in Japan are reported from Niigata City General Hospital, Japan.

  16. Influenza-A-pneumonie

    NARCIS (Netherlands)

    Veenstra, R P; Boelen, C C; Zijlstra, J G; Bos, A P; Ligtenberg, J J

    2000-01-01

    The majority of influenza cases are not associated with complications. Secondary bacterial pneumonia, commonly caused by Streptococcus pneumoniae or Staphylococcus aureus, is well known to most clinicians. Primary influenza viral pneumonia, characterized by rapidly progressive hypoxia and

  17. Fc functional antibodies in humans with severe H7N9 and seasonal influenza

    Science.gov (United States)

    Vanderven, Hillary A.; Liu, Lu; Ana-Sosa-Batiz, Fernanda; Nguyen, Thi H.O.; Wan, Yanmin; Hogarth, P. Mark; Tilmanis, Danielle; Parsons, Matthew S.; Hurt, Aeron C.; Davenport, Miles P.; Kotsimbos, Tom; Cheng, Allen C.; Kedzierska, Katherine; Zhang, Xiaoyan; Xu, Jianqing; Kent, Stephen J.

    2017-01-01

    BACKGROUND. Both seasonal and novel avian influenza viruses can result in severe infections requiring hospitalization. Anti-influenza antibodies (Abs) with Fc-mediated effector functions, such as Ab-dependent cellular cytotoxicity (ADCC), are of growing interest in control of influenza but have not previously been studied during severe human infections. As such, the objective of this study was to examine Fc-mediated Ab functions in humans hospitalized with influenza infection. METHODS. Serum Ab response was studied in subjects hospitalized with either pandemic H7N9 avian influenza virus in China (n = 18) or circulating seasonal influenza viruses in Melbourne, Australia (n = 16). Recombinant soluble Fc receptor dimer ELISAs, natural killer (NK) cell activation assays, and Ab-dependent killing assays with influenza-infected target cells were used to assess the Fc functionality of anti-influenza hemagglutinin (HA) Abs during severe human influenza infection. RESULTS. We found that the peak generation of Fc functional HA Abs preceded that of neutralizing Abs for both severe H7N9 and seasonal influenza infections. Subjects who succumbed to complications of H7N9 infection demonstrated reduced HA-specific Fc receptor–binding Abs (in magnitude and breadth) immediately prior to death compared with those who survived. Subjects who recovered from H7N9 and severe seasonal influenza infections demonstrated increased Fc receptor–binding Abs not only against the homologous infecting strain but against HAs from different influenza A subtypes. CONCLUSION. Collectively, survivors of severe influenza infection rapidly generate a functional Ab response capable of mediating ADCC against divergent influenza viruses. Broadly binding HA Abs with Fc-mediated functions may be a useful component of protective immunity to severe influenza infection. FUNDING. The National Health and Medical Research Council ([NHMRC] grants 1023294, 1041832, and 1071916), the Australian Department of Health

  18. Advances in influenza vaccination

    NARCIS (Netherlands)

    L.A. Reperant (Leslie); G.F. Rimmelzwaan (Guus); A.D.M.E. Osterhaus (Albert)

    2014-01-01

    textabstractInfluenza virus infections yearly cause high morbidity and mortality burdens in humans, and the development of a new influenza pandemic continues to threaten mankind as a Damoclean sword. Influenza vaccines have been produced by using egg-based virus growth and passaging techniques that

  19. Changes in cytokine levels and NK cell activation associated with influenza.

    Directory of Open Access Journals (Sweden)

    Stephanie Jost

    Full Text Available Several studies have highlighted the important role played by murine natural killer (NK cells in the control of influenza infection. However, human NK cell responses in acute influenza infection, including infection with the 2009 pandemic H1N1 influenza virus, are poorly documented. Here, we examined changes in NK cell phenotype and function and plasma cytokine levels associated with influenza infection and vaccination. We show that absolute numbers of peripheral blood NK cells, and particularly those of CD56(bright NK cells, decreased upon acute influenza infection while this NK cell subset expanded following intramuscular influenza vaccination. NK cells exposed to influenza antigens were activated, with higher proportions of NK cells expressing CD69 in study subjects infected with seasonal influenza strains. Vaccination led to increased levels of CD25+ NK cells, and notably CD56(bright CD25+ NK cells, whereas decreased amounts of this subset were present in the peripheral blood of influenza infected individuals, and predominantly in study subjects infected with the 2009 pandemic H1N1 influenza virus. Finally, acute influenza infection was associated with low plasma concentrations of inflammatory cytokines, including IFN-γ, MIP-1β, IL-2 and IL-15, and high levels of the anti-inflammatory cytokines IL-10 and IL-1ra. Altogether, these data suggest a role for the CD56(bright NK cell subset in the response to influenza, potentially involving their recruitment to infected tissues and a local production and/or uptake of inflammatory cytokines.

  20. Inmunización para influenza y neumococo en prevención cardiovascular

    Directory of Open Access Journals (Sweden)

    María Inés Sosa Liprandi

    2014-06-01

    Full Text Available La relación entre las infecciones respiratorias producidas por el virus de la influenza y el neumococo y los eventos cardiovasculares motivaron la reunión de un grupo interdisciplinario (cardiólogos, clínicos e infectólogos, con el objeto de analizar la evidencia entre la asociación de estos fenómenos y el rol de las estrategias de inmunización en la prevención de la enfermedad cardiovascular. El presente documento sintetiza las conclusiones del grupo de trabajo. El análisis de revisiones sistemáticas sugiere una evidencia consistente entre la infección por influenza y neumococo como desencadenantes de infarto agudo de miocardio y muerte cardiovascular. Los estudios publicados en los últimos 15 años sugieren que la vacunación para influenza y neumococo reducen el riesgo de síndromes coronarios agudos. Con la evidencia existente y teniendo en cuenta los análisis de costo-efectividad, ahorro de costos y perfil de seguridad de las vacunas, las sociedades científicas y agencias gubernamentales de salud, tanto nacionales como internacionales, recomiendan fuertemente la incorporación de la inmunización en el grupo de pacientes con enfermedad cardiovascular crónica.

  1. Cryptoporus volvatus extract inhibits influenza virus replication in vitro and in vivo.

    Directory of Open Access Journals (Sweden)

    Li Gao

    Full Text Available Influenza virus is the cause of significant morbidity and mortality, posing a serious health threat worldwide. Here, we evaluated the antiviral activities of Cryptoporus volvatus extract on influenza virus infection. Our results demonstrated that the Cryptoporus volvatus extract inhibited different influenza virus strain replication in MDCK cells. Time course analysis indicated that the extract exerted its inhibition at earlier and late stages in the replication cycle of influenza virus. Subsequently, we confirmed that the extract suppressed virus internalization into and released from cells. Moreover, the extract significantly reduced H1N1/09 influenza virus load in lungs and dramatically decreased lung lesions in mice. And most importantly, the extract protected mice from lethal challenge with H1N1/09 influenza virus. Our results suggest that the Cryptoporus volvatus extract could be a potential candidate for the development of a new anti-influenza virus therapy.

  2. Cryptoporus volvatus Extract Inhibits Influenza Virus Replication In Vitro and In Vivo

    Science.gov (United States)

    Si, Jianyong; Liu, Jinhua; Sun, Guibo; Sun, Xiaobo; Cao, Li

    2014-01-01

    Influenza virus is the cause of significant morbidity and mortality, posing a serious health threat worldwide. Here, we evaluated the antiviral activities of Cryptoporus volvatus extract on influenza virus infection. Our results demonstrated that the Cryptoporus volvatus extract inhibited different influenza virus strain replication in MDCK cells. Time course analysis indicated that the extract exerted its inhibition at earlier and late stages in the replication cycle of influenza virus. Subsequently, we confirmed that the extract suppressed virus internalization into and released from cells. Moreover, the extract significantly reduced H1N1/09 influenza virus load in lungs and dramatically decreased lung lesions in mice. And most importantly, the extract protected mice from lethal challenge with H1N1/09 influenza virus. Our results suggest that the Cryptoporus volvatus extract could be a potential candidate for the development of a new anti-influenza virus therapy. PMID:25437846

  3. Que hay en el horizonte sobre el virus del papiloma humano, vacunas y el control del cáncer

    Directory of Open Access Journals (Sweden)

    Patricia J. García

    2007-07-01

    Full Text Available Esta revisión provee una visión general sobre las infecciones genitales producidas por el virus del papiloma humano (VPH y de las neoplasias relacionadas con éste y la información sobre las expectativas crecientes de la vacunación como medio de prevención. Se explora como se han desarrollado las vacunas contra el VPH y que aspectos hay que tener en cuenta para una posible implementación de un programa de vacunación para prevenir el cáncer cervical, como los costos, el público objetivo (varones, mujeres o ambos, grupos de riesgo, a que edad vacunarlos, consideraciones que debemos tener en cuenta en la promoción de la vacuna, que pasaría con los programas de detección precoz de cáncer cervical y cuales son los potenciales problemas que tendría en países en desarrollo.

  4. Evaluación de vacunas peptídicas contra el virus de la fiebre aftosa en bovinos : Aislamiento y caracterización de mutantes de escape

    OpenAIRE

    Tami, María Cecilia

    1999-01-01

    EI virus de la fiebre aftosa (VFA) pertenece a la familia Picomaviridae y es el agente causal de la fiebre aftosa (FA). Esta enfermedad causa grandes pérdidas económicas en el mundo y se controla mediante vacunación regular con una vacuna a virus inactivado. Esta vacuna presenta desventajas relacionadas principalmente con la manipulación de grandes cantidades de virus vivo y la inactivación incompleta de las preparaciones virales. En este trabajo se evaluó el potencial de vacunas peptídicas r...

  5. Efectividad de la vacuna frente al neumococo en el anciano. Revisión sistemática y metaanálisis

    National Research Council Canada - National Science Library

    Puig-Barberà, J; Belenguer Varea, A; Goterris Pinto, M; Brines Benlliure, M.J

    2002-01-01

    Objetivo. Estimar la efectividad de la vacuna neumocócica para evitar enfermedad por Streptococcus pneumoniae en ancianos. Diseño. Revisión sistemática y metaanálisis. Fuentes de datos. MEDLINE, años 1964 a 2000...

  6. La evidencia acerca de la controversia de las vacunas que contienen timerosal y su asociación con el autismo

    Directory of Open Access Journals (Sweden)

    Lisset García-Fernández

    2013-06-01

    Full Text Available La vacunación es una de las medidas de mayor impacto en la salud pública para la reducción de la morbimortalidad infantil. El timerosal es un compuesto orgánico del mercurio utilizado como preservante de los frascos multidosis. Eventualmente, en el Perú, surgen olas de controversia acerca de la seguridad de estas vacunas, asociándolas especialmente con el autismo. Como resultado de estas controversias, se han propuesto, incluso, leyes que prohíben este tipo de vacunas, lo que tendría un importante impacto en los costos y en los aspectos logísticos de la estrategia nacional de vacunación. En este artículo se revisa la literatura sobre las principales controversias acerca de las vacunas que contienen timerosal y su supuesta asociación con el autismo. Se realiza una aproximación histórica sobre estas controversias, se hace una actualización de la evidencia científica disponible al momento, y se revisa la posición de los organismos internacionales más importantes con respecto a este tema. Se concluye que la evidencia científica no apoya la noción que exista una asociación entre el uso del timerosal en las vacunas con los trastornos del espectro autista en niños.

  7. Tiempo libre de enfermedad en infecciones urinarias recurrentes según profilaxis con antibiótico o con vacuna bacteriana

    OpenAIRE

    Santo Bueno, Pedro José

    2014-01-01

    [ES]Estudio comparativo de dos tipos de tratamientos profilacticos, antibioterapia supresiva y vacuna bacteriana, en infecciones urinarias de repetición, para determinar el tiempo libre de enfermedad, entendida como el tiempo transcurrido entre la finalización de la profilaxis y la aparición de un episodio de infeccion urinario.

  8. Intracytoplasmic Trapping of Influenza Virus by a Lipophilic Derivative of Aglycoristocetin

    NARCIS (Netherlands)

    Vanderlinden, Evelien; Vanstreels, Els; Boons, Eline; ter Veer, Wouter; Huckriede, Anke; Daelemans, Dirk; Van Lommel, Alfons; Roth, Erzsebet; Sztaricskai, Ferenc; Herczegh, Pal; Naesens, Lieve

    We report on a new anti-influenza virus agent, SA-19, a lipophilic glycopeptide derivative consisting of aglycoristocetin coupled to a phenylbenzyl-substituted cyclobutenedione. In Madin-Darby canine kidney cells infected with influenza A/H1N1, A/H3N2, or B virus, SA-19 displayed a 50% antivirally

  9. Swine- Origin Influenza A (H1N1) Pandemic Revisited | Mathew ...

    African Journals Online (AJOL)

    Since the beginning of January 2008 sporadic cases of infections in humans caused by influenza A (H1N1) virus- resistant to available anti-influenza drugs have been reported worldwide [1,2]. The World Health Organization (WHO) in its report published on 18 March 2009 indicated that during weeks 1- 4 (28 December ...

  10. CD206+ Cell Number Differentiates Influenza A (H1N1pdm09 from Seasonal Influenza A Virus in Fatal Cases

    Directory of Open Access Journals (Sweden)

    Heidi G. Rodriguez-Ramirez

    2014-01-01

    Full Text Available In 2009, a new influenza A (H1N1 virus affected many persons around the world. There is an urgent need for finding biomarkers to distinguish between influenza A (H1N1pdm09 and seasonal influenza virus. We investigated these possible biomarkers in the lung of fatal cases of confirmed influenza A (H1N1pdm09. Cytokines (inflammatory and anti-inflammatory and cellular markers (macrophages and lymphocytes subpopulation markers were analyzed in lung tissue from both influenza A (H1N1pdm09 and seasonal influenza virus. High levels of IL-17, IFN-γ, and TNF-α positive cells were identical in lung tissue from the influenza A (H1N1pdm09 and seasonal cases when compared with healthy lung tissue (P<0.05. Increased IL-4+ cells, and CD4+ and CD14+ cells were also found in high levels in both influenza A (H1N1pdm09 and seasonal influenza virus (P<0.05. Low levels of CD206+ cells (marker of alternatively activated macrophages marker in lung were found in influenza A (H1N1pdm09 when compared with seasonal influenza virus (P<0.05, and the ratio of CD206/CD14+ cells was 2.5-fold higher in seasonal and noninfluenza group compared with influenza A (H1N1pdm09 (P<0.05. In conclusion, CD206+ cells differentiate between influenza A (H1N1pdm09 and seasonal influenza virus in lung tissue of fatal cases.

  11. Caracterización antigénica y molecular de los virus influenza A (H3N2 circulantes en Cuba y su relación con las cepas vacunales (1995-98

    Directory of Open Access Journals (Sweden)

    Suset Oropesa-Fernández

    2015-12-01

    Full Text Available Los cambios antigénicos continuos que ocurren en las glicoproteínas de envoltura (hemaglutinina y neuraminidasa de los virus influenza, se deben a las mutaciones puntuales y a las promovidas por la selección positiva del sistema inmune, que dan origen a las epidemias anuales y reordenamientos de segmentos genómicos, causa de las temidas pandemias. Los intentos para controlar la influenza mediante la vacunación tienen hasta ahora un éxito limitado y son obstaculizados por estos cambios. En Cuba, país subtropical, las infecciones respiratorias agudas constituyen la primera causa de asistencia médica entre las enfermedades infecciosas y la cuarta causa de muerte asociada con la neumonía. La vigilancia para la influenza, en este país, se monitorea por el Laboratorio de Referencia Nacional de Influenza del Instituto de Medicina Tropical ¨Pedro Kouri¨. Este trabajo tiene el objetivo de caracterizar antigénica y genómicamente a 21 cepas de influenza aisladas durante 1995-96 hasta 1997-98, y conocer su similitud con las de circulación internacional, incluidas en las vacunas antigripales de igual periodo. La caracterización antigénica y genómica se realizó mediante las técnicas de inhibición de la hemaglutinación, la inmunoperoxidasa y un sistema de reverso transcripción-reacción en cadena de la polimerasa, respectivamente. Mediante las tres técnicas, el 100% de los aislamientos pertenecieron al tipo A y subtipo H3N2 y permitió clasificarlos como similares a las cepas de circulación internacional recomendadas en la composición de la vacuna antigripal correspondiente a esas temporadas.

  12. Validación de un ELISA para la cuantificación de las impurezas proteicas de la cepa hospedera en el principio activo de la vacuna recombinante cubana contra la hepatitis B

    National Research Council Canada - National Science Library

    Eliana Pérez; Susset Valderrama; Alain Baxera; Yunaisy Jiménez; Gerardo García; Lourdes Costa; Marisel Quintana

    2014-01-01

    Se validó un inmunoensayo tipo sandwich de doble anticuerpo para cuantificar las impurezas proteicas de la cepa hospedera que pueden estar presentes en el principio activo de la vacuna cubana contra la hepatitis B...

  13. Rheumatoid arthritis and the incidence of influenza and influenza-related complications: a retrospective cohort study

    Directory of Open Access Journals (Sweden)

    Blumentals William A

    2012-08-01

    Full Text Available Abstract Background Patients with rheumatoid arthritis (RA are known to be at increased risk of infection, particularly if they are taking drugs with immunomodulatory effects. There is a need for more information on the risk of influenza in patients with RA. Methods A retrospective cohort study was carried out using data gathered from a large US commercial health insurance database (Thomson Reuters Medstat MarketScan from 1 January 2000 to 31 December 2007. Patients were ≥18 years of age, with at least two RA claims diagnoses. The database was scanned for incidence of seasonal influenza and its complications on or up to 30 days after an influenza diagnosis in RA patients and matched controls. Other factors accounted for included medical conditions, use of disease-modifying anti-rheumatic drugs (DMARDs, use of biological agents, influenza vaccination and high- or low-dose corticosteroids. Incidence rate ratios (IRRs were calculated for influenza and its complications in patients with RA. Results 46,030 patients with RA and a matching number of controls had a median age of 57 years. The incidence of influenza was higher in RA patients than in controls (409.33 vs 306.12 cases per 100,000 patient-years, and there was a 2.75-fold increase in incidence of complications in RA. Presence or absence of DMARDs or biologics had no significant effect. The adjusted IRR of influenza was statistically significant in patients aged 60–69 years, and especially among men. A significantly increased rate of influenza complications was observed in women and in both genders combined (but not in men only when all age groups were combined. In general, the risk of influenza complications was similar in RA patients not receiving DMARDs or biologics to that in all RA patients. Pneumonia rates were significantly higher in women with RA. Rates of stroke/myocardial infarction (MI were higher in men, although statistical significance was borderline. Conclusions RA is

  14. The evolving history of influenza viruses and influenza vaccines.

    Science.gov (United States)

    Hannoun, Claude

    2013-09-01

    The isolation of influenza virus 80 years ago in 1933 very quickly led to the development of the first generation of live-attenuated vaccines. The first inactivated influenza vaccine was monovalent (influenza A). In 1942, a bivalent vaccine was produced after the discovery of influenza B. It was later discovered that influenza viruses mutated leading to antigenic changes. Since 1973, the WHO has issued annual recommendations for the composition of the influenza vaccine based on results from surveillance systems that identify currently circulating strains. In 1978, the first trivalent vaccine included two influenza A strains and one influenza B strain. Currently, there are two influenza B lineages circulating; in the latest WHO recommendations, it is suggested that a second B strain could be added to give a quadrivalent vaccine. The history of influenza vaccine and the associated technology shows how the vaccine has evolved to match the evolution of influenza viruses.

  15. Vigilancia de los serotipos y susceptibilidad antimicrobiana de Haemophilus influenzae en Colombia, 1994-2002.

    Directory of Open Access Journals (Sweden)

    María Victoria Ovalle

    2003-06-01

    Full Text Available La enfermedad invasora causada por Haemophilus influenzae, serotipo b, ha sido una de las mayores causas de morbilidad y mortalidad en la población infantil; afortunadamente, en algunos países con amplia cobertura de la vacuna conjugada esta situación ha cambiado. En 1994 se inició en el Grupo de Microbiología un programa de vigilancia de la susceptibilidad antimicrobiana y de los serotipos de aislamientos invasores de H. influenzae, remitidos por los hospitales y Laboratorios de Salud Pública del país como componente de los programas de vigilancia en red de infección respiratoria aguda y meningitis bacteriana aguda. El objetivo de este trabajo fue determinar la evolución de los serotipos y los patrones de susceptibilidad antimicrobiana de los aislamientos invasores de H. influenzae obtenidos de 1994 al 2002 y realizar un nuevo análisis sobre el impacto de la vacuna conjugada de H. influenzae, serotipo b, en Colombia. De 1994 a 2002 se han estudiado 683 aislamientos; 379 (55,5% de pacientes del género masculino; 370 (54,2% de menores de 1 año; 227 (33,2% de 1 a 5 años; 19 (2,8% de 6 a 14 años; 38 (5,6% de mayores de 14 años, y de 29 (4,2% no se tenía el dato de la edad; 493 (72,2% fueron recuperados de pacientes con meningitis, 181 (26,5% de neumonía y 9 (0,9% de otras enfermedades. El 85,1% de los aislamientos fueron H. influenzae, serotipo b, 12,9% no capsulares y 2,0% de otros serotipos (10 a, 1 d, 1 e y 2 f. Del total de aislamientos, 12% fueron productores de beta-lactamasa; 13,9%, resistentes a ampicilina; 12,7%, a trimetoprim sulfametoxazol (SXT; 5,4%, a cloranfenicol, y 1% a cefuroxima; todos fueron sensibles a ceftriaxona. Durante este período se observó un incremento en la resistencia de los aislamientos a SXT (5% al 13%, pero la diferencia no fue estadísticamente significativa (p=0,1. Con la vigilancia se pudo determinar una disminución significativa de los casos de meningitis en los menores de 1 año y en el

  16. Well-tolerated Spirulina extract inhibits influenza virus replication and reduces virus-induced mortality.

    Science.gov (United States)

    Chen, Yi-Hsiang; Chang, Gi-Kung; Kuo, Shu-Ming; Huang, Sheng-Yu; Hu, I-Chen; Lo, Yu-Lun; Shih, Shin-Ru

    2016-04-12

    Influenza is one of the most common human respiratory diseases, and represents a serious public health concern. However, the high mutability of influenza viruses has hampered vaccine development, and resistant strains to existing anti-viral drugs have also emerged. Novel anti-influenza therapies are urgently needed, and in this study, we describe the anti-viral properties of a Spirulina (Arthrospira platensis) cold water extract. Anti-viral effects have previously been reported for extracts and specific substances derived from Spirulina, and here we show that this Spirulina cold water extract has low cellular toxicity, and is well-tolerated in animal models at one dose as high as 5,000 mg/kg, or 3,000 mg/kg/day for 14 successive days. Anti-flu efficacy studies revealed that the Spirulina extract inhibited viral plaque formation in a broad range of influenza viruses, including oseltamivir-resistant strains. Spirulina extract was found to act at an early stage of infection to reduce virus yields in cells and improve survival in influenza-infected mice, with inhibition of influenza hemagglutination identified as one of the mechanisms involved. Together, these results suggest that the cold water extract of Spirulina might serve as a safe and effective therapeutic agent to manage influenza outbreaks, and further clinical investigation may be warranted.

  17. Well-tolerated Spirulina extract inhibits influenza virus replication and reduces virus-induced mortality

    Science.gov (United States)

    Chen, Yi-Hsiang; Chang, Gi-Kung; Kuo, Shu-Ming; Huang, Sheng-Yu; Hu, I-Chen; Lo, Yu-Lun; Shih, Shin-Ru

    2016-01-01

    Influenza is one of the most common human respiratory diseases, and represents a serious public health concern. However, the high mutability of influenza viruses has hampered vaccine development, and resistant strains to existing anti-viral drugs have also emerged. Novel anti-influenza therapies are urgently needed, and in this study, we describe the anti-viral properties of a Spirulina (Arthrospira platensis) cold water extract. Anti-viral effects have previously been reported for extracts and specific substances derived from Spirulina, and here we show that this Spirulina cold water extract has low cellular toxicity, and is well-tolerated in animal models at one dose as high as 5,000 mg/kg, or 3,000 mg/kg/day for 14 successive days. Anti-flu efficacy studies revealed that the Spirulina extract inhibited viral plaque formation in a broad range of influenza viruses, including oseltamivir-resistant strains. Spirulina extract was found to act at an early stage of infection to reduce virus yields in cells and improve survival in influenza-infected mice, with inhibition of influenza hemagglutination identified as one of the mechanisms involved. Together, these results suggest that the cold water extract of Spirulina might serve as a safe and effective therapeutic agent to manage influenza outbreaks, and further clinical investigation may be warranted. PMID:27067133

  18. Eficácia e segurança da vacina brasileira contra hepatite B em recém-nascidos Eficiencia y seguridad de la vacuna brasilera contra hepatitis B en recién-nacidos Efficacy and safety of the Brazilian vaccine against Hepatitis B in newborns

    Directory of Open Access Journals (Sweden)

    Expedito José de Albuquerque Luna

    2009-12-01

    Full Text Available OBJETIVO: Analisar a eficácia e segurança de vacina recombinante contra hepatite B em recém-nascidos. MÉTODOS: O estudo foi conduzido em hospital geral do município de Guarulhos, SP, entre 2002 e 2005. A vacina recombinante contra hepatite B do Instituto Butantan (VrHB-IB foi analisada em dois ensaios clínicos. Em ambos os ensaios, os recém-nascidos foram alocados aleatoriamente ao grupo experimental ou controle (vacina de referência. Os recém-nascidos receberam três doses das vacinas, uma em até 24 h após o nascimento e as subseqüentes 30 e 180 dias após. No primeiro ensaio 538 recém-nascidos completaram o protocolo e no segundo ensaio, 486. Considerou-se critério de equivalência a diferença na soroproteção inferior a 5%. RESULTADOS: A soroproteção no primeiro ensaio (anti HBs > 10mUI/ml foi de 92,5% (247/267 no grupo experimental, comparada a 98,5% (267/271 no grupo controle (p = 0,001. Com este resultado, a VrHB-IB não atingiu o critério de equivalência estabelecido. Após o aumento da concentração de antígeno na vacina para 25¼g, a soroproteção no segundo ensaio foi de 100% no grupo experimental e 99,2% no grupo controle. Nenhum evento adverso grave foi registrado. CONCLUSÕES: A vacina VrHB-IB modificada foi considerada equivalente à vacina de referência e seu uso recomendado à vacinação de recém-nascidos.OBJETIVO: Analizar la eficiencia y seguridad de vacuna recombinante contra hepatitis B en recién-nacidos. MÉTODOS: El estudio fue conducido en hospital general del municipio de Guarulhos, Sureste de Brasil, entre 2002 y 2005. La vacuna recombinante contra hepatitis B del Instituto Butantan (VrHB-IB fue analizada en dos ensayos clínicos. En ambos ensayos, los recién-nacidos fueron distribuidos aleatoriamente en el grupo experimental o control (vacuna de referencia. Los recién-nacidos recibieron tres dosis de las vacunas, una en máximo 24 h posterior al nacimiento y las subsecuentes 30 y 180 d

  19. Influenza-Sediment Interactions

    Science.gov (United States)

    Trusiak, A.; Block, K. A.; Katz, A.; Gottlieb, P.; Alimova, A.; Galarza, J.; Wei, H.; Steiner, J. C.

    2013-12-01

    A typical water fowl can secrete 1012 influenza virions per day. Therefore it is not unexpected that influenza virions interact with sediments in the water column. The influence of sediments on avian influenza virions is not known. With the threat of avian influenza emerging into the human population, it is crucial to understand virus survivability and residence time in a body of water. Influenza and clay sediments are colloidal particles and thus aggregate as explained by DLVO (Derjaguin & Landau, Verwey & Overbeek) theory. Of great importance is an understanding of the types of particulate or macromolecular components that bind the virus particles, and whether the virus remains biologically active. We present results of hetero-aggregation and transmission electron microscopy experiments performed with influenza A/PR8/38. Influenza particles are suspended with sediment and minimal nutrients for several days, after which the components are evaluated to determine influenza concentration and survivability. Transmission electron microscopy results are reported on the influenza-sediment aggregates to elucidate structure and morphology of the components.

  20. Impacto de la retirada de la vacuna de varicela en los casos atendidos en un hospital de tercer nivel

    OpenAIRE

    Conejo Fernández, Antonio José

    2017-01-01

    Estudio del impacto que ha tenido la retirada de la vacuna frente a la varicela de las farmacias comunitarias en España sobre el número de casos de varicela atendidos en Urgencias Pediátricas y en planta de hospitalización pediátrica en un hospital pediátrico de tercer nivel de Málaga. Además, se realiza una estimación de las consecuencias sobre el volumen de población susceptible a la varicela en la provincia de Málaga y su posible relación con los cambios observados en los casos de varicela...

  1. La vacuna contra la hepatitis B, un reto al cáncer hepático.

    Directory of Open Access Journals (Sweden)

    Mercedes Sánchez Sánchez

    2000-06-01

    Full Text Available El cáncer hepático es el tipo de neoplasia más difundido en las regiones donde el virus de la hepatitis B (VHB tiene alta prevalencia. Actualmente existe en el mundo una cantidad considerable de portadores asintomáticos, lo que hace que sea cada vez más complejo el control de la infección. Sin embargo, con el advenimiento de la vacuna contra el virus de la hepatitis B y su inclusión en el Programa Ampliado de Inmunización, esta situación pudiera cambiar, e ir reduciendo en el futuro el número de nuevos casos y los portadores, lo que traería como consecuencia una disminución de la mortalidad por cáncer hepático como secuela de este virus.

  2. ESTRUCTURA MOLECULAR Y ANTIGÉNICA DE LA VACUNA CONTRA EL VIRUS DEL PAPILOMA HUMANO 16 (VPH 16)

    OpenAIRE

    VÍCTOR ANDRÉS VANEGAS; ARLETH IVONNE RUBIO; ASTRID MILENA BEDOYA; GLORIA INÉS SÁNCHEZ

    2008-01-01

    La proteína L1 del Virus del Papiloma Humano (VPH) constituye el 80% de la cápside viral. Las vacunas profilácticas contra el VPH son sintetizadas a partir de la proteína L1 ensamblada en Partículas similares al Virus (del inglés VLP), las cuales son altamente inmunogénicas generando anticuerpos específicos de tipo y en algunos casos pueden presentar reacción cruzada entre tipos de VPH filogenéticamente próximos. La estructura de la proteína L1 del VPH es importante porque confiere estabilida...

  3. Búsqueda e identificación de nuevos candidatos a vacuna contra la malaria producida por Plasmodium vivax

    Directory of Open Access Journals (Sweden)

    Andrés Mauricio Pinzón Velasco

    2004-07-01

    bioinformáticas, estableciendo diversos patrones de alineamiento, así como niveles de similitud no menores al 40%. A pesar de un riguroso enmascaramiento tanto de las secuencias protéicas de P. falciparum, como del genoma de P. vivax, en este último fue evidente una alta presencia de regiones repetitivas que no fueron enmascaradas por ninguna de las fuentes de ADN repetitivo presente en la base de datos de REPBASE, lo cual lleva a pensar que dichas regiones pueden ser específicas de este tipo de organismos. Finalmente se encontraron coincidencias entre 76 secuencias proteicas con actividad antigénica de P. falciparum y el genoma hasta ahora secuenciado de P. vivax, que cumplían con los requisitos mínimos para establecer los niveles de coincidencia, entre las cuales se determinó que cuatro constituyen importantes candidatos a una vacuna contra la malaria producida por P. vivax.

  4. Evaluación del impacto de la vacuna contra rotavirus en Colombia usando métodos rápidos de evaluación

    Directory of Open Access Journals (Sweden)

    Karol Cotes

    2013-10-01

    Full Text Available OBJETIVO: Estimar la efectividad de la vacuna monovalente antirrotavírica para prevenir la hospitalización por enfermedad diarreica aguda en niños menores de 2 años en cinco ciudades de Colombia. MÉTODOS: Se realizó una encuesta poblacional sobre una muestra probabilística de niños mayores de 2 meses y menores de 24 meses de edad en cinco ciudades de Colombia (Barranquilla, Bogotá, Cali, Cartagena y Riohacha en el período de agosto a octubre de 2010. La vacuna fue introducida en el Programa Ampliado de Inmunizaciones en enero de 2009. Se estimaron las coberturas de vacunación contra rotavirus por grupos de edad y la incidencia acumulada de hospitalización por diarrea severa, y se evaluó la magnitud de la asociación entre la vacunación con una o dos dosis de vacuna antirrotavírica y la hospitalización por diarrea, utilizando la razón de probabilidades (RP ajustada por edad y otros factores de importancia epidemiológica. La efectividad de la vacunación se estimó usando la expresión 1 - RP. RESULTADOS: La cobertura de vacunación con una dosis de vacuna fue de 87,3%. En los 12 meses previos a la encuesta 43,2% (1 453 niños de menores de 24 meses presentaron diarrea, y de ellos, 5,2% (174 niños fueron hospitalizados por esta causa. La efectividad de dos dosis de vacuna antirrotavírica para prevenir la hospitalización por diarrea severa fue de 68% (intervalo de confianza de 95%: 55%-77%. CONCLUSIONES: La vacunación contra rotavirus en Colombia protege contra la hospitalización por diarrea por cualquier causa. El uso de encuestas transversales se mostró adecuado para evaluar rápidamente la efectividad de un programa de vacunación con una nueva vacuna.

  5. Inhibition of influenza virus internalization by (-)-epigallocatechin-3-gallate.

    Science.gov (United States)

    Kim, Meehyein; Kim, So-Yeon; Lee, Hye Won; Shin, Jin Soo; Kim, Pilho; Jung, Young-Sik; Jeong, Hyeong-Seop; Hyun, Jae-Kyung; Lee, Chong-Kyo

    2013-11-01

    (-)-Epigallocatechin-3-gallate (EGCG), one of the major flavonoid components of green tea, is known to have a broad antiviral activity against several enveloped viruses, including the influenza virus. However, its mode of action and the mechanism that allows it to target influenza virus molecules have not been fully elucidated. Thus, this study investigated the molecular mechanism by which EGCG suppresses influenza virus infections. EGCG was found to block an early step in the influenza viral life cycle, but it did not affect viral adsorption to target cells or viral RNA replication. However, EGCG inhibited hemifusion events between virus particles and the cellular membrane by reducing the viral membrane integrity, thereby resulting in the loss of the cell penetration capacity of the influenza virus. EGCG also marginally suppressed the viral and nonviral neuraminidase (NA) activity in an enzyme-based assay system. In conclusion, it is suggested that the anti-influenza viral efficacy of EGCG is attributable to damage to the physical properties of the viral envelope and partial inhibition of the NA surface glycoprotein. These results may facilitate future investigations of the antiviral activity of EGCG against other enveloped viruses as well as influenza virus. Copyright © 2013 Elsevier B.V. All rights reserved.

  6. Excess Mortality Associated with Influenza among Tuberculosis Deaths in South Africa, 1999-2009.

    Directory of Open Access Journals (Sweden)

    Sibongile Walaza

    Full Text Available Published data on the interaction between influenza and pulmonary tuberculosis (PTB are limited. We aimed to estimate the influenza-associated mortality among individuals with PTB in South Africa from 1999-2009.We modelled the excess influenza-associated mortality by applying Poisson regression models to monthly PTB and non-tuberculosis respiratory deaths, using laboratory-confirmed influenza as a covariate.PTB deaths increased each winter, coinciding with influenza virus circulation. Among individuals of any age, mean annual influenza-associated PTB mortality rate was 164/100,000 person-years (n = 439. The rate of non-tuberculosis respiratory deaths was 27/100,000 (n = 1125 for HIV-infected and 5/100,000 (n = 2367 for HIV-uninfected individuals of all ages. Among individuals aged <65 years, influenza-associated PTB mortality risk was elevated compared to influenza-associated non-tuberculosis respiratory deaths in HIV-infected (relative risk (RR: 5.2; 95% CI: 4.6-5.9 and HIV-uninfected individuals (RR: 61.0; CI: 41.4-91.0. Among individuals aged ≥65 years, influenza-associated PTB mortality risk was elevated compared to influenza-associated non-tuberculosis respiratory deaths in HIV-uninfected individuals (RR: 13.0; 95% CI: 12.0-14.0.We observed an increased risk of influenza-associated mortality in persons with PTB compared to non-tuberculosis respiratory deaths. If confirmed in other settings, our findings may support recommendations for active inclusion of patients with TB for influenza vaccination and empiric influenza anti-viral treatment of patients with TB during influenza epidemics.

  7. Universal antibodies against the highly conserved influenza fusion peptide cross-neutralize several subtypes of influenza A virus

    Energy Technology Data Exchange (ETDEWEB)

    Hashem, Anwar M. [Centre for Vaccine Evaluation, Biologics and Genetic Therapies Directorate, HPFB, Health Canada, Ottawa, ON (Canada); Department of Microbiology, Faculty of Medicine, King Abdulaziz University, Jeddah (Saudi Arabia); Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON (Canada); Van Domselaar, Gary [National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB (Canada); Li, Changgui; Wang, Junzhi [National Institute for the Control of Pharmaceutical and Biological Products, Beijing (China); She, Yi-Min; Cyr, Terry D. [Centre for Vaccine Evaluation, Biologics and Genetic Therapies Directorate, HPFB, Health Canada, Ottawa, ON (Canada); Sui, Jianhua [Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, 44 Binney Street, Boston, MA 02115 (United States); He, Runtao [National Microbiology Laboratory, Public Health Agency of Canada, Winnipeg, MB (Canada); Marasco, Wayne A. [Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Department of Medicine, Harvard Medical School, 44 Binney Street, Boston, MA 02115 (United States); Li, Xuguang, E-mail: Sean.Li@hc-sc.gc.ca [Centre for Vaccine Evaluation, Biologics and Genetic Therapies Directorate, HPFB, Health Canada, Ottawa, ON (Canada); Department of Biochemistry, Microbiology and Immunology, University of Ottawa, Ottawa, ON (Canada)

    2010-12-10

    Research highlights: {yields} The fusion peptide is the only universally conserved epitope in all influenza viral hemagglutinins. {yields} Anti-fusion peptide antibodies are universal antibodies that cross-react with all influenza HA subtypes. {yields} The universal antibodies cross-neutralize different influenza A subtypes. {yields} The universal antibodies inhibit the fusion process between the viruses and the target cells. -- Abstract: The fusion peptide of influenza viral hemagglutinin plays a critical role in virus entry by facilitating membrane fusion between the virus and target cells. As the fusion peptide is the only universally conserved epitope in all influenza A and B viruses, it could be an attractive target for vaccine-induced immune responses. We previously reported that antibodies targeting the first 14 amino acids of the N-terminus of the fusion peptide could bind to virtually all influenza virus strains and quantify hemagglutinins in vaccines produced in embryonated eggs. Here we demonstrate that these universal antibodies bind to the viral hemagglutinins in native conformation presented in infected mammalian cell cultures and neutralize multiple subtypes of virus by inhibiting the pH-dependant fusion of viral and cellular membranes. These results suggest that this unique, highly-conserved linear sequence in viral hemagglutinin is exposed sufficiently to be attacked by the antibodies during the course of infection and merits further investigation because of potential importance in the protection against diverse strains of influenza viruses.

  8. Antibody administration in experimental influenza increases survival and enhances the effect of oseltamivir

    DEFF Research Database (Denmark)

    Pourroy, Brit Naldahl Jessen; Kolmos, Hans Jørn; Nielsen, Lars Peter

    2012-01-01

    and treatment of a number of infectious diseases. In this experimental study anti-influenza antibodies were passively administrated to mice, subsequently they were infected with influenza virus and treated with oseltamivir. The aim was to investigate, if anti-influenza antibodies influenced the out come...... of oseltamivir treatment and development of resistance towards oseltamivir. We show, that oseltamivir alone was not able to effectively prevent a fatal outcome, but that oseltamivir administered together with a limited amount of antibodies, resulted in improvement of the clinical condition of the mice...

  9. Evaluación de la eficiencia de la vacunación antigripal en la población laboral española Efficiency of influenza vaccination in the working population in Spain

    Directory of Open Access Journals (Sweden)

    José Ramón de Juanes

    2006-03-01

    Full Text Available Introducción: La gripe es la mayor causa de morbimortalidad en el mundo. Actualmente, las vacunas contra la gripe son efectivas y seguras. Las intervenciones que reduzcan la carga de la enfermedad deben analizarse desde el punto de vista clínico y económico. Objetivos: Evaluar la eficiencia de un programa de vacunación contra la gripe en la población laboral española. Métodos: Modelo teórico de análisis de costes y beneficios en términos de ahorro para una cohorte de 1.000 trabajadores entre 16 y 65 años de edad vacunada, y otra no vacunada, a 1 año desde la perspectiva social. Intervenciones: vacunación contra la gripe respecto a no vacunación. Mediciones principales: datos epidemiológicos y clínicos de incidencia de gripe y efectividad de la vacuna. Datos de uso de recursos directos (de atención primaria y especializada e indirectos obtenidos por consenso de 5 expertos en medicina preventiva, microbiología, medicina del trabajo y economía de la salud. Datos de costes unitarios (euros de 2003. Se realizó un análisis de sensibilidad con la incidencia de gripe, la efectividad de la vacuna y los días de ausencia del trabajo por gripe. Resultados: En el escenario base, la vacuna permite ahorrar 35 euros netos por trabajador (el 88% corresponde al ahorro en pérdidas de productividad evitadas. El análisis de sensibilidad indica que los valores umbral de incidencia de gripe y de ausencia del trabajo son del 6% y de 1,5 días, respectivamente, a partir de los cuales la vacunación se asocia con el ahorro neto. Conclusiones: Vacunar contra la gripe a la población laboral española puede comportar un ahorro neto a la sociedad.Introduction: Influenza is a major cause of morbidity and mortality worldwide. Currently, licensed influenza vaccines are safe and effective. Any intervention aimed at reducing the burden of illness is worth analyzing from a clinical and economic perspective. Objective: To assess the costs and benefits of an

  10. Avian influenza virus

    Science.gov (United States)

    Avian influenza virus (AIV) is type A influenza that is adapted to avian host species. Although the virus can be isolated from numerous avian species, the natural host reservoir species are dabbling ducks, shorebirds and gulls. Domestic poultry species (poultry being defined as birds that are rais...

  11. Seasonal Influenza: An Overview

    Science.gov (United States)

    Li, Christina; Freedman, Marian

    2009-01-01

    Seasonal influenza is a major cause of morbidity and mortality in the United States. It also has major social and economic consequences in the form of high rates of absenteeism from school and work as well as significant treatment and hospitalization costs. In fact, annual influenza epidemics and the resulting deaths and lost days of productivity…

  12. Haemophilus influenzae biotype VII.

    OpenAIRE

    Gratten, M

    1983-01-01

    A hitherto unreported biotype of Haemophilus influenzae is described. The isolate is noncapsulate and fails to decarboxylate ornithine or hydrolyze urea but is a strong indole producer. Its frequency is low. It is suggested that this newly recognized biotype of H. influenzae be designated biotype VII.

  13. Towards universal influenza vaccines?

    NARCIS (Netherlands)

    A.D.M.E. Osterhaus (Albert); R.A.M. Fouchier (Ron); G.F. Rimmelzwaan (Guus)

    2011-01-01

    textabstractVaccination is the most cost-effective way to reduce the considerable disease burden of seasonal influenza. Although seasonal influenza vaccines are effective, their performance in the elderly and immunocompromised individuals would benefit from improvement. Major problems related to the

  14. Impacto de la vacuna del virus del papiloma humano en mujeres en edad fértil: revisión sistemática de literatura

    OpenAIRE

    Belalcazar Bernal, Andrea Ximena

    2014-01-01

    Introducción. Con la creación de la vacuna contra el virus de papiloma humano en los años ochentas, se ha promovido su aplicación de manera sistemática para evitar el cáncer cervical, que es la segunda causa de mortalidad por cáncer en mujeres en edad fértil. Actualmente se desconoce el impacto de los resultados de su aplicación. Se pretendió evaluar la mejor evidencia relacionada con los resultados de la vacuna contra VPH en mujeres en edad fértil. Metodología Se realizó una revisión sist...

  15. Aceptabilidad de la vacuna contra el VPH en estudiantes universitarios españoles durante la etapa pre-vacunal: un estudio transversal

    OpenAIRE

    Caballero Pérez, Pablo; Tuells Hernández, José; Rementería, Joseba; Nolasco Bonmatí, Andreu; NAVARRO-LÓPEZ,VICENTE; Arístegui, Javier

    2015-01-01

    Introducción. El cáncer de cuello de útero (CCU), segunda causa de mortalidad por cáncer en mujeres, está asociado a la infección por virus de papiloma humano (VPH), cuya máxima prevalencia se sitúa entre los 20 y 24 años de edad. Desde 2006 se dispone de una vacuna contra el VPH. El objetivo de este estudio es evaluar los conocimientos sobre CCU, la infección por VPH y su vacuna, valorando su aceptabilidad en población universitaria. Métodos. Estudio transversal sobre 1.750 estudiantes de la...

  16. Evaluación de la toxicidad por dosis única de la vacuna antitetánica vax-TET en ratas Sprague Dawley

    Directory of Open Access Journals (Sweden)

    Yulieé López.

    2007-12-01

    Full Text Available La vacuna vax-TET® está indicada en la prevención del tétanos y es efectiva si se logra un completo y apropiado esquema de inmunización. Para investigar el potencial tóxico de este producto se realizó una prueba toxicológica con una dosis única, por vía intramuscular, en un volumen de 0,2 mL en ratas Sprague Dawley. La composición de la vacuna de ensayo probada fue la misma de la vacuna comercial. Los animales fueron observados diariamente en busca de síntomas locales y sistémicos de toxicidad. Se realizaron mediciones del consumo de agua y alimento, así como del peso corporal. Dos semanas después de la inoculación las ratas fueron sacrificadas por métodos de eutanasia sin dolor y sometidas a necropsia. No se observaron muertes ni síntomas de toxicidad en los animales estudiados. Tampoco se encontraron diferencias de interés toxicológico entre los grupos experimentales en cuanto a las variables medidas. El estudio anatomopatológico reveló la presencia de formaciones granulomatosas de tipo macrofágico asociadas, fundamentalmente, al hidróxido de aluminio. Estos resultados permitieron concluir que, bajo las condiciones del estudio y según los criterios establecidos, esta vacuna no produce efectos adversos en el modelo animal usado, por lo que se considera potencialmente no tóxica para humanos.

  17. Reactogenicidad e inmunogenicidad de una nueva vacuna de toxoide tetánico y diftérico con concentración reducida en adolescentes cubanos

    Directory of Open Access Journals (Sweden)

    Rolando Felipe Ochoa.

    2006-08-01

    Full Text Available Se realizó un estudio aleatorizado, controlado y a doble ciegas en 225 adolescentes cubanos entre 13 y 16 años de edad, con el objetivo de evaluar la reactogenicidad y la inmunogenicidad de una nueva vacuna de toxoide tetánico y toxoide diftérico con concentración reducida, producida en el Instituto Finlay, con respecto a su similar comercial IMOVAX dT adult de Aventis Pasteur. Se tomaron muestras de suero antes y 21 días después de la vacunación. La reactogenicidad de ambas vacunas fue similar. Los síntomas y signos, tanto locales como generales fueron moderados y aparecieron principalmente durante las primeras 72 h después de la vacunación. Todos los voluntarios vacunados alcanzaron niveles protectores (³0,1 UI/mL de antitoxina contra el tétanos y la difteria. El 99,25% de los inmunizados con la vacuna experimental y el 98,36% de los voluntarios del grupo control presentaron niveles de antitoxina tetánica correspondientes a una protección de larga duración (³1,0 UI/mL; para la antitoxina diftérica se alcanzaron estos niveles en el 81,20% y 80,33% de los voluntarios en cada grupo. Los títulos medios geométricos de antitoxina tetánica (21,73 UI/mL y antitoxina diftérica (2,55 UI/mL inducidos por la nueva vacuna fueron superiores (p<0,05 a los del grupo control: 15,55 UI/mL y 1,84 UI/Ml respectivamente(p<0.05.

  18. Partial depletion of natural CD4⁺CD25⁺ regulatory T cells with anti-CD25 antibody does not alter the course of acute influenza A virus infection.

    Directory of Open Access Journals (Sweden)

    Richard J Betts

    Full Text Available Foxp3⁺CD4⁺ regulatory T cells represent a T cell subset with well-characterized immunosuppressive effects during immune homeostasis and chronic infections, and there is emerging evidence to suggest these cells temper pulmonary inflammation in response to acute viral infection. Recent studies have demonstrated treatment with PC61 CD25-depleting antibody potentiates inflammation in a murine model of RSV infection, while paradoxically delaying recruitment of CD8⁺ T cells to the site of inflammation. The present study therefore sought to examine the role of these cells in a murine model of acute influenza A virus infection through the administration of PC61 CD25-depleting antibody. PC61 antibody is able to partially deplete CD25⁺Foxp3⁺ regulatory T cells to a comparable degree as seen within previous work examining RSV, however this does not alter influenza A-virus induced mortality, weight loss, viral clearance and cellularity within the lung. Collectively, these data demonstrate that partial depletion of CD4⁺CD25⁺ regulatory T cells with PC61 antibody does not alter the course of influenza A virus infection.

  19. Serums and vaccines to fight the 1918-1919 influenza pandemic in Spain

    Directory of Open Access Journals (Sweden)

    Porras Gallo, María Isabel

    2008-12-01

    Full Text Available Against the background of the renewed interest aroused in recent years by the influenza pandemic of 1918-1919, and the leading role now played by research analysing the process of innovation in medicine, this paper assesses the role played by serums and vaccines —the new resources of the medical science of the time— in the fight against the influenza outbreak of 1918-1919. The paper highlights the dependence on combined scientific, social, economic and professional factors, and also shows the main consequences arising from the fine-tuning and implementation of these therapeutic and prophylactic resources.

    En el marco de la renovada actualidad alcanzada por la pandemia de gripe de 1918-1919 en los últimos años y del protagonismo logrado por los estudios que analizan el proceso de innovación en Medicina, el presente trabajo analiza el papel representado por sueros y vacunas —los nuevos recursos de la ciencia médica del momento— en la lucha contra la gripe de 1918-1919. El estudio pone de relieve su dependencia de los factores científicos, sociales, económicos y profesionales que concurrieron, y muestra también las principales consecuencias derivadas de la puesta a punto y uso de los citados recursos terapéuticos y profilácticos.

  20. INTRODUCCIÓN DE NUEVAS VACUNAS: PROCESOS POLÍTICOS, ADMINISTRATIVOS Y FINANCIEROS EN LA TOMA DE DECISIONES DEL PAI-BRASIL

    Directory of Open Access Journals (Sweden)

    Carla Magda A.S. Domingues

    2012-07-01

    Full Text Available Se presentan los antecedentes del PAI en el Brasil remontándose al año de 1804 en que se inicia el programa de vacunación en Brasil aplicando la vacuna contra la viruela hasta llegar a 1973 cuando se crea el Programa Nacional de Inmunizaciones en Brasil, y a partir de ahí se mantiene un esquema básico de vacunación hasta llegar al 2012 cuando se introducen las vacunas VIP y pentavalentes. Muestra las alteraciones sufridas en el Calendario de Vacunación del 2012, para llegar a la reformulación de un Nuevo Calendario de Vacunación a partir del 2012. Señala las estrategias nacionales de vacunación enmarcadas en acciones de rutina, campañas y control de brotes. Hace referencia a los criterios de inclusión de nuevas vacunas referidos a aspectos: epidemiológicos, inmunológicos, tecnológicos, logística, socio-económicos, aprobación por los Comités y presupuesto. Registra las novedades ocurridas en el Sistema de Informaciones del Programa Nacional de Inmunizaciones, relacionadas con la situación actual, propuesta y Resolución Ministerial. Por último señala los desafíos que debe enfrentar el Sistema enmarcados principalmente en la capacidad para mantener altas coberturas de vacunación.

  1. Multi-Omics Studies towards Novel Modulators of Influenza A Virus–Host Interaction

    Directory of Open Access Journals (Sweden)

    Sandra Söderholm

    2016-09-01

    Full Text Available Human influenza A viruses (IAVs cause global pandemics and epidemics. These viruses evolve rapidly, making current treatment options ineffective. To identify novel modulators of IAV–host interactions, we re-analyzed our recent transcriptomics, metabolomics, proteomics, phosphoproteomics, and genomics/virtual ligand screening data. We identified 713 potential modulators targeting 199 cellular and two viral proteins. Anti-influenza activity for 48 of them has been reported previously, whereas the antiviral efficacy of the 665 remains unknown. Studying anti-influenza efficacy and immuno/neuro-modulating properties of these compounds and their combinations as well as potential viral and host resistance to them may lead to the discovery of novel modulators of IAV–host interactions, which might be more effective than the currently available anti-influenza therapeutics.

  2. C-Methylated Flavonoids from Cleistocalyx operculatus and Their Inhibitory Effects on Novel Influenza A (H1N1) Neuraminidase

    DEFF Research Database (Denmark)

    Dao, Trong-Tuan; Tung, Bui-Thanh; Nguyen, Phi-Hung

    2010-01-01

    As part of an ongoing study focused on the discovery of anti-influenza agents from plants, four new (1-4) and 10 known (5-14) C-methylated flavonoids were isolated from a methanol extract of Cleistocalyx operculatus buds using an influenza H1N1 neuraminidase inhibition assay. Compounds 4, 7, 8...

  3. Aproximación al uso de hongos entomopatógenos y vacunas para el control sostenible de garrapatas en sistemas ganaderos: revisión

    Directory of Open Access Journals (Sweden)

    Ana Carolina Moncada González

    2015-01-01

    Full Text Available La resistencia desarrollada por las garrapatas frente a los acaricidas de síntesis, hace necesario replantear las estrategias utilizadas actualmen - te para su control. Los programas de manejo integrado de parásitos se presentan como una alternativa que, al promover estrategias de con - trol basadas en la ecología y la epidemiología de cada especie de parásito, reducen el riesgo de desarrollo de resistencia. Dichas estrategias incluyen la aplicación de vacunas antigarrapata y hongos entomopatógenos que afectan la viabi - lidad y la reproducción en las garrapatas. Sin embargo, la información obtenida entre estudios sobre hongos y vacunas ha sido inconsistente, por lo que hoy en día ambas representan áreas de investigación bastante activas. El propósito de este trabajo consistió en realizar una revisión descriptiva sobre los mecanismos de acción de la vacuna antigarrapata y los hongos entomopatógenos, en la búsqueda de una po - sible complementariedad que permita el diseño de planes de aplicación conjunta, con miras a mejorar los resultados de control en sistemas ganaderos. En la primera parte del documento se revisa la actual problemática asociada al uso y abuso de los acaricidas de síntesis, haciendo un énfasis particular en el tema de resistencia; posteriormente, se describen los mecanismos de acción de hongos y vacunas que afectan la re - producción y supervivencia en garrapatas, y se incluye información relevante sobre su eficacia. Se espera que la información aquí recolectada, sirva como base para elaborar estudios que permitan identificar la utilidad de los hongos entomopatógenos y las vacunas antigarrapata al interior de los programas de manejo integrado de parásitos en ganadería.

  4. An Amphibian Host Defense Peptide Is Virucidal for Human H1 Hemagglutinin-Bearing Influenza Viruses.

    Science.gov (United States)

    Holthausen, David J; Lee, Song Hee; Kumar, Vineeth Tv; Bouvier, Nicole M; Krammer, Florian; Ellebedy, Ali H; Wrammert, Jens; Lowen, Anice C; George, Sanil; Pillai, Madhavan Radhakrishna; Jacob, Joshy

    2017-04-18

    Although vaccines confer protection against influenza A viruses, antiviral treatment becomes the first line of defense during pandemics because there is insufficient time to produce vaccines. Current antiviral drugs are susceptible to drug resistance, and developing new antivirals is essential. We studied host defense peptides from the skin of the South Indian frog and demonstrated that one of these, which we named "urumin," is virucidal for H1 hemagglutinin-bearing human influenza A viruses. This peptide specifically targeted the conserved stalk region of H1 hemagglutinin and was effective against drug-resistant H1 influenza viruses. Using electron microscopy, we showed that this peptide physically destroyed influenza virions. It also protected naive mice from lethal influenza infection. Urumin represents a unique class of anti-influenza virucide that specifically targets the hemagglutinin stalk region, similar to targeting of antibodies induced by universal influenza vaccines. Urumin therefore has the potential to contribute to first-line anti-viral treatments during influenza outbreaks. Copyright © 2017 Elsevier Inc. All rights reserved.

  5. NK cells exacerbate the pathology of influenza virus infection in mice.

    Science.gov (United States)

    Zhou, Gang; Juang, Shih Wei W; Kane, Kevin P

    2013-04-01

    NK cells offer a first line of defense against viruses and are considered beneficial to the host during infection. Nevertheless, little is understood regarding the phenotype and function of NK cells in the lung during influenza virus infection. We found that the frequency of NK cells in mouse lung increased during influenza infection, with the majority of a mature phenotype. Cell surface CD107a and intracellular IFN-γ were detected in cells expressing multiple NK-cell receptors in infected lung, suggesting that NK cells were activated during infection. The activating receptor NKp46 was predominantly negative on such cells, possibly as a result of encountering influenza HA. Depletion of NK cells in vivo with anti-asialo GM1 or anti-NK1.1 reduced mortality from influenza infection and surviving mice recovered their body weight. Pathology induced by NK cells was only observed with high, not medium or low-dose influenza infection, indicating that the severity of infection influences NK-cell-mediated pathology. Furthermore, adoptive transfer of NK cells from influenza-infected lung, but not uninfected lung, resulted in more rapid weight loss and increased mortality of influenza-infected mice. Our results indicate that during severe influenza infection of the lung, NK cells have a deleterious impact on the host, promoting mortality. © 2013 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim.

  6. Vaccines against papillomavirus infections and disease Vacunas contra el virus del papiloma humano y cáncer cervical invasor

    Directory of Open Access Journals (Sweden)

    Luisa Lina Villa

    2003-01-01

    Full Text Available Squamous cell carcinoma of the uterine cervix is the second cause of cancer-related deaths in women, the higher incidence being observed in developing countries. Infection with oncogenic types of human papillomavirus (HPV is considered the major risk factor for the development of malignancies in the uterine cervix. However, HPV is considered to be a necessary but not sufficient cause for cervical cancer and, therefore, other factors contribute to the carcinogenic process, both present in the environment and from the host. Studies performed in animals, and more recently in humans, indicate that vaccination against the capsid proteins of the virus can prevent efficiently from infection. Furthermore, therapeutic vaccines are under investigation aiming the regression of papillomavirus induced tumors. The scientific basis for the development of papillomavirus vaccines and present status of clinical trials will be addressed in this chapter.El cáncer de células escamosas del cérvix uterino es la segunda causa de muerte relacionada con cáncer en mujeres en el mundo; la incidencia más alta se ha observado en países en desarrollo. La infección con tipos oncogénicos de virus de papiloma humano es considerado el factor de riesgo principal para el desarrollo de malignidad en el cérvix uterino. Sin embargo, el virus es considerado una causa necesaria pero no suficiente para desarrollo de cáncer cervical y, por lo tanto, existen otros factores en el ambiente y en el huésped que contribuyen al proceso carcinogénico. Estudios desarrollados en animales, y más recientemente en humanos, indican que la vacunación en contra de la cápside de las proteínas del virus puede prevenir eficientemente la infección en forma profiláctica; además, las vacunas terapéuticas están bajo investigación con el propósito de promover regresión de los tumores inducidos por virus de papiloma humano. Las bases científicas de las vacunas desarrolladas contra este

  7. ESTRUCTURA MOLECULAR Y ANTIGÉNICA DE LA VACUNA CONTRA EL VIRUS DEL PAPILOMA HUMANO 16 (VPH 16

    Directory of Open Access Journals (Sweden)

    VÍCTOR ANDRÉS VANEGAS

    2008-01-01

    Full Text Available La proteína L1 del Virus del Papiloma Humano (VPH constituye el 80% de la cápside viral. Las vacunas profilácticas contra el VPH son sintetizadas a partir de la proteína L1 ensamblada en Partículas similares al Virus (del inglés VLP, las cuales son altamente inmunogénicas generando anticuerpos específicos de tipo y en algunos casos pueden presentar reacción cruzada entre tipos de VPH filogenéticamente próximos. La estructura de la proteína L1 del VPH es importante porque confiere estabilidad a la cápside mediante el establecimiento de interacciones intra e intercapsoméricas lo que asegura la integridad viral y antigénicamente porque contiene los epítopes que inducen la respuesta inmune protectora. En estudios en los que se evaluó la antigenicidad de la proteína L1 se determinó que los epítopes inmunodominantes de la cápside viral se encuentran en los bucles B-C, D-E, F-G, H-I y en el extremo C-terminal. Estos bucles son poco conservados entre los diferentes genotipos y se encuentran en segmentos de la proteína expuestos en la superficie de la cápside. Los aminoácidos situados en los bucles B-C, F-G y H-I son primordiales para el reconocimiento por los anticuerpos neutralizantes. Los diferentes subtipos y variantes presentan cambios en estos aminoácidos o en residuos que conforman otros epítopes. En esta revisión se presentará un estado del arte de la proteína L1 del VPH genotipo 16, la estructura y su importancia en el desarrollo de vacunas contra la infección producida por este virus.

  8. L-carnosine modulates respiratory burst and reactive oxygen species production in neutrophil biochemistry and function: may oral dosage form of non-hydrolized dipeptide L-carnosine complement anti-infective anti-influenza flu treatment, prevention and self-care as an alternative to the conventional vaccination?

    Science.gov (United States)

    Babizhayev, Mark A; Deyev, Anatoliy I; Yegorov, Yegor E

    2014-05-01

    Influenza A is a viral disease of global dimension, presenting with high morbidity and mortality in annual epidemics, and in pandemics which are of infrequent occurrence but which have very high attack rates. Influenza vaccines of the future must be directed toward use of conserved group-specific viral antigens, such as are present in transitional proteins which are exposed during the fusion of virus to the host cell. Influenza probes revealed a continuing battle for survival between host and parasite in which the host population updates the specificity of its pool of humoral immunity by contact with and response to infection with the most recent viruses which possess altered antigenic specificity in their hemagglutinin (HA) ligand. It is well known that the HA protein is found on the surface of the influenza virus particle and is responsible for binding to receptors on host cells and initiating infection. Polymorphonuclear neutrophils (PMN) have been reported to be involved in the initial host response to influenza A virus (IAV). Early after IAV infection, neutrophils infiltrate the airway probably due to release of chemokines that attract PMN. Clearly, severe IAV infection is characterized by increased neutrophil influx into the lung or upper respiratory tract. Carnosine (β-alanyl-L-histidine) and anserine (N-β-alanyl-1-methyl-L-histidine) are found in skeletal muscle of most vertebrates, including those used for food; for example, 100 g of chicken breast contains 400 mg (17.6 mmol/L) of carnosine and 1020 mg (33.6 mmol/l) of anserine. Carnosine-stimulated respiratory burst in neutrophils is a universal biological mechanism of influenza virus destruction. Our own studies revealed previously unappreciated functional effects of carnosine and related histidine containing compounds as a natural biological prevention and barrier against Influenza virus infection, expand public understanding of the antiviral properties of imidazole-containing dipeptide based

  9. Treating Influenza (Flu)

    Science.gov (United States)

    Treating Influenza (Flu) Information for People at High Risk for Flu Complications Do you have Asthma, Diabetes, or Chronic Heart Disease? ... risk of serious illness if you get the flu. Asthma, diabetes and chronic heart disease were among ...

  10. Haemophilus influenzae biotype VIII.

    OpenAIRE

    Sottnek, F O; Albritton, W L

    1984-01-01

    Six Haemophilus influenzae strains could not be classified as biotypes I through VII. The strains were indole, urease, and ornithine decarboxylase negative. We propose that they be classified as biotype VIII, a previously unreported biotype.

  11. Influenza (Flu) Viruses

    Science.gov (United States)

    ... Virus Testing Clinical Signs & Symptoms of Influenza Symptoms & Laboratory Diagnosis Information for Clinicians on Rapid Diagnostic Testing for ... Help: How do I view different file formats (PDF, DOC, PPT, MPEG) on this site? Adobe PDF ...

  12. Seasonal Influenza Questions & Answers

    Science.gov (United States)

    ... Virus Testing Clinical Signs & Symptoms of Influenza Symptoms & Laboratory Diagnosis Information for Clinicians on Rapid Diagnostic Testing for ... Help: How do I view different file formats (PDF, DOC, PPT, MPEG) on this site? Adobe PDF ...

  13. Influenza and IBD

    Science.gov (United States)

    ... influenza virus as well as the H1N1 flu virus, so only a single vaccination is necessary this year. Patients on steroids, immunosuppressant therapies, and biologic therapies should discuss the risks and ...

  14. Vaccination against seasonal influenza

    CERN Multimedia

    DG Unit

    2009-01-01

    As every year, the Medical Service is taking part in the campaign to promote vaccination against seasonal influenza. Vaccination against seasonal influenza is especially recommended for people suffering from chronic lung, cardio-vascular or kidney conditions or diabetes, for those recovering from a serious illness or surgical operation and for everyone over the age of 65. The influenza virus is transmitted by air and contact with contaminated surfaces, hence the importance of washing hands regularly with soap and / or disinfection using a hydro-alcoholic solution. From the onset of symptoms (fever> 38°, chills, cough, muscle aches and / or joint pain, fatigue) you are strongly recommended to stay at home to avoid spreading the virus. In the present context of the influenza A (H1N1) pandemic, it is important to dissociate these two illnesses and emphasise that the two viruses and the vaccines used to combat them are quite different and that protection against one will not pr...

  15. Animal and human influenzas.

    Science.gov (United States)

    Peiris, M; Yen, H-L

    2014-08-01

    Influenza type A viruses affect humans and other animals and cause significant morbidity, mortality and economic impact. Influenza A viruses are well adapted to cross species barriers and evade host immunity. Viruses that cause no clinical signs in wild aquatic birds may adapt in domestic poultry to become highly pathogenic avian influenza viruses which decimate poultry flocks. Viruses that cause asymptomatic infection in poultry (e.g. the recently emerged A/H7N9 virus) may cause severe zoonotic disease and pose a major pandemic threat. Pandemic influenza arises at unpredictable intervals from animal viruses and, in its global spread, outpaces current technologies for making vaccines against such novel viruses. Confronting the threat of influenza in humans and other animals is an excellent example of a task that requires a One Health approach. Changes in travel, trade in livestock and pets, changes in animal husbandry practices, wet markets and complex marketing chains all contribute to an increased risk of the emergence of novel influenza viruses with the ability to cross species barriers, leading to epizootics or pandemics. Coordinated surveillance at the animal- human interface for pandemic preparedness, risk assessment, risk reduction and prevention at source requires coordinated action among practitioners in human and animal health and the environmental sciences. Implementation of One Health in the field can be challenging because of divergent short-term objectives. Successful implementation requires effort, mutual trust, respect and understanding to ensure that long-term goals are achieved without adverse impacts on agricultural production and food security.

  16. Influenza virus isolation.

    Science.gov (United States)

    Krauss, Scott; Walker, David; Webster, Robert G

    2012-01-01

    The isolation of influenza viruses is important for the diagnosis of respiratory diseases in lower animals and humans, for the detection of the infecting agent in surveillance programs, and is an essential element in the development and production of vaccine. Since influenza is caused by a zoonotic virus it is necessary to do surveillance in the reservoir species (aquatic waterfowls), intermediate hosts (quails, pigs), and in affected mammals including humans. Two of the hemagglutinin (HA) subtypes of influenza A viruses (H5 and H7) can evolve into highly pathogenic (HP) strains for gallinaceous poultry; some HP H5 and H7 strains cause lethal infection of humans. In waterfowls, low pathogenic avian influenza (LPAI) isolates are obtained primarily from the cloaca (or feces); in domestic poultry, the virus is more often recovered from the respiratory tract than from cloacal samples; in mammals, the virus is most often isolated from the respiratory tract, and in cases of high pathogenic avian influenza (HPAI) from the blood and internal organs of infected birds. Virus isolation procedures are performed by inoculation of clinical specimens into embryonated eggs (primarily chicken eggs) or onto a variety of primary or continuous tissue culture systems. Successful isolation of influenza virus depends on the quality of the sample and matching the appropriate culture method to the sample type.

  17. MÉTODOS MULTIVARIADOS PARA ENCAUZAR LA MEJORA DE LA CALIDAD DE UNA VACUNA CONTRA EL CÁNCER

    Directory of Open Access Journals (Sweden)

    Aida Rodríguez Hernández

    2007-09-01

    Full Text Available

    Este trabajo se realizó con el objetivo de encontrar las relaciones entre las variables del proceso productivo y el patrón cromatográfico de una vacuna terapéutica contra el cáncer, característica esta indicativa de la reproducibilidad del producto. Primeramente se empleó el análisis de conglomerados (análisis de cluster para agrupar lotes de producción y posteriormente se empleó el análisis discriminante para encontrar la explicación de estas agrupaciones según las variables del proceso. La determinación de estas relaciones, unida a la búsqueda en la literatura, permitió señalar un camino para mejorar el proceso, dirigiendo el control hacia las variables más influyentes en la variabilidad del producto.

  18. Avian And Other Zoonotic Influenza

    Science.gov (United States)

    ... sheets Fact files Questions & answers Features Multimedia Contacts Influenza (Avian and other zoonotic) Fact sheet Reviewed January ... known to infect or cause illness in people. Influenza type A viruses are of most significance to ...

  19. Miller Fisher syndrome associated with influenza A infection.

    Science.gov (United States)

    Hara, Makoto; Morita, Akihiko; Ichihara, Kazuaki; Kashima, Yoji; Kamei, Satoshi; Kuwahara, Motoi; Kusunoki, Susumu

    2012-01-01

    A 36-year-old, previously healthy man presented with Miller Fisher syndrome (MFS) five days after he was diagnosed with an influenza A infection by a rapid antigen test. He had not received any recent vaccinations. He had no loss of consciousness. Bilateral ophthalmoplegia, blepharoptosis, areflexia, and ataxic gait were noted. One week after treatment with intravenous immunoglobulin, his ophthalmoplegia, blepharoptosis, and ataxic gait had gradually improved, and his deep tendon reflexes returned. Anti-GQ1b IgG antibodies were detected in his serum. There has been no previous report of postinfectious MFS following confirmed an influenza A infection in an adult.

  20. Influenza: exposing the true killer

    OpenAIRE

    Van Epps, Heather L.

    2006-01-01

    In the early 1930s, Richard Shope isolated influenza virus from infected pigs. Shope's finding was quickly followed by the isolation of the influenza virus from humans, proving that a virus—not a bacterium, as was widely believed—caused influenza.

  1. Improving pandemic influenza risk assessment

    Science.gov (United States)

    Assessing the pandemic risk posed by specific non-human influenza A viruses remains a complex challenge. As influenza virus genome sequencing becomes cheaper, faster and more readily available, the ability to predict pandemic potential from sequence data could transform pandemic influenza risk asses...

  2. Prescripción y vigilancia de la inmunoterapia sublingual con vacunas estandarizadas de ácaros domésticos en un servicio de alergología

    Directory of Open Access Journals (Sweden)

    Mirta Álvarez

    2012-12-01

    Full Text Available Las vacunas terapéuticas para la alergia, también llamadas inmunoterapia alergeno específica, consisten en la administración de dosis progresivamente crecientes del alergeno al cual el individuo está sensibilizado, con el objetivo de alcanzar tolerancia al mismo y disminuir la sintomatología clínica. Se realizó un estudio descriptivo, de corte transversal para determinar la seguridad de las vacunas de ácaros domésticos (VALERGEN, administradas mediante gotas por vía sublingual. Se verificaron sus eventos adversos en pacientes alérgicos, atendidos en el Departamento de Alergología del hospital universitario "Calixto García", que asistieron a cambios de vacunas en el mes de septiembre de 2010, así como la frecuencia de prescripción de vacunas alergénicas en el período enero-septiembre del mismo año. Se incluyeron 130 pacientes con tratamiento de inmunoterapia sublingual con VALERGEN, con una edad media de 19,6 años (rango 1-75; el 40,7% tenía 17 años o menos. El tipo de vacuna más empleada resultó ser la multialergénica (63,8%. El ácaro más empleado fue el Dermatophagoides pteronyssinus, seguido de Blomia tropicalis . El 71,55% de los casos se encontraban en fase de mantenimiento. Se reportaron cuatro eventos adversos (3,1% locales leves, que no requirieron tratamiento ni cambio de pauta de vacunación. Se comprobó que las vacunas sublinguales VALERGEN son seguras y bien toleradas en los pacientes alérgicos.

  3. Semisynthetic teicoplanin derivatives as new influenza virus binding inhibitors: synthesis and antiviral studies.

    Science.gov (United States)

    Bereczki, Ilona; Kicsák, Máté; Dobray, Laura; Borbás, Anikó; Batta, Gyula; Kéki, Sándor; Nikodém, Éva Nemes; Ostorházi, Eszter; Rozgonyi, Ferenc; Vanderlinden, Evelien; Naesens, Lieve; Herczegh, Pál

    2014-08-01

    In order to obtain new, cluster-forming antibiotic compounds, teicoplanin pseudoaglycone derivatives containing two lipophilic n-octyl chains have been synthesized. The compounds proved to be poor antibacterials, but, surprisingly, they exhibited potent anti-influenza virus activity against influenza A strains. This antiviral action was related to inhibition of the binding interaction between the virus and the host cell. Related analogs bearing methyl substituents in lieu of the octyl chains, displayed no anti-influenza virus activity. Hence, an interaction between the active, dually n-octylated compounds and the lipid bilayer of the host cell can be postulated, to explain the observed inhibition of influenza virus attachment. Copyright © 2014 Elsevier Ltd. All rights reserved.

  4. Salivary agglutinin and lung scavenger receptor cysteine-rich glycoprotein 340 have broad anti-influenza activities and interactions with surfactant protein D that vary according to donor source and sialylation

    DEFF Research Database (Denmark)

    Hartshorn, Kevan L.; Ligtenberg, Antoon; White, Mitchell R.

    2006-01-01

    has co-operative interactions with SP-D in viral neutralization and aggregation assays. We now report that salivary gp-340 can, in some cases, strongly antagonize certain antiviral activities of SP-D. This effect was associated with greater binding of salivary gp-340 to the carbohydrate recognition......We previously found that scavenger receptor cysteine-rich gp-340 (glycoprotein-340), isolated from lung or saliva, directly inhibits human IAVs (influenza A viruses). We now show that salivary gp-340 has broad antiviral activity against human, equine and porcine IAV strains. Although lung...... and salivary gp-340 are identical in protein sequence, salivary gp-340 from one donor had significantly greater antiviral activity against avian-like IAV strains which preferentially bind sialic acids in alpha(2,3) linkage. A greater density of alpha(2,3)-linked sialic acids was present on the salivary gp-340...

  5. Inmunizaciones en la adolescencia

    Directory of Open Access Journals (Sweden)

    Dr. V. Jacob Cohen

    2011-01-01

    Se agregan vacunas especiales en caso de viaje a zonas endémicas, como es el caso de rabia, encefalitis japonesa o fiebre amarilla; tema que no se incluye en este artículo, propio de la medicina del viajero, o tampoco el de aquellos con mayor susceptibilidad a infecciones específicas como las vacunas anti neumocócica 23 valente, anti meningocócica no conjugada o anti Hemophilus influenza b (Ej., Asplénicos, Hipogamaglobulinemia, S. nefrótico etc..

  6. Evaluación de los programas de vacunación mediante estudios serológicos y vacunas distribuidas Evaluation of vaccination programs through serological studies and distributed vaccines

    OpenAIRE

    Pedro Plans

    2005-01-01

    Antecedentes: El objetivo del estudio fue comparar las coberturas vacunales en escolares para la vacuna triple vírica (sarampión-rubéola-parotiditis), DTP (difteria-tétanos-tos ferina) y poliomielitis, obtenidas a partir de las vacunas distribuidas a los centros de vacunación, las vacunaciones declaradas y el análisis serológico de anticuerpos. Métodos: La cobertura vacunal se obtuvo a partir de los antecedentes de vacunación recogidos en un cuestionario y mediante el análisis serológico de a...

  7. Francisco Xavier Balmis y las Juntas de Vacuna, un ejemplo pionero para implementar la vacunación Francisco Xavier Balmis and the vaccine network, a pioneering example of vaccination implementation

    OpenAIRE

    José Tuells; Susana María Ramírez Martín

    2011-01-01

    La primera campaña mundial de vacunación organizada fue efectuada en América y las Filipinas por la Real Expedición Filantrópica de la Vacuna (1803-1810). La labor de Balmis como director y de Salvany, subdirector, no se limitó al mero transporte del fluido vacunal a través de los niños vacuníferos sino también al sistema organizativo que aplicaron. Las Juntas de Vacuna fueron una red de centros creados para preservar y transportar el fluido vacuno en buenas condiciones hasta los lugares de v...

  8. Conocimientos y percepción de las madres de familia y profesores acerca de las vacunas aplicadas en campañas de vacunación en las instituciones educativas del nivel secundario cercado de Tacna 2008

    OpenAIRE

    Paredes Espejo, Yanela Elízabeth

    2011-01-01

    Se investigó los conocimientos y la percepción de las madres de familia y profesores acerca de las vacunas aplicadas en Campañas de Vacunación en las Instituciones Educativas del nivel secundario. Las vacunas, que protegen contra las enfermedades mediante la inducción de inmunidad, se administran de forma generalizada y sistemática en todo el mundo de acuerdo con el principio de sentido común de que es preferible que las personas no caigan enfermas a tener que tratarlas una vez que lo ...

  9. Respuesta IgG inducida en población de riesgo vacunada con vax-SPIRAL (Vacuna Antileptospirósica Trivalente:canicola, copenhageni y mozdok

    Directory of Open Access Journals (Sweden)

    Yoandra Rodríguez

    2001-06-01

    Full Text Available La respuesta IgG sérica inducida por la aplicación de la vacuna antileptospirósica trivalente (canicola, copenhageni, mozdok vax-SPIRAL fue evaluada en dos poblaciones de riesgo del municipio San José de Las Lajas, La Habana, Cuba. Fueron determinados los niveles de anticuerpos IgG antes y después de la vacunación mediante ELISA, empleando como antígeno de recubrimiento células completas inactivadas de los serovares componentes de la vacuna. Se definió como criterio de respuesta el incremento en dos veces de la concentración de IgG posterior a la vacunación. La vacuna indujo una respuesta de anticuerpos IgG similar para los tres serovares en ambas poblaciones, obteniéndose entre 63,77% y 70,04% de respuesta. Se observó una elevada seroprevalencia de anticuerpos contra los tres serovares antes de la vacunación. Se obtuvieron además diferencias estadísticas significativas (p<0,05 entre los niveles de IgG antes y después de la vacunación en las dos poblaciones. Estos resultados constituyen la primera demostración de la capacidad inmunogénica de vax- SPIRAL en población de riesgo expuesta y una evidencia de que la respuesta está influenciada, entre otros factores, por el contacto previo con el germen.

  10. Activación del polisacárido capsular de Streptococcus pneumoniae serotipo 23F para la obtención de vacunas conjugadas

    Directory of Open Access Journals (Sweden)

    Janoi Chang-Calderón

    2017-04-01

    Full Text Available En la actualidad, las vacunas conjugadas constituyen un gran hito en el desarrollo de fármacos que protegen contra las enfermedades infecciosas. Estas vacunas no solo disminuyen drásticamente la mortalidad y morbilidad de diferentes enfermedades causadas por bacterias en la población infantil; sino que también repercuten sobre la población no vacunada. Las vacunas conjugadas se basan en establecer una unión covalente entre un polisacárido y una proteína portadora para lo cual existen diferentes procedimientos químicos. Todos los procedimientos de conjugación requieren la presencia de grupos reactivos complementarios que muchas veces son generados en ambas macromoléculas. Este trabajo se enfoca en el estudio de la reacción de fragmentación y de la oxidación peryódica sobre el polisacárido capsular serotipo 23F de Streptococcus pneumoniae para su uso como antígeno vacunal. Se estableció la fragmentación del polisacárido mediante hidrólisis con ácido acético y trifluoroácetico. En el caso de la reacción de oxidación se encontró que la cantidad de moles de peryodato de sodio y la temperatura influyen de manera directamente proporcional sobre la generación de grupos carbonilos. Adicionalmente se demostró que el sustituyente glicerol-fosfatos presente en la estructura del serotipo 23F es relevante para conservar la antigenicidad. El procedimiento descrito permite obtener conjugados inmunogénicos a partir del polisacárido capsular de Streptococcus pneumoniae serotipo 23F en el modelo de conejos.

  11. Influenza sentinel surveillance network

    Science.gov (United States)

    Torner, Nuria; Baricot, Maretva; Martínez, Ana; Toledo, Diana; Godoy, Pere; Dominguez, Ángela; Primary care physicians’ Network of Catalonia (PID, the Influenza Sentinel Surveillance

    2013-01-01

    The aim of this study was to evaluate the outcome of a collaborative action between Public Health services and Primary Care in the context of a case-control study on effectiveness of pharmaceutical and non-pharmaceutical measures to prevent hospitalization in a pandemic situation. To carry out this research the collaborative action of the primary care physicians members of the Influenza surveillance network was needed, they had to recall clinical information from influenza A(H1N1)pmd09 confirmed outpatient cases and negative outpatient controls matching their corresponding hospitalized confirmed case. A survey questionnaire to assess involvement of Influenza Sentinel Surveillance Primary care physicians’ Network of Catalonia (PIDIRAC) regarding the outpatient case and control outreach during the pandemic influenza season was performed. A total of 71,1% of completed surveys were received. Perception of pandemic activity was considered to be similar to seasonal influenza activity in 43.8% or higher but not unbearable in 37.5% of the replies. There was no nuisance reported from patients regarding neither the questions nor the surveyor. Collaborative research between Public Health services and Primary Care physicians enhances Public Health actions and research. PMID:23396181

  12. Modeling Influenza Antigenic Shift and Drift with LEGO Bricks

    Directory of Open Access Journals (Sweden)

    Boriana Marintcheva

    2016-05-01

    Full Text Available The concepts of antigenic shift and drift could be found in almost every microbiology and virology syllabus, usually taught in the context of Influenza virus biology. They are central to understanding viral diversity and evolution and have direct application to anti-flu vaccine design and effectiveness. To aid student understanding of the concepts, I have developed an exercise to visualize the mechanistic aspects of antigenic shift and drift using LEGO bricks. This hands-on/minds-on exercise asks students to replicate viruses taking into account the error-prone nature of Influenza RNA polymerase and to package model virions from a host cell infected with two different Influenza strains, while keeping track of the level of diversity of newly propagated viral particles. The exercise can be executed in any type of classroom for about 10 minutes and if desired, extended to emphasize quantitative skills, molecular biology concepts, or to trigger discussion of key issues in vaccine design.

  13. Cardiovascular exercise training extends influenza vaccine seroprotection in sedentary older adults: the immune function intervention trial.

    Science.gov (United States)

    Woods, Jeffrey A; Keylock, K Todd; Lowder, Thomas; Vieira, Victoria J; Zelkovich, William; Dumich, Sara; Colantuano, Kim; Lyons, Kristin; Leifheit, Kurt; Cook, Marc; Chapman-Novakofski, Karen; McAuley, Edward

    2009-12-01

    To determine whether cardiovascular exercise training resulted in improved antibody responses to influenza vaccination in sedentary elderly people who exhibited poor vaccine responses. Single-site randomized parallel-arm 10-month controlled trial. University of Illinois at Urbana-Champaign. One hundred forty-four sedentary, healthy older (69.9 +/- 0.4) adults. Moderate (60-70% maximal oxygen uptake) cardiovascular exercise was compared with flexibility and balance training. The primary outcome was influenza vaccine response, as measured according to hemagglutination inhibition (HI) anti-influenza antibody titer and seroprotective responses (HI titer > or =40). Secondary measures included cardiovascular fitness and body composition. Of the 160 participants enrolled, 144 (90%) completed the 10-month intervention with excellent compliance ( approximately 83%). Cardiovascular, but not flexibility, exercise intervention resulted in improvements in indices of cardiovascular fitness, including maximal oxygen uptake. Although not affecting peak (e.g., 3 and 6 weeks) postvaccine anti-influenza HI titers, cardiovascular exercise resulted in a significant increase in seroprotection 24 weeks after vaccination (30-100% dependent on vaccine variant), whereas flexibility training did not. Participants randomized to cardiovascular exercise experienced improvements in influenza seroprotection throughout the entire influenza season, whereas those in the balance and flexibility intervention did not. Although there were no differences in reported respiratory tract infections, the exercise group exhibited reduced overall illness severity and sleep disturbance. These data support the hypothesis that regular endurance exercise improves influenza vaccine responses.

  14. Estudio de toxicidad por dosis única y tolerancia local de una vacuna antimeningocócica tipo B en ratas Sprague Dawley

    OpenAIRE

    Juan F. Núñez; Lucy Herrera; Juan F. Infante; Pablo González; Viviana Pérez; Maylén Argamacilla; Jorge Mayo; Eligio Sosa; Néstor González; José Dupuig; Vismark Torres; Niurka Rodríguez.

    2006-01-01

    La vacuna antimeningocócica tipo B, objetivo de este estudio, contiene vesículas purificadas de la membrana externa del meningococo del serogrupo B de la cepa (Cu- 385 - 83 ) B:4:P1.19,15. El esquema de vacunación propuesto en humanos consiste en tres dosis de 0,5 mL, separadas por un intervalo óptimo de ocho semanas. El objetivo de este estudio de toxicidad en ratas Sprague Dawley (SD) fue determinar la toxicidad potencial, letalidad, órganos, sistemas susceptibles y otros eventos adversos, ...

  15. Infección invasiva por Streptococcus pneumoniae tras la introducción de la vacuna heptavalente antineumocócica

    OpenAIRE

    Pérez Rodríguez, Mª Teresa

    2013-01-01

    La enfermedad invasiva por S. pneumoniae (EISP) constituye la forma más grave de infección por este microorganismo, con una elevada mortalidad incluso con un tratamiento antibiótico correcto. Tras la introducción de la vacuna antineumocócica conjugada heptavalente (VPC-7) en 2001 se han observado diferentes modificaciones en la incidencia, en las formas clínicas de presentación de la enfermedad, así como en la tasa de resistencia a antimicrobianos. Todo ello se ha relacionado con un reemplaza...

  16. Respuesta inmune humoral y celular a la vacuna Brucella abortus cepa RB51 en vaquillas en pastoreo suplementadas con selenio y α-tocoferol

    OpenAIRE

    V Leyán; R Chihuailaf; M Ortega

    2015-01-01

    Con el objetivo de evaluar el efecto de una suplementación con selenio y α-tocoferol sobre la respuesta inmune a la vacuna Brucella abortus cepa RB51, se emplearon cuatro grupos de seis vaquillas en pastoreo. Tres meses previo al inicio del ensayo, los grupos Se-T y Se fueron suplementados en dosis única con selenato de bario (1 mg selenio/kg peso vivo) y los grupos Se-T y T con 500 UI de α-tocoferol/100 kg cada dos meses. El grupo C fue mantenido sin suplementación. Una vez establecidas las ...

  17. Conocimiento del virus del papiloma humano y su vacuna por parte de mujeres de una zona rural de Querétaro, México

    OpenAIRE

    Medina Fernández, Isai Arturo; Gallegos-Torres, Ruth Magdalena; Cervera-Baas, María Eugenia; Cob-Tejeda, Rudy Antonio; Jiménez-Laces, Jenny; Ibarra-Escobedo, Omar

    2016-01-01

    Introducción: El virus del papiloma humano (VPH) tiene una alta prevalencia en mujeres jóvenes, por lo que considera un problema de salud pública. Al respecto, en el año 2011, México ocupó el decimonoveno lugar de las enfermedades transmisibles y más del 90% de casos de cáncer cérvicouterino están ligados a esa enfermedad. El objetivo del estudio fue determinar el nivel de conocimientos sobre el VPH, la vacuna y las conductas de riesgo de mujeres adultas jóvenes de una comunidad rural de San ...

  18. Representaciones e identidades del discurso especista: el caso de la carne vacuna y sus derivados en la Argentina (2000-2012)

    OpenAIRE

    Navarro, Alexandra Ximena Carolina

    2016-01-01

    Esta investigación pretende indagar acerca de cuáles son los discursos y prácticas que estructuran al especismo antropocéntrico en Argentina desde la arista específica de la alimentación con carne vacuna. El objetivo fundamental es exponer, evidenciar y visibilizar los elementos que subyacen a estas prácticas y los discursos que las sostienen. En este sentido se propone realizar al mismo tiempo un ejercicio de desnaturalización, comprendiendo que esto implica un trabajo de reconocimiento de l...

  19. Desarrollo de una vacuna profiláctica de segunda generación contra el papilomavirus humano Development of a second generation prophylactic vaccine against human papillomavirus

    Directory of Open Access Journals (Sweden)

    Alonso Leonardo

    2011-06-01

    Full Text Available Los papilomavirus humanos (HPV son el agente etiológico del cáncer cervical (CC, la segunda causa de muerte por cáncer en mujeres. Se estima que medio millón de nuevos cánceres se diagnostica cada año, ocurriendo la mayoría de ellos en países en vías de desarrollo debido a la ausencia o ineficiencia de los programas masivos de detección temprana. Recientemente se han introducido en el mercado dos vacunas profilácticas contra las principales cepas oncogénicas de HPV, la cepa 16 y 18, responsables por el 80% de todos los CC. Estas vacunas se obtienen en forma recombinante y han demostrado ser extremadamente seguras y eficaces. Sin embargo, su impacto inmediato en la incidencia de la infección por HPV en países en vías de desarrollo será mínimo, debido principalmente al alto costo de las mismas. Existe la necesidad de contar con vacunas de segunda generación, de bajo costo y de aplicación masiva que permitan disminuir sensiblemente el número de CC en la población. Con este objetivo hemos desarrollado una plataforma de expresión recombinante que permite obtener partículas tipo virus (VLPs con las cuales es posible formular vacunas efectivas y accesibles contra la infección por HPV.Human papillomaviruses (HPV are the etiologic agent for cervical cancer (CC, the second cause of cancer death in women worldwide. It is estimated that half a million new cases are diagnosed each year, mostly in developing countries due to the lack of massive programs for early detection of the virus. Recently, two prophylactic vaccines against the main oncogenic HPV types 16 and 18 (responsible for 80% of CC have been introduced into market. Both of these vaccines, obtained as recombinants, have been shown to be safe and effective; however, their high cost works against its immediate impact in the incidence of HPV infection in developing and low-income countries. There is a need to have in hand second generation, low cost vaccines of massive use

  20. DESARROLLO DE CEPAS BACTERIANAS ATENUADAS COMO VACUNAS ORALES VIVAS Y PRODUCCION DE ANTIGENOS RECOMBINANTES PARA INMUNIZACION CONTRA PATOGENOS HUMANOS Y DE ANIMALES

    OpenAIRE

    VENEGAS ESPARZA, ALEJANDRO

    2003-01-01

    El proyecto tenia como objetivo principal el desarrollo de vacunas orales basadas en la generación de mutantes bacterianos del género Salmonella, en genes metabólicos o relacionados con la replicación del material genético para asegurar que estas bacterias estuvieran efectivamente atenuadas en su virulencia, o al menos, su proliferación en el vacunado fuera limitada a un corto período. Este proyecto ha permitido efectivamente obtener un sistema (bacteria atenuada) portador de antígen...

  1. Recomendación sobre la vacuna contra la tosferina para los preadolescentes y adolescentes (Whooping Cough Vaccine Recommendation for Preteens and Teens)

    Centers for Disease Control (CDC) Podcasts

    2015-04-13

    Este podcast proporciona información acerca de la tosferina y la recomendación de que todos los preadolescentes reciban la vacuna Tdap a los 11 o 12 años para ayudar a protegerlos contra esta grave enfermedad.  Created: 4/13/2015 by National Center for Immunization and Respiratory Diseases (NCIRD), Division of Bacterial Diseases (DBD), Meningitis and Vaccine Preventable Diseases Branch (MVPDB).   Date Released: 4/13/2015.

  2. Estratégias de campo em ensaios clínicos com novas vacinas produzidas no Brasil Estrategias de campo en ensayos clínicos con nuevas vacunas producidas en Brasil Clinical trials field strategies with novel vaccines produced in Brazil

    Directory of Open Access Journals (Sweden)

    Emília de Faria Carniel

    2012-06-01

    Full Text Available OBJETIVO: Relatar as estratégias de campo utilizadas em dois ensaios clínicos com vacinas desenvolvidas pelo Instituto Butantan, em 2004 e 2006. MÉTODOS: Estudo do tipo relato de experiência, em que se descreve o planejamento e a operacionalização dos ensaios clínicos, que avaliaram a imunogenicidade e a segurança da vacina BCG combinada com a vacina da hepatite B (VrHB-IB e da tetravalente bacteriana modificada pela extração do lipopolissacarídeo (LPS do componente pertussis (DTPm/Hib. RESULTADOS: As principais estratégias de campo utilizadas foram: a Parceria entre os pesquisadores e os gestores da Secretaria Municipal de Saúde e b Realização dos procedimentos da pesquisa nos domicílios ou nos Centros de Saúde frequentados pelos participantes. No primeiro estudo, foram vacinados 552 recém-nascidos na maternidade com a BCG/VrHB-IB (combinadas ou separadas e nos domicílios, com as duas doses subsequentes de VrHB-IB. O segundo estudo incluiu 241 lactentes em Centros de Saúde da rede municipal, vacinados com tetravalente bacteriana (com componente pertussis total ou modificado. Em ambos os estudos, amostras de sangue foram colhidas nas residências. Não houve relatos de eventos adversos. A adesão foi de 90,2% para o primeiro estudo e 93,8%, para o segundo. As vacinas foram administradas nas datas preconizadas pelo Programa Nacional de Imunizações e as coletas de sangue, de acordo com o cronograma dos estudos. CONCLUSÕES: As estratégias utilizadas facilitaram o recrutamento das crianças e garantiram cumprir o protocolo da pesquisa com alta adesão, sem interferir no vínculo da família com o Serviço de Saúde, no calendário vacinal ou no seguimento pediátrico dos participantes.OBJETIVO: Relatar las estrategias de campo utilizadas en dos ensayos clínicos con vacunas desarrolladas por el Instituto Butantan, en 2004 y 2006. MÉTODOS: Estudio de tipo relato de experiencia, en que se describe la planificación y la

  3. Equine influenza in Brazil

    Directory of Open Access Journals (Sweden)

    Patricia Filippsen Favaro

    2016-06-01

    Full Text Available Equine influenza virus (EIV (H3N8 and H7N7 is the causative agent of equine influenza, or equine flu. The H7N7 subtype has been considered to be extinct worldwide since 1980. Affected animals have respiratory symptoms that can be worsened by secondary bacterial respiratory infection, thereby leading to great economic losses in the horse-breeding industry. In Brazil, equine influenza outbreaks were first reported in 1963 and studies on hemagglutination antibodies against viral subtypes in Brazilian horses have been conducted since then. The objective of the present review was to present the history of the emergence of EIV around the world and in Brazil and the studies that have thus far been developed on EIV in Brazilian equines.

  4. Memory B cells and CD8⁺ lymphocytes do not control seasonal influenza A virus replication after homologous re-challenge of rhesus macaques.

    Directory of Open Access Journals (Sweden)

    Timothy D Carroll

    Full Text Available This study sought to define the role of memory lymphocytes in the protection from homologous influenza A virus re-challenge in rhesus macaques. Depleting monoclonal antibodies (mAb were administered to the animals prior to their second experimental inoculation with a human seasonal influenza A virus strain. Treatment with either anti-CD8α or anti-CD20 mAbs prior to re-challenge had minimal effect on influenza A virus replication. Thus, in non-human primates with pre-existing anti-influenza A antibodies, memory B cells and CD8α⁺ T cells do not contribute to the control of virus replication after re-challenge with a homologous strain of influenza A virus.

  5. Immune response to influenza A/H1N1 vaccine in inflammatory bowel disease patients treated with anti TNF-α agents: effects of combined therapy with immunosuppressants.

    Science.gov (United States)

    Andrisani, G; Frasca, D; Romero, M; Armuzzi, A; Felice, C; Marzo, M; Pugliese, D; Papa, A; Mocci, G; De Vitis, I; Rapaccini, G L; Blomberg, B B; Guidi, L

    2013-05-01

    Our first objective was to evaluate the immune response to the adjuvanted 2009 A/H1N1 pandemic (pH1N1) vaccine in inflammatory bowel disease (IBD) patients treated with anti-TNF-α alone or combined with immunosuppressants (IS). Second and third aims were the safety of pH1N1 vaccine and the effects on IBD clinical activity. 36 patients with Crohn's disease (CD) and 26 with ulcerative colitis (UC) and thirty-one healthy control (HC) subjects were enrolled. 47 patients were on anti TNF-α maintenance monotherapy and 15 on anti TNF-α combined with IS. Sera were collected at baseline (T0) and 4 weeks after the vaccination (T1) for antibody determination by hemagglutination inhibition (HAI). Disease activity was monitored at T0 and T1. Seroprotective titers (≥1:40) in patients were comparable to HC. Seroconvertion rate (≥4 fold increase in HAI titer) was lower than HC in IBD patients (p=0.009), either on anti TNF-α monotherapy (p=0.034) or combined with IS (p=0.011). Geometric mean titer (GMT) of antibodies at T1 was significantly lower in patients on combined therapy versus those on monotherapy (p=0.0017) and versus HC (p=0.011). The factor increase of GMT at T1 versus T0 was significantly lower in IBD patients versus HC (p=0.042), and in those on combined immunosuppression, both versus monotherapy (p=0.0048) and HC (p=0.0015). None of the patients experienced a disease flare. Our study has shown a suboptimal response to pH1N1 vaccine in IBD patients on therapy with anti TNF-α and IS compared to those on anti-TNF-α monotherapy and HC. Copyright © 2012 European Crohn's and Colitis Organisation. Published by Elsevier B.V. All rights reserved.

  6. Propuesta de un algoritmo para evaluar la causalidad de eventos adversos en los Ensayos Clínicos de Vacunas.

    Directory of Open Access Journals (Sweden)

    María de los A. Peña.

    2008-12-01

    Full Text Available En el transcurso de los ensayos clínicos usualmente se designa a una comisión, la cual se encarga de evaluar la causalidad de los eventos adversos que se reportan y transcriben en los cuadernos de recogida de datos. Para llegar a contestar la pregunta de: ¿si una vacuna que se está estudiando ha causado un evento adverso?, los decisores pueden tomar diferentes caminos, por lo que obviamente la conclusión final podría variar mucho y la evaluación deficiente puede generar conclusiones erróneas, lo que confirma la necesidad de disponer de un procedimiento para definir las categorías que se utilizarán para analizar y clasificar la relación de causalidad. Una forma de contestar a la pregunta es mediante la construcción de un algoritmo. En relación con los ensayos clínicos no encontramos en la literatura un algoritmo que sea el "patrón clave" para establecer o descartar la causalidad, sin embargo es factible diseñarlo partiendo de la metodología internacional utilizada poscomercialización, lo cual fue el propósito de este trabajo. Se diseñó una primera propuesta que fue analizada individual y colectivamente por el grupo multidisciplinario de la Gerencia Médica del Instituto Finlay. Finalmente se aprobó por consenso el algoritmo que puede ser útil para aplicar en los ensayos clínicos dentro y fuera de la institución.

  7. Fragmentación del polisacárido de Neisseria meningitidis serogrupo C para su uso en vacunas conjugadas

    Directory of Open Access Journals (Sweden)

    Osmir Cabrera

    2001-12-01

    Full Text Available Las infecciones meningocócicas son una causa importante de morbilidad y mortalidad en el mundo. Los serogrupos B y C son los responsables de la mayoría de los casos reportados en muchos países e incluso en países desarrollados. Las vacunas meningocócicas que contienen al polisacárido capsular purificado del meningococo C inducen en adultos protección por la presencia de anticuerpos bactericidas en sueros, pero son pobremente inmunogénicos en niños pequeños y pueden inducir tolerancia. La inmunogenicidad de los polisacáridos o sus fragmentos puede ser mejorada por la conjugación a proteínas transportadoras. El objetivo de este estudio fue obtener oligosacáridos C (Os-C a partir de la depolimerización del polisacárido de Neisseria meningitidis serogrupo C (Ps-C por hidrólisis ácida, calor y peryodato de sodio y evaluar la conservación de sus propiedades antigénicas mediante un ELISA de inhibición. Se determinó la pérdida de grupos O-acetilos, así como, la talla molecular relativa por filtración en gel y se observaron diferencias significativas entre los OS-C obtenidos en cada método. Las propiedades antigénicas fueron dependientes del tamaño molecular de los Os-C, así como de la presencia de los grupos O-acetilos en los oligosacáridos. Los Os-C obtenidos por la hidrólisis ácida mostraron similares propiedades antigénicas a las del polisacárido.

  8. Oscillococcinum for influenza treatment

    Directory of Open Access Journals (Sweden)

    Luigi Alberto Marrari

    2012-01-01

    Full Text Available The use of a complementary medicine approach, and specifically of the popular medicine Oscillococcinum, for the treatment of influenza-like syndromes remains controversial. This brief paper analyses the currently available literature on this homeopathic preparation and the Cochrane Collaboration’s 2006 systematic review, along with other recent studies, in order to clarify certain fundamental aspects of its use in the treatment of influenza. In the light of the reported findings, and applying the rigorous criteria of evidence-based medicine, we suggest that this medicine should be placed in category "BI".

  9. Mortalidad en México por influenza y neumonía (1990-2005 Mortality due to influenza and pneumonia in Mexico between 1990 and 2005

    Directory of Open Access Journals (Sweden)

    Pablo Kuri-Morales

    2006-10-01

    Full Text Available OBJETIVO: Estimar el impacto de la vacuna contra la influenza en personas menores de dos años y mayores de 65, a través del análisis de la mortalidad por influenza y neumonía en la República mexicana entre 1990 y 2005, y determinar el patrón estacional de comportamiento de la mortalidad, la tendencia de mortalidad por volumen de defunciones por periodo estacional y la velocidad de mortalidad. MATERIAL Y MÉTODOS: Los datos se tomaron del Sistema Epidemiológico y Estadístico de Defunciones (SEED-SSA. RESULTADOS: El análisis mostró una tendencia de defunciones a la baja con una rapidez respectiva de 509 y 29 defunciones menos por año, así como una interrupción de la tendencia ascendente de la mortalidad por la vacunación. CONCLUSIONES: La intervención por vacunación tiene costos positivos, tanto económicos como de calidad de vida, por lo que su implementación debe considerarse en un contexto que refleje una menor incidencia de hospitalizaciones y muertes.OBJECTIVE: To estimate the impact of influenza vaccine in infants less than two years of age and in elders more than sixty-five years of age, through the analysis of mortality due to influenza and pneumonia in Mexico, between 1990 and 2005. To determine the seasonal pattern of mortality, the tendency of mortality by volume of deaths per seasonal period, and the speed rate of mortality. MATERIAL AND METHODS: Data were taken from the Epidemiological and Statistical Mortality System (SEED-SSA per its abbreviation in Spanish. RESULTS AND CONCLUSIONS: The analysis showed there is a tendency of deaths decrease at a rate of 509 deaths less per year in the infants group and 29 deaths less in the elders group. Also, the ascending tendency of mortality was interrupted by vaccination. The vaccination intervention has a positive economic effect and also helps improve the quality of life. Therefore, its implementation is expected to lower hospital admissions and deaths.

  10. Comparison of two rapid influenza A/B test kits with reference methods showing high specificity and sensitivity for influenza A infection.

    Science.gov (United States)

    Booth, Susanne; Baleriola, Cristina; Rawlinson, William D

    2006-05-01

    The rapid detection of influenza viruses is important for forming preventative strategies, directing initiation of anti-viral therapy, detecting potential avian influenza viruses, and excluding influenza-like pathogens, such as SARS. The ImmunoCard STAT! Flu A and B Plus test (Meridian Bioscience, Cincinnati, OH) is a new point of care (POC) test utilizing influenza-specific monoclonal antibodies for rapid diagnosis. The performance of this assay was compared to the established POC Binax NowFlu A and NowFlu B test, and the reference diagnostic standards of viral culture, indirect immunofluorescence (IFA), and RT-PCR where appropriate. Testing of nasopharyngeal aspirates (NPA) from children, throat swabs, and nasal swabs from adults indicated ImmunoCard STAT! specificity of 98% and 100% for influenza A and B, respectively in 224 specimens. The Binax test showed specificity of 99% and 100%, respectively for influenza A and B. Sensitivity results were identical for both rapid detection kits (80% and 47% for Flu A and B, respectively). Overall results were very similar for both testing devices with the advantage of ImmunoCard STAT! Flu A and B Plus test detecting influenza A and B with sharp and easy to read results. Copyright 2006 Wiley-Liss, Inc.

  11. Fluzone High-Dose Seasonal Influenza Vaccine

    Science.gov (United States)

    ... Variant Pandemic Other Fluzone High-Dose Seasonal Influenza Vaccine Questions & Answers Language: English (US) Español Recommend on ... flu season. What is Fluzone High-Dose influenza vaccine? Fluzone High-Dose is an influenza vaccine, manufactured ...

  12. The Virosome concept in influenza vaccines

    NARCIS (Netherlands)

    Wilschut, J; Huckriede, A; Bungener, L; Daemen, T; Stegmann, T; Palache, A

    2004-01-01

    Reconstituted influenza virus envelopes (virosomes) represent efficient influenza vaccines inducing high antibody titers upon intramuscular adminsitration. Virosomes are reconstituted viral envelopes which retain the cell entry and membrane fusion characteristics of native influenza virus. Here, we

  13. Avian Influenza A Virus Infections in Humans

    Science.gov (United States)

    ... Pandemic Other Avian Influenza A Virus Infections in Humans Language: English (US) Español Recommend on Facebook Tweet ... A Viruses Avian Influenza A Virus Infections in Humans Although avian influenza A viruses usually do not ...

  14. Protection against H5N1 by multiple immunizations with seasonal influenza vaccine in mice is correlated with H5 cross-reactive antibodies

    NARCIS (Netherlands)

    Roos, Anna; Roozendaal, Ramon; Theeuwsen, Jessica; Riahi, Sarra; Vaneman, Joost; Tolboom, Jeroen; Dekking, Liesbeth; Koudstaal, Wouter; Goudsmit, Jaap; Radošević, Katarina

    2015-01-01

    Background: Current seasonal influenza vaccines are believed to confer protection against a narrow range of virus strains. However, their protective ability is commonly estimated based on an in vitro correlate of protection that only considers a subset of anti-influenza antibodies that are typically

  15. Influenza Vaccines: Unmet Needs and Recent Developments

    Science.gov (United States)

    Noh, Ji Yun

    2013-01-01

    Influenza is a worldwide public health concern. Since the introduction of trivalent influenza vaccine in 1978, vaccination has been the primary means of prevention and control of influenza. Current influenza vaccines have moderate efficacy, good safety, and acceptable tolerability; however, they have unsatisfactory efficacy in older adults, are dependent on egg supply for production, and are time-consuming to manufacture. This review outlines the unmet medical needs of current influenza vaccines. Recent developments in influenza vaccines are also described. PMID:24475351

  16. Equine influenza: An overview

    Directory of Open Access Journals (Sweden)

    S. P. Waghmare

    2010-08-01

    Full Text Available Equine influenza virus is a leading cause of respiratory disease in the horses. The disease is the OIE listed disease of equines, ponies, mules and donkeys and spreads very fast. The sporadic outbreaks of the disease have occurred all over the country. Many cases have been reported in Delhi, Meerut, Saharanpur, Jaipur, Hisar, Calcutta, Ahmedabad. Nearly all the horses at Matheran (Hill station were infected with influenza. The disease has spread like wildfire at the stables of Royal Western India Turf Club (RWITC at Pune and suspended the Mumbai racing season for prolonged period of time resulting in marked economic losses. After affecting racing in Mumbai, Calcutta and New Delhi, the dreaded equine influenza has spread to Karnataka and Mysore. An outbreak of disease has marred the racing season across the country. The disease was first detected in Jammu & Kashmir before entering the central region Horses at the army polo clubs and Delhi equestrian center were also affected. As per the recent survey conducted by the army across India, it has been found that 5400 horses are infected so far, especially thoroughbred most severely. Nearly, 95 % of horses on a major farm in India are suspected of suffering from equine influenza. The government also banned inter-state movement of horses for three months to contain the disease. [Vet World 2010; 3(4.000: 194-197

  17. ADULT INFLUENZA VACCINATION GUIDELINE

    African Journals Online (AJOL)

    meeting to consider the draft guideline. Financial sponsor. Development supported by an ... respiratory vaccinations consensus meeting was held in. Gauteng (see below). Participants were invited ..... Boorman D. Influenza vaccine and its relationship to absenteeism in the workplace. Occupational Health SA 1997; 3: 29-30.

  18. Vaccination against seasonal influenza

    CERN Multimedia

    SC Unit

    2009-01-01

    As every year, the Medical Service is taking part in the campaign to promote vaccination against seasonal influenza. Vaccination against seasonal influenza is especially recommended for people suffering from chronic lung, cardio-vascular or kidney conditions or diabetes, for those recovering from a serious illness or surgical operation and for everyone over the age of 65. The influenza virus is transmitted by air and contact with contaminated surfaces, hence the importance of washing hands regularly with soap and / or disinfection using a hydro-alcoholic solution. From the onset of symptoms (fever> 38°, chills, cough, muscle aches and / or joint pain, fatigue) you are strongly recommended to stay at home to avoid spreading the virus. In the present context of the influenza A (H1N1) pandemic, it is important to dissociate these two illnesses and emphasise that the two viruses and the vaccines used to combat them are quite different and that protection against one will not provide protection against the...

  19. ADULT INFLUENZA VACCINATION GUIDELINE

    African Journals Online (AJOL)

    Infections with the influenza virus and Streptococcus pneumoniae are associated with considerable morbidity and ... for Disease Control and Prevention, Atlanta, Georgia; CNS = central nervous system; COPD = chronic .... During delivery and storage, the vaccine should be kept at. 2 - gcC in cold chain, and stored in the ...

  20. Estudio comparativo del efecto protector de dos esquemas de inmunización con una vacuna recombinante contra la Hepatitis B en estudiantes del área de ciencias de la salud susceptibles

    National Research Council Canada - National Science Library

    Marocho; Vildózola; Valencia; Romero; Huamán; Solano; Chumpitaz; Medina; Pareja

    2005-01-01

    ... (acortado y convencional) en menor tiempo y con menos dosis. Hipotesis: Los 3 esquemas de dosificación en la vacuna contra la hepatitis B generan anticuerpos por encima de 10 ug/100 ml generando igual efecto de protección. Diseño...

  1. vax-SPIRAL®, vacuna trivalente (Canicola-Icterohaemorragiae-Pomona. Capacidad protectogénica cruzada frente al reto con L. Ballum de alta patogenicidad en el modelo Hámster Sirio Dorado.

    Directory of Open Access Journals (Sweden)

    Mariela Naranjo

    2008-08-01

    Full Text Available En Cuba, desde 1997 se viene aplicando en grupos de riesgo una vacuna contra la leptospirosis (vax-SPIRAL® dirigida contra los serogrupos Canicola, Icterohaemorragiae y Pomona. Sin embargo, en los últimos años la situación epidemiológica del país ha variado y en la actualidad el serogrupo Ballum alcanza la más alta incidencia, haciéndose necesario conocer el grado de protección de vax-SPIRAL® frente a este serogrupo. Para ello se evaluó la protección cruzada de vax-SPIRAL® frente al serogrupo L. Ballum en el modelo animal Hámster Sirio Dorado, con una y dos dosis de esta vacuna. Se emplearon, además, diferentes dosis de la vacuna y diferentes lotes vacunales. En todos los casos se determinó la prevalencia de leptospira en los principales órganos diana, luego del reto contra 100 y 10 000 DL50 de las cepas de L. Ballum altamente virulentas (cepas 12399, 42600 y 60. Los resultados mostraron un 100% de protección de los animales inmunizados frente a la infección letal y el estado de portador con una y dos dosis de la vacuna. En ningún caso se apreciaron síntomas característicos de infección en los órganos diana.

  2. Algunos aspectos inmunológicos e inmunogenéticos de la infección con el virus de la hepatitis B (VHB y de la aplicación de vacunas antihepatitis B

    Directory of Open Access Journals (Sweden)

    Antonio Iglesias Gamarra

    1991-12-01

    Full Text Available Hemos querido analizar las observaciones relacionadas con los estudios de inmunología celular asociada a la hepatitis B y a la vacuna. Desde el inicio de la década de los 80s se han practicado en el mundo numerosos estudios inmunológicos como: producción in vitro de anticuerpos, estudios de proliferación celular mediante antígenos solubles y mitógenos, estudios de subpoblaciones de células T. búsqueda de efectos del macrófago o de las células B y T. análisis de posibles trastornos en la generación de factores supresores. Observamos que muchos de estos estudios eran contradictorios y en los inicios de nuestro trabajo, a pesar del gasto excesivo que tuvimos tratando de producir anticuerpos in vitro anti-HBs, fue imposible lograrlo; por lo que decidimos hacer los estudios de cinética de proliferación celular y a través de la técnica del panning, en la cual utilizamos un anticuerpo monoclonal anti-CD8 que se une al plato de cultivo cuya superficie es de poliestireno, logramos así separar la subpoblación CD4 de la CD8; y posteriormente realizamos los experimentos de reconstitución que nos clarificó la hipótesis de Yunis y Alper sobre la no respuesta a un antígeno determinado; es decir, que la no respuesta se debe a un defecto en la estructura genética-inmunogenética durante la segregación y a una falla en la presentación antigénica. Para lograr estas explicaciones hemos querido analizar los diferentes estudios y compararlos con el nuestro. Finalmente creemos que usando las diferentes tablas se pueda analizar los datos. Es posible que aún queden muchas dudas, pero el tiempo y la investigación en esta área harán que se aclaren; creemos que en Colombia, al realizar los estudios básicos en nuestras etnias, el futuro será más promisorio y a corto plazo.

  3. The susceptibility of circulating human influenza viruses to tizoxanide, the active metabolite of nitazoxanide.

    Science.gov (United States)

    Tilmanis, Danielle; van Baalen, Carel; Oh, Ding Yuan; Rossignol, Jean-Francois; Hurt, Aeron C

    2017-11-01

    Nitazoxanide is a thiazolide compound that was originally developed as an anti-parasitic agent, but has recently been repurposed for the treatment of influenza virus infections. Thought to exert its anti-influenza activity via the inhibition of hemagglutinin maturation and intracellular trafficking in infected cells, the effectiveness of nitazoxanide in treating patients with non-complicated influenza is currently being assessed in phase III clinical trials. Here, we describe the susceptibility of 210 seasonal influenza viruses to tizoxanide, the active circulating metabolite of nitazoxanide. An optimised cell culture-based focus reduction assay was used to determine the susceptibility of A(H1N1)pdm09, A(H3N2), and influenza B viruses circulating in the southern hemisphere from the period March 2014 to August 2016. Tizoxanide showed potent in vitro antiviral activity against all influenza viruses tested, including neuraminidase inhibitor-resistant viruses, allowing the establishment of a baseline level of susceptibility for each subtype. Median EC 50 values (±IQR) of 0.48 μM (0.33-0.71), 0.62 μM (0.56-0.75), 0.66 μM (0.62-0.69), and 0.60 μM (0.51-0.67) were obtained for A(H1N1)pdm09, A(H3N2), B(Victoria lineage), and B(Yamagata lineage) influenza viruses respectively. There was no significant difference in the median baseline tizoxanide susceptibility for each influenza subtype tested. This is the first report on the susceptibility of circulating viruses to tizoxanide. The focus reduction assay format described is sensitive, robust, and less laborious than traditional cell based antiviral assays, making it highly suitable for the surveillance of tizoxanide susceptibility in circulating seasonal influenza viruses. Copyright © 2017 The Authors. Published by Elsevier B.V. All rights reserved.

  4. Fatores associados à cobertura vacinal em adolescentes Factores asociados a la cobertura por vacunas en adolescentes Factors associated to the vaccination covering in adolescents

    Directory of Open Access Journals (Sweden)

    Ayla Maria Calixto de Carvalho

    2010-01-01

    Full Text Available OBJETIVO: Analisar os fatores associados à condição de estar vacinado entre adolescentes de uma área da Estratégia Saúde da Família de Teresina - PI. MÉTODOS: Estudo de natureza quantitativa e do tipo seccional. A amostra foi constituída por 261 adolescentes e a análise foi realizada por meio da estatística descritiva. RESULTADOS: A cobertura vacinal contra rubéola, sarampo e caxumba foi de 5,4%; para a vacina contra difteria e tétano, foi de 22,9%; para a vacina contra hepatite-B: foi 27,2% e 35,2% para a vacina contra febre amarela. CONCLUSÃO: A baixa cobertura vacinal encontrada neste estudo está relacionada: às oportunidades perdidas de vacinação (65,5%; à deficiência de conhecimento sobre as vacinas, a faixa etária maior de 15 anos (Razão da Prevalência (RP = 2,85; Índice de Confiança (IC 95% = 1,63-4,99; o sexo masculino (RP = 2,04; IC95% =1,15-3,62.OBJETIVO: Analizar los factores asociados a la condición de estar vacunado entre adolescentes, en un área de la Estrategia Salud de la Familia, en la ciudad de Teresina, en el estado de Piauí. MÉTODOS: Estudio de naturaleza cuantitativa y de tipo seccional. La muestra fue constituida por 261 adolescentes y el análisis fue realizado por medio de la estadística descriptiva. RESULTADOS: La cobertura por vacuna contra rubéola, sarampión e caxumba fue de 5,4%; para la vacuna contra la difteria y tétano, fue de 22,9%; para la vacuna contra hepatitis-B, fue 27,2% y de 35,2% para la vacuna contra la fiebre amarilla. CONCLUSIÓN: La baja cobertura por vacunación encontrada en este estudio está relacionada a: 1 las oportunidades perdidas de vacunación (65,5%; a la deficiencia de conocimiento sobre las vacunas, al intervalo de edad mayor de 15 años [Razón de la Prevalencia (RP = 2,85; Índice de Confianza (IC 95% = 1,63-4,99]; al sexo masculino (RP = 2,04; IC95% =1,15-3,62.OBJECTIVE: To analyze the factors associated to the condition of to be vaccinated among

  5. Relevance of Helicobacter pylori virulence factors for vaccine development Relevancia de los factores de virulencia de helicobacter pylori para el desarrollo de vacunas

    Directory of Open Access Journals (Sweden)

    Luz del Carmen Hernández-Hernández

    2009-01-01

    í, los individuos infectados por cepas que expresan estos factores de virulencia probablemente desarrollan enfermedades severas como el cáncer gástrico. Sin embargo, la ancestral relación entre H. pylori y los humanos sugiere que algunas cepas pueden ser beneficiosas para la salud humana. Por lo tanto, la administración generalizada de tratamientos con antibiótico podría eventualmente causar problemas. El desarrollo de vacunas con base en factores de virulencia que confieran protección a largo plazo es la mejor estrategia para el control y/o eliminación de cepas patógenas. Los diferentes esquemas y formulaciones de inmunización diseñados para evaluar las vacunas con base en factores de virulencia en modelos animales han dado resultados prometedores. Sin embargo, ha sido necesario probar si estos resultados pueden ser reproducidos en humanos. Este trabajo revisa los recientes estudios de vacunación que han explorado esta posibilidad: vacunas orales usando ureasa o células completas-inactivadas con LT como adyuvante y ureasa expresada en vectores de Salmonella spp.; además de una vacuna intramuscular multicomponente con hidróxido de aluminio como adyuvante. Aunque estos estudios han logrado limitado éxito han establecido las bases para el desarrollo de una vacuna eficaz contra esta infección.

  6. Evaluacion de la tecnica de contraimmunoelectroforesis para determinar la potencia antigena de las vacunas antirrabicas Evaluation ot the counterimmunoelectrophoresis technique to determine the antigenic potency of antirrabic vaccines

    Directory of Open Access Journals (Sweden)

    Graciela Miceli

    1993-12-01

    Full Text Available El método recomendado por la Organización Mundial de la Salud (OMS para la prueba de potencia de vacunas antirrábicas como producto final es la prueba NIH. Algunas técnicas in vitro se han propuesto para el control durante el proceso de produción y complementan el ensayo in vivo antes mencionado. Este trabajo presenta los resultados obtenidos cuando se utilizó la técnica de contrainmunoelectroforésis (CIE para determinar el contenido de antígenos en muestras de 84 y 40 lotes de vacunas antirrábicas producidas en tejido nervioso de cerebro de ratón lactante mediante cultivo de tejidos, respectivamente. La evaluación de las muestras en, y en torno de, las 0.3 UI por ambos métodos muestran que, en la práctica, un título CIE de 1:4 cumpliría con un mínimo de potencia de la prueba NIH. Un bajo grado de variabilidad de la prueba CIE fue observada en nuestro laboratorio cuando dos lotes de vacunas de referencia de trabajo y 7 lotes de vacunas antirrábicas, de diferente origen y actividad, fueron ensayadas en cinco pruebas independientes. Todos los títulos se ubicaron dentro de una dilución doble, lo que es indicativo de su reproducibilidad. Se observó buena sensibilidad para detectar el deterioro del antígeno en el ensayo de degradación térmica, cuando muestras de 3 lotes de vacuna líquida de cerebro de ratón lactante fueron mantenidas a4 y 37ºC cada una, por 28 días. Se evaluaron semanalmente por los ensayos de CIE y NIH. Finalmente, se observó que el ensayo de CIE podría ser utilizado por los productores para estimar el punto final de los procesos de concentración para que se corresponda con un valor antigénico deseado en la prueba de potencia NIH.The method recommended by the World Health Organization (WHO for the potency assay of human and animal rabies vaccines as final product is the NIH test. Some in vitro techniques have been proposed for in process testing and supplement the in vivo test mentioned above. This

  7. Triple Combination of Oseltamivir, Amantadine, and Ribavirin Displays Synergistic Activity against Multiple Influenza Virus Strains In Vitro ▿

    Science.gov (United States)

    Nguyen, Jack T.; Hoopes, Justin D.; Smee, Donald F.; Prichard, Mark N.; Driebe, Elizabeth M.; Engelthaler, David M.; Le, Minh H.; Keim, Paul S.; Spence, R. Paul; Went, Gregory T.

    2009-01-01

    The recurring emergence of influenza virus strains that are resistant to available antiviral medications has become a global health concern, especially in light of the potential for a new influenza virus pandemic. Currently, virtually all circulating strains of influenza A virus in the United States are resistant to either of the two major classes of anti-influenza drugs (adamantanes and neuraminidase inhibitors). Thus, new therapeutic approaches that can be rapidly deployed and that will address the issue of recurring resistance should be developed. We have tested double and triple combinations of the approved anti-influenza drugs oseltamivir and amantadine together with ribavirin against three influenza virus strains using cytopathic effect inhibition assays in MDCK cells. We selected A/New Caledonia/20/99 (H1N1) and A/Sydney/05/97 (H3N2) as representatives of the wild-type versions of the predominant circulating seasonal influenza virus strains and A/Duck/MN/1525/81 (H5N1) as a representative of avian influenza virus strains. Dose-response curves were generated for all drug combinations, and the degree of drug interaction was quantified using a model that calculates the synergy (or antagonism) between the drugs in double and triple combinations. This report demonstrates that a triple combination of antivirals was highly synergistic against influenza A virus. Importantly, the synergy of the triple combination was 2- to 13-fold greater than the synergy of any double combination depending on the influenza virus subtype. These data support the investigation of a novel combination of oseltamivir, amantadine, and ribavirin as an effective treatment for both seasonal and pandemic influenza virus, allowing the efficient use of the existing drug supplies. PMID:19620324

  8. Characterization and evaluation of monoclonal antibodies developed for typing influenza A and influenza B viruses.

    OpenAIRE

    Walls, H H; Harmon, M.W.; Slagle, J J; Stocksdale, C; Kendal, A P

    1986-01-01

    Monoclonal antibodies that are broadly reactive with influenza A or influenza B viruses were produced as stable reagents for typing influenza viruses. Monoclonal antibodies to influenza A were specific for either matrix protein or nucleoprotein. The antibodies to influenza B were specific for nucleoprotein or hemagglutinin protein. In an enzyme immunoassay procedure, influenza A antibodies detected H1N1, H2N2, and H3N2 influenza A virus strains collected between 1934 and 1984. Each of the inf...

  9. Características de los vídeos en español publicados en YouTube sobre la vacuna contra el virus del papiloma humano

    Directory of Open Access Journals (Sweden)

    José Tuells

    2015-01-01

    Full Text Available Fundamentos: Internet constituye un recurso de búsqueda de información relacionada con la salud. El objetivo de este trabajo fue conocer las características de los vídeos en idioma español de YouTube relacionados con la vacuna contra el virus del papiloma humano (VPH. Métodos: Se realizó un estudio observacional a partir de una búsqueda en YouTube el 26 de julio de 2013, con las palabras claves: “vacuna virus papiloma humano”, “vacuna VPH”, “vacuna Gardasil”, “vacuna Cervarix”. Se establecieron categorías por tipo, fuente de publicación y predisposición favorable o no hacia la vacuna. Se registró el número de visitas, tiempo de duración de los videos y origen de los 20 vídeos más visitados. Resultados. Se encontraron 1.080 videos registrados, 170 fueron seleccionados y clasificados como: noticias locales (n=39; 37 favorables, 2 desfavorables; 2:06:29; 42972 visitas, noticias nacionales (n=32; 30/2; 1:49:27; 50138 visitas, creados por subscritores de YouTube (n=21; 13/8; 2:50:35; 144655 visitas, entrevistas (n=21; 20/1; 1:44:39; 10991 visitas, anuncios (n=21; 19/2; 0:27:05; 28435 visitas, conferencias (n=17; 15/2; 3:25:39; 27206 visitas, documentales (n=16; 12/4; 2:11:31; 30629 visitas, y noticias internacionales (n=3; 3/0; 0:11:33; 1667 visitas. De los 20 videos más reproducidos predominan los favorables a la vacunación (n=12; 0:43:43; 161.789 visitas frente a los desfavorables (n=8; 2:44:14; 86.583 visitas. Conclusiones. Predominan los videos que tiene una opinión favorable hacia la vacuna contra el VPH, aunque los videos de contenido negativo son los más extensos y reproducidos-

  10. Eficacia y seguridad de una vacuna contra la leptospirosis humana en Cuba Efficacy and safety of a vaccine against human leptospirosis in Cuba

    Directory of Open Access Journals (Sweden)

    Raydel Martínez

    2004-04-01

    Full Text Available OBJETIVOS: Evaluar la eficacia de la vacuna cubana contra la leptospirosis vax-SPIRAL y aportar información adicional acerca de la seguridad de esta vacuna. MÉTODOS: Ensayo de eficacia (fase III controlado, aleatorizado y con doble enmascaramiento de la vacuna cubana contra la leptospirosis vax-SPIRAL (Instituto Finlay, Cuba. Como control se utilizó la vacuna recombinante contra la hepatitis B Heberbiovac-HB (Heber Biotec, Cuba. Como unidad de aleatorización para la asignación al grupo de estudio o al grupo testigo se emplearon los 523 consultorios de los médicos de familia existentes en los municipios seleccionados. El estudio abarcó a toda persona de 20 a 64 años de edad de uno u otro sexo que residía en los municipios de Ranchuelo, Quemado, Santo Domingo, Encrucijada, Corralillo, Cifuentes y Camajuaní, en la provincia de Villa Clara, ubicada en la región central de Cuba, que aceptó participar voluntariamente en el ensayo. La vacunación se efectuó en los consultorios de los médicos de familia entre febrero y julio de 1998, con un intervalo de 6 semanas entre las dos dosis. El período de seguimiento fue de 12 meses. Se consideró positivo un caso si había recibido las dos dosis de la vacuna asignada y había enfermado de leptospirosis, con diagnóstico confirmado mediante métodos serológicos y microbiológicos, después de 21 días de aplicada la segunda dosis. Se calcularon la eficacia de la vacuna y el riesgo relativo (RR de enfermar de leptospirosis después de la vacunación. Para el estudio de seguridad se escogió a dos personas al azar entre las personas vacunadas en cada uno de los consultorios que participaron en el estudio de eficacia. El seguimiento de las reacciones adversas locales y sistémicas lo realizaron los médicos de familia durante los siete días posteriores a la aplicación de cada dosis. El nivel de significación se fijó en 0,05. RESULTADOS: En total se vacunó a 101 832 personas, de las cuales 50

  11. Formative research to shape HPV vaccine introduction strategies in Peru Investigación formativa relacionada con el diseño de estrategias para introducir la vacuna contra el VPH en Perú

    Directory of Open Access Journals (Sweden)

    Rosario M Bartolini

    2010-06-01

    Full Text Available OBJECTIVE: To understand the sociocultural environment, health systems' capacities, and policy processes related to cervical cancer and HPV vaccines in order to inform HPV vaccine introduction. MATERIAL AND METHODS: Mixed-method formative research using qualitative and quantitative data collection techniques. Participants included girls, parents, community leaders, health and education officials, and policymakers. RESULTS: Respondents, including policymakers, generally supported HPV vaccine introduction, due partly to appreciation for the benefits of vaccination and the desire to prevent cancer. Community-level concerns regarding safety and quality of services will need to be addressed. The immunization system in Peru is strong and has capacity for including the HPV vaccine. CONCLUSION: Formative research provides key insights to help shape an effective program for HPV vaccine introduction.OBJETIVO: Comprender el contexto sociocultural, las capacidades del sistema de salud y las condiciones políticas vinculadas al cáncer cervical y a la vacuna contra el VPH para diseñar una estrategia apropiada de introducción de la vacuna contra el VPH. MATERIAL Y MÉTODOS: Investigación formativa usando técnicas cualitativas y cuantitativas. Los participantes incluyeron niños, padres, líderes, funcionarios del sector salud y educación, y diseñadores de políticas. RESULTADOS: Generalmente se apoya la introducción de la vacuna contra el VPH, dado que se aprecian los beneficios de la vacunación y se desea prevenir el cáncer. En la comunidad se encontraron preocupaciones sobre seguridad, confianza y calidad de atención. El sistema de inmunizaciones en el Perú es eficiente y tiene la capacidad para incluir la vacuna contra el VPH. CONCLUSIONES: La investigación formativa permite comprender elementos clave que ayudan a diseñar un programa efectivo para la introducción de la vacuna contra el VPH.

  12. Efectividad y duración de la inmunidad de la vacuna frente al meningococo serogrupo A y C

    Directory of Open Access Journals (Sweden)

    Luis García Comas

    2000-01-01

    Full Text Available FUNDAMENTO: La Comunidad de Madrid detectó a partir de 1995 un incremento del número de casos de enfermedad meningocócica por serogrupo C. En 1997 se realizó una campaña de inmunización masiva sobre la población de 18 meses a 19 años. El objetivo de este estudio es conocer la respuesta inmunitaria producida por la vacuna y su relación con la edad. MÉTODOS: Se seleccionó una muestra de 1.003 niños vacunados durante la campaña. Se extrajo una muestra de sangre antes de la vacunación y tras uno, seis (solo <5a y doce meses. Para valorar la respuesta inmune se midieron niveles de anticuerpos bactericidas y totales. RESULTADOS: La prevalencia de seroconversión medida por anticuerpos bactericidas es 89,6%. La respuesta es baja en menores de 3 años (34,8%, aumenta con la edad y a partir de los 7 años supera el 90%. A los 6 meses, la prevalencia de niveles protectores en menores de 5 años desciende notablemente (31,3%. Al año, la prevalencia desciende notablemente, especialmente en menores de 7 años. La proporción de individuos con respuesta de anticuerpos totales al mes supera el 90% y se mantiene elevada al año en todos los grupos edad (97,5%. CONCLUSIONES: La respuesta medida mediante anticuerpos totales entra en contradicción con la respuesta clínica a la vacunación y la medida mediante anticuerpos bactericidas infraestima la protección si se compara con los resultados de efectividad vacunal, por lo que es necesario buscar indicadores biológicos que se correlacionen de manera adecuada con la respuesta clínica tras la vacunación.

  13. INMUNOLOGÍA DE LA POLIOMIELITIS: VACUNAS, PROBLEMAS PARA LA PREVENCION/ERRADICACION E INTERVENCIONES DE FUTURO

    Directory of Open Access Journals (Sweden)

    Eduardo Fernández-Cruz Pérez

    2013-01-01

    Full Text Available La poliomielitis es una enfermedad infectocontagiosa que afecta preferentemente a los niños menores de 5 años y está causada por el poliovirus, un enterovirus perteneciente a la familia Picornaviridae. El virus entra a través de la mucosa oral y se multiplica en las células del epitelio tanto de la orofaringe como del tracto gastrointestinal, liberando virus a nivel de las secreciones orofaríngeas y a través de la materia fecal. La vía de transmisión es fecal-oral y/o oral-oral. La mayoría de los casos de infección son asintomáticos y autolimitados al tracto gastrointestinal. Eventualmente puede diseminarse al sistema nervioso central y afectar a las motoneuronas del asta anterior de la médula espinal ocasionando parálisis e incluso la muerte El curso natural de la infección depende de múltiples factores, como el tipo de inóculo viral (serotipos VP1, 2 y 3 y factores del huésped/sistema inmunológico, que incluye el estado nutricional, las infecciones concurrentes y la capacidad de inducir respuestas inmunológicas protectoras sistémicas de tipo humoral, con anticuerpos antivíricos circulantes neutralizantes, y respuestas de la inmunidad de mucosas y adaptativa. Discutiremos los aspectos actuales de la inmunopatogénesis de la infección por el poliovirus, la interacción huésped-virus y la eficacia y los problemas en el desarrollo de las estrategias con las diferentes vacunas antipoliovirus, para que la inmunización sea más efectiva en relación a la inducción de los mecanismos protectores que evitan el des- arrollo de la enfermedad, la transmisión del virus, los rebrotes de infección y eventualmente facilitan la consecución de su erradicación.

  14. Using Complementary and Alternative Medicines to Target the Host Response during Severe Influenza

    Directory of Open Access Journals (Sweden)

    Lisa M. Alleva

    2010-01-01

    Full Text Available It is now accepted that an overwhelming inflammatory response is the cause of human deaths from avian H5N1 influenza infection. With this in mind we sought to examine the literature for examples of complementary and alternative medicines that reduce inflammation, and to place the results of this search in the context of our own work in a mouse model of influenza disease, using a pharmaceutical agent with anti-inflammatory properties. Two Chinese herbs, Angelica sinensis (Dang Gui and Salvia miltiorrhiza (Danshen, have been recently shown to protect mice during lethal experimental sepsis via inhibition of the novel inflammatory cytokine High Mobility Group Box 1 protein (HMGB1. Biochanin A, a ligand of the peroxisome proliferator activated receptors (PPAR alpha and gamma and the active isoflavone in Trifolium pratense (red clover, has anti-inflammatory properties, and thus could be used as an influenza treatment. This is of great interest since we have recently shown that gemfibrozil, a drug used to treat hyperlipidemia in humans and a synthetic ligand of PPAR alpha, significantly reduces the mortality associated with influenza infections in mice. The inflammation-modulating abilities of these natural agents should be considered in light of what is now known about the mechanisms of fatal influenza, and tested as potential candidates for influenza treatments in their own right, or as adjunct treatments to antivirals.

  15. High Affinity Antibodies against Influenza Characterize the Plasmablast Response in SLE Patients After Vaccination.

    Science.gov (United States)

    Kaur, Kaval; Zheng, Nai-Ying; Smith, Kenneth; Huang, Min; Li, Lie; Pauli, Noel T; Henry Dunand, Carole J; Lee, Jane-Hwei; Morrissey, Michael; Wu, Yixuan; Joachims, Michelle L; Munroe, Melissa E; Lau, Denise; Qu, Xinyan; Krammer, Florian; Wrammert, Jens; Palese, Peter; Ahmed, Rafi; James, Judith A; Wilson, Patrick C

    2015-01-01

    Breakdown of B cell tolerance is a cardinal feature of systemic lupus erythematosus (SLE). Increased numbers of autoreactive mature naïve B cells have been described in SLE patients and autoantibodies have been shown to arise from autoreactive and non-autoreactive precursors. How these defects, in the regulation of B cell tolerance and selection, influence germinal center (GC) reactions that are directed towards foreign antigens has yet to be investigated. Here, we examined the characteristics of post-GC foreign antigen-specific B cells from SLE patients and healthy controls by analyzing monoclonal antibodies generated from plasmablasts induced specifically by influenza vaccination. We report that many of the SLE patients had anti-influenza antibodies with higher binding affinity and neutralization capacity than those from controls. Although overall frequencies of autoreactivity in the influenza-specific plasmablasts were similar for SLE patients and controls, the variable gene repertoire of influenza-specific plasmablasts from SLE patients was altered, with increased usage of JH6 and long heavy chain CDR3 segments. We found that high affinity anti-influenza antibodies generally characterize the plasmablast responses of SLE patients with low levels of autoreactivity; however, certain exceptions were noted. The high-avidity antibody responses in SLE patients may also be correlated with cytokines that are abnormally expressed in lupus. These findings provide insights into the effects of dysregulated immunity on the quality of antibody responses following influenza vaccination and further our understanding of the underlying abnormalities of lupus.

  16. High Affinity Antibodies against Influenza Characterize the Plasmablast Response in SLE Patients After Vaccination.

    Directory of Open Access Journals (Sweden)

    Kaval Kaur

    Full Text Available Breakdown of B cell tolerance is a cardinal feature of systemic lupus erythematosus (SLE. Increased numbers of autoreactive mature naïve B cells have been described in SLE patients and autoantibodies have been shown to arise from autoreactive and non-autoreactive precursors. How these defects, in the regulation of B cell tolerance and selection, influence germinal center (GC reactions that are directed towards foreign antigens has yet to be investigated. Here, we examined the characteristics of post-GC foreign antigen-specific B cells from SLE patients and healthy controls by analyzing monoclonal antibodies generated from plasmablasts induced specifically by influenza vaccination. We report that many of the SLE patients had anti-influenza antibodies with higher binding affinity and neutralization capacity than those from controls. Although overall frequencies of autoreactivity in the influenza-specific plasmablasts were similar for SLE patients and controls, the variable gene repertoire of influenza-specific plasmablasts from SLE patients was altered, with increased usage of JH6 and long heavy chain CDR3 segments. We found that high affinity anti-influenza antibodies generally characterize the plasmablast responses of SLE patients with low levels of autoreactivity; however, certain exceptions were noted. The high-avidity antibody responses in SLE patients may also be correlated with cytokines that are abnormally expressed in lupus. These findings provide insights into the effects of dysregulated immunity on the quality of antibody responses following influenza vaccination and further our understanding of the underlying abnormalities of lupus.

  17. Trends in global warming and evolution of matrix protein 2 family from influenza A virus.

    Science.gov (United States)

    Yan, Shao-Min; Wu, Guang

    2009-12-01

    The global warming is an important factor affecting the biological evolution, and the influenza is an important disease that threatens humans with possible epidemics or pandemics. In this study, we attempted to analyze the trends in global warming and evolution of matrix protein 2 family from influenza A virus, because this protein is a target of anti-flu drug, and its mutation would have significant effect on the resistance to anti-flu drugs. The evolution of matrix protein 2 of influenza A virus from 1959 to 2008 was defined using the unpredictable portion of amino-acid pair predictability. Then the trend in this evolution was compared with the trend in the global temperature, the temperature in north and south hemispheres, and the temperature in influenza A virus sampling site, and species carrying influenza A virus. The results showed the similar trends in global warming and in evolution of M2 proteins although we could not correlate them at this stage of study. The study suggested the potential impact of global warming on the evolution of proteins from influenza A virus.

  18. Epidemiological and virological characteristics of influenza B: results of the Global Influenza B Study

    NARCIS (Netherlands)

    Caini, S.; Huang, Q.S.; Ciblak, M.A.; Kusznierz, G.; Owen, R.; Wangchuk, S.; Henriques, C.M.P.; Njouom, R.; Fasce, R.A.; Yu, H.J.; Feng, L.Z.; Zambon, M.; Clara, A.W.; Kosasih, H.; Puzelli, S.; Kadjo, H.A.; Emukule, G.; Heraud, J.M.; Ang, L.W.; Venter, M.; Mironenko, A.; Brammer, L.; Mai, L.T.Q.; Schellevis, F.G.; Plotkin, S.; Paget, J.

    2015-01-01

    Introduction: Literature on influenza focuses on influenza A, despite influenza B having a large public health impact. The Global Influenza B Study aims to collect information on global epidemiology and burden of disease of influenza B since 2000. Methods: Twenty-six countries in the Southern (n=5)

  19. Epidemiological and virological characteristics of influenza B: results of the global influenza B study.

    NARCIS (Netherlands)

    Caini, S.; Sue Huang, Q.; Ciblak, M.A.; Kusznierz, G.; Owen, R.; Wangchuk, S.; Henriques, C.M.P.; Njouom, R.; Fasce, R.A.; Yu, H.; Feng, L.; Zambon, M.; Clara, A.W.; Kosasih, H.; Puzelli, S.; Kasjo, H.A.; Emukule, G.; Hereaud, J.M.; Ang, L.W.; Venter, M.; Mironenko, A.; Brammer, L.; Mai, L.T.Q.; Schellevis, F.; Plotkin, S.; Paget, J.

    2015-01-01

    Introduction: Literature on influenza focuses on influenza A, despite influenza B having a large public health impact. The Global Influenza B Study aims to collect information on global epidemiology and burden of disease of influenza B since 2000. Methods Twenty-six countries in the Southern (n = 5)

  20. Epidemiological and virological characteristics of influenza B: results of the Global Influenza B Study

    NARCIS (Netherlands)

    Caini, S.; Huang, Q.S.; Ciblak, M.A.; Kusznierz, G.; Owen, R.; Wangchuk, S.; Henriques, C.M.; Njouom, R.; Fasce, R.A.; Yu, H.; Feng, L.; Zambon, M.; Clara, A.W.; Kosasih, H.; Puzelli, S.; Kadjo, H.A.; Emukule, G.; Heraud, J.M.; Ang, L.W.; Venter, M.; Mironenko, A.; Brammer, L.; Mai, T.Q. le; Schellevis, F.; Plotkin, S.; Paget, J.

    2015-01-01

    INTRODUCTION: Literature on influenza focuses on influenza A, despite influenza B having a large public health impact. The Global Influenza B Study aims to collect information on global epidemiology and burden of disease of influenza B since 2000. METHODS: Twenty-six countries in the Southern (n =

  1. Structure-Based Drug Design Targeting a Subunit Interaction of Influenza Virus RNA Polymerase

    Science.gov (United States)

    Sugiyama, Kanako; Obayashi, Eiji; Yoshida, Hisashi; Park, Sam-Yong

    Influenza A virus is a major human and animal pathogen with the potential to cause catastrophic loss of life. Influenza virus reproduces rapidly, mutates frequently, and occasionally crosses species barriers. The recent emergence of swine-origin influenza H1N1 and avian influenza related to highly pathogenic forms of the human virus has highlighted the urgent need for new effective treatments. Here, we describe two crystal structures of complexes made by fragments of PA and PB1, and PB1 and PB2. These novel interfaces are surprisingly small, yet they play a crucial role in regulating the 250 kDa polymerase complex, and are completely conserved among swine, avian and human influenza viruses. Given their importance to viral replication and strict conservation, the PA/PB1 and PB1/PB2 interfaces appear to be promising targets for novel anti-influenza drugs of use against all strains of influenza A virus. It is hoped that the structures presented here will assist the search for such compounds.

  2. Structural insights into the membrane fusion mechanism mediated by influenza virus hemagglutinin.

    Science.gov (United States)

    Ni, Fengyun; Chen, Xiaorui; Shen, Jun; Wang, Qinghua

    2014-02-11

    Membrane fusion is involved in many fundamental cellular processes and entry of enveloped viruses into host cells. Influenza type A virus HA has long served as a paradigm for mechanistic studies of protein-mediated membrane fusion via large-scale structural rearrangements induced by acidic pH. Here we report the newly determined crystal structure of influenza B virus HA2 in the postfusion state. Together with a large number of previously determined prefusion structures of influenza A and B virus HA and a postfusion structure of influenza A/H3N2 HA2, we identified conserved features that are shared between influenza A and B virus HA in the conformational transition and documented substantial differences that likely influence the detailed mechanisms of this process. Further studies are needed to dissect the effects of these and other structural differences in HA conformational changes and influenza pathogenicity and transmission, which may ultimately expedite the discovery of novel anti-influenza fusion inhibitors.

  3. Antiviral Efficacy of Verdinexor In Vivo in Two Animal Models of Influenza A Virus Infection.

    Directory of Open Access Journals (Sweden)

    Olivia Perwitasari

    Full Text Available Influenza A virus (IAV causes seasonal epidemics of respiratory illness that can cause mild to severe illness and potentially death. Antiviral drugs are an important countermeasure against IAV; however, drug resistance has developed, thus new therapeutic approaches are being sought. Previously, we demonstrated the antiviral activity of a novel nuclear export inhibitor drug, verdinexor, to reduce influenza replication in vitro and pulmonary virus burden in mice. In this study, in vivo efficacy of verdinexor was further evaluated in two animal models or influenza virus infection, mice and ferrets. In mice, verdinexor was efficacious to limit virus shedding, reduce pulmonary pro-inflammatory cytokine expression, and moderate leukocyte infiltration into the bronchoalveolar space. Similarly, verdinexor-treated ferrets had reduced lung pathology, virus burden, and inflammatory cytokine expression in the nasal wash exudate. These findings support the anti-viral efficacy of verdinexor, and warrant its development as a novel antiviral therapeutic for influenza infection.

  4. Antiviral Efficacy of Verdinexor In Vivo in Two Animal Models of Influenza A Virus Infection.

    Science.gov (United States)

    Perwitasari, Olivia; Johnson, Scott; Yan, Xiuzhen; Register, Emery; Crabtree, Jackelyn; Gabbard, Jon; Howerth, Elizabeth; Shacham, Sharon; Carlson, Robert; Tamir, Sharon; Tripp, Ralph A

    2016-01-01

    Influenza A virus (IAV) causes seasonal epidemics of respiratory illness that can cause mild to severe illness and potentially death. Antiviral drugs are an important countermeasure against IAV; however, drug resistance has developed, thus new therapeutic approaches are being sought. Previously, we demonstrated the antiviral activity of a novel nuclear export inhibitor drug, verdinexor, to reduce influenza replication in vitro and pulmonary virus burden in mice. In this study, in vivo efficacy of verdinexor was further evaluated in two animal models or influenza virus infection, mice and ferrets. In mice, verdinexor was efficacious to limit virus shedding, reduce pulmonary pro-inflammatory cytokine expression, and moderate leukocyte infiltration into the bronchoalveolar space. Similarly, verdinexor-treated ferrets had reduced lung pathology, virus burden, and inflammatory cytokine expression in the nasal wash exudate. These findings support the anti-viral efficacy of verdinexor, and warrant its development as a novel antiviral therapeutic for influenza infection.

  5. Interaction of influenza A virus M1 matrix protein with caspases.

    Science.gov (United States)

    Zhirnov, O P; Ksenofontov, A L; Kuzmina, S G; Klenk, H D

    2002-05-01

    In this investigation, an ability of influenza A virus M1 matrix protein to bind intracellular caspases, the key enzymes of cell apoptosis, has been examined. Protein-protein binding on polystyrene plates and polyvinyl pyrrolidone membrane was employed for this purpose. Under a comparative study of caspases-3, -6, -7, -8 influenza virus M1 protein specifically bound caspase-8 and weakly bound caspase-7. Using a computer analysis of the N-terminal region of M1 protein, a site similar to the anti-caspase site of baculovirus p35 protein, which inhibits caspases and displays antiapoptotic activity, was identified. These results are in good agreement with the supposition that influenza virus M1 protein is involved in a caspase-8-mediated apoptosis pathway in influenza virus infected cells.

  6. [Influenza vaccine and adjuvant].

    Science.gov (United States)

    Nakayama, Tetsuo

    2011-01-01

    Adjuvant is originated from the Latin word "adjuvare" which means "help" in English to enhance the immunological responses when given together with antigens. The beginning of adjuvant was mineral oil which enhanced the immune response when it was given with inactivated Salmonella typhimurium. Aluminium salt was used to precipitate diphtheria toxoid and increased level of antibody response was demonstrated when administered with alum-precipitated antigens. Since 1930, aluminium salt has been used as DTaP (diphtheria-tetanus-acellular pertussis vaccine) adjuvant. Many candidates were tested for adjuvant activity but only aluminum salt is allowed to use for human vaccines. New adjuvant MF59, oil-in-water emulsion type, was developed for influenza vaccine for elderly (Fluad) and series of AS adjuvant are used for hepatitis B, pandemic flue, and human papiloma virus vaccines. Oil-adjuvanted influenza pandemic vaccines induced higher antibody response than alum-adjuvanted vaccine with higher incidence of adverse events, especially for local reactions. Alum-adjuvanted whole virion inactivated H5N1 vaccine was developed in Japan, and it induced relatively well immune responses in adults. When it applied for children, febrile reaction was noted in approximately 60% of the subjects, with higher antibodies. Recent investigation on innate immunity demonstrates that adjuvant activity is initiated from the stimulation on innate immunity and/or inflammasome, resulting in cytokine induction and antigen uptake by monocytes and macrophages. The probable reason for high incidence of febrile reaction should be investigated to develop a safe and effective influenza vaccine.

  7. Seguridad de la vacuna de la gripe en el receptor de trasplante de órgano sólido

    OpenAIRE

    Bulnes Ramos, Ángel

    2016-01-01

    La infección por influenza en los pacientes receptores de trasplante de órgano sólido (TOS) se ha asociado con altas tasas de morbilidad y mortalidad, especialmente en los primeros tres meses tras el trasplante. La vacunación de la gripe se ha propuesto como una medida eficaz para la prevención de la infección en estos pacientes. La mayoría de los estudios realizados para evaluar la eficacia de la vacunación en este grupo de pacientes han reflejado una respuesta humoral óptima en el receptor ...

  8. PANDEMIC SWINE INFLUENZA VIRUS: PREPAREDNESS ...

    African Journals Online (AJOL)

    Zamzar

    pandemic planning. Keywords: Pandemic, swine, influenza, virus, preparedness. INTRODUCTION. Effective pandemic preparedness and response should involve .... disaster. Academy of Emerging Medicine 2006;. 13: 1118-1129. 11. Coker R.J, Mounier-Jack S. Pandemic influenza preparedness in the Asia- pacific region.

  9. Avian influenza surveillance and diagnosis

    Science.gov (United States)

    Rapid detection and accurate identification of low (LPAI) and high pathogenicity avian influenza (HPAI) is critical to controlling infections and disease in poultry. Test selection and algorithms for the detection and diagnosis of avian influenza virus (AIV) in poultry may vary somewhat among differ...

  10. Rekonvalescens og sygemelding efter influenza

    DEFF Research Database (Denmark)

    Pedersen, Court

    2009-01-01

    Seasonal influenza has a significant impact on individuals and society alike. In otherwise healthy adults, a typical case of seasonal influenza is associated with six to eight days of clinical symptoms, and about four to five days of sick leave. Transmission mainly takes place during the initial...

  11. Influenza: diagnosis, management, and prophylaxis.

    OpenAIRE

    Wiselka, M

    1994-01-01

    Influenza causes enormous morbidity, death, and economic loss. Annual vaccination is strongly recommended for groups at high risk. Amantadine is effective treatment for and prophylaxis against influenza A during epidemics. New developments include rapid laboratory diagnosis, live attenuated vaccines, and antiviral drugs.

  12. Influenza vaccines : The virosome concept

    NARCIS (Netherlands)

    Wilschut, Jan

    2009-01-01

    Influenza virosomes are virus-like particles, which retain the cell binding and membrane fusion properties of the native virus, but lack the viral genetic material. These functional characteristics of influenza virosomes form the basis for their immunogenicity First, the repetitive arrangement of

  13. Influenza: prevention, prophylaxis and treatment

    African Journals Online (AJOL)

    period from 1997 to 2001, influenza and pneumonia combined was one of the top five causes of death for both males and females.1. Influenza illness ... chain outlet of flu vaccines and offering symptomatic treatment. Early flu patients .... who use the vaccine, thus healthcare professionals should not hesitate to vaccinate this ...

  14. Haemophilus influenzae and oxidative stress

    Directory of Open Access Journals (Sweden)

    Alistair eHarrison

    2012-03-01

    Full Text Available Haemophilus influenzae is a commensal of the human upper respiratory tract. H. influenzae can, however, move out of its commensal niche and cause multiple respiratory tract diseases. Such diseases include otitis media in young children, as well as exacerbations of chronic obstructive pulmonary disease, sinusitis, conjunctivitis and bronchitis. During the course of colonization and infection, H. influenzae must withstand oxidative stress generated by multiple reactive oxygen species produced endogenously, by other co-pathogens and by host cells. H. influenzae has therefore evolved multiple mechanisms that protect the cell against oxygen-generated stresses. In this review, we will describe these systems. Moreover, we will compare how H. influenzae obviates the effect of oxidative stress as a necessary phenotype for its roles as both a successful commensal and pathogen, relative to the well-described systems in Escherichia coli.

  15. Identification of small molecule inhibitors for influenza a virus using in silico and in vitro approaches.

    Directory of Open Access Journals (Sweden)

    Juliann Nzembi Makau

    Full Text Available Influenza viruses have acquired resistance to approved neuraminidase-targeting drugs, increasing the need for new drug targets for the development of novel anti-influenza drugs. Nucleoprotein (NP is an attractive target since it has an indispensable role in virus replication and its amino acid sequence is well conserved. In this study, we aimed to identify new inhibitors of the NP using a structure-based drug discovery algorithm, named Nagasaki University Docking Engine (NUDE, which has been established especially for the Destination for GPU Intensive Machine (DEGIMA supercomputer. The hit compounds that showed high binding scores during in silico screening were subsequently evaluated for anti-influenza virus effects using a cell-based assay. A 4-hydroxyquinolinone compound, designated as NUD-1, was found to inhibit the replication of influenza virus in cultured cells. Analysis of binding between NUD-1 and NP using surface plasmon resonance assay and fragment molecular orbital calculations confirmed that NUD-1 binds to NP and could interfere with NP-NP interactions essential for virus replication. Time-of-addition experiments showed that the compound inhibited the mid-stage of infection, corresponding to assembly of the NP and other viral proteins. Moreover, NUD-1 was also effective against various types of influenza A viruses including a clinical isolate of A(H1N1pdm09 influenza with a 50% inhibitory concentration range of 1.8-2.1 μM. Our data demonstrate that the combined use of NUDE system followed by the cell-based assay is useful to obtain lead compounds for the development of novel anti-influenza drugs.

  16. Los precios de la carne vacuna en Buenos Aires colonial. Una interpelación historiográfica e histórica

    Directory of Open Access Journals (Sweden)

    Andrea Dupuy

    2014-12-01

    Full Text Available En el ámbito de los estudios de mercado, los precios constituyen los principales indicadores del comportamiento de la economía, aun los de Antiguo Régimen. El objetivo del presente trabajo es abordar el análisis de los precios de la carne vacuna de la ciudad de Buenos Aires colonial partiendo de la idea de que este mercado, al igual que los de las distintas ciudades hispanoamericanas, presentó a lo largo de la etapa colonial una regularidad predominante. Y aun cuando estuvo atravesado por situaciones críticas de escasez, estos factores no lograron modificar sustancialmente, desde una mirada de largo plazo, las características del mismo.

  17. Problemas bioéticos en la investigación de nuevas vacunas: ¿obedecen a razones de salud pública?

    Directory of Open Access Journals (Sweden)

    Juan Carlos Tealdi

    2015-01-01

    Full Text Available Los problemas éticos de las investigaciones sobre vacunas han crecido en las últimas décadas en frecuencia y magnitud debido a la posición dominante de la industria farmacéutica en el desarrollo de esos estudios. Las tradicionales cuestiones de seguridad y eficacia se han visto agravadas por el conflicto de intereses introducido por la competencia comercial en un mercado a escala global de miles de millones de dólares. La integridad profesional de los investigadores, la responsabilidad moral de los patrocinadores, y la regulación y control por parte de los Estados nacionales, se muestra cuestionada en varios ejemplos. Los resultados de estos cambios son las amenazas a la protección de los derechos de las personas incluidas en estas investigaciones y el discutible progreso que resulta para la salud pública.

  18. Vectores recombinantes basados en el virus modificado de ankara (MVA) como vacunas preventivas y terapéuticas contra el SIDA

    OpenAIRE

    Heeney, Jonathan L.; Mooij, Petra; Nájera García, José Luis; Jiménez, Victoria; Esteban, Mariano; Gómez, Carmen E.

    2005-01-01

    Vectores Recombinantes basados en el Virus Modificado de Ankara (MVA) como Vacunas Preventivas y Terapéuticas contra el SIDA. Losvirus recombinantes de la invención contienen secuencias que se encuentran insertadas en el mismo sitio de inserción del MVA y permiten la expresión simultánea de varios antígenos, una proteína Env del VIH-I consistente en una proteína gpl20 carente de secuencias correspondientes a la proteína gp41, y una proteína quiméricade fusión de Gag, Pol y Nef. Son virus esta...

  19. Optimization of an In Situ Cellular ELISA Performed on Influenza A Virus-Infected Monolayers for Screening of Antiviral Agents

    Science.gov (United States)

    1999-02-04

    the specific conditions necessary for susceptibility testing of influenza A virus to antiviral agents such as amount of inoculum size. duration of... conditions of in situ Maintenance media (without fetal bovine cellular ELISA performed on influenza A virus serum) was formulated with 3.0 igml of...obtained the best differ- a new anti-microbial nanoemulsion disinfectant ence between uninfected and infected cells and the (Novavax. Rockville, MD

  20. The rationale for quadrivalent influenza vaccines

    OpenAIRE

    Ambrose, Christopher S.; Levin, Myron J.

    2012-01-01

    Two antigenically distinct lineages of influenza B viruses have circulated globally since 1985. However, licensed trivalent seasonal influenza vaccines contain antigens from only a single influenza B virus and thus provide limited immunity against circulating influenza B strains of the lineage not present in the vaccine. In recent years, predictions about which B lineage will predominate in an upcoming influenza season have been no better than chance alone, correct in only 5 of the 10 seasons...

  1. Nivel de corte de los ELISAs para cuantificación de anticuerpos inducidos por la vacuna antimeningocócica VA-MENGOC-BC

    Directory of Open Access Journals (Sweden)

    Rolando Ochoa

    2001-06-01

    Full Text Available Para medir el grado de protección inducido por vacunas antimeningocócicas se ha establecido el Ensayo Bactericida en Suero (EBS y se perfeccionan otros ensayos inmunobiológicos, sin embargo, es necesario contar con pruebas sencillas como el ELISA, capaz de evaluar un gran número de muestras. Se estimó el nivel de corte de los ELISAs para la cuantificación de IgG humana contra los antígenos de VA-MENGOC-BC, vacuna antimeningocócica compuesta por vesículas proteicas de membrana externa de meningococo B y polisacárido capsular de meningococo C, con respecto a un panel de muestras de suero de lactantes, caracterizado por Ensayo Bactericida en Sangre Total (EBST. Los valores correspondientes a la máxima sensibilidad y especificidad fueron respectivamente; 2 μg/mL y 12 μg/mL para antipolisacárido C, y 1000 U/mL y 7000 U/mL para antiproteínas de membrana externa. La mayor coincidencia se obtuvo con 6 μg/mL y 2500 U/mL. Se evaluó otro panel de muestras de suero de adolescentes entre 14 y 18 años, por ELISA y EBS para Neisseria meningitidis serogrupos B y C, alcanzándose una buena concordancia. Doce años después de la inmunización con VA-MENGOC-BC persiste una importante concentración de anticuerpos contra los antígenos vacunales en los sueros estudiados.

  2. Perspectivas para el desarrollo de vacunas e inmunoterapia contra cáncer cervicouterino Perspectives for vaccines and immunotherapy against cervical cancer

    Directory of Open Access Journals (Sweden)

    LILIANA GUZMÁN-ROJAS

    1998-01-01

    Full Text Available El cáncer cervicouterino representa un grave problema de salud pública, debido a la asociación de la neoplasia con el virus del papiloma humano; actualmente se realizan estudios usando estrategias dirigidas a combatir este patógeno, mediante vacunas, que podrían ser de gran utilidad para el control de la progresión de la enfermedad. El estudio tanto de la inmunología humoral como celular ha servido para el desarrollo de vacunas. Así, la utilización de partículas virales sintéticas para el estudio de anticuerpos neutralizantes y el uso de proteínas tempranas virales, entre otras, para la inducción de inmunidad mediada por células, han sido la pauta para realizar estudios que dirijan la respuesta inmune para prevenir la infección celular tanto hacia células infectadas no transformadas como hacia células transformadas viralmente con resultados favorables.Cervical cancer represents a severe public health problem and has been associated to the presence of human papillomavirus. Strategies are presently being tested which target the virus to attempt to control disease progress. Studies on the humoral and cell-mediated immunity of the papillomavirus infection have been useful in the development of a vaccine. Synthetic virus-like particles have been validated as vaccine against several animal papillomaviruses and used to map the seroepidemiology of the human papillomavirus infection, and define neutralizing antibodies. Induction of cell-mediated immunity to HPV early proteins is bound to become a therapeutic approach to HPV infections. Recent advances have centered on directing the immune response to prevent infection, to virus-infected cells and to virally transformed cells, with favourable results.

  3. Decisiones de los padres que no arriesgan la vida de sus hijos, pero que los exponen a daños serios: no a las vacunas

    Directory of Open Access Journals (Sweden)

    Jéssica H. Guadarrama-Orozco

    2015-09-01

    Full Text Available La decisión de los padres de no aplicar vacunas que son “obligatorias” a sus hijos genera dilemas en los médicos y pediatras. ¿Qué debe hacerse cuando los padres no consienten la aplicación de vacunas a sus niños? ¿Esto sitúa a los niños en riesgo suficientemente grave como para que amerite la notificación a los servicios de protección infantil del Estado y que se trate como negligencia de parte de los padres? ¿Qué debe hacerse cuando, por no inmunizar a sus hijos, se pone en riesgo a terceros? El principio del interés superior del menor implica velar por el beneficio del niño sobre cualquier otra situación. Al respecto, los padres antivacunas tienen argumentos para justificar su postura. Los médicos no pueden obligar a los padres a vacunar a sus hijos. Sin embargo, bajo el mismo principio, deben velar por el bienestar del niño y permanecer alerta de que los padres no rebasen el umbral de daño al menor. Si los padres ponen en riesgo de daño grave a su hijo al tomar la decisión de no vacunarlo, entonces estará justificada la intervención legal en la decisión. Este recurso debe ser la última opción, pues los conflictos, en su mayoría, deben resolverse en el seno de la relación del médico con los padres.

  4. Estudios de estabilidad de vida de estante en condiciones de estrés de la vacuna antileptospirósica vax-SPIRAL®

    Directory of Open Access Journals (Sweden)

    Maylén Machado

    2007-04-01

    Full Text Available Los estudios de estabilidad constituyen requisito fundamental para avalar el Registro Médico Sanitario de un nuevo medicamento. Por tal motivo se diseñó y llevó a cabo un proyecto de estudio de estabilidad de vida de estante y en condiciones de estrés térmico a la vacuna antileptospirósica cubana vax-SPIRAL®, donde se evaluaron las propiedades físicoquímicas y biológicas fundamentales del producto (características organolépticas, pH, concentración de tiomersal, inocuidad inespecífica, potencia y esterilidad, con el objetivo de recomendar las condiciones de almacenamiento que garantizarán su calidad y se propone la fecha de vencimiento. Para esto, parte de las muestras se conservaron a temperatura de 2-8 ºC durante 30 meses (vida de estante, y las muestras restantes de cada uno de los lotes en estudio se incubaron a 37 ºC por 7 días; 25 ºC por 30 días y 45 ºC por 3 días (temperaturas de estrés. Se concluyó que la vacuna vax-SPIRAL® puede ser considerada un producto estable para los parámetros evaluados en el presente estudio, siempre que se mantenga a la temperatura de 2-8 ºC. Se propone un período de validez de 24 meses para esas condiciones.

  5. Homology modelling and insilico analysis of neuraminidase protein in H1N1 Influenza A virus

    Directory of Open Access Journals (Sweden)

    Abhilash Manohar

    2011-02-01

    Full Text Available In this work, modelling of Neuraminidase protein of Influenza A virus (A/Himeji/1/2009(H1N1 neuraminidase (NA protein was done using Modeller 9V2. Modelled structure was submitted to protein model database and could be downloaded using accession number PM0075830. The modelled protein structure was subjected to In silco analysis using various bioinformatics tools. Two anti-influenza drugs currently being used to treat infected patients are oseltamivir (Tamiflu and zanamivir (Relenza, both of which target the neuraminidase enzyme of the virus. Reports of the emergence of drug resistance make the development of new anti-influenza molecules a priority. Hence the modelled structure of H1NI Neuraminidase could be very useful for in silico analysis of potential neuraminidase inhibitors.

  6. Replication of influenza A virus in swine umbilical cord epithelial stem-like cells.

    Science.gov (United States)

    Khatri, Mahesh; Chattha, Kuldeep S

    2015-01-01

    In this study, we describe the isolation and characterization of epithelial stem-like cells from the swine umbilical cord and their susceptibility to influenza virus infection. Swine umbilical cord epithelial stem cells (SUCECs) expressed stem cell and pluripotency associated markers such as SSEA-1, SSEA-4, TRA 1-60 and TRA 1-81 and Oct4. Morphologically, cells displayed polygonal morphology and were found to express epithelial markers; pancytokeratin, cytokeratin-18 and occludin; mesenchymal cell markers CD44, CD90 and haematopoietic cell marker CD45 were not detected on these cells. The cells had extensive proliferation and self- renewal properties. The cells also possessed immunomodulatory activity and inhibited the proliferation of T cells. Also, higher levels of anti-inflammatory cytokine IL-10 were detected in SUCEC-T cell co-cultures. The cells were multipotent and differentiated into lung epithelial cells when cultured in epithelial differentiation media. We also examined if SUCECs are susceptible to infection with influenza virus. SUCECs expressed sialic acid receptors, used by influenza virus for binding to cells. The 2009 pandemic influenza virus and swine influenza virus replicated in these cells. SUCECs due to their differentiation and immunoregulatory properties will be useful as cellular therapy in a pig model for human diseases. Additionally, our data indicate that influenza virus can infect SUCECs and may transmit influenza virus from mother to fetus through umbilical cord and transplantation of influenza virus-infected stem cells may transmit infection to recipients. Therefore, we propose that umbilical cord cells, in addition to other agents, should also be tested for influenza virus before cryopreservation for future use as a cell therapy for disease conditions.

  7. Design, synthesis and biological evaluation of novel L-ascorbic acid-conjugated pentacyclic triterpene derivatives as potential influenza virus entry inhibitors.

    Science.gov (United States)

    Wang, Han; Xu, Renyang; Shi, Yongying; Si, Longlong; Jiao, Pingxuan; Fan, Zibo; Han, Xu; Wu, Xingyu; Zhou, Xiaoshu; Yu, Fei; Zhang, Yongmin; Zhang, Liangren; Zhang, Lihe; Zhou, Demin; Xiao, Sulong

    2016-03-03

    Since the influenza viruses can rapidly evolve, it is urgently required to develop novel anti-influenza agents possessing a novel mechanism of action. In our previous study, two pentacyclic triterpene derivatives (Q8 and Y3) have been found to have anti-influenza virus entry activities. Keeping the potential synergy of biological activity of pentacyclic triterpenes and l-ascorbic acid in mind, we synthesized a series of novel l-ascorbic acid-conjugated pentacyclic triterpene derivatives (18-26, 29-31, 35-40 and 42-43). Moreover, we evaluated these novel compounds for their anti-influenza activities against A/WSN/33 virus in MDCK cells. Among all evaluated compounds, the 2,3-O,O-dibenzyl-6-deoxy-l-ascorbic acid-betulinic acid conjugate (30) showed the most significant anti-influenza activity with an EC50 of 8.7 μM, and no cytotoxic effects on MDCK cells were observed. Time-of-addition assay indicated that compound 30 acted at an early stage of the influenza life cycle. Further analyses revealed that influenza virus-induced hemagglutination of chicken red blood cells was inhibited by treatment of compound 30, and the interaction between the influenza hemagglutinin (HA) and compound 30 was determined by surface plasmon resonance (SPR) with a dissociation constant of KD = 3.76 μM. Finally, silico docking studies indicated that compound 30 and its derivative 31 were able to occupy the binding pocket of HA for sialic acid receptor. Collectively, these results suggested that l-ascorbic acid-conjugated pentacyclic triterpenes were promising anti-influenza entry inhibitors, and HA protein associated with viral entry was a promising drug target. Copyright © 2016 Elsevier Masson SAS. All rights reserved.

  8. Imunogenicidade da vacina brasileira contra hepatite B em adultos Inmunogenicidad de la vacuna brasilera contra hepatitis B en adultos Immunogenicity of the Brazilian hepatitis B vaccine in adults

    Directory of Open Access Journals (Sweden)

    José Cássio de Moraes

    2010-04-01

    Full Text Available OBJETIVO: Avaliar a imunogenicidade e segurança da vacina contra hepatite B, após o aumento na concentração do antígeno HBsAg para 25 μg, em comparação à vacina de referência. MÉTODOS: Ensaio com alocação aleatória e mascaramento simples, comparando a VrHB-IB (Instituto Butantan com a vacina de referência (Engerix B®, Glaxo Smith Kline. Os voluntários, entre 31 e 40 anos de idade (n=419, foram alocados aleatoriamente ao grupo experimental (n=216 ou ao grupo controle (n=203, e receberam três doses de vacina. A primeira dose foi administrada no momento do recrutamento, a segunda e terceira 30 e 180 dias depois respectivamente, entre 2004 e 2005. Amostras de sangue foram colhidas para análise sorológica antes da randomização, e após a segunda e terceira doses. Foi realizada a vigilância ativa de eventos adversos durante os cinco primeiros dias após a vacinação. As diferenças foram avaliadas pelos testes do qui-quadrado e exato de Fisher, com nível de significância de 5%. RESULTADOS: Não se observaram eventos adversos graves. A soroporteção foi confirmada em 98,6% (213/216 dos voluntários do grupo experimental, em comparação a 95,6% (194/203 do grupo controle. Os títulos geométricos médios foram de 12.557 e 11.673, respectivamente. CONCLUSÕES: A vacina brasileira foi considerada equivalente à vacina de referência e seu uso recomendado para adultos.OBJETIVO: Evaluar la inmunogenicidad y seguridad de la vacuna contra hepatitis B, posterior al aumento en la concentración del antígeno HBsAg para 25mg, en comparación a la vacuna de referencia. MÉTODOS: Ensayo con distribución aleatoria y enmascaramiento simple, comparando la VrHB-IB (Instituto Butantan con la vacuna de referencia (Engerix BÒ, Glaxo Smith Kline. Los voluntarios, entre 31 y 40 años de edad (n=419, fueron distribuidos aleatoriamente en el grupo experimental (n=216 o en el grupo control (n=203, y recibieron tres dosis de la vacuna. La primera

  9. Inactivated influenza virus vaccine is efficient and reduces IL-4 and IL-6 in allergic asthma mice.

    Science.gov (United States)

    Jian, You-Ru; Chang, Sui-Yuan; Lin, Pin-Yi; Yang, Yao-Hsu; Chuang, Ya-Hui

    2013-11-01

    Allergic asthma is a globally respiratory inflammatory disease. Influenza virus is a respiratory pathogen that causes yearly epidemics and results in high rates of morbidity and mortality. Patients with allergic asthma had a more severe symptom and a higher mortality when they were infected with influenza virus. Hence, influenza vaccination is recommended for patients with asthma. We evaluated the efficacy and effects of influenza vaccination on allergic asthma in a mouse model. Ovalbumin-immunized mice were inoculated with inactivated influenza virus A/Puerto Rico/8/34 (PR8) as vaccines and morbidity or mortality and allergic asthma features of these mice were analyzed. Mice inoculated with inactivated PR8 induced high levels of anti-PR8 IgG2a and upregulation of Toll-like receptor (TLR) 7. Vaccinated allergic mice were healthy when they were challenged with live influenza virus while none of non-vaccinated allergic mice survived. Furthermore, inactivated influenza virus vaccine induced neither extra airway inflammation nor asthma features such as IgE, airway hyper-reactivity, and eosinophilia in allergic mice. Particularly, decreased frequency of immune cell infiltrated airways and Th2 cytokines IL-4 and IL-6 production in the bronchoalveolar lavage fluid were noted in vaccinated allergic mice. These results suggested that inactivated influenza virus vaccine is efficient to protect allergic mice from further influenza infection, and it does not exacerbate but reduces IL-4 and IL-6 of allergic asthma. Influenza vaccination is essential and efficient for allergic subjects to protect influenza virus infection. © 2013 John Wiley & Sons Ltd.

  10. Determinantes de la vacunación antigripal en personal sanitario: temporada 2009-2010 Determinants of influenza vaccination in health staff: 2009-2010 season

    Directory of Open Access Journals (Sweden)

    José Sánchez-Payá

    2011-02-01

    Full Text Available Objetivos: Determinar las coberturas vacunales frente a la gripe estacional y frente a la nueva gripe A (H1N1 en la temporada 2009-2010 en trabajadores sanitarios y conocer sus factores determinantes. Métodos: Estudio transversal realizado en el Hospital General Universitario de Alicante en trabajadores sanitarios durante las campañas de vacunación antigripal 2008-2009 y 2009-2010. La campaña 2009-2010 se subdividió en dos fases: entre el 1-10-09 y el 13-11-09 se administró la vacuna de la gripe estacional 2009-2010; desde el 16-11-09 hasta el 30-12-09 se administró la vacuna frente al nuevo virus de la gripe A (H1N1. Cada fase estuvo precedida por una campaña promocional específica. En el momento de la vacunación, el trabajador sanitario cumplimentó un cuestionario que incluía un listado de motivos para vacunarse. Se calculó la frecuencia de vacunación y se compararon las coberturas vacunales de cada campaña, de manera global y por estamentos, utilizando la prueba de ji cuadrado. Resultados: La cobertura frente a la gripe estacional 2009-2010 fue del 31%, y frente a la nueva gripe A (H1N1 fue del 22,2% (pObjectives: To determine vaccination coverage against seasonal influenza and the new A (H1N1 influenza virus among healthcare personnel during the 2009-2010 season and to identify its determining factors. Methods: We performed a cross-sectional study among healthcare staff at the General University Hospital in Alicante (Spain during the 2008-2009 and 2009-2010 influenza vaccination campaigns. The 2009-2010 vaccination campaign was subdivided into two phases. In the first phase, from 1st October to 19th November, 2009, the seasonal influenza vaccine was administered; in the second phase, from 16th November to 30th December, 2009, vaccination against the new A (H1N1 influenza virus was performed. Each of the vaccine programs was preceded by a specific vaccination promotion campaign. Healthcare staff were asked to complete a brief

  11. 2012-2013 Seasonal Influenza Vaccine Effectiveness against Influenza Hospitalizations: Results from the Global Influenza Hospital Surveillance Network

    Science.gov (United States)

    Puig-Barberà, Joan; Natividad-Sancho, Angels; Launay, Odile; Burtseva, Elena; Ciblak, Meral A.; Tormos, Anita; Buigues-Vila, Amparo; Martínez-Úbeda, Sergio; Sominina, Anna

    2014-01-01

    Background The effectiveness of currently licensed vaccines against influenza has not been clearly established, especially among individuals at increased risk for complications from influenza. We used a test-negative approach to estimate influenza vaccine effectiveness (IVE) against hospitalization with laboratory-confirmed influenza based on data collected from the Global Influenza Hospital Surveillance Network (GIHSN). Methods and Findings This was a multi-center, prospective, active surveillance, hospital-based epidemiological study during the 2012–2013 influenza season. Data were collected from hospitals participating in the GIHSN, including five in Spain, five in France, and four in the Russian Federation. Influenza was confirmed by reverse transcription-polymerase chain reaction. IVE against hospitalization for laboratory-confirmed influenza was estimated for adult patients targeted for vaccination and who were swabbed within 7 days of symptom onset. The overall adjusted IVE was 33% (95% confidence interval [CI], 11% to 49%). Point estimates of IVE were 23% (95% CI, −26% to 53%) for influenza A(H1N1)pdm09, 30% (95% CI, −37% to 64%) for influenza A(H3N2), and 43% (95% CI, 17% to 60%) for influenza B/Yamagata. IVE estimates were similar in subjects influenza B/Yamagata were homogenous (I2 = 0.0%). Conclusions These results, which were based on data collected from the GIHSN during the 2012–2013 influenza season, showed that influenza vaccines provided low to moderate protection against hospital admission with laboratory-confirmed influenza in adults targeted for influenza vaccination. In this population, IVE estimates against A(H1N1)pdm09 were sensitive to age group and study site. Influenza vaccination was moderately effective in preventing admissions with influenza B/Yamagata for all sites and age groups. PMID:24945510

  12. Influenza in the acute hospital setting.

    Science.gov (United States)

    Salgado, Cassandra D; Farr, Barry M; Hall, Keri K; Hayden, Frederick G

    2002-03-01

    Influenza poses special hazards inside healthcare facilities and can cause explosive outbreaks of illness. Healthcare workers are at risk of acquiring influenza and thus serve as an important reservoir for patients under their care. Annual influenza immunisation of high-risk persons and their contacts, including healthcare workers, is the primary means of preventing nosocomial influenza. Despite influenza vaccine effectiveness, it is substantially underused by healthcare providers. Influenza can be diagnosed by culturing the virus from respiratory secretions and by rapid antigen detection kits; recognition of a nosocomial outbreak is important in order to employ infection-control efforts. Optimal control of influenza in the acute-care setting should focus upon reducing potential influenza reservoirs in the hospital, including: isolating patients with suspected or documented influenza, sending home healthcare providers or staff who exhibit typical symptoms of influenza, and discouraging persons with febrile respiratory illness from visiting the hospital during a known influenza outbreak in the community. (Note: influenza and other respiratory viruses can cause non-febrile illness but are still transmissible.) The antiviral M2 protein inhibitors (amantadine, rimantadine) and neuraminidase inhibitors (zanamivir, oseltamivir) have proven efficacy in treating and preventing influenza illness; however, their role in the prevention and control of influenza in the acute hospital setting remains to be more fully studied.

  13. Development of live attenuated influenza vaccines against pandemic influenza strains.

    Science.gov (United States)

    Coelingh, Kathleen L; Luke, Catherine J; Jin, Hong; Talaat, Kawsar R

    2014-07-01

    Avian and animal influenza viruses can sporadically transmit to humans, causing outbreaks of varying severity. In some cases, further human-to-human virus transmission does not occur, and the outbreak in humans is limited. In other cases, sustained human-to-human transmission occurs, resulting in worldwide influenza pandemics. Preparation for future pandemics is an important global public health goal. A key objective of preparedness is to gain an understanding of how to design, test, and manufacture effective vaccines that could be stockpiled for use in a pandemic. This review summarizes results of an ongoing collaboration to produce, characterize, and clinically test a library of live attenuated influenza vaccine strains (based on Ann Arbor attenuated Type A strain) containing protective antigens from influenza viruses considered to be of high pandemic potential.

  14. Influenza em animais heterotérmicos Influenza in heterothermics

    Directory of Open Access Journals (Sweden)

    Dalva Assunção Portari Mancini

    2004-06-01

    Full Text Available O objetivo foi pesquisar Ortomyxovirus em animais heterotérmicos. Coletou-se sangue de serpentes dos gêneros Bothrops e Crotalus e de sapo e rãs dos gêneros Bufo e Rana, para a detecção dos receptores de hemácias e anticorpos específicos, ao vírus influenza, pelos testes de hemaglutinação e inibição da hemaglutinação, respectivamente. Pelo teste de hemaglutinação, verificou-se que serpentes e sapos em cativeiro apresentaram receptores em suas hemácias para o vírus influenza, humano e eqüino do tipo A e tipo B. O mesmo ocorreu com serpentes recém chegadas. Quanto ao teste de inibição da hemaglutinação dos soros dos répteis observou-se títulos protetores de anticorpos aos vírus influenza tipo A (origens humana e eqüina e tipo B. Com soro de sapo não se observou reação de inibição da hemaglutinação porém, 83,3% das rãs obtiveram médias de 40UIH para algumas cepas. Conclui-se que animais heterotérmicos podem oferecer condições de hospedeiros aos vírus influenza, assim como susceptibilidade à infecção.The objective was to study Orthomyxovirus in heterothermic animals. Blood samples from snakes (genus Bothrops and Crotalus and from toads and frogs (genus Bufo and Rana were collected to evaluate the red cell receptors and antibodies specific to influenza virus by the hemagglutination and hemagglutination inhibition tests, respectively. Both snakes and toads kept in captivity presented receptors in their red cells and antibodies specific to either influenza virus type A (human and equine origin or influenza type B. The same was observed with recently captured snakes. Concerning the influenza hemagglutination inhibition antibodies protective levels were observed in the reptiles' serum, against influenza type A and type B. Unlike the toads, 83.3% of the frogs presented mean levels of Ab 40HIU for some influenza strains. It was concluded that heterothermic animals could offer host conditions to the influenza

  15. Avian Influenza: a global threat needing a global solution

    Directory of Open Access Journals (Sweden)

    Koh GCH

    2008-11-01

    Full Text Available Abstract There have been three influenza pandemics since the 1900s, of which the 1919–1919 flu pandemic had the highest mortality rates. The influenza virus infects both humans and birds, and mutates using two mechanisms: antigenic drift and antigenic shift. Currently, the H5N1 avian flu virus is limited to outbreaks among poultry and persons in direct contact to infected poultry, but the mortality rate among infected humans is high. Avian influenza (AI is endemic in Asia as a result of unregulated poultry rearing in rural areas. Such birds often live in close proximity to humans and this increases the chance of genetic re-assortment between avian and human influenza viruses which may produce a mutant strain that is easily transmitted between humans. Once this happens, a global pandemic is likely. Unlike SARS, a person with influenza infection is contagious before the onset of case-defining symptoms which limits the effectiveness of case isolation as a control strategy. Researchers have shown that carefully orchestrated of public health measures could potentially limit the spread of an AI pandemic if implemented soon after the first cases appear. To successfully contain and control an AI pandemic, both national and global strategies are needed. National strategies include source surveillance and control, adequate stockpiles of anti-viral agents, timely production of flu vaccines and healthcare system readiness. Global strategies such as early integrated response, curbing the disease outbreak at source, utilization of global resources, continuing research and open communication are also critical.

  16. Evaluación de los programas de vacunación mediante estudios serológicos y vacunas distribuidas Evaluation of vaccination programs through serological studies and distributed vaccines

    Directory of Open Access Journals (Sweden)

    Pedro Plans

    2005-12-01

    Full Text Available Antecedentes: El objetivo del estudio fue comparar las coberturas vacunales en escolares para la vacuna triple vírica (sarampión-rubéola-parotiditis, DTP (difteria-tétanos-tos ferina y poliomielitis, obtenidas a partir de las vacunas distribuidas a los centros de vacunación, las vacunaciones declaradas y el análisis serológico de anticuerpos. Métodos: La cobertura vacunal se obtuvo a partir de los antecedentes de vacunación recogidos en un cuestionario y mediante el análisis serológico de anticuerpos frente al sarampión para la vacuna triple vírica, y el tétanos para la vacuna DTP en una muestra representativa de escolares en 2001. La cobertura vacunal por registros se obtuvo dividiendo el número de individuos que podían haber completado la vacunación por la población objetivo. Se evaluó la concordancia entre los antecedentes de vacunación y los resultados serológicos mediante el índice kappa. Resultados: En los escolares de 6-8 y 9-11 años de edad se obtuvo una cobertura vacunal por cuestionario del 85,5 y el 87,6% para la vacuna DTP, del 89,9 y el 89,6% para la vacuna triple vírica, y del 90,4 y el 89,4% para la vacuna poliomielítica, respectivamente, mientras la cobertura vacunal por análisis serológico fue del 100 y el 99,6% para la vacuna DTP, y del 85,5 y el 93,3% para la vacuna triple vírica, respectivamente. La cobertura vacunal por registros fue significativamente mayor que la obtenida mediante estos 2 métodos: un 93,5 y un 100% para la vacuna DTP, un 96,3 y un 98,8% para la vacuna triple vírica, y un 100% para la vacuna poliomielítica. La concordancia obtenida entre los antecedentes de vacunación y los resultados serológicos fue muy baja (κ Background: The objective of this study was to compare vaccination coverage in schoolchildren for the measles-mumps-rubella (MMR and diphtheria-tetanus-pertussis (DTP triple vaccines, and the poliomyelitis vaccine based on: a vaccines distributed to vaccination

  17. Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines

    Science.gov (United States)

    Sridhar, Saranya; Brokstad, Karl A.; Cox, Rebecca J.

    2015-01-01

    Influenza is a major respiratory pathogen causing annual outbreaks and occasional pandemics. Influenza vaccination is the major method of prophylaxis. Currently annual influenza vaccination is recommended for groups at high risk of complications from influenza infection such as pregnant women, young children, people with underlying disease and the elderly, along with occupational groups such a healthcare workers and farm workers. There are two main types of vaccines available: the parenteral inactivated influenza vaccine and the intranasal live attenuated influenza vaccine. The inactivated vaccines are licensed from 6 months of age and have been used for more than 50 years with a good safety profile. Inactivated vaccines are standardized according to the presence of the viral major surface glycoprotein hemagglutinin and protection is mediated by the induction of vaccine strain specific antibody responses. In contrast, the live attenuated vaccines are licensed in Europe for children from 2–17 years of age and provide a multifaceted immune response with local and systemic antibody and T cell responses but with no clear correlate of protection. Here we discuss the immunological immune responses elicited by the two vaccines and discuss future work to better define correlates of protection. PMID:26343192

  18. Influenza Vaccination Strategies: Comparing Inactivated and Live Attenuated Influenza Vaccines

    Directory of Open Access Journals (Sweden)

    Saranya Sridhar

    2015-04-01

    Full Text Available Influenza is a major respiratory pathogen causing annual outbreaks and occasional pandemics. Influenza vaccination is the major method of prophylaxis. Currently annual influenza vaccination is recommended for groups at high risk of complications from influenza infection such as pregnant women, young children, people with underlying disease and the elderly, along with occupational groups such a healthcare workers and farm workers. There are two main types of vaccines available: the parenteral inactivated influenza vaccine and the intranasal live attenuated influenza vaccine. The inactivated vaccines are licensed from 6 months of age and have been used for more than 50 years with a good safety profile. Inactivated vaccines are standardized according to the presence of the viral major surface glycoprotein hemagglutinin and protection is mediated by the induction of vaccine strain specific antibody responses. In contrast, the live attenuated vaccines are licensed in Europe for children from 2–17 years of age and provide a multifaceted immune response with local and systemic antibody and T cell responses but with no clear correlate of protection. Here we discuss the immunological immune responses elicited by the two vaccines and discuss future work to better define correlates of protection.

  19. Inhibition of influenza A virus (H1N1 fusion by benzenesulfonamide derivatives targeting viral hemagglutinin.

    Directory of Open Access Journals (Sweden)

    Lei Zhu

    Full Text Available Hemagglutinin (HA of the influenza virus plays a crucial role in the early stage of the viral life cycle by binding to sialic acid on the surface of host epithelial cells and mediating fusion between virus envelope and endosome membrane for the release of viral genomes into the cytoplasm. To initiate virus fusion, endosome pH is lowered by acidification causing an irreversible conformational change of HA, which in turn results in a fusogenic HA. In this study, we describe characterization of an HA inhibitor of influenza H1N1 viruses, RO5464466. One-cycle time course study in MDCK cells showed that this compound acted at an early step of influenza virus replication. Results from HA-mediated hemolysis of chicken red blood cells and trypsin sensitivity assay of isolated HA clearly showed that RO5464466 targeted HA. In cell-based assays involving multiple rounds of virus infection and replication, RO5464466 inhibited an established influenza infection. The overall production of progeny viruses, as a result of the compound's inhibitory effect on fusion, was dramatically reduced by 8 log units when compared with a negative control. Furthermore, RO5487624, a close analogue of RO5464466, with pharmacokinetic properties suitable for in vivo efficacy studies displayed a protective effect on mice that were lethally challenged with influenza H1N1 virus. These results might benefit further characterization and development of novel anti-influenza agents by targeting viral hemagglutinin.

  20. PnuC and the utilization of the nicotinamide riboside analog 3-aminopyridine in Haemophilus influenzae.

    Science.gov (United States)

    Sauer, Elizabeta; Merdanovic, Melisa; Mortimer, Anne Price; Bringmann, Gerhard; Reidl, Joachim

    2004-12-01

    The utilization pathway for the uptake of NAD and nicotinamide riboside was previously characterized for Haemophilus influenzae. We now report on the cellular location, topology, and substrate specificity of PnuC. pnuC of H. influenzae is only distantly related to pnuC of Escherichia coli and Salmonella enterica serovar Typhimurium. When E. coli PnuC was expressed in an H. influenzae pnuC mutant, it was able to take up only nicotinamide riboside and not nicotinamide mononucleotide. Therefore, we postulated that PnuC transporters in general possess specificity for nicotinamide riboside. Earlier studies showed that 3-aminopyridine derivatives (e.g., 3-aminopyridine adenine dinucleotide) are inhibitory for H. influenzae growth. By testing characterized strains with mutations in the NAD utilization pathway, we show that 3-aminopyridine riboside is inhibitory to H. influenzae and is taken up by the NAD-processing and nicotinamide riboside route. 3-Aminopyridine riboside is utilized effectively in a pnuC+ background. In addition, we demonstrate that 3-aminopyridine adenine dinucleotide resynthesis is produced by NadR. 3-Aminopyridine riboside-resistant H. influenzae isolates were characterized, and mutations in nadR could be detected. We also tested other species of the family Pasteurellaceae, Pasteurella multocida and Actinobacillus actinomycetemcomitans, and found that 3-aminopyridine riboside does not act as a growth inhibitor; hence, 3-aminopyridine riboside represents an anti-infective agent with a very narrow host range.

  1. Screening for Neuraminidase Inhibitory Activity in Traditional Chinese Medicines Used to Treat Influenza

    Directory of Open Access Journals (Sweden)

    Xian-Ying Yang

    2016-08-01

    Full Text Available Objective: To screen for influenza virus neuraminidase inhibition and to provide a reference for the clinical treatment of influenza using traditional Chinese medicines (TCM. In this study, 421 crude extracts (solubilized with petroleum ether, ethanol, ethyl acetate, and aqueous solvents were obtained from 113 TCM. The medicine extracts were then reacted with oseltamivir, using 2’-(4-methylumbelliferyl-α-D-N-acetylneuraminic acid (MUNANA as the substrate, to determine influenza virus neuraminidase activity using a standard fluorimetric assay. It was found that Chinese medicine extracts from Pyrola calliantha, Cynanchum wilfordii, Balanophora involucrata and Paeonia delavayi significantly inhibited neuraminidase activity at a concentration of 40 μg/mL. Dose-dependent inhibitory assays also revealed significant inhibition. The IC50 range of the TCM extracts for influenza virus neuraminidase was approximately 12.66–34.85 μg/mL, respectively. Some Chinese medicines have clear anti-influenza viral effects that may play an important role in the treatment of influenza through the inhibition of viral neuraminidase. The results of this study demonstrated that plant medicines can serve as a useful source of neuraminidase (NA inhibitors and further investigation into the pharmacologic activities of these extracts is warranted.

  2. Relação entre morbidade hospitalar e cobertura vacinal contra Influenza A Relación entre morbilidad hospitalaria y cobertura de inmunización contra la Influenza A Relationship between hospital morbidity and vaccination coverage against Influenza A

    Directory of Open Access Journals (Sweden)

    Fernanda Ribeiro Baptista Marques

    2012-01-01

    Full Text Available OBJETIVO: Analisar o perfil dos indivíduos acometidos pelo vírus Influenza A (H1N1, e o impacto vacinal nos grupos prioritários à vacinação. MÉTODOS: Estudo ecológico, observacional, de caráter retrospectivo, com população de indivíduos residentes na cidade de Maringá-PR e submetidos à internação por Influenza A entre 2009 e 2010. RESULTADOS: No ano de 2009, ocorreram 614 internações decorrentes de infecção pelo vírus Influenza A em Maringá-PR. A disponibilização da vacina fez com que o número de acometidos diminuísse para 169 em 2010, ocorrendo impacto vacinal nos seguintes grupos populacionais: gestantes, portadores de doenças crônicas e adultos de 20 a 39 anos. CONCLUSÃO: Identificou-se a necessidade de estender a faixa etária de vacinação para crianças de 2 a 4 anos e preenchimento dos impressos de vacinação dos indivíduos e grupos vacinados com maior rigor.OBJETIVO: Analizar el perfil de los individuos afectados por el virus Influenza A (H1N1, y el impacto de las inmunizaciones en los grupos prioritarios a la vacunación. MÉTODOS: Estudio ecológico, observacional, de carácter retrospectivo, realizado con población de individuos residentes en la ciudad de Maringá-PR y sometidos a internamiento por Influenza A entre 2009 y 2010. RESULTADOS: En el año de 2009, ocurrieron 614 internamientos como consecuencia de infección por el virus Influenza A en Maringá-PR. La disponibilidad de la vacuna hizo con que el número de efectados disminuya a 169 en 2010, ocurriendo impacto de las inmunizaciones en los siguientes grupos poblacionales: gestantes, portadores de enfermedades crónicas y adultos de 20 a 39 años. CONCLUSIÓN: Se identificó la necesidad de extender el grupo etáreo de vacunación para niños de 2 a 4 años y el llenado con mayor rigor de los impresos de vacunación de los individuos y grupos vacunados.OBJECTIVE: To analyze the profile of the individuals affected by the Influenza A virus (H1N1

  3. Flublok Seasonal Influenza (Flu) Vaccination

    Science.gov (United States)

    ... Virus Testing Clinical Signs & Symptoms of Influenza Symptoms & Laboratory Diagnosis Information for Clinicians on Rapid Diagnostic Testing for ... Help: How do I view different file formats (PDF, DOC, PPT, MPEG) on this site? Adobe PDF ...

  4. Influenza Prevention: Information for Travelers

    Science.gov (United States)

    ... Virus Testing Clinical Signs & Symptoms of Influenza Symptoms & Laboratory Diagnosis Information for Clinicians on Rapid Diagnostic Testing for ... Help: How do I view different file formats (PDF, DOC, PPT, MPEG) on this site? Adobe PDF ...

  5. Influenza vaccinations and chemosensory function.

    Science.gov (United States)

    Doty, Richard L; Berman, Austin H; Izhar, Mohammad; Hamilton, Hugh B; Villano, Danylko; Vazquez, Britney E; Warrum, Maja N; Mahbob, Mariam

    2014-01-01

    Although influenza vaccines have saved millions of lives, some have been associated with extremely rare adverse effects such as Guillain-Barré syndrome, Bell's palsy, and optic neuritis. Despite the fact that olfactory loss after an influenza vaccination is noted in one case report, no quantitative olfactory testing was performed. Hence, it is unclear whether, in fact, olfactory dysfunction can be associated with such vaccinations. This study was designed to (1) identify patients from the University of Pennsylvania Smell and Taste Center who attributed their empirically determined chemosensory disturbances to influenza vaccinations and (2) determine whether influenza vaccinations add to the degree of olfactory or gustatory dysfunction due to other causes. A retrospective analysis of self-reported etiologies of 4554 consecutive patients presenting to the University of Pennsylvania Smell and Taste Center with complaints of chemosensory dysfunction was performed. Those who reported dysfunction secondary to influenza vaccinations were identified. Additionally, in a subset of 925 patients for whom detailed inoculation histories were available, it was determined whether the number of lifetime inoculations added to the deficits due to other causes. Nine of the 4554 patients (0.19%) attributed olfactory disturbances to an influenza vaccination. None complained of taste dysfunction. All nine had abnormally low scores on the University of Pennsylvania Smell Identification Test (p vaccinations and the chemosensory test scores. In accord with previous studies, age and sex were significantly related to the test scores. A very small percentage of the 4554 patients evaluated (0.19%) attributed their chemosensory dysfunction to a prior influenza vaccination. No influences of the number of lifetime influenza vaccinations on the test scores were evident in the subset of 925 patients whose dysfunction was due to other causes.

  6. Influenza in Bristol Bay, 1919

    OpenAIRE

    Maria Gilson deValpine

    2015-01-01

    The 1918 influenza pandemic has been blamed for as many as 50 million deaths worldwide. Like all major disasters, the full story of the pandemic includes smaller, less noted episodes that have not attracted historical attention. The story of the 1919 wave of the influenza pandemic in Bristol Bay Alaska is one such lost episode. It is an important story because the most accessible accounts—the Congressional Record and t...

  7. Characteristics of seasonal influenza A and B in Latin America: influenza surveillance data from ten countries.

    NARCIS (Netherlands)

    Caini, S.; Alonso, W.J.; Balmaseda, A.; Bruno, A.; Busto, P.; Castillo, L.; Lozano, C. de; Mora, D. de; Fasce, R. A.; Ferreira de Almeida, W.A.; Kusznierz, G.F.; Lara, J.; Matute, M.L.; Moreno, B.; Pessanha Henriques, C.M.; Rudi, J.M.; El-Guerche Séblain, C.; Schellevis, F.; Paget, J.

    2017-01-01

    Introduction: The increased availability of influenza surveillance data in recent years justifies an actual and more complete overview of influenza epidemiology in Latin America. We compared the influenza surveillance systems and assessed the epidemiology of influenza A and B, including the

  8. Influenza vaccines: an Asia-Pacific perspective.

    Science.gov (United States)

    Jennings, Lance C

    2013-11-01

    This article provides an overview of some aspects of seasonal, pre-pandemic and pandemic influenza vaccines and initiatives aimed to increase influenza vaccine use within the Asia-Pacific region. Expanding the use of influenza vaccines in the Asia-Pacific region faces many challenges. Despite the recent regional history for the emergence of novel viruses, SARS, the H5N1 and H7N9, and the generation of and global seeding of seasonal influenza viruses and initiatives by WHO and other organisations to expand influenza awareness, the use of seasonal influenza vaccines remains low. The improvement in current vaccine technologies with the licensing of quadrivalent, live-attenuated, cell culture-based, adjuvanted and the first recombinant influenza vaccine is an important step. The development of novel influenza vaccines able to provide improved protection and with improved manufacturing capacity is also advancing rapidly. However, of ongoing concern are seasonal influenza impact and the low use of seasonal influenza vaccines in the Asia-Pacific region. Improved influenza control strategies and their implementation in the region are needed. Initiatives by the World Health Organization (WHO), and specifically the Western Pacific Regional Office of WHO, are focusing on consistent vaccine policies and guidelines in countries in the region. The Asian-Pacific Alliance for the Control of Influenza (APACI) is contributing through the coordination of influenza advocacy initiates. © 2013 Blackwell Publishing Ltd.

  9. Meeting the challenge: prevention of pneumococcal disease with conjugate vaccines Al encuentro del reto: prevención de la enfermedad neumocócica con vacunas conjugadas

    Directory of Open Access Journals (Sweden)

    Irma Gabriela Echániz-Avilés

    2001-08-01

    Full Text Available Streptococcus pneumoniae is one of the leading causes of both invasive and noninvasive diseases in the pediatric population and continues to represent a significant public health burden worldwide. The increasing incidence of antibioticresistant strains of the pathogen has complicated treatment and management of the various pneumococcal disease manifestations. Thus, the best management strategy may be the prevention of pneumococcal diseases through vaccination. Although several pneumococcal conjugate vaccines have been clinically studied in infants and children, only a 7-valent conjugate vaccine (PNCRM7; Prevnar®/Prevenar® is currently approved for the prevention of invasive disease. Vaccination with PNCRM7 is safe and effective in infants and young children. Routine vaccination with the conjugate vaccine could improve outcomes by safeguarding against the development of antibiotic-resistant strains of S. pneumoniae, thus simplifying the management of pneumococcal disease. Additionally, the overall costs associated with the treatment of pneumococcal diseases could be substantially reduced, particularly in developing countries. The time has come for fully applying this new advancement against S. pneumoniae, to benefit the children of the world. The Spanish version of this paper is available at: http://www.insp.mx/salud/index.htmlStreptococcus pneumoniae es uno de los principales agentes causantes de enfermedades invasoras y no invasoras en la población pediátrica y sigue representando uno de los principales problemas de salud pública a nivel mundial. La incidencia creciente de cepas resistentes a diversos antimicrobianos ha complicado el tratamiento y manejo de varias de las manifestaciones de la enfermedad neumocócica. Con éstas consideraciones, la mejor estrategia de manejo es la prevención de éstas enfermedades a través de la vacunación. A pesar de que se han estudiado diversas vacunas neumocócicas conjugadas en niños, solo una

  10. Vacuna contra la fiebre hemorrágica argentina Candid#1 producida en la Argentina: Inmunogenicidad y seguridad Candid#1 vaccine against Argentine Hemorrhagic Fever produced in Argentina: Immunogenicity and safety

    Directory of Open Access Journals (Sweden)

    Delia A. Enria

    2010-06-01

    Full Text Available Se realizó un estudio clínico en 946 voluntarios humanos sanos, donde se comparó la vacuna Candid#1 producida en Argentina con la elaborada en EE.UU., que había sido utilizada en estudios previos. Como objetivo primario se evaluó la equivalencia en la eficacia utilizando como marcador subrogante a la inmunogenicidad medida por detección de anticuerpos neutralizantes. Como objetivo secundario se evaluó la equivalencia en inocuidad comparando las tasas de reacciones adversas. Ambas vacunas mostraron una tasa equivalente de inmunogenicidad ligeramente superior al 95.5%, que es la eficacia estimada para Candid #1 en estudios previos. No se observaron eventos adversos graves relacionados con la vacuna. Los eventos adversos generales considerados relacionados fueron de escasa significación clínica y de resolución espontánea o con tratamiento sintomático; se presentaron en los receptores de ambas vacunas en tasas equivalentes (29.9% para la vacuna fabricada en la Argentina y 35.0% para la fabricada en EE.UU., e incluyeron: cefalea, decaimiento, mialgias, plaquetopenia leve (A clinical study in 946 human volunteers was done to compare Candid #1 vaccine manufactured in Argentina with the vaccine produced in USA that had been previously used. The efficacy was evaluated using immunogenicity measured by the detection of neutralizing antibodies as a subrogate marker. Safety was evaluated comparing the rate of adverse events. Both vaccines showed a comparable rate of seroconversion, slighty higher than the efficacy estimated from previous studies (95.5%. There were no severe adverse events related to the vaccines. The general events considered related to the vaccines were not clinically relevant and disappeared either spontaneously or with symptomatic treatment. Similar rates of adverse events (29.9% for the Argentine vaccine and 35.0% for the USA vaccine were found for both vaccines. These included: headache, weakness, myalgias, mild low blood

  11. Cadena del frío para la conservación de las vacunas en los centros de atención primaria de un área de Madrid: mantenimiento y nivel de conocimientos

    Directory of Open Access Journals (Sweden)

    Ortega Molina Paloma

    2002-01-01

    Full Text Available Fundamento. Las vacunas son medicamentos termolábiles y para garantizar su inmunogenicidad y eficacia protectora, dentro de los programas de inmunización, es imprescindible mantener la cadena de frío. El elemento fundamental en esta cadena es el personal responsable de las vacunas, que debe conocer las características de estabilidad de cada preparado con el fin de evitar errores durante su manipulación. El objetivo de este trabajo fue conocer cómo se realiza el mantenimiento de la cadena del frío en equipos de atención primaria de un área sanitaria de la Comunidad Autónoma de Madrid, así como establecer el grado de información que poseen los responsables de las vacunas con respecto a la termoestabilidad de las mismas. Métodos. Se ha realizado un estudio transversal en 46 puntos de vacunación en atención primaria. La recogida de los datos se realizó mediante entrevista personal por un único investigador. Resultados. La tasa de participación fue del 93,5% (43/46. En todos los casos existía termómetro de máxima y mínima y registro mensual de la temperatura. Se observó una temperatura inadecuada en tres ocasiones (6,97%. El porcentaje de profesionales que conocía el efecto que la congelación producía sobre las vacunas fue muy diverso: 53.5%, 51.2%, 44.2% y 53.5% para difteria-tétanos-pertussis (DTP, hepatitis B (VHB, polio oral (VPO y rubéola-sarampión-paperas (RSP respectivamente. Y sólo el 32% conocía el test de agitación. Conclusión. La formación de los profesionales sobre el efecto que las altas temperaturas ocasionan en las vacunas era correcta, pero es necesario reforzar su formación sobre la inestabilidad que presentan los preparados adsorbidos cuando se someten a congelación.

  12. An AGM model for changes in complement during pregnancy: neutralization of influenza virus by serum is diminished in late third trimester.

    Directory of Open Access Journals (Sweden)

    Anne E Mayer

    Full Text Available Pregnant women in the third trimester are at increased risk of severe influenza disease relative to the general population, though mechanisms behind this are not completely understood. The immune response to influenza infection employs both complement (C' and antibody (Ab. The relative contributions of these components to the anti-viral response are difficult to dissect because most humans have pre-existing influenza-specific Abs. We developed the African green monkey (AGM as a tractable nonhuman primate model to study changes in systemic innate immunity to influenza during pregnancy. Because the AGMs were influenza-naïve, we were able to examine the role of C' in influenza virus neutralization using serum from non-pregnant animals before and after influenza infection. We determined that serum from naïve AGMs neutralized influenza via C', while post-infection neutralization did not require C', suggesting an Ab-mediated mechanism. The latter mimicked neutralization using human serum. Further, we found that ex vivo neutralization of influenza with both naïve and influenza-immune AGM serum occurred by virus particle aggregation and lysis, with immune serum lysing virus at a much higher rate than naïve serum. We hypothesized that the anti-influenza C' response would diminish late in AGM pregnancy, corresponding with the time when pregnant women suffer increased influenza severity. We found that influenza neutralization capacity is significantly diminished in serum collected late in the third trimester. Strikingly, we found that circulating levels of C3, C3a, and C4 are diminished late in gestation relative to nonpregnant animals, and while neutralization capacity and serum C3a return to normal shortly after parturition, C3 and C4 levels do not. This AGM model system will enable further studies of the role of physiologic and hormonal changes in downregulating C'-mediated anti-viral immunity during pregnancy, and it will permit the identification

  13. An AGM model for changes in complement during pregnancy: neutralization of influenza virus by serum is diminished in late third trimester.

    Science.gov (United States)

    Mayer, Anne E; Parks, Griffith D

    2014-01-01

    Pregnant women in the third trimester are at increased risk of severe influenza disease relative to the general population, though mechanisms behind this are not completely understood. The immune response to influenza infection employs both complement (C') and antibody (Ab). The relative contributions of these components to the anti-viral response are difficult to dissect because most humans have pre-existing influenza-specific Abs. We developed the African green monkey (AGM) as a tractable nonhuman primate model to study changes in systemic innate immunity to influenza during pregnancy. Because the AGMs were influenza-naïve, we were able to examine the role of C' in influenza virus neutralization using serum from non-pregnant animals before and after influenza infection. We determined that serum from naïve AGMs neutralized influenza via C', while post-infection neutralization did not require C', suggesting an Ab-mediated mechanism. The latter mimicked neutralization using human serum. Further, we found that ex vivo neutralization of influenza with both naïve and influenza-immune AGM serum occurred by virus particle aggregation and lysis, with immune serum lysing virus at a much higher rate than naïve serum. We hypothesized that the anti-influenza C' response would diminish late in AGM pregnancy, corresponding with the time when pregnant women suffer increased influenza severity. We found that influenza neutralization capacity is significantly diminished in serum collected late in the third trimester. Strikingly, we found that circulating levels of C3, C3a, and C4 are diminished late in gestation relative to nonpregnant animals, and while neutralization capacity and serum C3a return to normal shortly after parturition, C3 and C4 levels do not. This AGM model system will enable further studies of the role of physiologic and hormonal changes in downregulating C'-mediated anti-viral immunity during pregnancy, and it will permit the identification of therapeutic

  14. Crosstalk between animal and human influenza viruses

    Science.gov (United States)

    Ozawa, Makoto; Kawaoka, Yoshihiro

    2017-01-01

    Although outbreaks of highly pathogenic avian influenza in wild and domestic birds have been posing the threat of a new influenza pandemic for the last decade, the first pandemic of the 21st century came from swine viruses. This fact emphasizes the complexity of influenza viral ecology and the difficulty of predicting influenza viral dynamics. Complete control of influenza viruses seems impossible. However, we must minimize the impact of animal and human influenza outbreaks by learning lessons from past experiences and recognizing the current status. Here, we review the most recent influenza virology data in the veterinary field, including aspects of zoonotic agents and recent studies that assessed the pandemic potential of H5N1 highly pathogenic avian influenza viruses. PMID:25387011

  15. Influenza Virus Infection of Marine Mammals.

    Science.gov (United States)

    Fereidouni, Sasan; Munoz, Olga; Von Dobschuetz, Sophie; De Nardi, Marco

    2016-03-01

    Interspecies transmission may play a key role in the evolution and ecology of influenza A viruses. The importance of marine mammals as hosts or carriers of potential zoonotic pathogens such as highly pathogenic H5 and H7 influenza viruses is not well understood. The fact that influenza viruses are some of the few zoonotic pathogens known to have caused infection in marine mammals, evidence for direct transmission of influenza A virus H7N7 subtype from seals to man, transmission of pandemic H1N1 influenza viruses to seals and also limited evidence for long-term persistence of influenza B viruses in seal populations without significant genetic change, makes monitoring of influenza viruses in marine mammal populations worth being performed. In addition, such monitoring studies could be a great tool to better understand the ecology of influenza viruses in nature.

  16. Swine Influenza (Swine Flu) in Pigs

    Science.gov (United States)

    ... Variant Other Key Facts about Swine Influenza (Swine Flu) in Pigs Language: English (US) Español Recommend on ... similar to outbreaks in humans. How many swine flu viruses are there? Like influenza viruses in humans ...

  17. Immune response to influenza vaccine in hemodialysis patients with chronic renal failure.

    Science.gov (United States)

    Mastalerz-Migas, Agnieszka; Steciwko, Andrzej; Brydak, Lidia B

    2013-01-01

    Chronic renal failure and dialysis belong to contraindications to vaccination with live vaccines. The objective of this study was to evaluate the humoral response to influenza vaccination consisting of the formation of antibodies against hemagglutinin and neuraminidase in patients undergoing chronic hemodialysis due to chronic renal failure. The study included 173 patients treated at a dialysis station in the Silesian region in Poland. The patients were assigned to the following groups: Group A-71 hemodialysis patients, mean age 65.4 ± 14.5 years; mean time of dialysis therapy 38.9 ± 31.7 months, vaccinated against influenza; Group B-39 hemodialysis patients, mean age 64 ± 13.5 years; mean time of dialysis therapy 45.0 ± 45.2 months, not vaccinated against influenza; and Group C-63 healthy patients, mean age 44.1 ± 21.2 years, vaccinated against influenza - control group. The vaccinated patients (Groups A & C) received a single dose of Agrippal influenza vaccine (Novartis) containing hemagglutinin from three strains of the influenza virus: A/Brisbane/59/2007 (H1N1), A/Brisbane/10/2007 (H3N2), and B/Brisbane/60/2008. The serological response to vaccination was assessed from antihemagglutinin (anti-HA) and antineuraminidase antibody assays (anti-NA). We found that the protection level of antibodies (protection rate) against H1 was only 40% among the vaccinated hemodialysis patients, as opposed to 65% in controls. The level of anti-H3 antibodies was similar in both groups of vaccines; 68% in dialysis patients and 75% in controls. The level of anti-HB antibodies was higher in the dialysis patient than in controls; 70% vs. 38%, respectively. The response rate to H1 antigen a month after vaccination was almost twice lower in the hemodialysis patients than in healthy controls vaccinated against influenza; 37% vs. 65%, respectively. We conclude that there is a rather insufficient serological response in the group of hemodialysis patients vaccinated with a single dose

  18. Influenza A virus infection of intestinal epithelial cells enhances the adhesion ability of Crohn's disease associated Escherichia coli strains.

    Science.gov (United States)

    Aleandri, Marta; Conte, Maria Pia; Simonetti, Giovanna; Panella, Simona; Celestino, Ignacio; Checconi, Paola; Marazzato, Massimiliano; Longhi, Catia; Goldoni, Paola; Nicoletti, Mauro; Barnich, Nicolas; Palamara, Anna Teresa; Schippa, Serena; Nencioni, Lucia

    2015-01-01

    Modifications of intestinal glycoreceptors expression, in particular CEACAM6, typically found in ileal Crohn's disease (CD), favor, among the commensal species of microbiota, the enrichment in Escherichia coli. Removal of protein glycosidic residues by neuraminidase, a sialidase typical of influenza virus, increases adhesion ability of Escherichia coli to Caco-2 intestinal cells. In this study we investigated whether influenza virus infection of human intestinal epithelial cells could influence the adhesiveness of different Escherichia coli strains isolated from CD patients by altering surface glycoreceptors. Influenza virus infection of intestinal cells increased exposure of galactose and mannose residues on the cell surface. In particular, glycoreceptors Thomsen-Friedenreich and CEACAM6 were over-expressed in influenza virus infected cells. In the same experimental conditions, a significant increase in bacterial adhesiveness was observed, independently of their own adhesive ability. The increase was reverted by treatment with anti-TF and anti-CEACAM6 antibodies. Interestingly, influenza virus was able to efficiently replicate in human primary intestinal cells leading to TF exposure. Finally, intestinal infected cells produced high levels of pro-inflammatory cytokines compared to control. Overall these data suggest that influenza virus infection, could constitute an additional risk factor in CD patients.

  19. Estrogen mediates innate and adaptive immune alterations to influenza infection in pregnant mice.

    Directory of Open Access Journals (Sweden)

    Michael A Pazos

    Full Text Available Pregnancy is a leading risk factor for severe complications during an influenza virus infection. Women infected during their second and third trimesters are at increased risk for severe cardiopulmonary complications, premature delivery, and death. Here, we establish a murine model of aerosolized influenza infection during pregnancy. We find significantly altered innate antiviral responses in pregnant mice, including decreased levels of IFN-β, IL-1α, and IFN-γ at early time points of infection. We also find reduced cytotoxic T cell activity and delayed viral clearance. We further demonstrate that pregnancy levels of the estrogen 17-β-estradiol are able to induce key anti-inflammatory phenotypes in immune responses to the virus independently of other hormones or pregnancy-related stressors. We conclude that elevated estrogen levels result in an attenuated anti-viral immune response, and that pregnancy-associated morbidities occur in the context of this anti-inflammatory phenotype.

  20. Fully human broadly neutralizing monoclonal antibodies against influenza A viruses generated from the memory B cells of a 2009 pandemic H1N1 influenza vaccine recipient

    Energy Technology Data Exchange (ETDEWEB)

    Hu, Weibin [Molecular Virus Unit, Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200025 (China); Chen, Aizhong [Key Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031 (China); Miao, Yi [Shanghai Xuhui Central Hospital, Shanghai 200031 (China); Xia, Shengli [Center for Disease Control and Prevention of Henan Province, Zhengzhou 450016 (China); Ling, Zhiyang; Xu, Ke; Wang, Tongyan [Molecular Virus Unit, Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200025 (China); Xu, Ying; Cui, Jun; Wu, Hongqiang; Hu, Guiyu; Tian, Lin; Wang, Lingling [Key Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031 (China); Shu, Yuelong [Chinese Center for Disease Control and Prevention, Beijing 102206 (China); Ma, Xiaowei [Hualan Biological Bacterin Company, Xinxiang 453003 (China); Xu, Bianli; Zhang, Jin [Center for Disease Control and Prevention of Henan Province, Zhengzhou 450016 (China); Lin, Xiaojun, E-mail: linxiaojun@hualan.com [Hualan Biological Bacterin Company, Xinxiang 453003 (China); Bian, Chao, E-mail: cbian@sibs.ac.cn [Key Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031 (China); Sun, Bing, E-mail: bsun@sibs.ac.cn [Molecular Virus Unit, Key Laboratory of Molecular Virology and Immunology, Institut Pasteur of Shanghai, Chinese Academy of Sciences, Shanghai 200025 (China); Key Laboratory of Molecular Cell Biology, Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031 (China)

    2013-01-20

    Whether the 2009 pandemic H1N1 influenza vaccine can induce heterosubtypic cross-protective anti-hemagglutinin (HA) neutralizing antibodies is an important issue. We obtained a panel of fully human monoclonal antibodies from the memory B cells of a 2009 pandemic H1N1 influenza vaccine recipient. Most of the monoclonal antibodies targeted the HA protein but not the HA1 fragment. Among the analyzed antibodies, seven mAbs exhibited neutralizing activity against several influenza A viruses of different subtypes. The conserved linear epitope targeted by the neutralizing mAbs (FIEGGWTGMVDGWYGYHH) is part of the fusion peptide on HA2. Our work suggests that a heterosubtypic neutralizing antibody response primarily targeting the HA stem region exists in recipients of the 2009 pandemic H1N1 influenza vaccine. The HA stem region contains various conserved neutralizing epitopes with the fusion peptide as an important one. This work may aid in the design of a universal influenza A virus vaccine.

  1. Comportamiento reactogénico de la vacuna cubana contra la hepatitis B en niños física y mentalmente discapacitados

    Directory of Open Access Journals (Sweden)

    Plácido Pedroso Flaquet

    2000-10-01

    Full Text Available Se estudió la reactogenicidad de la vacuna recombinante cubana contra el virus de la hepatitis B, derivada de células de levadura (Heberbiovac-HB, al aplicar dosis de 5 y 10 mg y emplear el esquema de inmunización 0, una segunda dosis al mes y la tercera a los 6 meses a 2 grupos de niños física y mentalmente discapacitados de 5 a 14 años de edad. Los síntomas observados en el total de la población estudiada fueron de 5,1 %, mientras que en los grupos vacunados con 10 y 5 mg, la sintomatología fue de 4,8 y 5,4 % respectivamente; sin que se encontraran diferencias significativas en los síntomas postvacunales entre los grupos de estudio. El signo predominante fue la febrícula con el 84,9 % de las observaciones positivas encontradas. En nuestro estudio se constató la baja reactogenicidad de la vacuna Heberbiovac-HB, lo que la hizo segura y recomendable para la protección contra el virus de la hepatitis B en los grupos de niños impedidos físicos y mentales estudiadosThe reactogenecity of the Cuban recombinant yeast-derived hepatitis B vaccine (Heberbiovac-HB was studied on administering doses of 5 and 10 mg and using the immunization scheme 0 in 2 groups of physical and mentally disabled children aged 5-14. The second dose was given at a month and the third one at 6 months. The symptoms observed in the whole population under study were 5,1 %, whereas in the groups vaccinated with 5 and 10 mg, the symptomatology was 4,8 and 5,4 %, respectively. No significant differences were observed in the postvaccinal symptoms between the studied groups. The predominant sign was low-grade fever with 84,9 % of the positive observations found. In our study, it was confirmed the low reactogenecity of the Heberbiovac-HB vaccine, which makes it safe and recommendable for the protection against the hepatitis B virus in the groups of physical and mentally disabled children that were studied

  2. Introducción de un ELISA como ensayo alternativo en la determinación de la potencia de vacunas antitetánicas

    Directory of Open Access Journals (Sweden)

    Juan Carlos Ramírez

    2005-05-01

    Full Text Available Por más de medio siglo de uso, la vacunación con el toxoide tetánico ha mostrado un elevado porcentaje de eficacia en la prevención del tétanos. Este trabajo pretende introducir un ensayo inmunoenzimático en fase sólida (ELISA como método alternativo a la prueba de seroneutralización in vivo utilizada en la evaluación de la potencia de las vacunas antitetánicas.Se desarrolló un ELISA de tipo indirecto para la cuantificación de antitoxina tetánica en suero de curiel a partir de un estándar con 29 UI/mL, previamente calibrado. Se determinó la precisión, exactitud y linealidad del ensayo. Se analizó la correlación entre el ELISA y la prueba biológica mediante la evaluación de un total de 75 muestras de sueros por ambos métodos. Por último, se estudió la respuesta individual de un grupo de animales contra 15 lotes de toxoide tetánico. El ensayo demostró ser preciso y exacto, con imprecisiones inferiores al 20% y valores de recuperación entre el 90–110%. Las desviaciones del paralelismo mostraron coeficientes de variación alrededor del 10%. El análisis por regresión lineal mostró una buena correlación entre el ELISA y el ensayo biológico (R2= 0,989. El método alternativo desarrollado probó ser una herramienta útil para la determinación de la potencia de vacunas antitetánicas a partir de la evaluación independiente de la respuesta de cada animal contra el toxoide tetánico.Los niveles de seroprotección alcanzados se encontraron entre el 83–100%.

  3. Costo-utilidad de la vacuna contra el virus de papiloma humano en mujeres peruanas Cost- utility of the vaccine against the human papiloma virus in peruvian women

    Directory of Open Access Journals (Sweden)

    Alfonso Gutiérrez-Aguado

    2011-09-01

    Full Text Available Objetivos. Estimar el costo-utilidad de la vacuna contra el Virus de Papiloma Humano (VPH en las mujeres peruanas luego de la aplicación de la vacuna cuando tenían 10 años de edad. Materiales y métodos. Se realizó un análisis de costo-utilidad empleando el modelo oculto de Markov en una cohorte hipotética de mujeres peruanas, basado en la información de parámetros epidemiológicos, costos asociados al Cáncer de cuello uterino (CCU y la eficacia y los costos de la vacunación contra el VPH. Los costos de la vacunación se estimaron desde la perspectiva del Ministerio de Salud de Perú y se compararon con los años de vida ajustados por calidad (AVAC utilizando una tasa de descuento del 5 %. Resultados. El costo anual de la vacunación fue de USD 16 861 490, para el tamizaje con Papanicolau fue de USD 3 060 793 y los costos asociados al CCU fueron de USD 15 580 000. La razón de costo-utilidad incremental (RCUI fue de 6775 USD/AVAC. Conclusiones. La vacunación contra el VPH puede resultar costo-útil comparada con el no vacunar.Objetives. To estimate the cost-utility of the vaccine against the Human Papiloma Virus (HPV in peruvian women after the application of the vaccine at 10 years of age. Materials and methods. A cost-utility analysis was performed using the Markov´s hidden model in a hypothetical cohort of peruvian women, based on the information on epidemiological parameters, costs associated to uterine cervical cancer (UCC and the efficacy and costs of the vaccine against the HPV. The vaccination costs were estimated from the Peruvian Ministry of Health perspective and were compared against the quality-adjusted life years (QALYs, using a discount rate of 5%. Results. The annual cost of the vaccination was USD 16’861,490, for the Papanicoau screening it was USD 3’060,793 and the costs associated to the UCC were USD 15’580,000. The incremental cost utility ratio (ICUR was 6,775 USD/QALY. Conclusions. Vaccination against HPV

  4. Economic impact of pneumococcal conjugate vaccination in Brazil, Chile, and Uruguay Impacto económico de la vacuna antineumocócica conjugada en Brasil, Chile y Uruguay

    Directory of Open Access Journals (Sweden)

    Dagna O. Constenla

    2008-08-01

    Full Text Available OBJECTIVES: To evaluate the economic impact of vaccination with the pneumococcal 7-valent conjugate vaccine (PCV7 in Brazil, Chile, and Uruguay. METHODS: A decision analytic model was constructed to compare pneumococcal vaccination of children 0-5 years old with no vaccination in Brazil, Chile, and Uruguay. Costs and health outcomes were analyzed from the societal perspective. Vaccine, demographic, epidemiologic, and cost data were incorporated into this economic analysis. RESULTS: At the rate of diphtheria-tetanus-pertussis (DTP vaccine coverage and a vaccine price of US$ 53 per dose, PCV7 was projected to prevent 23 474 deaths per year in children under 5 years old in the three countries studied, thus averting 884 841 disability-adjusted life years (DALYs yearly. To vaccinate the entire birth cohort of the three countries, total vaccine costs would be US$ 613.9 million. At US$ 53 per dose, the cost per DALY averted from a societal perspective would range from US$ 664 (Brazil to US$ 2 019 (Chile. At a cost of US$ 10 per dose, vaccine cost is lower than the overall cost of illness averted (US$ 125 050 497 versus US$ 153 965 333, making it cost effective and cost-saving. CONCLUSIONS: The results of this study demonstrate that the incorporation of PCV7 vaccine at US$ 53 per dose confers health benefits at extra costs. It is unclear whether vaccination at the current price is affordable to these countries.OBJETIVOS: Evaluar el impacto económico de la aplicación de la vacuna antineumocócica conjugada heptavalente (PCV7 en Brasil, Chile y Uruguay. MÉTODOS: Se elaboró un modelo analítico de decisiones para comparar la vacunación antineumocócica de los niños de 0-5 años de edad con la no vacunación, en Brasil, Chile y Uruguay. Los costos y los desenlaces para la salud se analizaron desde el punto de vista de la sociedad. Al análisis económico se incorporaron los costos y los datos demográficos, epidemiológicos y de la vacuna. RESULTADOS

  5. Influenza antivirals currently in late?phase clinical trial

    OpenAIRE

    Koszalka, Paulina; Tilmanis, Danielle; Hurt, Aeron C.

    2017-01-01

    Influenza antiviral drugs are important for the control of influenza, most specifically for the treatment of influenza patients with severe disease following infection with a seasonal influenza virus, a newly emerging influenza strain, or in the event of a pandemic. Many influenza antivirals that are currently under investigation in late?stage clinical trials differ in their mechanism of action compared to drugs currently licensed for the treatment of influenza. Nitazoxanide and DAS181 target...

  6. Lysosome-associated membrane glycoprotein 3 is involved in influenza A virus replication in human lung epithelial (A549 cells

    Directory of Open Access Journals (Sweden)

    Wang Jianwei

    2011-08-01

    Full Text Available Abstract Background Influenza A virus mutates rapidly, rendering antiviral therapies and vaccines directed against virus-encoded targets ineffective. Knowledge of the host factors and molecular pathways exploited by influenza virus will provide further targets for novel antiviral strategies. However, the critical host factors involved in influenza virus infection have not been fully defined. Results We demonstrated that LAMP3, a member of lysosome-associated membrane glycoprotein (LAMP family, was significantly induced in human lung epithelial (A549 cells upon influenza A virus infection. Knockdown of LAMP3 expression by RNA interference attenuated production of viral nucleoprotein (NP as well as virus titers. Confocal microscopy results demonstrated that viral NP is colocalized within LAMP3 positive vesicles at early stages of virus infection. Furthermore, knockdown of LAMP3 expression led to a reduction in nuclear accumulation of viral NP and impeded virus replication. Conclusions LAMP3 is an influenza A virus inducible gene, and plays an important role in viral post-entry steps. Our observations may provide insights into the mechanism of influenza virus replication and potential targets for novel anti-influenza therapeutics.

  7. Adenovirus-vectored drug-vaccine duo as a rapid-response tool for conferring seamless protection against influenza.

    Directory of Open Access Journals (Sweden)

    Jianfeng Zhang

    Full Text Available Few other diseases exert such a huge toll of suffering as influenza. We report here that intranasal (i.n. administration of E1/E3-defective (ΔE1E3 adenovirus serotype 5 (Ad5 particles rapidly induced an anti-influenza state as a means of prophylactic therapy which persisted for several weeks in mice. By encoding an influenza virus (IFV hemagglutinin (HA HA1 domain, an Ad5-HA1 vector conferred rapid protection as a prophylactic drug followed by elicitation of sustained protective immunity as a vaccine for inducing seamless protection against influenza as a drug-vaccine duo (DVD in a single package. Since Ad5 particles induce a complex web of host responses, which could arrest influenza by activating a specific arm of innate immunity to impede IFV growth in the airway, it is conceivable that this multi-pronged influenza DVD may escape the fate of drug resistance that impairs the current influenza drugs.

  8. Protection from the 2009 H1N1 pandemic influenza by an antibody from combinatorial survivor-based libraries.

    Directory of Open Access Journals (Sweden)

    Arun K Kashyap

    2010-07-01

    Full Text Available Influenza viruses elude immune responses and antiviral chemotherapeutics through genetic drift and reassortment. As a result, the development of new strategies that attack a highly conserved viral function to prevent and/or treat influenza infection is being pursued. Such novel broadly acting antiviral therapies would be less susceptible to virus escape and provide a long lasting solution to the evolving virus challenge. Here we report the in vitro and in vivo activity of a human monoclonal antibody (A06 against two isolates of the 2009 H1N1 pandemic influenza virus. This antibody, which was obtained from a combinatorial library derived from a survivor of highly pathogenic H5N1 infection, neutralizes H5N1, seasonal H1N1 and 2009 "Swine" H1N1 pandemic influenza in vitro with similar potency and is capable of preventing and treating 2009 H1N1 influenza infection in murine models of disease. These results demonstrate broad activity of the A06 antibody and its utility as an anti-influenza treatment option, even against newly evolved influenza strains to which there is limited immunity in the general population.

  9. Characterization of influenza vaccine immunogenicity using influenza antigen microarrays.

    Directory of Open Access Journals (Sweden)

    Jordan V Price

    Full Text Available Existing methods to measure influenza vaccine immunogenicity prohibit detailed analysis of epitope determinants recognized by immunoglobulins. The development of highly multiplex proteomics platforms capable of capturing a high level of antibody binding information will enable researchers and clinicians to generate rapid and meaningful readouts of influenza-specific antibody reactivity.We developed influenza hemagglutinin (HA whole-protein and peptide microarrays and validated that the arrays allow detection of specific antibody reactivity across a broad dynamic range using commercially available antibodies targeted to linear and conformational HA epitopes. We derived serum from blood draws taken from 76 young and elderly subjects immediately before and 28±7 days post-vaccination with the 2008/2009 trivalent influenza vaccine and determined the antibody reactivity of these sera to influenza array antigens.Using linear regression and correcting for multiple hypothesis testing by the Benjamini and Hochberg method of permutations over 1000 resamplings, we identified antibody reactivity to influenza whole-protein and peptide array features that correlated significantly with age, H1N1, and B-strain post-vaccine titer as assessed through a standard microneutralization assay (p<0.05, q <0.2. Notably, we identified several peptide epitopes that were inversely correlated with regard to age and seasonal H1N1 and B-strain neutralization titer (p<0.05, q <0.2, implicating reactivity to these epitopes in age-related defects in response to H1N1 influenza. We also employed multivariate linear regression with cross-validation to build models based on age and pre-vaccine peptide reactivity that predicted vaccine-induced neutralization of seasonal H1N1 and H3N2 influenza strains with a high level of accuracy (84.7% and 74.0%, respectively.Our methods provide powerful tools for rapid and accurate measurement of broad antibody-based immune responses to influenza

  10. Influenza and risk of later celiac disease

    DEFF Research Database (Denmark)

    Kårhus, Line Lund; Gunnes, Nina; Størdal, Ketil

    2018-01-01

    OBJECTIVES: Influenza has been linked to autoimmune conditions, but its relationship to subsequent celiac disease (CD) is unknown. Our primary aim was to determine the risk of CD after influenza. A secondary analysis examined the risk of CD following pandemic influenza vaccination. METHODS...

  11. VIRUSES ASSOCIATED WITH HUMAN AND ANIMAL INFLUENZA ...

    African Journals Online (AJOL)

    DR. AMINU

    in humans, dogs, horses and pigs; populations of camels, ferrets, cats, seals, mink and whales also show evidence ... flu, Horse Flu and Dog flu. Influenza virus A. This genus has one species, influenza A virus ..... Hay, A., Gregory, V., Douglas, A., and Lin, Y. (2001). “The evolution of human influenza viruses” Philos Trans R.

  12. 77 FR 34783 - Highly Pathogenic Avian Influenza

    Science.gov (United States)

    2012-06-12

    ... Avian Influenza AGENCY: Animal and Plant Health Inspection Service, USDA. ACTION: Interim rule... importation of bird and poultry products from regions where any subtype of highly pathogenic avian influenza... avian influenza (HPAI). On January 24, 2011, we published in the Federal Register (76 FR 4046-4056...

  13. 76 FR 24793 - Highly Pathogenic Avian Influenza

    Science.gov (United States)

    2011-05-03

    ... Inspection Service 9 CFR Parts 93, 94, and 95 RIN 0579-AC36 Highly Pathogenic Avian Influenza AGENCY: Animal... products from regions where any subtype of highly pathogenic avian influenza is considered to exist. The... vaccinated for certain types of avian influenza, or that have moved through regions where any subtype of...

  14. History and evolution of influenza vaccines.

    Science.gov (United States)

    Crovari, P; Alberti, M; Alicino, C

    2011-09-01

    Since the isolation of influenza virus in 1933, a great deal of work was carried out in order to develop influenza vaccines and improve these fundamental tools of prevention in terms of production, quality control, safety and tolerability, and immunogenicity. The paper summarizes the cornerstones of the continuous evolution of influenza vaccines and the most recent and promising developments in this field.

  15. Pandemic swine influenza virus: Preparedness planning | Ojogba ...

    African Journals Online (AJOL)

    The novel H1N1 influenza virus that emerged in humans in Mexico in early 2009 and transmitted efficiently in the human population with global spread was declared a pandemic strain. The introduction of different avian and human influenza virus genes into swine influenza viruses often result in viruses of increased fitness ...

  16. Influenza Vaccination in Community Dwelling Elderly Persons

    NARCIS (Netherlands)

    A.C.G. Voordouw (Bettie)

    2005-01-01

    textabstractAn influenza epidemic was first described in 1173, although there are reports of influenza as early as 412 BC. Recurrent epidemics and incidental pandemics caused by influenza virus are documented since the last 400 years. These were based upon clinical observation and epidemiology.

  17. Influenza: prevention, prophylaxis and treatment | Jones | South ...

    African Journals Online (AJOL)

    Influenza spreads rapidly to affect 515% of the global population on an annual basis. It is estimated that influenza causes between three and five million cases of severe illness and between a quarter and half a million deaths every year. In South Africa during the period from 1997 to 2001, influenza and pneumonia ...

  18. Antibody Responses with Fc-Mediated Functions after Vaccination of HIV-Infected Subjects with Trivalent Influenza Vaccine

    DEFF Research Database (Denmark)

    Kristensen, Anne B; Lay, William N; Ana-Sosa-Batiz, Fernanda

    2016-01-01

    This study seeks to assess the ability of seasonal trivalent inactivated influenza vaccine (TIV) to induce nonneutralizing antibodies (Abs) with Fc-mediated functions in HIV-uninfected and HIV-infected subjects. Functional influenza-specific Ab responses were studied in 30 HIV-negative and 27 HIV......-positive subjects immunized against seasonal influenza. All 57 subjects received the 2015 TIV. Fc-mediated antihemagglutinin (anti-HA) Ab activity was measured in plasma before and 4 weeks after vaccination using Fc-receptor-binding assays, NK cell activation assays, and phagocytosis assays. At baseline, the HIV......-positive group had detectable but reduced functional Ab responses to both vaccine and nonvaccine influenza antigens. TIV enhanced Fc-mediated Ab responses in both HIV-positive and HIV-negative groups. A larger rise was generally observed in the HIV-positive group, such that there was no difference in functional...

  19. Soluble Host Defense Lectins in Innate Immunity to Influenza Virus

    Science.gov (United States)

    Ng, Wy Ching; Tate, Michelle D.; Brooks, Andrew G.; Reading, Patrick C.

    2012-01-01

    Host defenses against viral infections depend on a complex interplay of innate (nonspecific) and adaptive (specific) components. In the early stages of infection, innate mechanisms represent the main line of host defense, acting to limit the spread of virus in host tissues prior to the induction of the adaptive immune response. Serum and lung fluids contain a range of lectins capable of recognizing and destroying influenza A viruses (IAV). Herein, we review the mechanisms by which soluble endogenous lectins mediate anti-IAV activity, including their role in modulating IAV-induced inflammation and disease and their potential as prophylactic and/or therapeutic treatments during severe IAV-induced disease. PMID:22665991

  20. Seasonal Influenza Epidemics and El Ninos

    Directory of Open Access Journals (Sweden)

    Olusegun Steven Ayodele Oluwole

    2015-11-01

    Full Text Available Seasonal influenza epidemics occur annually during the winter in the north and south hemispheres, but timing of peaks and severity vary seasonally. Low humidity, which enhances survival and transmission of influenza virus, is the major risk factor. Both El Nino and La Nina phases of El Nino-southern oscillation (ENSO, which determine inter-annual variation of precipitation, are putative risk factors. This study was done to determine if seasonality, timing of peak, and severity of influenza epidemics are coupled to phases of ENSO. Monthly time series of positive specimens for influenza viruses and of multivariate El Nino-Southern Oscillation Index from January 2000 to August 2015 were analyzed. Seasonality, wavelet spectra, and cross wavelet spectra analyses were performed. Of 31 countries in the dataset, 21 were in north hemisphere and 10 in south hemisphere. Highest number of influenza occurred in January in the north hemisphere, but in July in the south hemisphere, p < 0.0001. Seasonal influenza epidemic was coupled to El Nino, while low occurrence was coupled to La Nina. The moderate La Nina of 2010–2011 was followed by weak seasonal influenza epidemic. The influenza pandemic of 2009–2010 followed the moderate El Nino of 2009–2010, which had three peaks. Spectrograms showed time varying periodicities of 6–48 months for ENSO, 6–24 months for north hemisphere influenza, and 6–12 months for south hemisphere influenza. Cross spectrograms showed time varying periodicities at 6–36 months for ENSO and influenza in both hemispheres, p < 0.0001. Phase plots showed that influenza time series lagged ENSO in both hemispheres. Severity of seasonal influenza increases during El Nino, but decreases during La Nina. Coupling of seasonality, timing, and severity of influenza epidemics to the strength and waveform of ENSO indicate that forecast models of El Nino should be integrated into surveillance programmes for influenza epidemics.

  1. Impacto de la vacunación contra Haemophilus influenzae tipo b en Cuba

    Directory of Open Access Journals (Sweden)

    Dickinson Félix O.

    2001-01-01

    Full Text Available Objetivo. Determinar el impacto de la vacunación de menores de 2 años en Cuba contra Haemophilus influenzae tipo b (Hib, principal agente causal de la meningitis bacteriana en ese país. Métodos. La disponibilidad de vacunas conjugadas eficaces contra Hib motivó la vacunación nacional en 1999 de niños menores de 2 años, que alcanzó una cobertura de 97%. El impacto se evaluó mediante el Sistema Nacional de Vigilancia de Meningoencefalitis Bacterianas (SNVMEB. Resultados. La eficacia global de la vacunación se estimó en 99% y la incidencia general de la meningoencefalitis por Hib disminuyó de 1,3 a 0,6 por 100 000 habitantes (46,1%, observándose la mayor reducción en niños menores de 5 años (56,1%. En los menores de 1 año se redujo 70,5% y en el resto de los grupos de menores de 5 años disminuyó entre 25,9 y 49,6%. En el grupo diana para la vacunación, la incidencia se redujo 61,1%; entre los niños de este grupo que contrajeron la meningoencefalitis por Hib, solamente 8 (24,2% estaban vacunados, 7 de ellos con una sola dosis, aplicada 1 mes antes de enfermar. Conclusiones. Se ha demostrado que la vacunación a gran escala de los niños menores de 2 años contra Hib en Cuba a través del SNVMEB ha logrado disminuir notablemente la incidencia de meningoencefalitis por Hib.

  2. Traditional and New Influenza Vaccines

    Science.gov (United States)

    Wong, Sook-San

    2013-01-01

    SUMMARY The challenges in successful vaccination against influenza using conventional approaches lie in their variable efficacy in different age populations, the antigenic variability of the circulating virus, and the production and manufacturing limitations to ensure safe, timely, and adequate supply of vaccine. The conventional influenza vaccine platform is based on stimulating immunity against the major neutralizing antibody target, hemagglutinin (HA), by virus attenuation or inactivation. Improvements to this conventional system have focused primarily on improving production and immunogenicity. Cell culture, reverse genetics, and baculovirus expression technology allow for safe and scalable production, while adjuvants, dose variation, and alternate routes of delivery aim to improve vaccine immunogenicity. Fundamentally different approaches that are currently under development hope to signal new generations of influenza vaccines. Such approaches target nonvariable regions of antigenic proteins, with the idea of stimulating cross-protective antibodies and thus creating a “universal” influenza vaccine. While such approaches have obvious benefits, there are many hurdles yet to clear. Here, we discuss the process and challenges of the current influenza vaccine platform as well as new approaches that are being investigated based on the same antigenic target and newer technologies based on different antigenic targets. PMID:23824369

  3. Effective influenza vaccines for children

    Science.gov (United States)

    Banzhoff, Angelika; Stoddard, Jeffrey J.

    2012-01-01

    Seasonal influenza causes clinical illness and hospitalization in all age groups; however, conventional inactivated vaccines have only limited efficacy in young children. MF59®, an oil-in-water emulsion adjuvant, has been used since the 1990s to enhance the immunogenicity of influenza vaccines in the elderly, a population with waning immune function due to immunosenescence.   Clinical trials now provide information to support a favorable immunogenicity and safety profile of MF59-adjuvanted influenza vaccine in young children. Published data indicate that Fluad®, a trivalent seasonal influenza vaccine with MF59, was immunogenic and well tolerated in young children, with a benefit/risk ratio that supports routine clinical use. A recent clinical trial also shows that Fluad provides high efficacy against PCR-confirmed influenza. Based on the results of clinical studies in children, the use of MF59-adjuvanted vaccine offers the potential to enhance efficacy and make vaccination a viable prevention and control strategy in this population. PMID:22327501

  4. An audit of influenza and pneumococcal vaccination in rheumatology outpatients

    Directory of Open Access Journals (Sweden)

    Mitchell William S

    2007-07-01

    Full Text Available Abstract Background Influenza and pneumococcal vaccination are recommended for a number of clinical risk groups including patients treated with major immunosuppressant disease modifying anti-rheumatic drugs. Such immunisation is not only safe but immunogenic in patients with rheumatic diseases. We sought to establish dual vaccination rates and significant influencing factors amongst our hospital rheumatology outpatients. Method We audited a sample of 101 patients attending hospital rheumatology outpatient clinics on any form of disease modifying treatment by clinical questionnaire and medical record perusal. Further data were collected from the local immunisation coordinating agency and analysed by logistic regression modelling. Results Although there was a high rate of awareness with regard to immunisation, fewer patients on major immunosuppressants were vaccinated than patients with additional clinical risk factors against influenza (53% vs 93%, p Conclusion Influenza and pneumococcal immunisation is suboptimal amongst patients on current immunosuppressant treatments attending rheumatology outpatient clinics. Raising awareness amongst patients may not be sufficient to improve vaccination rates and alternative strategies such as obligatory pneumococcal vaccination prior to treatment initiation and primary care provider education need to be explored.

  5. Universal influenza vaccines, science fiction or soon reality?

    Science.gov (United States)

    de Vries, Rory D; Altenburg, Arwen F; Rimmelzwaan, Guus F

    2015-01-01

    Currently used influenza vaccines are only effective when the vaccine strains match the epidemic strains antigenically. To this end, seasonal influenza vaccines must be updated almost annually. Furthermore, seasonal influenza vaccines fail to afford protection against antigenically distinct pandemic influenza viruses. Because of an ever-present threat of the next influenza pandemic and the continuous emergence of drift variants of seasonal influenza A viruses, there is a need for an universal influenza vaccine that induces protective immunity against all influenza A viruses. Here, we summarize some of the efforts that are ongoing to develop universal influenza vaccines.

  6. De Quervain thyroiditis in the course of H1N1 influenza infection.

    Science.gov (United States)

    Michas, G; Alevetsovitis, G; Andrikou, I; Tsimiklis, S; Vryonis, E

    2014-01-01

    Viral infections have been frequently associated with subacute (De Quervain) thyroiditis and autoimmune thyroid diseases. In the present case report we document a rare case of De Quervain thyroiditis in the course of H1N1 influenza infection. A 17-year-old previously healthy female that was treated in the General Hospital of Kalamata developed an influenza-like syndrome that was accompanied by palpitations, thyroid enlargement, and increased C-reactive protein. Polymerase chain reaction assay confirmed the diagnosis of H1N1 virus infection. Serum thyroid-stimulating hormone was suppressed to zero while the levels of free thyroxine and triiodothyronine were increased. The patient was treated with non-steroidal anti-inflammatory drugs and thyroid function was gradually restored without evolving to a hypothyroid phase. To our knowledge this is the second case described in the literature of De Quervain thyroiditis associated with H1N1 influenza infection.

  7. Influenza Gain-of-Function Experiments: Their Role in Vaccine Virus Recommendation and Pandemic Preparedness

    Science.gov (United States)

    Webby, R. J.; Webster, R. G.; Kelso, A.; Barr, I. G.; McCauley, J. W.; Daniels, R. S.; Wang, D.; Shu, Y.; Nobusawa, E.; Itamura, S.; Tashiro, M.; Harada, Y.; Watanabe, S.; Odagiri, T.; Ye, Z.; Grohmann, G.; Harvey, R.; Engelhardt, O.; Smith, D.; Hamilton, K.; Claes, F.; Dauphin, G.

    2014-01-01

    Abstract In recent years, controversy has arisen regarding the risks and benefits of certain types of gain-of-function (GOF) studies involving avian influenza viruses. In this article, we provide specific examples of how different types of data, including information garnered from GOF studies, have helped to shape the influenza vaccine production process—from selection of candidate vaccine viruses (CVVs) to the manufacture and stockpiling of safe, high-yield prepandemic vaccines for the global community. The article is not written to support a specific pro- or anti-GOF stance but rather to inform the scientific community about factors involved in vaccine virus selection and the preparation of prepandemic influenza vaccines and the impact that some GOF information has had on this process. PMID:25505124

  8. Influenza gain-of-function experiments: their role in vaccine virus recommendation and pandemic preparedness.

    Science.gov (United States)

    Schultz-Cherry, S; Webby, R J; Webster, R G; Kelso, A; Barr, I G; McCauley, J W; Daniels, R S; Wang, D; Shu, Y; Nobusawa, E; Itamura, S; Tashiro, M; Harada, Y; Watanabe, S; Odagiri, T; Ye, Z; Grohmann, G; Harvey, R; Engelhardt, O; Smith, D; Hamilton, K; Claes, F; Dauphin, G

    2014-12-12

    In recent years, controversy has arisen regarding the risks and benefits of certain types of gain-of-function (GOF) studies involving avian influenza viruses. In this article, we provide specific examples of how different types of data, including information garnered from GOF studies, have helped to shape the influenza vaccine production process-from selection of candidate vaccine viruses (CVVs) to the manufacture and stockpiling of safe, high-yield prepandemic vaccines for the global community. The article is not written to support a specific pro- or anti-GOF stance but rather to inform the scientific community about factors involved in vaccine virus selection and the preparation of prepandemic influenza vaccines and the impact that some GOF information has had on this process. Copyright © 2014 Schultz-Cherry et al.

  9. Influenza Pandemic Infrastructure Response in Thailand

    Centers for Disease Control (CDC) Podcasts

    2009-03-05

    Influenza viruses change antigenic properties, or drift, every year and they create seasonal outbreaks. Occasionally, influenza viruses change in a major way, called a “shift." If an influenza virus shifts, the entire human population is susceptible to the new influenza virus, creating the potential for a pandemic. On this podcast, CDC's Dr. Scott Dowell discusses responding to an influenza pandemic.  Created: 3/5/2009 by Emerging Infectious Diseases.   Date Released: 3/5/2009.

  10. Effect of Lactobacillus paracasei subsp. paracasei, L. casei 431 on immune response to influenza vaccination and upper respiratory tract infections in healthy adult volunteers

    DEFF Research Database (Denmark)

    Jespersen, Lillian; Tarnow, Inge; Eskesen, Dorte

    2015-01-01

    assigned to receive an acidified milk drink containing ≥10(9) colony-forming units of L. casei 431 (n = 553) or placebo (n = 551) for 42 d. After 21 d, subjects received the seasonal influenza vaccination. Primary outcome was seroprotection rate (anti-influenza antibody titers by hemagglutination....... Hansen A/S) (hereafter, L. casei 431) on immune response to influenza vaccination and respiratory symptoms in healthy adults. DESIGN: A randomized double-blind, placebo-controlled trial was conducted in 1104 healthy subjects aged 18-60 y at 2 centers in Germany and Denmark. Subjects were randomly...

  11. Is influenza vaccination in asthma helpful?

    Science.gov (United States)

    Bueving, Herman J; Thomas, Siep; Wouden, Johannes C van der

    2005-02-01

    Influenza infections are frequently involved in asthma exacerbations. During influenza epidemics substantial excess morbidity due to respiratory tract complications is reported in all age categories as well as excess mortality among the elderly. Vaccines are available for protection against influenza. Worldwide, vaccination is advised and considered a quality point for asthma care. However, the protective effect of influenza vaccination in patients with asthma is still disputed. In order to establish the current state of affairs we reviewed the recent literature on the protective effect of influenza vaccination and its usefulness in patients with asthma. Several studies were found addressing influenza and the protective aspects of vaccination. They discussed the incidence, the adverse effects of vaccination, the coverage of influenza vaccination among patients with asthma and the effectiveness of the vaccine. Influenza vaccination can safely be used in patients with asthma. Allegations that vaccination could provoke asthma exacerbations are convincingly invalidated by previous and recent research. Although patients with asthma are one of the major target groups for immunization, vaccine coverage in all age categories remains low. So far, no unequivocal beneficial effect of influenza vaccination in patients with asthma was found in observational and experimental studies in the sense of reduction of asthma exacerbations and other complications. Recent studies confirm these negative findings. More long-term randomized, placebo-controlled studies, focusing on influenza- proven illness in patients with asthma, are needed to address the question of how helpful influenza vaccination is in these patients.

  12. The human side of influenza

    Science.gov (United States)

    Oshansky, Christine M.; Thomas, Paul G.

    2012-01-01

    A clear understanding of immunity in individuals infected with influenza virus is critical for the design of effective vaccination and treatment strategies. Whereas myriad studies have teased apart innate and adaptive immune responses to influenza infection in murine models, much less is known about human immunity as a result of the ethical and technical constraints of human research. Still, these murine studies have provided important insights into the critical correlates of protection and pathogenicity in human infection and helped direct the human studies that have been conducted. Here, we examine and review the current literature on immunity in humans infected with influenza virus, noting evidence offered by select murine studies and suggesting directions in which future research is most warranted. PMID:22362872

  13. The Flavonoid Isoliquiritigenin Reduces Lung Inflammation and Mouse Morbidity during Influenza Virus Infection.

    Science.gov (United States)

    Traboulsi, Hussein; Cloutier, Alexandre; Boyapelly, Kumaraswamy; Bonin, Marc-André; Marsault, Éric; Cantin, André M; Richter, Martin V

    2015-10-01

    The host response to influenza virus infection is characterized by an acute lung inflammatory response in which intense inflammatory cell recruitment, hypercytokinemia, and a high level of oxidative stress are present. The sum of these events contributes to the virus-induced lung damage that leads to high a level of morbidity and mortality in susceptible infected patients. In this context, we identified compounds that can simultaneously reduce the excessive inflammatory response and the viral replication as a strategy to treat influenza virus infection. We investigated the anti-inflammatory and antiviral potential activities of isoliquiritigenin (ILG). Interestingly, we demonstrated that ILG is a potent inhibitor of influenza virus replication in human bronchial epithelial cells (50% effective concentration [EC50] = 24.7 μM). In addition, our results showed that this molecule inhibits the expression of inflammatory cytokines induced after the infection of cells with influenza virus. We demonstrated that the anti-inflammatory activity of ILG in the context of influenza virus infection is dependent on the activation of the peroxisome proliferator-activated receptor gamma pathway. Interestingly, ILG phosphate (ILG-p)-treated mice displayed decreased lung inflammation as depicted by reduced cytokine gene expression and inflammatory cell recruitment. We also demonstrated that influenza virus-specific CD8(+) effector T cell recruitment was reduced up to 60% in the lungs of mice treated with ILG-p (10 mg/kg) compared to that in saline-treated mice. Finally, we showed that administration of ILG-p reduced lung viral titers and morbidity of mice infected with the PR8/H1N1 virus. Copyright © 2015, American Society for Microbiology. All Rights Reserved.

  14. Prevalence of Influenza Viruses (Influenza Like Illness In Regional Laboratory Avian Influenza Semarang

    Directory of Open Access Journals (Sweden)

    Ridha Wahyutomo

    2011-12-01

    Design and Method: Data from patients examined in the regional laboratory of avian influenza Semarang from April 2009 until December 2010 was collected. Samples were obtained from Malang sentinel, Yogyakarta sentinel and Semarang sentinel. Samples were examined using PCR to detect influenza A, influenza B, and swine flu. Result: out 1367 patients tested, 279 patients (20.41% were from Yogyakarta sentinel, 619 patients (45.28% were from Malang sentinel, and 467 patients (34.16% were from Semarang sentinel. Flu A virus was detected in 117 patients (8.5%. Influenza B virus was found in 39 patients (2.8%. H1 virus was detected in 5 patients (0.36%. H3 virus was detected in 45 patients (3.29%. Swine flu virus was detected in 3 patients in Malang. Conclusion: The highest prevalence of flu A and flu B examined in avian influenza regional laboratory Semarang was from Semarang sentinel, followed by Yogyakarta sentinel and Malang (Sains Medika, 3(2:157-161.

  15. A dual character of flavonoids in influenza A virus replication and spread through modulating cell-autonomous immunity by MAPK signaling pathways

    Science.gov (United States)

    Dong, Wenjuan; Wei, Xiuli; Zhang, Fayun; Hao, Junfeng; Huang, Feng; Zhang, Chunling; Liang, Wei

    2014-01-01

    Flavonoids are well known as a large class of polyphenolic compounds, which have a variety of physiological activities, including anti-influenza virus activity. The influenza A/WSN/33 infected A549 cells have been used to screen anti-influenza virus drugs from natural flavonoid compounds library. Unexpectedly, some flavonoid compounds significantly inhibited virus replication, while the others dramatically promoted virus replication. In this study, we attempted to understand these differences between flavonoid compounds in their antivirus mechanisms. Hesperidin and kaempferol were chosen as representatives of both sides, each of which exhibited the opposite effects on influenza virus replication. Our investigation revealed that the opposite effects produced by hesperidin and kaempferol on influenza virus were due to inducing the opposite cell-autonomous immune responses by selectively modulating MAP kinase pathways: hesperidin up-regulated P38 and JNK expression and activation, thus resulting in the enhanced cell-autonomous immunity; while kaempferol dramatically down-regulated p38 and JNK expression and activation, thereby suppressing cell-autonomous immunity. In addition, hesperidin restricted RNPs export from nucleus by down-regulating ERK activation, but kaempferol promoted RNPs export by up-regulating ERK activation. Our findings demonstrate that a new generation of anti-influenza virus drugs could be developed based on selective modulation of MAP kinase pathways to stimulate cell-autonomous immunity. PMID:25429875

  16. Influenza infection and Kawasaki disease

    Directory of Open Access Journals (Sweden)

    Xijing Huang

    2015-06-01

    Full Text Available INTRODUCTION: The objective of this study was to investigate the possible link between influenza (Flu infection and Kawasaki disease (KD. METHODS: We examined the medical records of 1,053 KD cases and 4,669 influenza infection cases hospitalized at our institute from January 1, 2011 to December 31, 2013. Cases of KD with concomitant influenza infection formed the KD + Flu group. Each KD + Flu case was matched with 2 KD cases and 2 influenza infection cases, and these cases were assigned to the KD group and Flu group, respectively. The differences in the principal clinical manifestations, course of disease, incomplete KD rate, intravenous immunoglobulin (IVIG resistance rate, and echocardiographic detection results between the KD + Flu group and KD group were compared. The fever durations and laboratory test results of these three groups were compared. RESULTS: 1 The seasonal variations of the KD + Flu group, KD group and Flu group were similar. 2 The morbidity rate of incomplete KD was higher in the KD + Flu group compared with the KD group. 3 Patients in the KD + Flu group exhibited a longer time to KD diagnosis compared with patients in the KD group. 4 The KD + Flu group exhibited the longest fever duration among the three groups. 5 The CRP and ESR values in the KD + Flu group were higher those in the Flu or KD groups. CONCLUSIONS: Concomitant influenza infection affects the clinical manifestations of KD and can impact the laboratory test results and the diagnosis and treatment of the disease. However, it remains unclear whether influenza contributes to KD etiology.

  17. On the epidemiology of influenza

    Directory of Open Access Journals (Sweden)

    Scragg Robert

    2008-02-01

    Full Text Available Abstract The epidemiology of influenza swarms with incongruities, incongruities exhaustively detailed by the late British epidemiologist, Edgar Hope-Simpson. He was the first to propose a parsimonious theory explaining why influenza is, as Gregg said, "seemingly unmindful of traditional infectious disease behavioral patterns." Recent discoveries indicate vitamin D upregulates the endogenous antibiotics of innate immunity and suggest that the incongruities explored by Hope-Simpson may be secondary to the epidemiology of vitamin D deficiency. We identify – and attempt to explain – nine influenza conundrums: (1 Why is influenza both seasonal and ubiquitous and where is the virus between epidemics? (2 Why are the epidemics so explosive? (3 Why do they end so abruptly? (4 What explains the frequent coincidental timing of epidemics in countries of similar latitude? (5 Why is the serial interval obscure? (6 Why is the secondary attack rate so low? (7 Why did epidemics in previous ages spread so rapidly, despite the lack of modern transport? (8 Why does experimental inoculation of seronegative humans fail to cause illness in all the volunteers? (9 Why has influenza mortality of the aged not declined as their vaccination rates increased? We review recent discoveries about vitamin D's effects on innate immunity, human studies attempting sick-to-well transmission, naturalistic reports of human transmission, studies of serial interval, secondary attack rates, and relevant animal studies. We hypothesize that two factors explain the nine conundrums: vitamin D's seasonal and population effects on innate immunity, and the presence of a subpopulation of "good infectors." If true, our revision of Edgar Hope-Simpson's theory has profound implications for the prevention of influenza.

  18. Vaccination against seasonal influenza

    CERN Multimedia

    GS Department

    2010-01-01

    This year, as usual, the Medical Service is helping to promote vaccination against seasonal influenza. Vaccination against seasonal flu is especially recommended for anyone who suffers from chronic pulmonary, cardio-vascular or kidney disease or diabetes, is recovering from a serious illness or major surgery, or is over 65 years of age. The flu virus is transmitted through the air and through contact with contaminated surfaces, so frequent hand-washing with soap and/or an antiseptic hand wash is of great importance. As soon as the first symptoms appear (fever above 38°, shivering, coughing, muscle and/or joint pains, generalised weakness), you are strongly recommended to stay at home to avoid spreading the virus. Anyone working on the CERN site who wishes to be vaccinated against seasonal flu should go to the Infirmary (Building 57, ground floor), with their dose of vaccine. The Medical Service will issue a prescription on the day of the vaccination for the purposes of reimbursement through UNIQA...

  19. Corticosteroids as adjunctive therapy in the treatment of influenza.

    Science.gov (United States)

    Rodrigo, Chamira; Leonardi-Bee, Jo; Nguyen-Van-Tam, Jonathan; Lim, Wei Shen

    2016-03-07

    Specific treatments for influenza are limited to neuraminidase inhibitors and adamantanes. Corticosteroids show evidence of benefit in sepsis and related conditions, most likely due to their anti-inflammatory and immunomodulatory properties. Although commonly prescribed for severe influenza, there is uncertainty over their potential benefit or harm. To systematically assess the effectiveness and potential adverse effects of corticosteroids as adjunctive therapy in the treatment of influenza, taking into account differences in timing and doses of corticosteroids. We searched CENTRAL (2015, Issue 5), MEDLINE (1946 to June week 1, 2015), EMBASE (1974 to June 2015), CINAHL (1981 to June 2015), LILACS (1982 to June 2015), Web of Science (1985 to June 2015), abstracts from the last three years of major infectious disease and microbiology conferences, and references of included articles. We included randomised controlled trials (RCTs), quasi-RCTs and observational studies that compared corticosteroid treatment with no corticosteroid treatment for influenza or influenza-like illness. We did not restrict studies by language of publication, influenza subtypes, clinical setting or age of participants. We selected eligible studies in two stages: sequential examination of title and abstract, followed by full text. Two pairs of review authors independently extracted data and assessed risk of bias. We pooled estimates of effect using random-effects meta-analysis models, where appropriate. We assessed heterogeneity using the I(2) statistic and assessed the quality of the evidence using the Grading of Recommendations Assessment, Development and Evaluation (GRADE) framework. We identified 19 eligible studies (3459 individuals), all observational; 13 studies (1917 individuals) were suitable for inclusion in the meta-analysis of mortality. Of these, 12 studied patients infected with 2009 influenza A H1N1 virus (H1N1pdm09). Risk of bias was greatest in the 'comparability domain' of the

  20. Correlación entre la tipificación capsular de aislamientos colombianos de Haemophilus influenzae por el método de aglutinación en lámina y la técnica de PCR.

    Directory of Open Access Journals (Sweden)

    Marylin Hidalgo

    2003-06-01

    Full Text Available En 1998 se inició en Colombia la inmunización de niños menores de un año de edad con la vacuna conjugada contra Haemophilus influenzae, serotipo b. En el 2000, el programa de vigilancia del Grupo de Microbiología del Instituto Nacional de Salud informó una disminución de 40% de los casos de meningitis por este microorganismo, la cual se atribuyó a la vacunación. En este programa de vigilancia se utiliza de rutina la técnica estandarizada de aglutinación en lámina para la tipificación capsular de H. influenzae. El objetivo de este trabajo fue establecer la concordancia entre la prueba de aglutinación en lámina y la técnica de PCR. Se estudiaron con ambas técnicas 146 aislamientos clínicos invasores de H. influenzae, obtenidos de niños menores de 5 años, recolectados a partir de 1999 hasta 2002, identificados y serotipificados por el laboratorio de referencia como parte de la vigilancia de la meningitis bacteriana aguda y la infección respiratoria aguda. Nuestros resultados mostraron una correlación de 93% en la tipificación capsular de H. influenzae, serotipo b, y de 92% con respecto al resto de serotipos. La técnica de aglutinación en lámina realizada con un estricto control de calidad continúa siendo una herramienta sensible y específica para la serotipificación de H. influenzae.

  1. Influenza, anthropology, and global uncertainties.

    Science.gov (United States)

    Atlani-Duault, Laëtitia; Kendall, Carl

    2009-07-01

    The response to the novel H1N1 influenza (swine flu) pandemic has been overwhelmingly biological and epidemiological in scope. While plans are moving forward on a vaccine, few of the social effects of a truly massive global catastrophe-or the issues of communication, responding to predictable inappropriate reactions, preparation of populations for these effects, or using local population resources in the epidemic-have been well considered. Anthropology can play an important and underutilized role in planning and responding to influenza and other global emergencies. This editorial discusses these issues and makes some preliminary recommendations.

  2. Investigation of the salicylaldehyde thiosemicarbazone scaffold for inhibition of influenza virus PA endonuclease.

    Science.gov (United States)

    Rogolino, Dominga; Bacchi, Alessia; De Luca, Laura; Rispoli, Gabriele; Sechi, Mario; Stevaert, Annelies; Naesens, Lieve; Carcelli, Mauro

    2015-10-01

    The influenza virus PA endonuclease is an attractive target for the development of novel anti-influenza virus therapeutics, which are urgently needed because of the emergence of drug-resistant viral strains. Reported PA inhibitors are assumed to chelate the divalent metal ion(s) (Mg²⁺ or Mn²⁺) in the enzyme's catalytic site, which is located in the N-terminal part of PA (PA-Nter). In the present work, a series of salicylaldehyde thiosemicarbazone derivatives have been synthesized and evaluated for their ability to inhibit the PA-Nter catalytic activity. Compounds 1-6 have been evaluated against influenza virus, both in enzymatic assays with influenza virus PA-Nter and in virus yield assays in MDCK cells. In order to establish a structure-activity relationship, the hydrazone analogue of the most active thiosemicarbazone has also been evaluated. Since chelation may represent a mode of action of such class of molecules, we studied the interaction of two of them, one with and one without biological activity versus the PA enzyme, towards Mg²⁺, the ion that is probably involved in the endonuclease activity of the heterotrimeric influenza polymerase complex. The crystal structure of the magnesium complex of the o-vanillin thiosemicarbazone ligand 1 is also described. Moreover, docking studies of PA endonuclease with compounds 1 and 2 were performed, to further analyse the possible mechanism of action of this class of inhibitors.

  3. Broad neutralizing human monoclonal antibodies against influenza virus from vaccinated healthy donors

    Energy Technology Data Exchange (ETDEWEB)

    Kubota-Koketsu, Ritsuko; Mizuta, Hiroyuki [Department of Virology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871 (Japan); Oshita, Masatoshi; Ideno, Shoji [Osaka Research Laboratory, Benesis Corporation, Yodogawa-ku, Osaka 532-6505 (Japan); Yunoki, Mikihiro [Osaka Research Laboratory, Benesis Corporation, Yodogawa-ku, Osaka 532-6505 (Japan); Department of Virology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871 (Japan); Kuhara, Motoki [Ina Laboratory, Medical and Biological Laboratories Corporation, Ltd., Ina, Nagano 396-0002 (Japan); Yamamoto, Naomasa [Department of Biochemistry, School of Pharmaceutical Sciences, Ohu University, Koriyama, Fukushima 963-8611 (Japan); Okuno, Yoshinobu [Kanonji Institute, The Research Foundation for Microbial Diseases of Osaka University, Kanonji, Kagawa 768-0061 (Japan); Ikuta, Kazuyoshi, E-mail: ikuta@biken.osaka-u.ac.jp [Department of Virology, Research Institute for Microbial Diseases, Osaka University, Suita, Osaka 565-0871 (Japan)

    2009-09-11

    Human monoclonal antibodies (HuMAbs) prepared from patients with viral infections could provide information on human epitopes important for the development of vaccines as well as potential therapeutic applications. Through the fusion of peripheral blood mononuclear cells from a total of five influenza-vaccinated volunteers, with newly developed murine-human chimera fusion partner cells, named SPYMEG, we obtained 10 hybridoma clones stably producing anti-influenza virus antibodies: one for influenza A H1N1, four for influenza A H3N2 and five for influenza B. Surprisingly, most of the HuMAbs showed broad reactivity within subtype and four (two for H3N2 and two for B) showed broad neutralizing ability. Importantly, epitope mapping revealed that the two broad neutralizing antibodies to H3N2 derived from different donors recognized the same epitope located underneath the receptor-binding site of the hemagglutinin globular region that is highly conserved among H3N2 strains.

  4. Evaluation of experimental vaccines for bovine viral diarrhea in bovines, ovines and guinea pigs Evaluación de vacunas experimentales para la diarrea viral bovina en bovinos, ovinos y cobayos

    Directory of Open Access Journals (Sweden)

    F. Fernández

    2009-06-01

    Full Text Available The bovine viral diarrhea virus (BVDV infection control should be based on elimination of persistently infected animals and on immunization through vaccination, to prevent fetal infection. However, the efficacy of inactivated BVDV vaccines is variable due to its low immunogenicity. This study evaluated the humoral immune response against homologous and heterologous strains of 7 inactivated BVDV vaccines, in bovines and two experimental models (ovine and guinea pig which might be used to test candidate vaccines. Vaccines formulated with BVDV Singer, Oregon, NADL, and multivalent, induced seroconversion in the three animal models studied, reaching antibody titres higher than 2. Vaccine containing 125C -genotype 2- only induced a low antibody response in ovine, while VS-115 NCP vaccine was not immunogenic. Furthermore, bovine sera at 60 dpv presented homologous as well as heterologous antibody response, indicating a high degree of cross-reactivity among the strains studied. However, when bovine sera were tested against the Argentine field strain 00-693, they showed the lowest levels of cross-reactivity, suggesting the need of continued surveillance to identify and characterize emerging field BVDV strains. Finally, optimal correlations between bovine-ovine and bovine-guinea pig models were observed, indicating that two alternative species could replace bovines when testing the immunogenicity of BVDV candidate vaccines.El control del virus de la diarrea viral bovina (VDVB se basa en la eliminación de animales persistentemente infectados, y la inmunización de hembras para prevenir infecciones fetales. La eficiencia de estas vacunas es variable por su baja inmunogenicidad. Se evaluó la respuesta inmune humoral contra virus homólogos y heterólogos de 7 vacunas experimentales inactivadas del VDVB en bovinos y en dos modelos experimentales (ovinos y cobayos. Las vacunas conteniendo VDVB Singer, Oregon, NADL y polivalentes indujeron seroconversión en

  5. VACINAS: PROGRESSOS E NOVOS DESAFIOS PARA O CONTROLE DE DOENÇAS IMUNOPREVENÍVEIS Vacunas: Progresos y Nuevos Retos para el Control de Enfermedades Prevenibles Vaccines: Progress nnd Challenges for the Control of Preventable Diseases

    Directory of Open Access Journals (Sweden)

    Fonseca Pinto Eduardo

    2011-12-01

    Full Text Available RESUMO Há mais de 200 anos a vacinação tem sido uma ferramenta muito efetiva na prevenção de doenças infecciosas e juntamente com o saneamento básico, o efeito prático da vacinação pode ser considerado o maior benefício à saúde pública do século XX. No entanto, o desenvolvimento de vacinas permanece um objetivo importante no campo da imunologia e na última década observa-se uma mudança em direção a uma abordagem mais racional, baseada em uma compreensão molecular da patogenicidade microbiana, na utilização de novas tecnologias recombinantes e no desenvolvimento de sistemas de liberação de vacinas mais efetivos. Este trabalho descreve o progresso no desenvolvimento de vacinas a partir dos primeiros relatos das práticas de vacinação, passando pelo estado atual de desenvolvimento de vacinas, pelas novas estratégias vacinais e pelo impacto da vacinação no controle das doenças imunopreveníveis. Palavras chave: doenças imunopreveníveis, novas estratégias, vacinas. RESUMEN Desde hace más de 200 años la vacunación ha sido una herramienta muy efectiva en la prevención de enfermedades infecciosas, junto con el saneamiento, el efecto práctico de la vacunación puede ser considerado como el mayor beneficio para la salud pública del siglo XX. Sin embargo, el desarrollo de vacunas sigue siendo un objetivo importante en el campo de la inmunología y en la última década ha habido un cambio hacia un enfoque más racional, basada en los hallazgos moleculares de la patogenia microbiana, el uso de nuevas tecnologías recombinantes y el desarrollo de sistemas de suministro de las vacunas más eficaces. En este trabajo se describen los progresos en el desarrollo de vacunas, partiendo de los primeros informes de prácticas de vacunación, hasta el estado actual del desarrollo de vacunas, las nuevas estrategias de vacunas y el impacto de la vacunación en el control de enfermedades prevenibles. Palabras

  6. Detection of influenza C virus but not influenza D virus in Scottish respiratory samples

    Science.gov (United States)

    Smith, Donald B.; Gaunt, Eleanor R.; Digard, Paul; Templeton, Kate; Simmonds, Peter

    2016-01-01

    Background A newly proposed genus of influenza virus (influenza D) is associated with respiratory disease in pigs and cattle. The novel virus is most closely related to human influenza C virus and can infect ferrets but infection has not been reported in humans. Objectives To ascertain if influenza D virus can be detected retrospectively in patient respiratory samples. Study design 3300 human respiratory samples from Edinburgh, Scotland, covering the period 2006–2008, were screened in pools of 10 by RT-PCR using primers capable of detecting both influenza C and D viruses. Results Influenza D was not detected in any sample. Influenza C was present in 6 samples (0.2%), compared with frequencies of 3.3% and 0.9% for influenza A and B viruses from RT-PCR testing of respiratory samples over the same period. Influenza C virus was detected in samples from individuals 45 years old, with cases occurring throughout the year. Phylogenetic analysis of nearly complete sequences of all seven segments revealed the presence of multiple, reassortant lineages. Conclusion We were unable to detect viruses related to influenza D virus in human respiratory samples. Influenza C virus was less prevalent than influenza A and B viruses, was associated with mild disease in the young (45 years) and comprised multiple, reassortant lineages. Inclusion of influenza C virus as part of a diagnostic testing panel for respiratory infections would be of limited additional value. PMID:26655269

  7. Vacuna fenol-insoluble contra la brucelosis humana: evaluacion del poder inmunogenico en cobayos Phenol insoluble extract vaccine for the prevention of brucellosis in humans: evaluation in guinea pigs

    Directory of Open Access Journals (Sweden)

    J. Bolpe

    1991-02-01

    Full Text Available Se examinó una vacuna diseñada para inmunizar al hombre, preparada con extracto de fenol insoluble, para determinar si protegía a cobayos contra el desafío con la cepa virulenta B. abortus 2308. Se incluyeron en el experimento las vacunas vivas atenuadas B. abortus cepa 19 y B. melitensis Rev. 1, para comparar los resultados. Se vacunaron 93 animales en cada grupo, que fueron subdivididos en subgrupos de 31 y se los desafió con 10(4, 10³ y 10² unidades formadoras de colonias de la cepa B. abortus 2308 virulenta. El análisis global de los resultados demostró una protección del 11.9% en animales vacunados con el extracto de fenol insoluble, 65% en los vacunados con B. abortus cepa 19 y 95% en el grupo que recibió vacuna B. melitensis Rev. 1.A phenol insoluble extract vaccine proposed to immunize men against brucellosis was tested for its ability in protecting guinea pigs against challenge with virulent Brucella abortus strain 2308. Living attenuated Brucella abortus strain 19 and B. melitensis Rev. 1 were included in the experiment for comparison. Ninety three animals were vaccinated in each group and subdivided in subgroups of 31 for challenge with 10(4,10³ and 10² colony forming units of virulent B. abortus 2308. A global analysis of the results showed protection of 11.9%, 65% and 95% in animals vaccinated with phenol insoluble extract, strain 19 and Rev. 1, respectively.

  8. Entre controversias científico-médicas y movilizaciones populares. Población epidémica y vacunas contra la fiebre hemorrágica argentina 1958-1990

    Directory of Open Access Journals (Sweden)

    Agnese, Graciela

    2013-06-01

    Full Text Available The emergence and gradual extension of a new epidemic disease, as it has been the Haemorrhagic Fever Argentina, from the Decade of the ‘ 50s, prompted the medical scientific research with the aim of finding a vaccine. In the period 1959-1990 developed three projects of vaccines with different results. This article aims to consider the behavior assumed by the epidemic population around the three vaccines in response to the tensions that exist between population and physicians and researchers in charge of vaccination campaigns; the struggles between the various scientific groups; the role of the press and the State.La irrupción y la progresiva extensión de una nueva enfermedad epidémica, como ha sido la Fiebre Hemorrágica Argentina, a partir de la década del ’50, impulsó la investigación científica médica con el objetivo fundamental de encontrar una vacuna. En el período 1959-1990 se desarrollaron tres proyectos de vacunas con distintos resultados. El objetivo de este artículo es considerar las conductas asumidas por la población epidémica en torno a las tres vacunas atendiendo a las tensiones existentes entre la población y los médicos e investigadores a cargo de las campañas de vacunación; las pugnas entre los distintos grupos científicos; el rol de la prensa y del estado.

  9. Respuesta inmune intratecal y características clínicas de la meningoencefalitis por Neisseria meningitidis en pacientes inmunizados con la vacuna cubana VA-MENGOC-BC®

    Directory of Open Access Journals (Sweden)

    Elena Noris-García

    2008-08-01

    Full Text Available La morbimortalidad por la enfermedad meningocócica en Cuba disminuyó notablemente después de la introducción de la vacuna VA-MENGOC-BC®. Sin embargo, años después de ser vacunados se han reportado algunos niños que enfermaron. En este trabajo nos propusimos describir el comportamiento neuroinmunológico y clínico de esta enfermedad en 12 pacientes vacunados que fueron ingresados en el Hospital Pediátrico de San Miguel del Padrón con el diagnóstico de meningoencefalitis producida por Neisseria meningitidis. Se tomaron muestras de forma simultánea de sangre y líquido cefalorraquídeo para la cuantificación de albúmina e inmunoglobulinas mayores por inmunodifusión radial; para el análisis de los resultados se tomó como referencia el registro histórico de los resultados de ocho pacientes no inmunizados que enfermaron antes de incluir esta vacuna en el Esquema Nacional de Vacunación. La respuesta neuroinmunológica y las características clínicas de los pacientes vacunados resultaron diferentes a lo observado previamente en pacientes no vacunados. El grupo vacunado mostró un cuadro menos grave de la enfermedad. El patrón de síntesis intratecal de inmunoglobulinas fue diferente entre los dos grupos. La media de la síntesis intratecal de IgG, IgM e IgA fue significativamente superior en el grupo de los pacientes no vacunados. Este estudio nos permitió concluir que en la muestra estudiada la vacuna modificó la respuesta neuroinmunológica y el cuadro clínico de la enfermedad.

  10. Influenza (Flu) vaccine (Live, Intranasal): What you need to know

    Science.gov (United States)

    ... is taken in its entirety from the CDC Influenza Live, Intranasal Flu Vaccine Information Statement (VIS): www.cdc.gov/vaccines/ ... flulive.html . CDC review information for Live, Intranasal Influenza VIS: Vaccine Information Statement Influenza Page last reviewed: ...

  11. Universal influenza vaccines, science fiction or soon reality?

    NARCIS (Netherlands)

    R.D. de Vries (Rory); A.F. Altenburg (Arwen); G.F. Rimmelzwaan (Guus)

    2015-01-01

    textabstractCurrently used influenza vaccines are only effective when the vaccine strains match the epidemic strains antigenically. To this end, seasonal influenza vaccines must be updated almost annually. Furthermore, seasonal influenza vaccines fail to afford protection against antigenically

  12. Symptoms of influenza virus infection in hospitalized patients

    NARCIS (Netherlands)

    van den Dool, C; Hak, E; Wallinga, J; van Loon, A M; Lammers, J W J; Bonten, M J M

    BACKGROUND: During influenza outbreaks, fever and cough are the most accurate symptoms in predicting influenza virus infection in the community. OBJECTIVE: To determine the usefulness of fever, cough, and other symptoms for diagnosing influenza virus infection in hospitalized patients. DESIGN:

  13. Universal influenza virus vaccines and therapeutic antibodies.

    Science.gov (United States)

    Nachbagauer, R; Krammer, F

    2017-04-01

    Current influenza virus vaccines are effective when well matched to the circulating strains. Unfortunately, antigenic drift and the high diversity of potential emerging zoonotic and pandemic viruses make it difficult to select the right strains for vaccine production. This problem causes vaccine mismatches, which lead to sharp drops in vaccine effectiveness and long response times to manufacture matched vaccines in case of novel pandemic viruses. To provide an overview of universal influenza virus vaccines and therapeutic antibodies in preclinical and clinical development. PubMed and clinicaltrials.gov were used as sources for this review. Universal influenza virus vaccines that target conserved regions of the influenza virus including the haemagglutinin stalk domain, the ectodomain of the M2 ion channel or the internal matrix and nucleoproteins are in late preclinical and clinical development. These vaccines could confer broad protection against all influenza A and B viruses including drift variants and thereby abolish the need for annual re-formulation and re-administration of influenza virus vaccines. In addition, these novel vaccines would enhance preparedness against emerging influenza virus pandemics. Finally, novel therapeutic antibodies against the same conserved targets are in clinical development and could become valuable tools in the fight against influenza virus infection. Both universal influenza virus vaccines and therapeutic antibodies are potential future options for the control of human influenza infections. Copyright © 2017 European Society of Clinical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved.

  14. Guía para la estandarización de técnicaGuía técnicas inmunoenzimáticas en ensayos de vacunas

    Directory of Open Access Journals (Sweden)

    Juan C. Martínez

    2000-09-01

    Full Text Available Se realizó una revisión sobre la estandarización de técnicas inmunoenzimáticas para ensayos preclínicos y clínicos de vacunas, elaborándose una guía práctica. Se analizan los principios a usar y los pasos a seguir para la optimización de un ensayo, incluyendo la preparación de estándares y controles. Se exponen nuestras experiencias.

  15. Vectores recombinantes basados en el virus modificado de Ankara (MVA), con deleción en el gen C6L, como vacunas contra el VIH/SIDA y otras enfermedades

    OpenAIRE

    García-Arriaza, J; Gómez, Carmen E.; Esteban, Mariano

    2011-01-01

    La presente invención se engloba dentro de los campos de la biología molecular y de la biotecnología. Específicamente se refiere a virus recombinantes basados en el virus modificado de Ankara (MVA) que expresan los antígenos gp120 y Gag-Pol-Nef del virus de la inmunodeficiencia humana (VIH-1) de subtipo B (MVA-B), sobre los que se ha delecionado el gen de vaccinia C6L, y que han sido diseñados para utilizarse como vacunas contra el VIH/SIDA y otras enfermedades.

  16. Vectores recombinantes basados en el virus modificado de ankara (MVA), con deleción en el gen C6L, como vacunas contra el VIH/SIDA y otras enfermedades

    OpenAIRE

    García-Arriaza, J; Gómez, Carmen E.; Esteban, Mariano

    2011-01-01

    [ES] La presente invención engloba dentro de los campos de la biología molecular y de la biotecnología. Especificamente se refiere a virus recombinantes basados en el virus modificado de Ankara (MVA) que expresan los antigenos gp120 y Gag-Pol-Nef del virus de la inmunodeficienciahumana (VIH-1) de subtipo B (MVA-B), sobre los que see ha delecionado el gen de vaccinia C6L, y que han sido diseñados para utilizarse como vacunas contra el VIH/SIDA y otras enfermedades.

  17. Caracterización de eventos adversos asociados a vacunas que inmunizan contra enfermedades infecciosas.Años 2006-2007 Characterization of adverse events associated with vaccines immunizing against infectious diseases. 2006-2007

    OpenAIRE

    Ivette Díaz Mato; Ashley Lázaro Chao Cardeso; Giset Jiménez López; Yanet López Valdés

    2010-01-01

    Se realizó un estudio descriptivo, transversal y retrospectivo para caracterizar los eventos adversos temporalmente asociados con las vacunas que se emplean en la prevención y el control de las enfermedades infecciosas, y que fueron notificados a la Unidad Coordinadora Nacional de Farmacovigilancia entre los años 2006-2007. Se determinó su comportamiento de acuerdo con la edad, sexo, procedencia de la notificación, personal que reporta, localización y severidad. Se identificaron además los pr...

  18. VACUNAS CONTRA EL HERPESVIRUS BOVINO-1: UNA MIRADA DESDE EL PASADO HACIA EL FUTURO DE LA INMUNIZACIÓN Bovine Herpesvirus-1 Vaccine’s: A Look From The Past To The Immunization Future

    Directory of Open Access Journals (Sweden)

    JULIÁN RUIZ-SAENZ

    Full Text Available El herpesvirus Bovino-1 (BHV-1 es uno de los principales patógenos que afecta el ganado; la infección primaria se acompaña de varias manifestaciones clínicas tales como la rinotraqueitis, aborto, vulvovaginitis/balanopostitis pustular y en algunos casos, enfermedad neurológica. Luego de la recuperación, la infección persiste durante toda la vida del individuo en un estado de latencia en ganglios nervioso trigémino o sacro. La Organización Mundial de Sanidad Animal (OIE reporta que la vacunación contra el BHV-1 puede ser efectiva en reducir las manifestaciones clínicas y en consecuencia las pérdidas económicas, pero no logra proteger completamente de la infección. Es por esto que durante los últimos años se han desarrollado gran cantidad de agentes vacunales que van desde las vacunas clásicas inactivadas hasta aquellas que usan tecnología de DNA recombinante. El presente artículo se enfoca en presentar una actualización acerca de las vacunas más usadas desde hace ya varios años y resumir los avances más importantes en la generación de nuevas vacunas contra el BHV-1; tratando así de abrir un nuevo panorama para la generación de vacunas en Colombia.Bovine herpesvirus-1 is one of the most important pathogens of cattle; the primary infection is characterized by clinical manifestations such as infectious bovine rhinotracheitis, abortion, infectious pustular vulvovaginitis and in some cases, neurological signs. After recovering, the virus establishes viral latency in sensory neurons of trigeminal or sacral ganglia. The World Organization for Animal Health (OIE reports that vaccination against BHV-1 could be useful to reduce the clinical manifestations and in consequence the economic looses, but it can not protect against the infection. Therefore, a huge amount of vaccines have been developed that includes from classic inactivation to recombinant DNA technologies. This paper makes an updated review about the most used vaccines

  19. Inmunogenicidad y capacidad protectora en hamsters de vacunas antileptospirósicas monovalentes de células enteras del serogrupo Ballum Immunogenicity and protective capacity of leptospiral whole-cell monovalent serogroup Ballum vaccines in hamsters

    Directory of Open Access Journals (Sweden)

    A. González

    2005-12-01

    Full Text Available El serogrupo Ballum de Leptospira constituye en la actualidad la primera causa de leptospirosis humana en Cuba. Vacunas de células enteras químicamente inactivadas fueron formuladas a partir de dos cepas clínicas de Leptospira interrogans serogrupo Ballum empleando como adyuvante hidróxido de aluminio. Los niveles de aglutininas inducidos en hamsters por una u otra preparación vacunal fueron estimados mediante aglutinación microscópica y la actividad IgG específica fue cuantificada mediante ELISA. La capacidad de protección homóloga y heteróloga contra la infección letal y subletal se determinó mediante el desafío con 100 y 10 000 DL50 de cinco cepas virulentas pertenecientes a los serogrupos Ballum, Canicola, Icterohaemorrhagiae y Pomona. Las evaluaciones realizadas demostraron que ambas vacunas fueron inmunogénicas e indujeron una completa protección homóloga en el modelo animal empleado. La protección cruzada frente a serogrupos heterólogos solo fue significativa en una de las preparaciones monovalentes frente al desafío con 100 DL50 de Canicola. Como resultado de este estudio se pudo comprobar la alta inmunogenicidad y capacidad protectora en hamsters de vacunas monovalentes de células enteras formuladas a partir de dos cepas candidatas vacunales del serogrupo de Leptospira de mayor circulación en humanos en Cuba no incluido en la vacuna actualmente disponible.Leptospira serogroup Ballum is at present the first cause of human leptospirosis in Cuba. Killed whole-cell vaccines were formulated with two clinical isolates of Leptospira interrogans serogroup Ballum using aluminum hydroxide as adjuvant. Agglutinins levels induced by each vaccine in hamsters were estimated by microscopic agglutination test and specific IgG activities were quantified by a whole cell-based enzyme-linked immunosorbent assay. Homologous and cross protective capacity against lethal and sublethal infection were determined in vaccinated animals by

  20. Recomendación sobre la vacuna contra la tosferina para los bebés y niños pequeños (Whooping Cough Vaccine Recommendation for Babies and Young Children)

    Centers for Disease Control (CDC) Podcasts

    2015-04-13

    Este podcast proporciona información acerca de la tosferina y la recomendación de que todos los niños reciban la vacuna DTaP según el calendario recomendado por los CDC para ayudar a protegerlos contra esta grave enfermedad.  Created: 4/13/2015 by National Center for Immunization and Respiratory Diseases (NCIRD), Division of Bacterial Diseases (DBD), Meningitis and Vaccine Preventable Diseases Branch (MVPDB).   Date Released: 4/13/2015.

  1. Antivirals and the control of influenza outbreaks.

    Science.gov (United States)

    Hota, Susy; McGeer, Allison

    2007-11-15

    During annual influenza epidemics, outbreaks of influenza in closed institutions are common. Among healthy children or young adults, such outbreaks are uncommonly associated with serious morbidity or mortality; however, in hospitals and nursing homes, attack rates as high as 60% and case-fatality rates as high as 50% have been reported. Annual influenza vaccination of both patients or residents and hospital and nursing home staff has had a substantial impact on mortality and has reduced the number of outbreaks. Nonpharmacologic interventions (e.g., handwashing and contact isolation of case patients) may reduce the spread of influenza, although evidence for their efficacy is lacking. Nonetheless, long-term care facilities for the elderly population with high vaccination rates and better-than-average infection-control programs have a 25%-50% chance of experiencing an influenza outbreak each year, with an expected resident attack rate of 35%-40%. Thus, antiviral drugs have been increasingly used to mitigate the impact of influenza outbreaks. There are 2 classes of antiviral drugs that are active against influenza: adamantanes and neuraminidase inhibitors. Drugs of the 2 classes appear to be equally effective for the treatment and prophylaxis of susceptible influenza A virus strains. However, adamantanes are not active against influenza B virus, and an increasing proportion of influenza A isolates are resistant to adamantanes. Adamantanes are associated with higher rates of adverse events than are neuraminidase inhibitors. There is substantial evidence that antiviral prophylaxis is effective in terminating outbreaks of seasonal influenza in closed institutions. If stockpiles are adequate, antiviral drugs are likely to be even more important in mitigating the impact of influenza transmission in health care institutions during the next influenza pandemic.

  2. Universal influenza vaccines, science fiction or soon reality?

    OpenAIRE

    Vries, Rory; Altenburg, Arwen; Rimmelzwaan, Guus

    2015-01-01

    textabstractCurrently used influenza vaccines are only effective when the vaccine strains match the epidemic strains antigenically. To this end, seasonal influenza vaccines must be updated almost annually. Furthermore, seasonal influenza vaccines fail to afford protection against antigenically distinct pandemic influenza viruses. Because of an ever-present threat of the next influenza pandemic and the continuous emergence of drift variants of seasonal influenza A viruses, there is a need for ...

  3. Formulation of influenza T cell peptides : in search of a universal influenza vaccine

    NARCIS (Netherlands)

    Soema, Peter Christiaan

    2015-01-01

    Current seasonal influenza vaccines rely on the induction of antibodies to neutralize the virus. However, influenza viruses frequently undergo genetic mutations due to antigenic drift and shift, altering the surface proteins hemagglutinin and neuraminidase to which antibodies usually bind. This

  4. Influenza vaccines to control influenza-associated bacterial infection: where do we stand?

    Science.gov (United States)

    Christopoulou, Ioanna; Roose, Kenny; Ibañez, Lorena Itatí; Saelens, Xavier

    2015-01-01

    Influenza A virus is a pathogen that is feared for its capacity to cause pandemics. In this review, we illustrate the clinical evidence which support the theory that bacterial co-infection is a considerable risk factor for exacerbated disease during pandemic and seasonal influenza, including infection with influenza B viruses. We provide an overview of the multiple and diverse mechanisms that help explain how influenza creates an opportunity for replication of secondary bacterial infections. Influenza vaccines and pneumococcal vaccines are widely used and often in overlapping target groups. We summarize the evidence for a protective effect of influenza immunization against bacterial infections, and vice versa of pneumococcal vaccines against influenza-associated pneumonia and lethality. It is important that future implementation of broadly protective influenza vaccines also takes into account protection against secondary bacterial infection.

  5. Control strategies against avian influenza

    Science.gov (United States)

    Since 1959, 40 epizootics of high pathogenicity avian influenza (HPAI) have occurred (Figure 1). Thirty-five of these epizootic HPAI viruses were geographically-limited (mostly to single countries), involved farm-to-farm spread and were eradicated from poultry by stamping-out programs; i.e. the HPAI...

  6. Influenza vaccines for avian species

    Science.gov (United States)

    Beginning in Southeast Asia, in 2003, a multi-national epizootic outbreak of H5N1 highly pathogenic avian influenza (HPAI) was identified in commercial poultry and wild bird species. This lineage, originally identified in Southern China in 1996 and then Hong Kong in 1997, caused severe morbidity an...

  7. Influenza Vaccine, Inactivated or Recombinant

    Science.gov (United States)

    ... die from flu, and many more are hospitalized.Flu vaccine can:keep you from getting flu, make flu ... What is inactivated or recombinant influenza vaccine?A dose of flu vaccine is recommended every flu season. Children 6 months through 8 years of age may need two ...

  8. Influenza: prevention, prophylaxis and treatment

    African Journals Online (AJOL)

    three and five million cases of severe illness and between a quarter and half a million deaths every year. In South ... Influenza illness causes substantial morbidity and mortality, with healthcare costs and lost productivity due to absenteeism resulting ... much further than simply providing a convenient and accessible cold-.

  9. Pandemic H1N1 influenza infection and vaccination in humans induces cross-protective antibodies that target the hemagglutinin stem

    Directory of Open Access Journals (Sweden)

    Christy Ann Thomson

    2012-05-01

    Full Text Available Most monoclonal antibodies (mAbs generated from humans infected or vaccinated with the 2009 pandemic H1N1 (pdmH1N1 influenza virus targeted the hemagglutinin (HA stem. These anti-HA stem mAbs mostly used IGHV1-69 and bound readily to epitopes on the conventional seasonal influenza and pdmH1N1 vaccines. The anti-HA stem mAbs neutralized pdmH1N1, seasonal influenza H1N1 and avian H5N1 influenza viruses by inhibiting HA-mediated fusion of membranes and protected against and treated heterologous lethal infections in mice with H5N1 influenza virus. This demonstrated that therapeutic mAbs could be generated a few months after the new virus emerged. Human immunization with the pdmH1N1 vaccine induced circulating antibodies that protected mice from lethal, heterologous H5N1 influenza infections. We observed that the dominant heterosubtypic antibody response against the HA stem correlated with the relative absence of memory B cells against the HA head of pdmH1N1, thus enabling the rare heterosubtypic memory B cells induced by seasonal influenza and specific for conserved sites on the HA stem to compete for T-cell help. These results support the notion that broadly protective antibodies against influenza would be induced by successive vaccination with conventional influenza vaccines based on subtypes of HA in viruses not circulating in humans.

  10. ESTRUCTURA MOLECULAR Y ANTIGÉNICA DE LA VACUNA CONTRA EL VIRUS DEL PAPILOMA HUMANO 16 (VPH 16 Antigenic and Molecular Structure of Human Papillomavirus (HPV 16 Vaccine

    Directory of Open Access Journals (Sweden)

    VÍCTOR ANDRÉS VANEGAS

    Full Text Available La proteína L1 del Virus del Papiloma Humano (VPH constituye el 80% de la cápside viral. Las vacunas profilácticas contra el VPH son sintetizadas a partir de la proteína L1 ensamblada en Partículas similares al Virus (del inglés VLP, las cuales son altamente inmunogénicas generando anticuerpos específicos de tipo y en algunos casos pueden presentar reacción cruzada entre tipos de VPH filogenéticamente próximos. La estructura de la proteína L1 del VPH es importante porque confiere estabilidad a la cápside mediante el establecimiento de interacciones intra e intercapsoméricas lo que asegura la integridad viral y antigénicamente porque contiene los epítopes que inducen la respuesta inmune protectora. En estudios en los que se evaluó la antigenicidad de la proteína L1 se determinó que los epítopes inmunodominantes de la cápside viral se encuentran en los bucles B-C, D-E, F-G, H-I y en el extremo C-terminal. Estos bucles son poco conservados entre los diferentes genotipos y se encuentran en segmentos de la proteína expuestos en la superficie de la cápside. Los aminoácidos situados en los bucles B-C, F-G y H-I son primordiales para el reconocimiento por los anticuerpos neutralizantes. Los diferentes subtipos y variantes presentan cambios en estos aminoácidos o en residuos que conforman otros epítopes. En esta revisión se presentará un estado del arte de la proteína L1 del VPH genotipo 16, la estructura y su importancia en el desarrollo de vacunas contra la infección producida por este virus.Human Papillomavirus L1 protein makes up 80% of the viral capsid and self assembles in Virus-like Particles (VLP; these particles are immunogenic, generate type-specific antibodies and can induce very limited cross-reactivity among highly homologous HPV types. In addition to its structural function, it confers the stability to the capsid by establishing disulfide bonds and other intra and intercapsomeric interactions, and also contains

  11. Influenza virus types and subtypes among pediatric patients having influenza like illness in summer season

    OpenAIRE

    Bishwanath Acharya; Bishnu Prasad Upadhyay; Shailaja Adhikari; Ajit Rayamajhi; Kanchan Thapa

    2016-01-01

    Background: Acute respiratory infections (ARIs) represent one of the major causes of childhood mortality and morbidity in Nepal. The Influenza virus is one of the common causes of viral ARIs and bacterial infection secondary to influenza contributes to majority of childhood death worldwide. However, the diagnosis of influenza virus infection is not routinely suggested in Nepal even for children clinically presenting with influenza like illness (ILI). Methods: With an aim to describe the statu...

  12. Fasciite necrotisante após vacina influenza: relato de caso Necrotizing fasciitis after influenza vaccine: case report

    Directory of Open Access Journals (Sweden)

    Guilherme Benjamin Brandão Pitta

    2011-06-01

    Full Text Available Paciente de 30 anos, do sexo masculino, apresentou, após vacinação contra influenza comum, dor intensa, edema e eritema em membro superior esquerdo no local da aplicação e febre contínua não aferida. Foi hospitalizado, porém houve agravamento progressivo do quadro e resistência ao tratamento com anti-inflamatórios e antibióticos, culminando em queda do estado geral, formação de coleção no local e convulsão febril. Optou-se por tratamento cirúrgico, submetendo-se o paciente a procedimentos para fasciotomia, desbridamento, drenagem de coleção e sutura de extenso ferimento em membro superior esquerdo.A 30-year-old male patient, after being vaccinated against the common influenza, presented severe pain, swelling and erythema at the site of injection on the left upper limb and had continuous fever that was not checked. He was admitted to the hospital,, but his clinical condition got worse, with no response to treatment with anti-inflammatory drugs and antibiotics. He developed an abscess at the site of vaccine injection, and high fever with febrile seizures. Surgical treatment was chosen, and the patient underwent debridement and drainage of the abscess, upper arm fasciotomy and repair of the extensive surgical wounds of the left arm.

  13. Serological characterization of guinea pigs infected with H3N2 human influenza or immunized with hemagglutinin protein

    Science.gov (United States)

    2010-01-01

    Background Recent and previous studies have shown that guinea pigs can be infected with, and transmit, human influenza viruses. Therefore guinea pig may be a useful animal model for better understanding influenza infection and assessing vaccine strategies. To more fully characterize the model, antibody responses following either infection/re-infection with human influenza A/Wyoming/03/2003 H3N2 or immunization with its homologous recombinant hemagglutinin (HA) protein were studied. Results Serological samples were collected and tested for anti-HA immunoglobulin by ELISA, antiviral antibodies by hemagglutination inhibition (HI), and recognition of linear epitopes by peptide scanning (PepScan). Animals inoculated with infectious virus demonstrated pronounced viral replication and subsequent serological conversion. Animals either immunized with the homologous HA antigen or infected, showed a relatively rapid rise in antibody titers to the HA glycoprotein in ELISA assays. Antiviral antibodies, measured by HI assay, were detectable after the second inoculation. PepScan data identified both previously recognized and newly defined linear epitopes. Conclusions Infection and/or recombinant HA immunization of guinea pigs with H3N2 Wyoming influenza virus resulted in a relatively rapid production of viral-specific antibody thus demonstrating the strong immunogenicity of the major viral structural proteins in this animal model for influenza infection. The sensitivity of the immune response supports the utility of the guinea pig as a useful animal model of influenza infection and immunization. PMID:20735849

  14. The threat of avian influenza H5N1: 'do we have the tools for the job'?

    Science.gov (United States)

    Oxford, John; Lambkin-Williams, Robert; Mann, Alex

    2007-01-01

    For the first time in human history virologists have the knowledge about the avian origin of pandemic influenza A viruses. Furthermore, in the last two decades a new class of anti influenza drugs, the neuraminidase inhibitors (NIs), has been developed from an academic discovery to a series of antiviral drugs to be used in the clinic. At present vaccinologists are producing influenza A (H5N1) vaccines to be stockpiled alongside the NIs to combat the first wave of an anticipated influenza pandemic. Studies from the 1918 infection calamity, the Spanish influenza, and the succeeding pandemics of 1957 and 1968, all caused by avian influenza A viruses, have shown how quickly such a virus can mutate to become less virulent (starting with 50% case fatality) and more infectious. Such a mutation cluster could lead to a rapid increase in world deaths, currently 170, to many millions. However there are optimistic analyses: judicious and swift application of NIs, vaccine and hygiene to an outbreak epicentre, most likely in South-East Asia, could break the chain of transmission.

  15. Serological characterization of guinea pigs infected with H3N2 human influenza or immunized with hemagglutinin protein

    Directory of Open Access Journals (Sweden)

    Bushnell Ruth V

    2010-08-01

    Full Text Available Abstract Background Recent and previous studies have shown that guinea pigs can be infected with, and transmit, human influenza viruses. Therefore guinea pig may be a useful animal model for better understanding influenza infection and assessing vaccine strategies. To more fully characterize the model, antibody responses following either infection/re-infection with human influenza A/Wyoming/03/2003 H3N2 or immunization with its homologous recombinant hemagglutinin (HA protein were studied. Results Serological samples were collected and tested for anti-HA immunoglobulin by ELISA, antiviral antibodies by hemagglutination inhibition (HI, and recognition of linear epitopes by peptide scanning (PepScan. Animals inoculated with infectious virus demonstrated pronounced viral replication and subsequent serological conversion. Animals either immunized with the homologous HA antigen or infected, showed a relatively rapid rise in antibody titers to the HA glycoprotein in ELISA assays. Antiviral antibodies, measured by HI assay, were detectable after the second inoculation. PepScan data identified both previously recognized and newly defined linear epitopes. Conclusions Infection and/or recombinant HA immunization of guinea pigs with H3N2 Wyoming influenza virus resulted in a relatively rapid production of viral-specific antibody thus demonstrating the strong immunogenicity of the major viral structural proteins in this animal model for influenza infection. The sensitivity of the immune response supports the utility of the guinea pig as a useful animal model of influenza infection and immunization.

  16. Ten influenza seasons in France: distribution and timing of influenza A and B circulation, 2003?2013

    OpenAIRE

    Mosnier, Anne; Caini, Saverio; Daviaud, Isabelle; Bensoussan, Jean-Louis; Stoll-Keller, Fran?oise; Bui, Tan Tai; Lina, Bruno; van der Werf, Sylvie; Cohen, Jean Marie

    2015-01-01

    Background Describing the circulation of influenza viruses and the characteristics of seasonal epidemics remains an essential tool to optimize the strategies of influenza prevention and control. Special attention has been recently paid to influenza B in the context of the availability of a quadrivalent vaccine, containing two influenza B strains. Methods We used data from a practitioners-based influenza surveillance network to describe the circulation of influenza viruses in France from 2003?...

  17. Effects of influenza vaccination and influenza illness on exacerbations in multiple sclerosis

    NARCIS (Netherlands)

    De Keyser, J; Zwanikken, C

    1998-01-01

    Despite reports that influenza vaccination appears to be safe in multiple sclerosis there is uncertainty which patients may benefit from it. By using a questionnaire we compared the effects of influenza illness (1995-1996 season) and influenza vaccination (autumn of 1996) on neurologic symptoms in

  18. Molecular detection and typing of influenza viruses. Are we ready for an influenza pandemic?

    NARCIS (Netherlands)

    MacKay, W.G.; Loon, A.M. van; Niedrig, M.; Meijer, A.; Lina, B.; Niesters, H.G.M.

    2008-01-01

    BACKGROUND: We cannot predict when an influenza pandemic will occur or which variant of the virus will cause it. Little information is currently available on the ability of laboratories to detect and subtype influenza viruses including the avian influenza viruses. OBJECTIVES: To assess the ability

  19. Updates on Influenza Vaccination in Children.

    Science.gov (United States)

    Campbell, Angela J P; Grohskopf, Lisa A

    2018-03-01

    Influenza vaccination is recommended for all children 6 months of age and older who do not have contraindications. This article provides an overview of information concerning burden of influenza among children in the United States; US-licensed influenza vaccines; vaccine immunogenicity, effectiveness, and safety; and recent updates relevant to use of these vaccines in pediatric populations. Influenza antiviral medications are discussed. Details concerning vaccine-related topics may be found in the current US Centers for Disease Control and Prevention/Advisory Committee on Immunization Practices recommendations for use of influenza vaccines (https://www.cdc.gov/vaccines/hcp/acip-recs/vacc-specific/flu.html). Additional information on influenza antivirals is located at https://www.cdc.gov/flu/professionals/antivirals/index.htm. Published by Elsevier Inc.

  20. Defining Influenza A Virus Hemagglutinin Antigenic Drift by Sequential Monoclonal Antibody Selection

    OpenAIRE

    Das, Suman R.; Hensley, Scott E.; Ince, William L.; Brooke, Christopher B.; Subba, Anju; Delboy, Mark G.; Russ, Gustav; Gibbs, James S.; Bennink, Jack R.; Yewdell, Jonathan W.

    2013-01-01

    Human influenza A virus (IAV) vaccination is limited by “antigenic drift,” rapid antibody-driven escape reflecting amino acid substitutions in the globular domain of hemagglutinin (HA), the viral attachment protein. To better understand drift, we used anti-hemagglutinin monoclonal Abs (mAbs) to sequentially select IAV escape mutants. Twelve selection steps, each resulting in a single amino acid substitution in the hemagglutinin globular domain, were required to eliminate antigenicity defined ...